subject,relation,object,sentence
major comorbidities,include,heart disease,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,infarction,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,coronary heart disease,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,hypertension,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,chronic bronchitis,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,bronchitis,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,cerebral infarction,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,diabetes,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
2019-nCoV,can cause,illness,"Although 2019-nCoV can cause a severe respiratory illness like SARS and MERS, evidence from clinics suggested that 2019-nCoV is generally less pathogenic than SARS-CoV, and much less than MERS-CoV."
2019-nCoV,illness like,SARS,"Although 2019-nCoV can cause a severe respiratory illness like SARS and MERS, evidence from clinics suggested that 2019-nCoV is generally less pathogenic than SARS-CoV, and much less than MERS-CoV."
2019-nCoV,is generally less pathogenic than,SARS-CoV,"Although 2019-nCoV can cause a severe respiratory illness like SARS and MERS, evidence from clinics suggested that 2019-nCoV is generally less pathogenic than SARS-CoV, and much less than MERS-CoV."
2019-nCoV,is,pathogenic,"Although 2019-nCoV can cause a severe respiratory illness like SARS and MERS, evidence from clinics suggested that 2019-nCoV is generally less pathogenic than SARS-CoV, and much less than MERS-CoV."
2019-nCoV,can cause,respiratory illness,"Although 2019-nCoV can cause a severe respiratory illness like SARS and MERS, evidence from clinics suggested that 2019-nCoV is generally less pathogenic than SARS-CoV, and much less than MERS-CoV."
2019-nCoV pneumonia,showed,involvement of opacity,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,basically showed,multifocal involvement of ground-glass opacity with consolidation,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,basically showed,multifocal involvement of ground-glass opacity sometimes with consolidation,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,basically showed,involvement of ground-glass opacity,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,showed,involvement of opacity with consolidation,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,basically showed,involvement of opacity,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,basically showed,multifocal involvement of opacity with consolidation,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,showed,multifocal involvement of ground-glass opacity with consolidation,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,showed,involvement of ground-glass opacity sometimes with consolidation,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
2019-nCoV pneumonia,basically showed,multifocal involvement,"The 2019-nCoV pneumonia basically showed a multifocal or unifocal involvement of ground-glass opacity (GGO), sometimes with consolidation and fibrosis."
coronavirus,is,enterocytetropic,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
coronavirus,is,novel,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
novel enterocytetropic virus,causing,diarrhea,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
Porcine delta coronavirus,is,novel emerging enterocytetropic virus,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
mortality,is in,suckling piglets,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
Porcine delta coronavirus,is,novel enterocytetropic virus,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
novel emerging virus,causing,diarrhea,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
virus,causing,diarrhea,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
Porcine delta coronavirus,is,novel virus,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
Porcine delta coronavirus,is,emerging virus,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
Porcine delta coronavirus,is,virus,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
Porcine delta coronavirus,is,enterocytetropic virus,"Porcine delta coronavirus (PDCoV) is a novel emerging enterocytetropic virus causing diarrhea, vomiting, dehydration, and mortality in suckling piglets."
new coronavirus,was,Similar to other coronaviruses as those reported,"Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human."
new coronavirus,spread from,human-to-human,"Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human."
coronavirus,spread via,aerosols,"Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human."
new coronavirus,was,reported,"Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human."
new coronavirus,spread via,aerosols,"Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human."
new coronavirus,spread via,natural aerosols,"Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human."
addressing,epidemiological and clinical effects of,SARS,"In order to assess the potential of the Wuhan 2019-nCoV to cause maternal, fetal and neonatal morbidity and other poor obstetrical outcomes, this communication reviews the published data addressing the epidemiological and clinical effects of SARS, MERS, and other coronavirus infections on pregnant women and their infants."
addressing,epidemiological and clinical effects on,pregnant women,"In order to assess the potential of the Wuhan 2019-nCoV to cause maternal, fetal and neonatal morbidity and other poor obstetrical outcomes, this communication reviews the published data addressing the epidemiological and clinical effects of SARS, MERS, and other coronavirus infections on pregnant women and their infants."
Infection,is with,Middle East respiratory syndrome coronavirus,Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) could be asymptomatic or cause mild influenza-like illness.
infection,is with,novel coronavirus,"To understand the time-dependent risk of infection on a cruise ship, the Diamond Princess, I estimated the incidence of infection with novel coronavirus (COVID-19)."
Major initial symptoms,included,fever with other symptoms,"Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache."
symptoms,included,fever with other less typical initial symptoms including heart palpitations,"Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache."
initial symptoms,included,fever with less typical symptoms observed at frequency including heart palpitations,"Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache."
symptoms,included,fever with other initial symptoms observed at frequency,"Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache."
Major initial symptoms,included,fever with symptoms observed at low frequency,"Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache."
most,manifestations of,viral pneumonia,"CONCLUSIONS: The majority of patients with 2019-nCoV coronavirus pneumonia present with fever as the first symptom, and most of them still showed typical manifestations of viral pneumonia on chest imaging."
great public health concern,Human infections with,coronaviruses including severe respiratory syndrome,"BACKGROUND: Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally."
public health concern,Human infections with,coronaviruses including acute syndrome,"BACKGROUND: Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally."
severe acute respiratory syndrome,including coronaviruses is,CoVs,"BACKGROUND: Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally."
dyspnea,accompanied by,complications acute distress syndrome,"RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome."
dyspnea,accompanied by,complications acute respiratory distress syndrome,"RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome."
dyspnea,accompanied by,complications respiratory distress syndrome,"RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome."
dyspnea,accompanied by,complications,"RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome."
dyspnea,accompanied by,complications distress syndrome,"RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome."
Corticosteroids,prevent,lung injury caused by pneumonia,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,prevent,lung injury caused,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,prevent,lung injury caused by severe community-acquired pneumonia,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,prevent,lung injury,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,are,widely used,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,prevent,lung injury caused by severe pneumonia,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,are,used,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
Corticosteroids,prevent,lung injury caused by community-acquired pneumonia,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
their excellent pharmacological effects,due to pneumonia is,sCAP,Corticosteroids are widely used to prevent lung injury caused by severe community-acquired pneumonia (sCAP) due to their excellent pharmacological effects on the suppression of exuberant and dysfunctional systematic inflammation5.
ratio,history of,smoking,"Multivariate logistic analysis indicated that age (odds ratio [OR], 8.546; 95% confidence interval [CI]: 1.628-44.864; Pâ€Š=â€Š0.011), history of smoking (OR, 14.285; 95% CI: 1.577-25.000; Pâ€Š=â€Š0.018), maximum body temperature at admission (OR, 8.999; 95% CI: 1.036-78.147, Pâ€Š=â€Š0.046), respiratory failure (OR, 8.772, 95% CI: 1.942-40.000; Pâ€Š=â€Š0.016), albumin (OR, 7.353, 95% CI: 1.098-50.000; Pâ€Š=â€Š0.003), and C-reactive protein (OR, 10.530; 95% CI: 1.224-34.701, Pâ€Š=â€Š0.028) were risk factors for disease progression."
age,history of,smoking,"CONCLUSIONS: Several factors that led to the progression of COVID-19 pneumonia were identified, including age, history of smoking, maximum body temperature on admission, respiratory failure, albumin, C-reactive protein."
posing,significant threats to,global health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,significant threats to,public health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,significant threats to,health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,threats to,health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,threats to,global public health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
severe infections,is in,humans,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,threats to,global health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,significant threats to,global public health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
posing,threats to,public health,"Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health."
pulmonary lesions,were found In,total,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
77 pulmonary lesions,were,found,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
77 pulmonary lesions,were,In total found including lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
pulmonary lesions,were found including,patchy lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
pulmonary lesions,were,found,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
77 pulmonary lesions,were found In,total,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
77 pulmonary lesions,were,In total found including patchy lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
pulmonary lesions,were,In total found including patchy lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
pulmonary lesions,were,In total found including lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
77 pulmonary lesions,were found including,lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
pulmonary lesions,were found including,lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
77 pulmonary lesions,were found including,patchy lesions,"In total, 77 pulmonary lesions were found, including patchy lesions (39%), large confluent lesions (13%), and small nodular lesions (48%)."
87%,had,more,"In total, 87% of all cases had two or more of runny nose/ congestion, cough, sore throat/hoarse voice or fever."
%,had,more,"In total, 87% of all cases had two or more of runny nose/ congestion, cough, sore throat/hoarse voice or fever."
sore throat,had,measured temperature,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
sore throat,had,measured temperature of â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
throat,had,temperature,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
sore throat,temperature of,â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
throat,had,measured temperature,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
throat,had,measured temperature of â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
throat,had,temperature of â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
sore throat,had,temperature of â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
sore throat,measured temperature of,â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
throat,measured temperature of,â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
sore throat,had,temperature,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
throat,temperature of,â‰¥ 37.8 C.,"The most common symptoms among residents were cough (85%), runny nose/congestion (79%), and sore throat/ hoarse voice (59%) and only 17% of residents had a measured temperature of â‰¥ 37.8C."
patients,is in,Zhejiang province,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
series.Setting,hospitals in,Zhejiang province,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
Design Retrospective case,confirmed,SARS-Cov-2 infection,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
China.Participants 62 patients,admitted to,hospital,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
Seven hospitals,is in,Zhejiang province,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
Design case,confirmed,SARS-Cov-2 infection,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
China.Participants 62 patients,admitted with,laboratory,"Objective To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Design Retrospective case series.Setting Seven hospitals in Zhejiang province, China.Participants 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection."
75-year-old male patient,is with,severe COVID-19 pneumonia,"We recently reported in Intensive Care Medicine the imaging changes of acute stage from a case of 75-year-old male patient with severe COVID-19 pneumonia combined acute respiratory distress syndrome (ARDS), septic shock, and multiple organ disfunction syndrome (MODS) who had a history of 10-year hypertension and 1-year diabetes."
116 patients,is in,3 HD units,"Thus, this study aimed to evaluate the effect of different isolation strategies on the prevention of secondary viral transmission and clinical outcomes among exposed HD patients.During the 2015 MERS-CoV outbreak in Korea, 116 patients in 3 HD units were incidentally exposed to individuals with confirmed MERS-CoV infection and underwent different types of isolation, which were as follows: single-room isolation (nâ€Š=â€Š54, 47%), cohort isolation (nâ€Š=â€Š46, 40%), and self-imposed quarantine (nâ€Š=â€Š16, 13%)."
individuals,is with,confirmed MERS-CoV infection,"Thus, this study aimed to evaluate the effect of different isolation strategies on the prevention of secondary viral transmission and clinical outcomes among exposed HD patients.During the 2015 MERS-CoV outbreak in Korea, 116 patients in 3 HD units were incidentally exposed to individuals with confirmed MERS-CoV infection and underwent different types of isolation, which were as follows: single-room isolation (nâ€Š=â€Š54, 47%), cohort isolation (nâ€Š=â€Š46, 40%), and self-imposed quarantine (nâ€Š=â€Š16, 13%)."
2015 MERS-CoV outbreak,is in,Korea,"Thus, this study aimed to evaluate the effect of different isolation strategies on the prevention of secondary viral transmission and clinical outcomes among exposed HD patients.During the 2015 MERS-CoV outbreak in Korea, 116 patients in 3 HD units were incidentally exposed to individuals with confirmed MERS-CoV infection and underwent different types of isolation, which were as follows: single-room isolation (nâ€Š=â€Š54, 47%), cohort isolation (nâ€Š=â€Š46, 40%), and self-imposed quarantine (nâ€Š=â€Š16, 13%)."
symptoms,included,fever,"Common symptoms included fever (136 [98.6%]), fatigue (96 [69.6%]), and dry cough (82 [59.4%])."
Common symptoms,included,fever,"Common symptoms included fever (136 [98.6%]), fatigue (96 [69.6%]), and dry cough (82 [59.4%])."
many,received,glucocorticoid therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
many,received,moxifloxacin,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
many,received,antibacterial therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
many,received,therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
patients,received,therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
patients,received,antiviral therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
Most patients,received,therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
Most patients,received,antiviral therapy,"Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%])."
patients,were transferred because of,complications including acute distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred because of,complications including acute respiratory distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred because of,complications including acute distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred because of,complications including respiratory distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred to,intensive care unit,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred to,ICU,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred because of,complications,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were,transferred,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred because of,complications including distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were,transferred,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred because of,complications including distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred to,intensive care unit,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred because of,complications including respiratory distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred because of,complications including acute respiratory distress syndrome,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred to,care unit,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
patients,were transferred to,ICU,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred to,care unit,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
Thirty-six patients,were transferred because of,complications,"Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%])."
two patients,presented with,decreased blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
six patients,is with,abnormal alanine aminotransferase,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
three patients,is with,abnormal aspartate aminotransferase,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
three patients,is with,elevated creatine kinase isoenzyme,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,decreased white blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,decreased white blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,decreased blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
",10 patients",is with,elevated creatine kinase,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,white blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,white blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
four patients,is with,elevated lactate dehydrogenase,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
five patients,is with,elevated C reactive protein,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
two patients,presented with,blood cell counts,"There were two patients presented with decreased white blood cell counts, five patients with elevated C reactive protein, six patients with abnormal alanine aminotransferase, three patients with abnormal aspartate aminotransferase,10 patients with elevated creatine kinase, three patients with elevated creatine kinase isoenzyme, four patients with elevated lactate dehydrogenase, and all with normal procalcitonin levels."
features,disorder of,lung textures,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
common features,were,glass shadows,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
features,were,glass shadows,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
chest,computed,tomography examinations,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
features,were,ground glass shadows,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
common features,disorder of,7 cases,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
common features,were,ground glass shadows,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
common features,disorder of,lung textures,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
features,disorder of,7 cases,"The chest computed tomography examinations showed that the common features were ground glass shadows (21 cases), blurred edges (18 cases), speckles and patchy shadows (17 cases), thickening and disorder of some lung textures (7 cases), and visible band shadows (7 cases)."
11-year-old child,was treated with,alpha-interferon,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
patients,were treated,due to reactions,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
27 patients,were treated,due to adverse reactions,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
lopinavir/ritonavir,is with,4 withdrawal,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
One 11-year-old child,was treated with,alpha-interferon,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
11-year-old child,was,treated,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
One 11-year-old child,was,treated,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
patients,were treated,due,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
11-year-old child,was treated with,alpha-interferon alone,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
27 patients,were treated,due to reactions,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
27 patients,were treated,due,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
patients,were,treated,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
patients,were treated,due to adverse reactions,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
One 11-year-old child,was treated with,alpha-interferon alone,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
27 patients,were,treated,"One 11-year-old child was treated with alpha-interferon alone, and 27 patients were treated with alpha-interferon inhalation plus lopinavir/ritonavir with 4 withdrawal due to adverse reactions."
initial symptoms,loss of,appetite,"The initial symptoms mainly were fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201)."
symptoms,were,fever,"The initial symptoms mainly were fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201)."
symptoms,loss of,appetite,"The initial symptoms mainly were fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201)."
symptoms,were,mainly fever,"The initial symptoms mainly were fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201)."
initial symptoms,were,mainly fever,"The initial symptoms mainly were fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201)."
initial symptoms,were,fever,"The initial symptoms mainly were fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201)."
major city,was,asked,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
hotline,has reached,capacity,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
hotline,has reached capacity,disease progressed,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
hotline,has reached capacity,asked,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
major city,create,its hotline,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
hotline,has reached,full capacity,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
major city,create,its own hotline,"The toll-free number 1922 served as a hotline for citizens to report suspicious symptoms or cases in themselves or others; as the disease progressed, this hotline has reached full capacity, so each major city was asked to create its own hotline as an alternative."
features,initial experience with,epidemiologic investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,initial experience with,investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,initial experience with,epidemiologic investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
date,was,February 25 2020,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
experience,is in,Singapore,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,initial experience with,epidemiologic investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,initial experience with,investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,experience with,investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,experience in,Singapore,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,experience with,epidemiologic investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,experience with,investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
4 hospitals,is in,Singapore,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,experience with,epidemiologic investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
follow-up date,was,February 25 2020,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,experience with,epidemiologic investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,initial experience with,investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
final follow-up date,was,February 25 2020,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,initial experience in,Singapore,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,experience with,epidemiologic investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,experience with,investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,experience in,Singapore,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
experience,is with,epidemiologic investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
features,initial experience in,Singapore,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,initial experience with,epidemiologic investigation,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,experience with,investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
final date,was,February 25 2020,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
clinical features,initial experience with,investigation of outbreak,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
SARS-CoV-2 infection.Clinical,were,collected including PCR cycle threshold values,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
Confirmed SARS-CoV-2 infection.Clinical,were,collected including PCR cycle threshold values,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
Confirmed SARS-CoV-2 infection.Clinical,were,collected including PCR cycle threshold values from nasopharyngeal swabs,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
SARS-CoV-2 infection.Clinical,were,collected including PCR cycle threshold values from swabs,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
Confirmed SARS-CoV-2 infection.Clinical,were,collected,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
SARS-CoV-2 infection.Clinical,were,collected including PCR cycle threshold values from nasopharyngeal swabs,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
SARS-CoV-2 infection.Clinical,were,collected,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
Confirmed SARS-CoV-2 infection.Clinical,were,collected including PCR cycle threshold values from swabs,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China.To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management.Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)â€“confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020.Confirmed SARS-CoV-2 infection.Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool."
nausea,developed,abnormal liver function test,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,mild tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,frequently mild tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
vomiting,developed,abnormal liver function test,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,frequently mild respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
diarrhea,developed,liver function test,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
diarrhea,developed,abnormal liver function test results.Among,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
vomiting,developed,liver function test results.Among,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
nausea,developed,liver function test results.Among,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,mild,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
diarrhea,developed,abnormal liver function test,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,frequently respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
vomiting,developed,liver function test,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
first patients,diagnosed with,SARS-CoV-2 infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
first patients,diagnosed with,SARS-CoV-2 infection in Singapore,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
18 patients,diagnosed with,SARS-CoV-2 infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
patients,diagnosed with,SARS-CoV-2 infection in Singapore,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,frequently tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,mild respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,mild tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
18 patients,diagnosed with,SARS-CoV-2 infection in Singapore,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
diarrhea,developed,liver function test results.Among,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,frequently respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
SARS-CoV-2 infection,is in,Singapore,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,frequently mild tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
first 18 patients,diagnosed with,SARS-CoV-2 infection in Singapore,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,mild respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
nausea,developed,liver function test,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
patients,diagnosed with,SARS-CoV-2 infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,frequently tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
presentation,was,respiratory,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
nausea,developed,abnormal liver function test results.Among,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
clinical presentation,was,frequently mild respiratory tract infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
vomiting,developed,abnormal liver function test results.Among,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
first 18 patients,diagnosed with,SARS-CoV-2 infection,"Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
2012 viruses,is in,2009/2010,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
Severe Acute Respiratory Syndrome coronavirus,coronavirus with,occasional outbreaks,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
Middle East Respiratory Syndrome coronavirus,is with,occasional outbreaks,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
2002/2003,in coronavirus is,Middle East Respiratory Syndrome coronavirus with occasional outbreaks since 2012 viruses like H1N1 pandemic,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
2012 viruses,since coronavirus is,MERSâ€CoV,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
occasional outbreaks,with coronavirus is,MERSâ€CoV,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
Severe Acute Respiratory Syndrome coronavirus,is in,2002/2003,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
Severe Acute Respiratory Syndrome coronavirus,coronavirus since,2012 viruses like H1N1 pandemic in 2009/2010,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
2002/2003,in coronavirus is,SARSâ€CoV,"These were coronaviruses such as the Severe Acute Respiratory Syndrome coronavirus (SARSâ€CoV) in 2002/2003, the Middle East Respiratory Syndrome coronavirus (MERSâ€CoV) with occasional outbreaks since 2012 or influenza viruses like the H1N1 pandemic in 2009/2010."
suggestion,use,angiotensin receptor 1 blockers,"A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections."
tentative suggestion,use,angiotensin receptor 1 blockers,"A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections."
Identification,select,treatment,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
people,has,lives,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,save,people 's lives,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
avoid,use of,antibiotics,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,is,important,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,select,appropriate treatment,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,stop,epidemics,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,avoid,use of antibiotics,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,avoid,unnecessary use,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,avoid,unnecessary use of antibiotics,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
avoid,unnecessary use of,antibiotics,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
Identification,avoid,use,"Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics."
mild febrile illness,is with,patchy pulmonary inflammation,"Although most patients present with mild febrile illness with patchy pulmonary inflammation, a significant portion develop severe acute respiratory distress syndrome (ARDS), with a current case fatality of 2.3-3%."
Patients,had,manifestations,"Patients had clinical manifestations of fever, cough, shortness of breath, diarrhea, vomiting and so on."
Patients,had,clinical manifestations of fever,"Patients had clinical manifestations of fever, cough, shortness of breath, diarrhea, vomiting and so on."
fever,shortness of,breath,"Patients had clinical manifestations of fever, cough, shortness of breath, diarrhea, vomiting and so on."
Patients,had,manifestations of fever,"Patients had clinical manifestations of fever, cough, shortness of breath, diarrhea, vomiting and so on."
Patients,had,clinical manifestations,"Patients had clinical manifestations of fever, cough, shortness of breath, diarrhea, vomiting and so on."
Position 723,is in,COVID-2019,"Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine."
proline,instead isoleucine at,position 1010,"Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine."
proline,instead isoleucine at,aminoacidic position 1010,"Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine."
proline,isoleucine at,position 1010,"Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine."
proline,isoleucine at,aminoacidic position 1010,"Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine."
Hubei Province,is in,Dec-19,"A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, Hubei Province in China in December 2019 and caused a serious type of pneumonia called coronavirus disease 2019 or COVID-19."
coronavirus,emerged in,Wuhan,"A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, Hubei Province in China in December 2019 and caused a serious type of pneumonia called coronavirus disease 2019 or COVID-19."
novel coronavirus,emerged in,Wuhan,"A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, Hubei Province in China in December 2019 and caused a serious type of pneumonia called coronavirus disease 2019 or COVID-19."
Hubei Province,is in,China,"A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, Hubei Province in China in December 2019 and caused a serious type of pneumonia called coronavirus disease 2019 or COVID-19."
outbreak,caused,worldwide panic,"Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic."
outbreak,caused,panic,"Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic."
outbreak,Currently caused,worldwide panic,"Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic."
outbreak,Currently caused,panic,"Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic."
patients,is with,SARS,"In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19."
use,is in,patients with COVID-19,"In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19."
patients,is with,COVID-19,"In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19."
Conclusion Fever,are,common symptoms in patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,most common symptoms,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are most common symptoms in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
patients,is with,2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are symptoms in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are most common symptoms in,patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are common symptoms in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are common symptoms in,patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,common symptoms in patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are most common symptoms in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,most common symptoms in patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are most common symptoms in,patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are symptoms in,patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,common symptoms,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are,common symptoms,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are common symptoms in,patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,symptoms in patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are,most common symptoms,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are common symptoms in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are,symptoms,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,most common symptoms in patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,symptoms in patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
common symptoms,is in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are symptoms in,patients with 2019-nCoV infection,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
cough,are symptoms in,patients,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Conclusion Fever,are,symptoms,"Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination."
Several people,have,muscle soreness,Several people have muscle soreness or fatigue as well as ARDS.
Several people,have,ARDS,Several people have muscle soreness or fatigue as well as ARDS.
people,have,fatigue,Several people have muscle soreness or fatigue as well as ARDS.
Several people,have,fatigue,Several people have muscle soreness or fatigue as well as ARDS.
people,have,muscle soreness,Several people have muscle soreness or fatigue as well as ARDS.
people,have,ARDS,Several people have muscle soreness or fatigue as well as ARDS.
throat,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
hemoptysis,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
Diarrhea,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
throat,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
shock,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
symptoms,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
symptoms,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
shock,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
other symptoms,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
hemoptysis,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
hemoptysis,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
headache,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
shock,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
sore throat,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
other symptoms,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
sore throat,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
Diarrhea,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
headache,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
throat,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
headache,occur in,small number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
symptoms,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
sore throat,only occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
Diarrhea,occur in,number,"Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients."
case fatality rate,is lower than,that of Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Acute Respiratory Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Severe Respiratory Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Severe Acute Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Respiratory Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Severe Acute Respiratory Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Severe Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is,lower,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
case fatality rate,is lower than,that of Acute Syndrome,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
patients,is with,2019-nCoV infection,The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
outbreak,could,could caused by coronavirus,"Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3?"
outbreak,could,Finally could caused,"Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3?"
outbreak,could,could caused by novel coronavirus,"Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3?"
outbreak,could,Finally could caused by novel coronavirus,"Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3?"
outbreak,could,could caused,"Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3?"
outbreak,could,Finally could caused by coronavirus,"Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3?"
enormous challenges,containing,spread,"A study from China CDC showed majority of patients (80.9%) were considered asymptomatic or mild pneumonia but released large amounts of viruses at the early phase of infection, which posed enormous challenges for containing the spread of COVID-19."
challenges,containing,spread,"A study from China CDC showed majority of patients (80.9%) were considered asymptomatic or mild pneumonia but released large amounts of viruses at the early phase of infection, which posed enormous challenges for containing the spread of COVID-19."
enormous challenges,containing,spread of COVID-19,"A study from China CDC showed majority of patients (80.9%) were considered asymptomatic or mild pneumonia but released large amounts of viruses at the early phase of infection, which posed enormous challenges for containing the spread of COVID-19."
patients,of majority is,80.90%,"A study from China CDC showed majority of patients (80.9%) were considered asymptomatic or mild pneumonia but released large amounts of viruses at the early phase of infection, which posed enormous challenges for containing the spread of COVID-19."
challenges,containing,spread of COVID-19,"A study from China CDC showed majority of patients (80.9%) were considered asymptomatic or mild pneumonia but released large amounts of viruses at the early phase of infection, which posed enormous challenges for containing the spread of COVID-19."
disease spectrum,differ from,SARS,Limited epidemiological and clinical data suggest that the disease spectrum of COVID-19 may differ from SARS or MERS.
their infections,come from,communities,"Since the COVID-19 infections in medical staff occurred all before the preventive and control measures for COVID-19 had been implemented,is was not ruled out that their infections might have come from communities."
COVID-19 infections,is in,medical staff,"Since the COVID-19 infections in medical staff occurred all before the preventive and control measures for COVID-19 had been implemented,is was not ruled out that their infections might have come from communities."
Methods,were,analyzed,"Methods The clinical, laboratory, and chest CT features of 20 pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab COVID-19 nucleic acid test were retrospectively analyzed during 23 January and 8 February 2020."
20 pediatric inpatients,is with,COVID-19 infection,"Methods The clinical, laboratory, and chest CT features of 20 pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab COVID-19 nucleic acid test were retrospectively analyzed during 23 January and 8 February 2020."
Methods,were retrospectively analyzed during,23-Jan,"Methods The clinical, laboratory, and chest CT features of 20 pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab COVID-19 nucleic acid test were retrospectively analyzed during 23 January and 8 February 2020."
Methods,were,retrospectively analyzed,"Methods The clinical, laboratory, and chest CT features of 20 pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab COVID-19 nucleic acid test were retrospectively analyzed during 23 January and 8 February 2020."
Methods,were analyzed during,23-Jan,"Methods The clinical, laboratory, and chest CT features of 20 pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab COVID-19 nucleic acid test were retrospectively analyzed during 23 January and 8 February 2020."
women,develop illness after,infection with viruses,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,develop illness after,infection with respiratory viruses,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
women,are,likely,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
women,are,more likely,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
infection,is with,respiratory viruses,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,develop,illness,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,develop,severe illness,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,develop illness after,infection with viruses,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
women,develop,illness,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
women,develop illness after,infection,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,develop illness after,infection,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
women,develop illness after,infection with respiratory viruses,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
women,develop,severe illness,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
physiological changes,is in,their immune systems,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,are,likely,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
pregnant women,are,more likely,"Clinical manifestation of COVID-19 infection during pregnancy Due to the physiological changes in their immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses."
Middle East respiratory syndrome coronavirus,are,In addition known,"In addition, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two notable strains of the coronavirus family, are both known to be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death7, 8."
Middle East respiratory syndrome coronavirus,are,known,"In addition, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two notable strains of the coronavirus family, are both known to be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death7, 8."
coronavirus,strains of,coronavirus family,"In addition, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two notable strains of the coronavirus family, are both known to be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death7, 8."
severe complications,for responsible is,admission to intensive care unit,"In addition, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two notable strains of the coronavirus family, are both known to be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death7, 8."
Middle East syndrome coronavirus,are,In addition known,"In addition, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two notable strains of the coronavirus family, are both known to be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death7, 8."
Middle East syndrome coronavirus,are,known,"In addition, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two notable strains of the coronavirus family, are both known to be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death7, 8."
Other symptoms,included,shortness,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,myalgia,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
Other symptoms,included,shortness of breath,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,diarrhea,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,malaise,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
Other symptoms,included,throat,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,sore throat,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
Other symptoms,included,malaise,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,shortness of breath,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
Other symptoms,included,diarrhea,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,shortness,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
symptoms,included,throat,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
Other symptoms,included,sore throat,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
Other symptoms,included,myalgia,"Other symptoms included myalgia, malaise, sore throat, diarrhea and shortness of breath."
fetal distress,is in,two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,fetal distress,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,distress in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,distress in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,distress,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,distress in two of nine patients of membranes,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
fetal distress,is in,two of nine patients of membranes,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,distress in two of nine patients in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,distress in two of nine patients of membranes in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,fetal distress in two of nine patients in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,fetal distress in two of nine patients of membranes in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,fetal distress in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,fetal distress in two of nine patients,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
Pregnancy complications,included,fetal distress in two of nine patients of membranes,Pregnancy complications that appeared after the onset of COVID-19 infection included fetal distress in two of nine patients and premature rupture of the membranes in two of nine patients.
nine pregnant women,is with,COVID-19 pneumonia,"Another series10 of nine pregnant women with COVID-19 pneumonia presenting from mid-trimester onwards, or during the postpartum period, reported similar findings except for one woman requiring ICU care and ventilation for acute respiratory distress syndrome after the infection was diagnosed 2?days postpartum."
pathogens,are recognized With,use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized among,adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,respiratory infections,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized With,expanding use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized With,use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized among,ill patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized among,ill adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized among,patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized among,patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized With,use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized among,adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,viral infections,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized With,use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected infections in,17,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized With,use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized With,expanding use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized among,ill patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized With,expanding use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized With,use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized With,use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized among,ill adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized With,expanding use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized among,adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized With,expanding use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized With,expanding use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized among,ill adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are,recognized,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,53 % of such patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are,increasingly recognized,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized With,use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,infections,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized With,expanding use,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized among,patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized With,expanding use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized With,expanding use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,RVIs,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized among,ill patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized With,expanding use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized With,expanding use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,respiratory viral infections,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized With,use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized among,adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are,increasingly recognized,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized With,expanding use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are recognized among,ill adult patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,53 % of patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized With,use of assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
pathogens,are increasingly recognized With,use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
studies,have detected,53%,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are recognized among,patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized among,ill patients,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are increasingly recognized With,use of molecular assays,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
viral pathogens,are,recognized,"With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17â€“53% of such patients."
Oseltamivir,is,used neuraminidase inhibitor,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality in ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality in patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,neuraminidase inhibitor,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality in critically ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality in ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,most widely used neuraminidase inhibitor for treatment,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality in critically ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,neuraminidase inhibitor for treatment of influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality in patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality in ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,widely used neuraminidase inhibitor for treatment of influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality in patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality in patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality in patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,used neuraminidase inhibitor for treatment of influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality in critically ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,most widely used neuraminidase inhibitor for treatment of influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality in critically ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality in ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality in ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality in critically ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,mortality in patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality in critically ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality in patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality in patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,reduced mortality in critically ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is,associated,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is,associated,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,neuraminidase inhibitor for treatment,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
reduced mortality,is in,critically ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality in critically ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,widely used neuraminidase inhibitor for treatment,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality in ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
ill patients,is with,influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
early use,is associated with,reduced mortality in ill patients,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,widely used neuraminidase inhibitor,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
use,is associated with,mortality in ill patients with influenza,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,most widely used neuraminidase inhibitor,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
Oseltamivir,is,used neuraminidase inhibitor for treatment,Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
Several pharmacologic interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
pharmacologic interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
Several interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
adjunctive interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
Several adjunctive pharmacologic interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
Several adjunctive interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
adjunctive pharmacologic interventions,have,have studied,"Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs."
required,form of,support,"About 15â€“20% of suspected and confirmed patients with SARS-CoV-2 infection in fever clinics developed severe hypoxemia (since the second week of disease course), and required some form of ventilatory support such as high-flow nasal cannula, and non-invasive and invasive mechanical ventilation."
required,form of,ventilatory support,"About 15â€“20% of suspected and confirmed patients with SARS-CoV-2 infection in fever clinics developed severe hypoxemia (since the second week of disease course), and required some form of ventilatory support such as high-flow nasal cannula, and non-invasive and invasive mechanical ventilation."
complications,might occur In,addition,"In addition, other complications might occur, including, but not limited to, shock, acute kidney injury, gastrointestinal bleeding, and rhabdomyolysis."
other complications,might occur In,addition,"In addition, other complications might occur, including, but not limited to, shock, acute kidney injury, gastrointestinal bleeding, and rhabdomyolysis."
actual practice situation,is in,our hospital,"Referring to the &quot;Diagnosis and Treatment Scheme for NCP (Trial Version 4 and 5)&quot; and combining the actual practice situation in our hospital with the &quot;Summary of New Coronavirus Files of Shanghai Renji Hospital&quot;, we summarize how to carry out the clinical practice of colorectal surgery under the situation of the prevention and control of the NCP epidemiology, meanwhile under such situation aiming the procedure of diagnose and treatment for emergency patients with colorectal tumor, we share the experiences of the diagnosis of colorectal tumor, the management of patients with colorectal cancer who are scheduled to be admitted for surgery, the protection of wards, the perioperative management."
patients,is with,colorectal cancer,"Referring to the &quot;Diagnosis and Treatment Scheme for NCP (Trial Version 4 and 5)&quot; and combining the actual practice situation in our hospital with the &quot;Summary of New Coronavirus Files of Shanghai Renji Hospital&quot;, we summarize how to carry out the clinical practice of colorectal surgery under the situation of the prevention and control of the NCP epidemiology, meanwhile under such situation aiming the procedure of diagnose and treatment for emergency patients with colorectal tumor, we share the experiences of the diagnosis of colorectal tumor, the management of patients with colorectal cancer who are scheduled to be admitted for surgery, the protection of wards, the perioperative management."
emergency patients,is with,colorectal tumor,"Referring to the &quot;Diagnosis and Treatment Scheme for NCP (Trial Version 4 and 5)&quot; and combining the actual practice situation in our hospital with the &quot;Summary of New Coronavirus Files of Shanghai Renji Hospital&quot;, we summarize how to carry out the clinical practice of colorectal surgery under the situation of the prevention and control of the NCP epidemiology, meanwhile under such situation aiming the procedure of diagnose and treatment for emergency patients with colorectal tumor, we share the experiences of the diagnosis of colorectal tumor, the management of patients with colorectal cancer who are scheduled to be admitted for surgery, the protection of wards, the perioperative management."
He,shortness of,breath,"He denied any fever, neck stiffness, headache, cough, shortness of breath, chest pain, or photophobia."
He,had,history,"He had a history of alcohol and tobacco use, type II diabetes mellitus and hypertension (both well controlled by drugs), and lacunar infarction (without sequela).DA - 2020/02/25"
He,had,history of alcohol use,"He had a history of alcohol and tobacco use, type II diabetes mellitus and hypertension (both well controlled by drugs), and lacunar infarction (without sequela).DA - 2020/02/25"
He,had,lacunar infarction without sequela,"He had a history of alcohol and tobacco use, type II diabetes mellitus and hypertension (both well controlled by drugs), and lacunar infarction (without sequela).DA - 2020/02/25"
He,had,type II diabetes,"He had a history of alcohol and tobacco use, type II diabetes mellitus and hypertension (both well controlled by drugs), and lacunar infarction (without sequela).DA - 2020/02/25"
He,had,lacunar infarction,"He had a history of alcohol and tobacco use, type II diabetes mellitus and hypertension (both well controlled by drugs), and lacunar infarction (without sequela).DA - 2020/02/25"
misuse,is in,bioterrorist events,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,considered as,candidates for misuse in bioterrorist events,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,currently considered as,candidates for misuse in bioterrorist events,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,considered as,candidates for misuse,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,currently considered as,candidates,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,considered as,candidates,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,currently considered as,candidates for misuse in events,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,currently considered as,candidates for misuse,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
viruses,considered as,candidates for misuse in events,"The viruses historically implicated or currently considered as candidates for misuse in bioterrorist events are poxviruses, filoviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses and a number of arboviruses causing encephalitis, including alpha- and flaviviruses."
half,developed,distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
pneumonia,developed,acute respiratory distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
half,developed,acute respiratory distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
pneumonia,developed,acute distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
half,developed,acute distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
pneumonia,developed,ARDS,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
pneumonia,developed,respiratory distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
half,developed,ARDS,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
half,developed,respiratory distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
pneumonia,developed,distress syndrome,All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).
common laboratory abnormalities,were,hypoalbuminemia,"The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count."
hypoalbuminemia,percentage of,lymphocytes,"The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count."
CM prevention programs,issued in,China,"METHODS: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respiratory syndrome (SARS) and H1N1 influenza, and CM prevention programs issued by health authorities in China since the COVID-19 outbreak were retrieved from different databases and websites till 12 February, 2020."
infections,is in,CM classics,"METHODS: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respiratory syndrome (SARS) and H1N1 influenza, and CM prevention programs issued by health authorities in China since the COVID-19 outbreak were retrieved from different databases and websites till 12 February, 2020."
CM prevention programs,issued by,health authorities,"METHODS: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respiratory syndrome (SARS) and H1N1 influenza, and CM prevention programs issued by health authorities in China since the COVID-19 outbreak were retrieved from different databases and websites till 12 February, 2020."
Based,could,could alternative approach for prevention of COVID-19,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Based,could,could alternative approach for prevention,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Based,could,could alternative approach,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
prevention,is in,high-risk population,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Based,could,could approach,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Based,could,could approach for prevention of COVID-19,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Based,could,could approach for prevention,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Based,be,alternative,"CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population."
Xiao,efficiency of,FDA-approved drugs including ribavirin,"Gengfu Xiao, Wu Zhong and Zhihong Hu, the antiviral efficiency of the FDA-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine (CQ) and two well-known broad-spectrum antiviral drugs remdesivir (RDV, GS-5734) and favipiravir (T-705) were evaluated against a clinical isolate of 2019-nCoV in a cell culture infection model (Wang et al.2020)."
Gengfu Xiao,were,evaluated against isolate,"Gengfu Xiao, Wu Zhong and Zhihong Hu, the antiviral efficiency of the FDA-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine (CQ) and two well-known broad-spectrum antiviral drugs remdesivir (RDV, GS-5734) and favipiravir (T-705) were evaluated against a clinical isolate of 2019-nCoV in a cell culture infection model (Wang et al.2020)."
Gengfu Xiao,were,evaluated,"Gengfu Xiao, Wu Zhong and Zhihong Hu, the antiviral efficiency of the FDA-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine (CQ) and two well-known broad-spectrum antiviral drugs remdesivir (RDV, GS-5734) and favipiravir (T-705) were evaluated against a clinical isolate of 2019-nCoV in a cell culture infection model (Wang et al.2020)."
Several,presented with,fever accompanied respiratory symptoms,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied symptoms congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied respiratory symptoms congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied respiratory symptoms nasal congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever accompanied respiratory symptoms nasal congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever accompanied symptoms,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied symptoms,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever accompanied symptoms congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied symptoms nasal congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,gradually presented with,fever accompanied respiratory symptoms,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever accompanied,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever accompanied symptoms nasal congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Several,presented with,fever accompanied respiratory symptoms congestion,"Several gradually presented with fever, fatigue, dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom gastrointestinal symptoms such as nausea, vomiting and diarrhea."
Children,has,Hospital,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
respiratory infection,is in,children caused by 2019-nCoV,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
National Children,has,Regional Medical Center further standardize,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
National recommendations,were,drafted,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
recommendations,were,drafted,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
Child Health,for Center is,National Children 's Regional Medical Center further standardize,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
2019-nCoV,is in,Zhejiang Province,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
Zhejiang Province,recommendations for,diagnosis of respiratory infection caused by 2019-nCoV,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
latest National recommendations,were,drafted,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
National Children,'s Center is,Hospital,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
National Children,'s Center is,Zhejiang University School of Medicine,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
National Children 's Regional Medical Center,School of,Medicine,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
latest recommendations,were,drafted,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
Zhejiang Province,in 2019-nCoV is,4th edition,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
National Clinical Research Center,Center 's,National Children,"Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCoV (the 4th edition) and current status of clinical practice in Zhejiang Province, recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health, theÂ National Childrenâ€™s Regional Medical Center, Childrenâ€™s Hospital, Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV."
Limited data,are,available,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
data,are available about,COVID-19 during pregnancy,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated with other pathogenic coronaviruses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated with pathogenic coronaviruses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
data,are available about,COVID-19,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated with coronaviruses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated with highly pathogenic coronaviruses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated with other highly pathogenic coronaviruses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
information,might provide,insights,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
data,are,available,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
COVID-19,into,effects during pregnancy,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
Limited data,are available about,COVID-19 during pregnancy,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
insights,information on,illnesses associated with other coronaviruses,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
Limited data,are available about,COVID-19,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
information,however might provide,insights,"Limited data are available about COVID-19 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (i.e., severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS)) might provide insights into COVID-19â€™s effects during pregnancy."
Background Patients,will experience,levels of anxiety,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,levels due,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,high levels due,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,levels of anxiety due,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,levels of anxiety due to isolation treatment,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,is with,Coronavirus Disease 2019,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,levels due to isolation treatment,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,high levels of anxiety due,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,high levels of anxiety due to isolation treatment,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,high levels,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,high levels due to isolation treatment,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,high levels of anxiety,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Background Patients,will experience,levels,Background Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment.
Dehydroandrographolide succinate injection,is,off-label,"Dehydroandrographolide succinate (DAS) injection, which was approved in China for the treatment of viral pneumonia and upper respiratory tract infections, is often off-label used for nebulization therapy to avoid the adverse drug reactions associated with the injection."
Dehydroandrographolide succinate injection,is,off-label used,"Dehydroandrographolide succinate (DAS) injection, which was approved in China for the treatment of viral pneumonia and upper respiratory tract infections, is often off-label used for nebulization therapy to avoid the adverse drug reactions associated with the injection."
Dehydroandrographolide succinate injection,is,often off-label,"Dehydroandrographolide succinate (DAS) injection, which was approved in China for the treatment of viral pneumonia and upper respiratory tract infections, is often off-label used for nebulization therapy to avoid the adverse drug reactions associated with the injection."
Dehydroandrographolide succinate injection,is,often off-label used,"Dehydroandrographolide succinate (DAS) injection, which was approved in China for the treatment of viral pneumonia and upper respiratory tract infections, is often off-label used for nebulization therapy to avoid the adverse drug reactions associated with the injection."
strategy,included,infection,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
strategy,included,maintaining,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
Four-Anti strategy,included,maintaining,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
Four-Anti strategy,included,anti-shock infection,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
strategy,included,anti-shock infection,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
Four-Anti strategy,included,maintaining of water,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
strategy,included,maintaining of water,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
Four-Anti strategy,included,infection,"The ""Four-Anti and Two-Balance""strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance."
repeated fever,should,should patients,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
elevated procalcitonin,should,should patients,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
should concerned.Some patients,is with,COVID-19,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
patients,is with,long course of disease,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
procalcitonin,should,should patients,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
should patients,showed,microbialdysbiosis,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
intestinal microbialdysbiosis,is with,decreasedprobiotics such Lactobacillus,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
fever,should,should patients,"Antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbialdysbiosis with decreasedprobiotics such as Lactobacillus and Bifidobacterium."
reduce,risk of,secondary infection,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of secondary infection,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,secondary infection due to translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,secondary infection due,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of infection due to bacterial translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of infection,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of secondary infection due,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of secondary infection due to translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,infection,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,infection due,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of infection due,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,infection due to bacterial translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,infection due to translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
reduce,risk of,secondary infection due to bacterial translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of infection due to translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
balance,reduce,risk of secondary infection due to bacterial translocation,Nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation.
fever,was,symptom,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was symptom Among,patients with pneumonia caused,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was common symptom Among,patients with pneumonia,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was common symptom Among,patients,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was symptom Among,patients with pneumonia caused by SARS-CoV-2,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was symptom Among,patients caused by SARS-CoV-2,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was common symptom Among,patients caused,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was symptom Among,patients caused,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was,common symptom,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was most common symptom Among,patients with pneumonia caused,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was symptom Among,patients with pneumonia,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was symptom Among,patients,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was most common symptom Among,patients,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was most common symptom Among,patients caused,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was most common symptom Among,patients with pneumonia,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was,most common symptom,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was common symptom Among,patients with pneumonia caused by SARS-CoV-2,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
patients,is with,pneumonia,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was common symptom Among,patients caused by SARS-CoV-2,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was most common symptom Among,patients with pneumonia caused by SARS-CoV-2,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was common symptom Among,patients with pneumonia caused,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,followed by,cough,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
fever,was most common symptom Among,patients caused by SARS-CoV-2,"Among the patients with pneumonia caused by the SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough."
Poor factors,include,Multilobular infiltration,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor prognostic factors,include,infiltration on chest imaging,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor prognostic factors,include,Multilobular infiltration on chest imaging,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor factors,include,infiltration on chest imaging,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor factors,include,Multilobular infiltration on chest imaging,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor prognostic factors,include,Multilobular infiltration,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor prognostic factors,include,infiltration,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Poor factors,include,infiltration,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
Hypertension,like conditions is,MuLBSTA score,"Poor prognostic factors include Multilobular infiltration on chest imaging, Lymphopenia, Bacterial co-infection, Smoking history, Chronic medical conditions like Hypertension and age >60 years (MuLBSTA score)."
tract,manifests as,pneumonia in humans,"Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is a betacoronavirus that affects the lower respiratory tract and manifests as pneumonia in humans."
respiratory tract,manifests as,pneumonia in humans,"Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is a betacoronavirus that affects the lower respiratory tract and manifests as pneumonia in humans."
pneumonia,is in,humans,"Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is a betacoronavirus that affects the lower respiratory tract and manifests as pneumonia in humans."
tract,manifests as,pneumonia,"Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is a betacoronavirus that affects the lower respiratory tract and manifests as pneumonia in humans."
respiratory tract,manifests as,pneumonia,"Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is a betacoronavirus that affects the lower respiratory tract and manifests as pneumonia in humans."
Novel COVID-19-infected pneumonia,is,characterized,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
COVID-19-infected pneumonia,is,characterized,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
Novel pneumonia,is characterized by,fever,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
pneumonia,is,characterized,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
Novel pneumonia,is,characterized,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
Novel COVID-19-infected pneumonia,is characterized by,fever,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
pneumonia,is characterized by,fever,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
COVID-19-infected pneumonia,is characterized by,fever,"Novel COVID-19-infected pneumonia (NCIP) is characterized by fever, fatigue, dry cough, and dyspnea."
paper,reviewed,diseases,"Through literature review, this paper reviewed the oral psychosomatic diseases closely related to patients' psychological state, such as oral mucosal disease, temporomandibular joint disease, bruxism, periodontal disease and so on."
paper,reviewed diseases Through,literature review,"Through literature review, this paper reviewed the oral psychosomatic diseases closely related to patients' psychological state, such as oral mucosal disease, temporomandibular joint disease, bruxism, periodontal disease and so on."
human coronaviruses,be efficiently inactivated by,surface disinfection procedures with 62,"The analysis of 22 studies reveals that human coronaviruses such as Severe Acute Respiratory Syndrome (SARS) coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus or endemic human coronaviruses (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be efficiently inactivated by surface disinfection procedures with 62â€“71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute."
coronaviruses,be efficiently inactivated by,surface disinfection procedures with 62,"The analysis of 22 studies reveals that human coronaviruses such as Severe Acute Respiratory Syndrome (SARS) coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus or endemic human coronaviruses (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be efficiently inactivated by surface disinfection procedures with 62â€“71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute."
cough,were,symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
82,had,C reactive protein,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
cough,were,common symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
82,had,elevated C reactive protein,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
Fever,were,most common symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
expectoration,were,symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
expectoration,were,most common symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
cough,were,most common symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
82,had,C protein,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
33,had,leukopenia,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
patients,had decreased,oxygen saturation,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
Fever,were,symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
expectoration,were,common symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
14 patients,had decreased,oxygen saturation,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
53,had,lymphopenia,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
Fever,were,common symptoms,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
82,had,elevated C protein,"Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C reactive protein."
chest,familiarize clinicians with,imaging manifestations of new outbreak,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed severe acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed severe syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed severe respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed severe acute syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize,clinicians,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with severe acute syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize radiologists with,imaging manifestations of outbreak,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize radiologists with,imaging manifestations,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize clinicians with,imaging manifestations of outbreak,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with severe respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize clinicians with,imaging manifestations,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
colleagues,have written to,Journal,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed,tomography findings,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed severe acute syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with severe syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed severe respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed severe syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed acute syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
cases,is with,microbiologically confirmed severe acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with acute syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize,radiologists,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,familiarize radiologists with,imaging manifestations of new outbreak,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with microbiologically confirmed acute syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with confirmed acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
chest,computed tomography findings in,cases with severe acute respiratory syndrome coronavirus 2,"and colleagues have written to this Journal describing the emergence of 2019 novel coronavirus disease (COVID-19).1 We have had an opportunity to examine in detail the chest computed tomography (CT) findings in cases with microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to familiarize radiologists and clinicians with the imaging manifestations of this new outbreak."
None,had,underlying diseases,"None of the patients had underlying diseases such as diabetes, malignant tumour or respiratory disease."
None,had,diseases,"None of the patients had underlying diseases such as diabetes, malignant tumour or respiratory disease."
presence,was,confirmed,"The presence of lymphopenia as a signature of severe COVID-19 was confirmed by Wang D et al, who, in their study published in JAMA, reported that ICU patients suffering this infection had a median lymphocyte count of 800 cells/mm,3 with non survivors exhibiting persistent lymphopenia.4 ICU patients present also with high levels of plasma cytokines.2 The existence of hyper-cytokinemia in COVID-19 patients with lymphopenia could indicate a poor control of the pathogen, as showed in severe patients infected with the 2009 Pandemic Influenza virus."
et al,indicate,control,"The presence of lymphopenia as a signature of severe COVID-19 was confirmed by Wang D et al, who, in their study published in JAMA, reported that ICU patients suffering this infection had a median lymphocyte count of 800 cells/mm,3 with non survivors exhibiting persistent lymphopenia.4 ICU patients present also with high levels of plasma cytokines.2 The existence of hyper-cytokinemia in COVID-19 patients with lymphopenia could indicate a poor control of the pathogen, as showed in severe patients infected with the 2009 Pandemic Influenza virus."
lymphopenia,were,also evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were also evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,Interestingly were also evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,Interestingly were also evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were,evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were,Interestingly also evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,Interestingly were evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
critical patients,is with,Severe Acute Respiratory Syndrome,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were,Interestingly evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,Interestingly were also evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were also evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,Interestingly were evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were also evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,Interestingly were evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were,Interestingly also evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were also evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were,also evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,were,Interestingly evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
lymphopenia,Interestingly were evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were evident due to,Coronavirus emerged,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
dysregulated immunological response .7,is In,their works,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,were,evident,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
hypercytokinemia,Interestingly were also evident due to,Coronavirus,"Interestingly, hypercytokinemia and lymphopenia were also evident in critical patients with Severe Acute Respiratory Syndrome due to the Coronavirus emerged in 2003 (SARS-CoV).5,6 These features (lymphopeniaâ€¯+â€¯hypercytokinemia) fit the characteristics of a particular immunological phenotype of community acquired pneumonia (CAP), lymphopenic CAP (L-CAP), which, as we recently demonstrated in an article published in the Journal of Infection, is associated with increased severity, mortality and a dysregulated immunological response.7 In their works, Yang X et al and Chen N et al propose a direct cytotoxic action of the virus to explain the low lymphocyte counts observed in the severe cases of COVID-19.3,8 But, in our opinion, host factors could also contribute to induce lymphopenia in these cases."
chronic diseases,induce,dysfunction,"Compared with those patients not requiring intensive care, COVID-19 patients admitted to the ICU are older and are more likely to have hypertension, diabetes, cardiovascular and cerebrovascular disease.4 Aging and chronic diseases induce chronic endothelial dysfunction."
chronic diseases,induce,chronic endothelial dysfunction,"Compared with those patients not requiring intensive care, COVID-19 patients admitted to the ICU are older and are more likely to have hypertension, diabetes, cardiovascular and cerebrovascular disease.4 Aging and chronic diseases induce chronic endothelial dysfunction."
chronic diseases,induce,endothelial dysfunction,"Compared with those patients not requiring intensive care, COVID-19 patients admitted to the ICU are older and are more likely to have hypertension, diabetes, cardiovascular and cerebrovascular disease.4 Aging and chronic diseases induce chronic endothelial dysfunction."
COVID-19 patients,admitted to,ICU,"Compared with those patients not requiring intensive care, COVID-19 patients admitted to the ICU are older and are more likely to have hypertension, diabetes, cardiovascular and cerebrovascular disease.4 Aging and chronic diseases induce chronic endothelial dysfunction."
COVID-19 patients admitted,are,older,"Compared with those patients not requiring intensive care, COVID-19 patients admitted to the ICU are older and are more likely to have hypertension, diabetes, cardiovascular and cerebrovascular disease.4 Aging and chronic diseases induce chronic endothelial dysfunction."
chronic diseases,induce,chronic dysfunction,"Compared with those patients not requiring intensive care, COVID-19 patients admitted to the ICU are older and are more likely to have hypertension, diabetes, cardiovascular and cerebrovascular disease.4 Aging and chronic diseases induce chronic endothelial dysfunction."
extravasation,explain,lymphopenia observed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces disassembly,we recently reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces disassembly,we reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces,we recently reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces,we reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,severe failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces disassembly,we reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces,we recently reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces disassembly,we recently reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces,we reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces disassembly,we reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,respiratory failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,respiratory failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
aged individuals,is with,chronic diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
extravasation,explain,lymphopenia,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,severe failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces disassembly,we recently reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along with,pro-coagulant state .9,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along In,aged individuals with diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along with,state .9,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,severe respiratory failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along In,individuals with diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along In,aged individuals with chronic diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,severe respiratory failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,respiratory failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,severe failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces,we recently reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along with,state .9,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along In,individuals with chronic diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,severe respiratory failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along In,aged individuals with chronic diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces,we reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
predisposing factors,presenting,failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,respiratory failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along with,pro-coagulant state .9,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along In,individuals with chronic diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along In,aged individuals,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along In,aged individuals with diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,severe failure following COVID-19 infection,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
interconnection,is in,patients with CAP,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces,we reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along In,individuals with diseases,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
inflammation,shedding along In,individuals,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces,we recently reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
factors,presenting,severe respiratory failure,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along In,aged individuals,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
dysfunction,induces disassembly,we recently reviewed in J Clin Med,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
endothelial dysfunction,induces disassembly,we reviewed,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
patients,is with,CAP,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
systemic inflammation,shedding along In,individuals,"As we recently reviewed in J Clin Med, endothelial dysfunction induces disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explain the lymphopenia observed in severe COVID-19 patients.9 Recent findings from our group have evidenced the interconnection between lymphopenia and endothelial dysfunction in patients with CAP and organ failure.10 Endothelial dysfunction induces also increased oxidative stress and systemic inflammation, glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state.9 In aged individuals with chronic diseases, these features could represent predisposing factors for presenting a severe respiratory failure following COVID-19 infection."
viral pneumonia,is with,unusual outbreak in Wuhan,"Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
kind,is in,Dec-19,"Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
unusual outbreak,is in,Wuhan,"Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
parameters,included,lobe,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
parameters,left,lung,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
whole lung,of density is,HU,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
parameters,mean,lesion density of lung,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
parameters,mean,HU,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
parameters,mean,lesion density,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
parameters,mean,lesion density of whole lung,"The parameters obtained using the computer tool included lung volume (mL), lesion volume (mL), lesion percentage (%), and mean lesion density (HU) of the whole lung, right lung, left lung, and each lobe."
Result results,showed,strong lesion density,"Result The results showed a strong to moderate correlation between lesion percentage scores obtained by radiologists and the computer software (r ranged from 0.7679 to 0.8373, Pâ€¯<â€¯0.05), and a moderate correlation between the proportion of GGO and mean lesion density (râ€¯=â€¯âˆ’0.5894, Pâ€¯<â€¯0.05), and proportion of consolidation and mean lesion density (râ€¯=â€¯0.6282, Pâ€¯<â€¯0.05)."
Result results,showed,strong to moderate correlation lesion density,"Result The results showed a strong to moderate correlation between lesion percentage scores obtained by radiologists and the computer software (r ranged from 0.7679 to 0.8373, Pâ€¯<â€¯0.05), and a moderate correlation between the proportion of GGO and mean lesion density (râ€¯=â€¯âˆ’0.5894, Pâ€¯<â€¯0.05), and proportion of consolidation and mean lesion density (râ€¯=â€¯0.6282, Pâ€¯<â€¯0.05)."
Result results,showed,strong to correlation lesion density,"Result The results showed a strong to moderate correlation between lesion percentage scores obtained by radiologists and the computer software (r ranged from 0.7679 to 0.8373, Pâ€¯<â€¯0.05), and a moderate correlation between the proportion of GGO and mean lesion density (râ€¯=â€¯âˆ’0.5894, Pâ€¯<â€¯0.05), and proportion of consolidation and mean lesion density (râ€¯=â€¯0.6282, Pâ€¯<â€¯0.05)."
Result results,showed,lesion density,"Result The results showed a strong to moderate correlation between lesion percentage scores obtained by radiologists and the computer software (r ranged from 0.7679 to 0.8373, Pâ€¯<â€¯0.05), and a moderate correlation between the proportion of GGO and mean lesion density (râ€¯=â€¯âˆ’0.5894, Pâ€¯<â€¯0.05), and proportion of consolidation and mean lesion density (râ€¯=â€¯0.6282, Pâ€¯<â€¯0.05)."
author,formulates,prevention management strategy,"In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."
author,of,unit,"In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."
author,provide,reference,"In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."
medical evidence,is In,paper,"In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."
key clinical problems,is in,hospital during epidemic period of NCP infection,"In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."
author,formulates,prevention management strategy of author 's unit,"In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."
results,suggest,effectiveness as drugs against emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,potent drugs against newly emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,potent drugs against HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,drugs against newly emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as drugs against emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,drugs against emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as drugs against HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as potent drugs against HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as potent drugs against emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,drugs,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,drugs against HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as potent drugs against emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,potent drugs,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness of,Sofosbuvir,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as drugs,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as drugs against newly emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as drugs against newly emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as potent drugs against HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,effectiveness as,potent drugs against emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as potent drugs,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as potent drugs,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness as potent drugs against newly emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as drugs against HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as potent drugs against newly emerged HCoV disease,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
results,suggest,effectiveness of Sofosbuvir as drugs,"Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease."
estimated mortality,is In,light of impact,"Infectious diseases, in particular pandemics and local epidemics, have influenced the course of wars, all descendants, including those of rulers, and the fate of peoples and nations.1 By way of example, we should remember the importance of malaria in the fall of the Roman Empire, the Black Death in the 14th century which killed nearly a third of the worldâ€™s population, and the impact of the â€œSpanishâ€ flu pandemic of 1918â€“19 in Portugal, which in a few months decimated 1% of the Portuguese population and reduced average life expectancy to 20 years and, more recently, smallpox, declared eradicated by the World Health Organization (WHO) in 1980 as a result of vaccination,2 and with an estimated mortality in the 20th century of between 300 and 500 million people.3 In light of this impact, it is legitimate to consider infections one of the main modellers of mankind and of present and future generations, as well as generations of the descendants of survivors."
estimated mortality,is in,20th century of between 300,"Infectious diseases, in particular pandemics and local epidemics, have influenced the course of wars, all descendants, including those of rulers, and the fate of peoples and nations.1 By way of example, we should remember the importance of malaria in the fall of the Roman Empire, the Black Death in the 14th century which killed nearly a third of the worldâ€™s population, and the impact of the â€œSpanishâ€ flu pandemic of 1918â€“19 in Portugal, which in a few months decimated 1% of the Portuguese population and reduced average life expectancy to 20 years and, more recently, smallpox, declared eradicated by the World Health Organization (WHO) in 1980 as a result of vaccination,2 and with an estimated mortality in the 20th century of between 300 and 500 million people.3 In light of this impact, it is legitimate to consider infections one of the main modellers of mankind and of present and future generations, as well as generations of the descendants of survivors."
importance,is in,fall of Roman Empire,"Infectious diseases, in particular pandemics and local epidemics, have influenced the course of wars, all descendants, including those of rulers, and the fate of peoples and nations.1 By way of example, we should remember the importance of malaria in the fall of the Roman Empire, the Black Death in the 14th century which killed nearly a third of the worldâ€™s population, and the impact of the â€œSpanishâ€ flu pandemic of 1918â€“19 in Portugal, which in a few months decimated 1% of the Portuguese population and reduced average life expectancy to 20 years and, more recently, smallpox, declared eradicated by the World Health Organization (WHO) in 1980 as a result of vaccination,2 and with an estimated mortality in the 20th century of between 300 and 500 million people.3 In light of this impact, it is legitimate to consider infections one of the main modellers of mankind and of present and future generations, as well as generations of the descendants of survivors."
Death,is in,14th century,"Infectious diseases, in particular pandemics and local epidemics, have influenced the course of wars, all descendants, including those of rulers, and the fate of peoples and nations.1 By way of example, we should remember the importance of malaria in the fall of the Roman Empire, the Black Death in the 14th century which killed nearly a third of the worldâ€™s population, and the impact of the â€œSpanishâ€ flu pandemic of 1918â€“19 in Portugal, which in a few months decimated 1% of the Portuguese population and reduced average life expectancy to 20 years and, more recently, smallpox, declared eradicated by the World Health Organization (WHO) in 1980 as a result of vaccination,2 and with an estimated mortality in the 20th century of between 300 and 500 million people.3 In light of this impact, it is legitimate to consider infections one of the main modellers of mankind and of present and future generations, as well as generations of the descendants of survivors."
Infectious diseases,is in,particular pandemics,"Infectious diseases, in particular pandemics and local epidemics, have influenced the course of wars, all descendants, including those of rulers, and the fate of peoples and nations.1 By way of example, we should remember the importance of malaria in the fall of the Roman Empire, the Black Death in the 14th century which killed nearly a third of the worldâ€™s population, and the impact of the â€œSpanishâ€ flu pandemic of 1918â€“19 in Portugal, which in a few months decimated 1% of the Portuguese population and reduced average life expectancy to 20 years and, more recently, smallpox, declared eradicated by the World Health Organization (WHO) in 1980 as a result of vaccination,2 and with an estimated mortality in the 20th century of between 300 and 500 million people.3 In light of this impact, it is legitimate to consider infections one of the main modellers of mankind and of present and future generations, as well as generations of the descendants of survivors."
world,of,population,"Infectious diseases, in particular pandemics and local epidemics, have influenced the course of wars, all descendants, including those of rulers, and the fate of peoples and nations.1 By way of example, we should remember the importance of malaria in the fall of the Roman Empire, the Black Death in the 14th century which killed nearly a third of the worldâ€™s population, and the impact of the â€œSpanishâ€ flu pandemic of 1918â€“19 in Portugal, which in a few months decimated 1% of the Portuguese population and reduced average life expectancy to 20 years and, more recently, smallpox, declared eradicated by the World Health Organization (WHO) in 1980 as a result of vaccination,2 and with an estimated mortality in the 20th century of between 300 and 500 million people.3 In light of this impact, it is legitimate to consider infections one of the main modellers of mankind and of present and future generations, as well as generations of the descendants of survivors."
8 cases,is with,lesion,"As for the lesion distribution, there were two cases with bilateral diffuse changes, 57 cases with multiple lesions, 8 cases with the lesion in only one lobe."
8 cases,is in,only one lobe,"As for the lesion distribution, there were two cases with bilateral diffuse changes, 57 cases with multiple lesions, 8 cases with the lesion in only one lobe."
57 cases,is with,multiple lesions,"As for the lesion distribution, there were two cases with bilateral diffuse changes, 57 cases with multiple lesions, 8 cases with the lesion in only one lobe."
Porcine epidemic diarrhea,causes,acute diarrhea,"Porcine epidemic diarrhea (PED), induced by porcine epidemic diarrhea virus (PEDV) causes acute diarrhea, vomiting, dehydration and high mortality in neonatal piglets, resulting in significant economic losses in the pig industries."
significant economic losses,is in,pig industries,"Porcine epidemic diarrhea (PED), induced by porcine epidemic diarrhea virus (PEDV) causes acute diarrhea, vomiting, dehydration and high mortality in neonatal piglets, resulting in significant economic losses in the pig industries."
Porcine diarrhea,causes,diarrhea,"Porcine epidemic diarrhea (PED), induced by porcine epidemic diarrhea virus (PEDV) causes acute diarrhea, vomiting, dehydration and high mortality in neonatal piglets, resulting in significant economic losses in the pig industries."
high mortality,is in,neonatal piglets,"Porcine epidemic diarrhea (PED), induced by porcine epidemic diarrhea virus (PEDV) causes acute diarrhea, vomiting, dehydration and high mortality in neonatal piglets, resulting in significant economic losses in the pig industries."
Porcine epidemic diarrhea,causes,diarrhea,"Porcine epidemic diarrhea (PED), induced by porcine epidemic diarrhea virus (PEDV) causes acute diarrhea, vomiting, dehydration and high mortality in neonatal piglets, resulting in significant economic losses in the pig industries."
Porcine diarrhea,causes,acute diarrhea,"Porcine epidemic diarrhea (PED), induced by porcine epidemic diarrhea virus (PEDV) causes acute diarrhea, vomiting, dehydration and high mortality in neonatal piglets, resulting in significant economic losses in the pig industries."
dry cough,are symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
fatigue,are,symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are common symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are,symptoms at onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are,common symptoms at onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
fatigue,are common symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are common symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are,symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are,symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are common symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are,common symptoms at onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are,common symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are,symptoms at onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are common symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are,common symptoms at onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
fatigue,are symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are,symptoms at onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are,common symptoms at onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are,common symptoms at onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
fatigue,are,common symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
fatigue,are common symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are,common symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are,symptoms at onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
fatigue,are symptoms at,onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are,symptoms at onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are,common symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
Fever,are common symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are common symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are,symptoms,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are,common symptoms at onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
dry cough,are,symptoms at onset of COVID-194,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
cough,are symptoms at,onset,"Fever, dry cough, and fatigue are common symptoms at onset of COVID-194."
41,of men is,30 73 %,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
infected patients,Most of were,men,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
diabetes,including 13 is,32%,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
Most,were men of,41,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
patients,Most of were,men,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
half,had,diseases,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
Most,were,men,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
half,had,underlying diseases,"Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%])."
symptoms,were,fever,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
Common symptoms,were,fever,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
39,of production is,11 28 %,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
41 patients,of fever is,cough,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
41 patients,of fever is,40 98 %,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
38,of one is,3%,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
symptoms,were fever of,41 patients,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
Common symptoms,were fever of,41 patients,"Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38)."
Complications,included,distress syndrome,"Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%])."
Complications,included,acute distress syndrome,"Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%])."
Complications,included,acute respiratory distress syndrome,"Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%])."
Complications,included,respiratory distress syndrome,"Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%])."
ICU patients,had plasma levels Compared with,non-ICU patients,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
ICU patients,had,plasma levels,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
ICU patients,had plasma levels Compared with,patients,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
ICU patients,had,plasma levels of IL2,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
ICU patients,had,higher plasma levels of IL2,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
ICU patients,had,higher plasma levels,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to severe syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to severe acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to severe acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to severe respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to severe syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to severe respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to severe respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to severe acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to severe acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to severe acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to severe acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to severe respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to severe acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar to acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,was,associated,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar to severe syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to acute respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,was associated with,ICU admission,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to respiratory syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe respiratory illness similar to severe syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of respiratory illness similar,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of severe illness similar,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
2019-nCoV infection,caused,clusters of illness similar to acute syndrome coronavirus,"Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFÎ±.|The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality."
proportion,was higher than,that in group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher than,that in non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher than,that,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,is in,severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,higher,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,Among symptoms higher than that,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher than,that in non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher Among,concomitant symptoms,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,Among concomitant symptoms higher than that,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,higher,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher than,that in group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,Among symptoms higher than that in group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,Among concomitant symptoms higher than that in group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,Among symptoms higher than that in non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher than,that,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was higher Among,symptoms,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,is in,severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
proportion,was,Among concomitant symptoms higher than that in non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
CD 4,was lower than,that,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
protein,were,higher,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
number,is in,severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
CD 4,was,lower,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
CD 4,number in,severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
CD 4,was lower than,that in non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
CD 4,was lower than,that in group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
right lung,were susceptible Compared with,non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
lung,were,more susceptible,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
right lung,were more susceptible Compared with,non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
lung,were,susceptible,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
lung,were susceptible Compared with,group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
lung,were more susceptible Compared with,group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
right lung,were susceptible Compared with,group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
lung,were susceptible Compared with,non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
right lung,were,more susceptible,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
lung,were more susceptible Compared with,non-severe group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
right lung,were,susceptible,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
right lung,were more susceptible Compared with,group,"No symptoms were found in patients with mild illness ( &chi; 2 =4.09, P &lt;0.05) .The proportion of fever and muscle soreness in the severe group was higher than that in the non-severe group ( &chi; 2 =4.40 and 22.67, P &lt;0.05).Among the concomitant symptoms, the proportion of cough and shortness of breath in the severe group was higher than that in the non-severe group ( &chi; 2 =8.46 and 4.80, P &lt;0.05).C-reactive protein and d-dimer were higher in the severe group than in the non-severe group ( t =43.44 and 37.13, P &lt;0.05), and the number of CD 3 + T lymphocyte cells, CD 4 + T lymphocyte cells and CD 8 + T lymphocyte cells in the severe group was lower than that in the non-severe group (Z=27.25, 20.60 and 17.36, P &lt;0.05).Compared with the non-severe group, both lungs and the right lung lower lobe were more susceptible to involved ( &chi; 2 =6.95&#21644;20.39, P &lt;0.05) ."
patients,may have,shock,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
respiratory distress syndrome septic shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,acute respiratory distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,acute distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,respiratory distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,septic shock,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
acute distress syndrome septic shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,acute distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
distress syndrome septic shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
acute respiratory distress syndrome shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,acute respiratory distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,septic shock,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
respiratory distress syndrome shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,acute respiratory distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,shock,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,acute respiratory distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
distress syndrome shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,acute distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
acute respiratory distress syndrome septic shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
People,suffer from,fever,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,respiratory distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,respiratory distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
acute distress syndrome shock,leading to,death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,acute distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,acute respiratory distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,acute respiratory distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,respiratory distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,acute distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,respiratory distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,respiratory distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,distress syndrome,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
patients,may have,acute distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,distress syndrome leading to death,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
severe patients,may have,distress syndrome leading,"People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death."
myalgia,is in,three,"Other symptoms, including cough (in four of nine patients), myalgia (in three), sore throat (in two), and malaise (in two), were also observed."
sore throat,is in,two,"Other symptoms, including cough (in four of nine patients), myalgia (in three), sore throat (in two), and malaise (in two), were also observed."
malaise,is in,two,"Other symptoms, including cough (in four of nine patients), myalgia (in three), sore throat (in two), and malaise (in two), were also observed."
public,use of,SARS,"We have read with great interest the Correspondence by Shibo Jiang and colleagues,1 in which they propose a name change for the newly emerged coronavirus,2 which was recently designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses.3 The authors argued that the use of SARS in the virus name could confuse the public about the disease that it causes; in addition, they noted that the name SARS-CoV-2 is not consistent with the disease name chosen by WHO, coronavirus disease 2019."
Taxonomy,on coronavirus is,SARS-CoV-2,"We have read with great interest the Correspondence by Shibo Jiang and colleagues,1 in which they propose a name change for the newly emerged coronavirus,2 which was recently designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses.3 The authors argued that the use of SARS in the virus name could confuse the public about the disease that it causes; in addition, they noted that the name SARS-CoV-2 is not consistent with the disease name chosen by WHO, coronavirus disease 2019."
use,confuse,public,"We have read with great interest the Correspondence by Shibo Jiang and colleagues,1 in which they propose a name change for the newly emerged coronavirus,2 which was recently designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses.3 The authors argued that the use of SARS in the virus name could confuse the public about the disease that it causes; in addition, they noted that the name SARS-CoV-2 is not consistent with the disease name chosen by WHO, coronavirus disease 2019."
public,use in,virus name,"We have read with great interest the Correspondence by Shibo Jiang and colleagues,1 in which they propose a name change for the newly emerged coronavirus,2 which was recently designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses.3 The authors argued that the use of SARS in the virus name could confuse the public about the disease that it causes; in addition, they noted that the name SARS-CoV-2 is not consistent with the disease name chosen by WHO, coronavirus disease 2019."
Coronavirus Study Group,by coronavirus is,SARS-CoV-2,"We have read with great interest the Correspondence by Shibo Jiang and colleagues,1 in which they propose a name change for the newly emerged coronavirus,2 which was recently designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses.3 The authors argued that the use of SARS in the virus name could confuse the public about the disease that it causes; in addition, they noted that the name SARS-CoV-2 is not consistent with the disease name chosen by WHO, coronavirus disease 2019."
use,is in,virus name,"We have read with great interest the Correspondence by Shibo Jiang and colleagues,1 in which they propose a name change for the newly emerged coronavirus,2 which was recently designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses.3 The authors argued that the use of SARS in the virus name could confuse the public about the disease that it causes; in addition, they noted that the name SARS-CoV-2 is not consistent with the disease name chosen by WHO, coronavirus disease 2019."
Fever,was,symptom in 49 of 58 patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
fever,was,symptom,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was,first symptom,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was first symptom of,58 patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was first symptom in,49,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was first symptom of,58 patients with NCP,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was symptom of,58 patients with NCP,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
49,in symptom is,84%,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was,symptom in 49 of 58 patients with NCP,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
first symptom,is in,severe NCP patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
fever,was symptom in,severe NCP patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
first symptom,is in,49,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
fever,was,first symptom,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
58 patients,of symptom is,84%,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
fever,was symptom in,NCP patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
fever,was first symptom in,severe NCP patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was symptom in,49,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
fever,was first symptom in,NCP patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was,first symptom in 49 of 58 patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was symptom of,58 patients,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
58 patients,is with,NCP,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was,symptom,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
Fever,was,first symptom in 49 of 58 patients with NCP,"Fever was the first symptom in 49 (84%) of 58 patients with NCP, and fever was the first symptom in both severe and critical NCP patients."
heavy NCP,showed,patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed,multiple patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
severe NCP,showed,double lung lesions,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed lung In,terms,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed,double lung lesions,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
heavy NCP,showed,multiple patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
heavy NCP,mainly showed,multiple patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
heavy NCP,mainly showed,patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,mainly showed,patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
heavy NCP,mainly showed,"33 36,92 %","In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,mainly showed,multiple patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed,lung,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
common NCP,showed,lung,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed,lung lesions,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
common NCP,showed lung In,terms of CT findings,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,mainly showed,"33 36,92 %","In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed,patches,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
heavy NCP,showed,"33 36,92 %","In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
severe NCP,showed,lung lesions,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed lung In,terms of CT findings,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
NCP,showed,"33 36,92 %","In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
common NCP,showed lung In,terms,"In terms of CT findings, common NCP showed double lung (40/58,71%) multiple (40 / 58,69%) ground glass (31/58,52%) or mixed (25 / 58,43%) lesions (56 / 58,97%); severe and critical NCP showed double lung lesions, heavy NCP mainly showed multiple (34 / 36,96%) patches (33 / 36,92%) mixed density lesions (26 / 36,72%); 9 severe NCP lesions were more than 3 cm Mixed density lesions."
patients,were more likely,higher than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
cohort,is with,COVID-19,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
authors,concluded by,use statistics,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher in cohort than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,is with,cancer,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were,likely,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher in cohort than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was higher in,cohort with COVID-19,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher in cohort with COVID-19,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher in cohort than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher in cohort with COVID-19 than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
authors,concluded by,use epidemiological statistics,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher in cohort,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was,higher,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
authors,concluded by,use,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was,higher in cohort with COVID-19 than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,is with,cancer histories,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher in cohort,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was,higher in cohort with COVID-19 than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was,higher in cohort than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were,more likely,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,develop,COVID-19,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was higher than,than population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
than population,is in,China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was higher than,than population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher in cohort with COVID-19,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher in cohort than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was,higher in cohort than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher in cohort with COVID-19 than in population in China,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
proportion,was higher in,cohort,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were more likely,higher in cohort with COVID-19 than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
patients,were likely,higher in cohort with COVID-19 than in population,"The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19."
everyone,is,susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is,contagious infection,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
age,is associated with,worse COVID-19 outcomes,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
patients,had,outcomes from COVID-19,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is contagious infection,susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
important morbidity factor,is,exposure,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
patients,is with,cancer,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
patients,had,outcomes,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
outcomes,patients with,cancer,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is contagious infection,to our knowledge susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is highly contagious infection,susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
patients,had,worse outcomes from COVID-19,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is,highly contagious infection,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
age,is associated with,COVID-19 outcomes,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is,infection,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
everyone,is susceptible to,our knowledge,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
age,is,associated,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
older age,is associated with,COVID-19 outcomes,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
older age,is associated with,worse COVID-19 outcomes,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
patients,had,worse outcomes,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is highly contagious infection,to our knowledge susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is infection,susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is infection,to our knowledge susceptible,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
worse outcomes,patients with,cancer,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
older age,is,associated,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
COVID-19,is,contagious,"COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source.2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63Â·1 years) to be significantly higher than for those without cancer (48Â·7 years), suggesting that older age is associated with worse COVID-19 outcomes"
risk,patients with,cancer,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
patients,had,higher risk,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
patients,had,risk,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
higher risk,patients with,cancer,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
patients,had,higher risk of COVID-19,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
patients,is with,cancer,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
patients,had,risk of COVID-19,The authors concluded that patients with cancer had a higher risk of COVID-19 and with a poorer prognosis than those without cancer.
whole population,is with,cancer,"Second, we reviewed the cancer history of the 18 individuals discussed in Liang and colleagues' Comment.1 We are concerned that such a small sample size with a large amount of heterogeneity, presenting as various cancer types with different biological behaviours, highly variable disease courses (from 0â€“16 years), and diverse treatment strategies, might be filled with contingency and thus not ideally representative of the whole population with cancer."
size,is with,large amount of heterogeneity,"Second, we reviewed the cancer history of the 18 individuals discussed in Liang and colleagues' Comment.1 We are concerned that such a small sample size with a large amount of heterogeneity, presenting as various cancer types with different biological behaviours, highly variable disease courses (from 0â€“16 years), and diverse treatment strategies, might be filled with contingency and thus not ideally representative of the whole population with cancer."
various cancer types,is with,different biological behaviours,"Second, we reviewed the cancer history of the 18 individuals discussed in Liang and colleagues' Comment.1 We are concerned that such a small sample size with a large amount of heterogeneity, presenting as various cancer types with different biological behaviours, highly variable disease courses (from 0â€“16 years), and diverse treatment strategies, might be filled with contingency and thus not ideally representative of the whole population with cancer."
patients,is with,coronavirus disease 2019,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
Summary Background cluster,were successively reported in,Wuhan,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
Summary Background cluster,were successively reported in,China,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
Summary Background cluster,were reported in,China,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
Summary Background cluster,were,reported,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
Summary Background cluster,were reported in,Wuhan,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
Summary Background cluster,were,successively reported,"Summary Background A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China."
differences,will determine,are striking similarities between SARS,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
same measures,be successful for,COVID-19,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will ultimately determine,are similarities,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
measures,also be successful for,COVID-19,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
same measures,be,also successful,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will determine,are similarities,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
same measures,be,successful,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will determine,are striking similarities,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will determine,are similarities between SARS,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
measures,be,also successful,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
same measures,also be successful for,COVID-19,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will ultimately determine,are striking similarities,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will ultimately determine,are striking similarities between SARS,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,is in,virus characteristics,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
measures,be successful for,COVID-19,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
measures,be,successful,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
differences,will ultimately determine,are similarities between SARS,"Although there are striking similarities between SARS and COVID-19, the differences in the virus characteristics will ultimately determine whether the same measures for SARS will also be successful for COVID-19."
clinical trials,are urgently required in,health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are,required,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are urgently required in,urgent health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
development,is,urgent,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are,urgently required,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are required in,health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
vaccine,development of is,urgent public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
development,is in,urgent health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
vaccine,development of is,urgent health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are urgently required in,urgent public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are required in,urgent health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
development,is in,health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are required in,health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are urgently required in,health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are required in,urgent public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
development,is in,public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are required in,public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are,urgently required,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
patients,is with,COVID-19.9 Care,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
development,is in,urgent public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
vaccine,development of is,health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
trials,are urgently required in,public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are required in,urgent health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are required in,urgent public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are urgently required in,urgent public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are urgently required in,public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are,required,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are urgently required in,urgent health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
development,is,public,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
clinical trials,are required in,public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
vaccine,development of is,public health priority,"Despite this, there have been reports of the use of oseltamivir, lopinavir/ritonavir, prednisone, antibiotics, and traditional Chinese medicine for the treatment of patients with COVID-19.9 Care should be taken to not give patients drugs of unknown efficacy, which might be detrimental to critically ill patients with COVID-19; clinical trials are urgently required in this context.10 Likewise, the development of a vaccine is an urgent public health priority."
Coronaviruses,responsible for,severe respiratory syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
health-care community,be,prepared,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
transmission,has,has suspected in one case .3 Consequences,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
health-care community,be prepared for,worst-case scenario .5,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
transmission,has,has suspected in one case .3 Consequences of infection with SARS-CoV-2,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
perinatal transmission,has,has suspected in one case .3 Consequences of infection,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
perinatal transmission,has,has suspected,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
transmission,has,has suspected in one case .3 Consequences of infection with SARS-CoV-2 for pregnancies,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
possibility,be,should considered,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
health-care community,be prepared for,worst-case scenario .5 Therefore,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
perinatal transmission,has,has suspected in one case .3 Consequences of infection with SARS-CoV-2,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
health-care community,be prepared for,scenario .5 Therefore,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
maternal death .1,transmission of,virus responsible for 2019 novel coronavirus disease,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,acute syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
infection,is with,SARS-CoV-2 for pregnancies,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,severe syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,severe acute syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
possibility,be,however should considered,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
perinatal transmission,has,has suspected in one case .3 Consequences of infection with SARS-CoV-2 for pregnancies,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,respiratory syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,severe acute respiratory syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,SARS,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
transmission,has,has suspected in one case .3 Consequences of infection,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
transmission,has,has suspected,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
.4 recent experience,is with,Zika virus,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
health-care community,be prepared for,scenario .5,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Coronaviruses,responsible for,acute respiratory syndrome,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
recommendations,are,urgently needed,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
perinatal transmission,has,has suspected in one case .3 Consequences,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
recommendations,are,needed,"Coronaviruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can cause severe adverse pregnancy outcomes, such as miscarriage, premature delivery, intrauterine growth restriction, and maternal death.1 , 2 Vertical transmission of the virus responsible for 2019 novel coronavirus disease (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not yet been detected, whereas perinatal transmission has been suspected in one case.3 Consequences of infection with SARS-CoV-2 for pregnancies are uncertain, with no evidence so far of severe outcomes for mothers and infants; however, the possibility should be considered.4 The recent experience with Zika virus suggests that when a new pathogen emerges, the health-care community should be prepared for the worst-case scenario.5 Therefore, recommendations for management of pregnant women at risk of SARS-CoV-2 infection are urgently needed."
Singapore,in patients is,causative virus of COVID-19,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
two patients,is with,false-positive results from rapid serological testing for dengue,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
false-positive results,with patients is,causative virus of COVID-19,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
two patients,virus of,COVID-19,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
two patients,is in,Singapore,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
Dengue,are,difficult,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
coronavirus,are,difficult,"Dengue and coronavirus disease 2019 (COVID-19) are difficult to distinguish because they have shared clinical and laboratory features.1 , 2 We describe two patients in Singapore with false-positive results from rapid serological testing for dengue, who were later confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative virus of COVID-19."
He,returned,worsening,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,worsening,89 Ã— 109/mL,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,returned with,persistent fever,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,returned to,primary health-care clinic,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,returned to,public primary health-care clinic,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,returned to,public health-care clinic,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,returned to,health-care clinic,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,returned with,fever,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,worsening,thrombocytopenia,"He returned to a public primary health-care clinic with persistent fever, worsening thrombocytopenia (89â€ˆÃ—â€ˆ109/mL), and new onset lymphopenia (0Â·43â€ˆÃ—â€ˆ109/mL)."
He,was referred for,dengue,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was referred for,dengue with cough,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was,referred to hospital for dengue with cough,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was,referred to hospital for dengue,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was referred for,dengue with worsening cough,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was,referred to hospital for dengue with worsening cough,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was referred to,hospital,He was referred to hospital for dengue with worsening cough and dyspnoea.
dengue,is with,worsening cough,He was referred to hospital for dengue with worsening cough and dyspnoea.
He,was,referred,He was referred to hospital for dengue with worsening cough and dyspnoea.
urine,tested,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
sample tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
sample,tested,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original sample urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original seropositive sample,tested,negative for dengue,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original seropositive sample urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
seropositive sample,tested,negative for dengue,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
additional urine,tested,negative for dengue,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original seropositive sample tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
sample,tested,negative for dengue,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original sample,tested,negative for dengue,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
additional urine,tested,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
seropositive sample,tested,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
seropositive sample tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
sample urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original seropositive sample,tested,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
additional urine,tested,blood samples,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original sample,tested,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
seropositive sample urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
sample additional urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original sample additional urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
urine,tested,negative for dengue,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
urine,tested,blood samples,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original sample tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
seropositive sample additional urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
original seropositive sample additional urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
additional urine tested,was,negative,"The original seropositive sample and additional urine and blood samples tested negative for dengue, chikungunya, and Zika viruses by RT-PCR,3 , 4 , 5 and a repeat dengue rapid test (SD Bioline) was also negative."
decrease,is in,duration of mechanical ventilation,"We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality."
effects,is in,ARDS,"We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality."
liver dysfunction,with 15 is,29%,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
Most patients,had,organ function damage,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
cardiac injury,with 12 is,23%,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
acute kidney injury,with 15 is,29%,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
patients,had,organ function damage,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
pneumothorax,with one is,2%,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
ARDS,with 35 is,67%,"Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax."
epidemiological features,are,similar,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
confirmed infection,is in,China .3,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
features,are,similar,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
emergence,has,parallels with 2003 outbreak,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
cause,are,similar,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
parallels,is with,2003 outbreak of severe acute respiratory syndrome,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
5327 patients,is with,confirmed infection in China .3,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
transmission pattern,are,similar,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
emergence,has,parallels,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
infectious cause,are,similar,"The emergence of the 2019-nCoV pneumonia has parallels with the 2003 outbreak of severe acute respiratory syndrome (SARS), which was caused by another coronavirus that killed 349 of 5327 patients with confirmed infection in China.3 Although the diseases have different clinical presentations, the infectious cause, epidemiological features, fast transmission pattern, and insufficient preparedness of health authorities to address the outbreaks are similar."
situation,is causing,mental health problems,"The severe situation is causing mental health problems such as stress, anxiety, depressive symptoms, insomnia, denial, anger, and fear."
severe situation,is causing,health problems,"The severe situation is causing mental health problems such as stress, anxiety, depressive symptoms, insomnia, denial, anger, and fear."
situation,is causing,health problems,"The severe situation is causing mental health problems such as stress, anxiety, depressive symptoms, insomnia, denial, anger, and fear."
severe situation,is causing,mental health problems,"The severe situation is causing mental health problems such as stress, anxiety, depressive symptoms, insomnia, denial, anger, and fear."
contact,tracing with,unprotected exposure,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
contact,tracing with,unprotected exposure in hospitals,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
infection isolation,was,implemented,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
early airborne infection isolation,was,implemented,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
31-Dec-19,is in,Hong Kong.Methods,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
contact,tracing for,healthcare workers,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
unprotected exposure,is in,hospitals,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
Hong Kong.Methods,in December is,day 1,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
cluster,is in,China,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
early infection isolation,was,implemented,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
contact,tracing for,HCWs,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
contact,tracing with,exposure,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
airborne infection isolation,was,implemented,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
contact,tracing with,exposure in hospitals,"Background:To describe the infection control preparedness for Coronavirus Disease (COVID-19) due to SARS-CoV-2 [previously known as 2019-novel coronavirus] in the first 42 days after announcement of a cluster of pneumonia in China, on 31 December 2019 (day 1) in Hong Kong.Methods:A bundle approach of active and enhanced laboratory surveillance, early airborne infection isolation, rapid molecular diagnostic testing, and contact tracing for healthcare workers (HCWs) with unprotected exposure in the hospitals was implemented."
transmission,is,important,"Hospital-associated transmission is an important route of spreading the 2019 novel coronavirus (2019-nCoV) infection and pneumonia (Corona Virus Disease 2019, COVID-19) [1]."
have recognized,was responsible for,emerging zoonosis,"Bats have been recognized as one of the most important reservoirs for emerging viruses and the transmission of a coronavirus that originated in bats to humans via intermediate hosts was responsible for the high-impact emerging zoonosis, severe acute respiratory syndrome (SARS) (2-10) ."
have recognized,was responsible for,zoonosis,"Bats have been recognized as one of the most important reservoirs for emerging viruses and the transmission of a coronavirus that originated in bats to humans via intermediate hosts was responsible for the high-impact emerging zoonosis, severe acute respiratory syndrome (SARS) (2-10) ."
Bats,have,have recognized,"Bats have been recognized as one of the most important reservoirs for emerging viruses and the transmission of a coronavirus that originated in bats to humans via intermediate hosts was responsible for the high-impact emerging zoonosis, severe acute respiratory syndrome (SARS) (2-10) ."
have recognized,was responsible for,high-impact emerging zoonosis,"Bats have been recognized as one of the most important reservoirs for emerging viruses and the transmission of a coronavirus that originated in bats to humans via intermediate hosts was responsible for the high-impact emerging zoonosis, severe acute respiratory syndrome (SARS) (2-10) ."
have recognized,was,responsible,"Bats have been recognized as one of the most important reservoirs for emerging viruses and the transmission of a coronavirus that originated in bats to humans via intermediate hosts was responsible for the high-impact emerging zoonosis, severe acute respiratory syndrome (SARS) (2-10) ."
have recognized,was responsible for,high-impact zoonosis,"Bats have been recognized as one of the most important reservoirs for emerging viruses and the transmission of a coronavirus that originated in bats to humans via intermediate hosts was responsible for the high-impact emerging zoonosis, severe acute respiratory syndrome (SARS) (2-10) ."
patients,had,illness,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
patients,had,chronic medical illness,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
illness,including,11%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
patients,had,chronic illness,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
diabetes,with 4 is,11%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
chronic illness,including,11%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
patients,had,medical illness,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
chronic illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
chronic illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
medical illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
chronic medical illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
chronic medical illness,including,11%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
medical illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
chronic medical illness,including,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
hypertension,with 8 is,22%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
medical illness,including,11%,"Ten (27%) patients had chronic medical illness, including 4 (11%) with diabetes, 8 (22%) with hypertension, and 8 (22%) with digestive system disease."
51-year-old male taxi driver,had myalgia On,January 20 2020,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
male taxi driver,had fever On,January 20 2020,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
male taxi driver,had,myalgia,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
male taxi driver,went to,pharmacy,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
51-year-old male taxi driver,had fever On,January 20 2020,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
51-year-old male taxi driver,went to,local pharmacy,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
51-year-old male taxi driver,had,myalgia,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
male taxi driver,had myalgia On,January 20 2020,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
male taxi driver,had,fever,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
51-year-old male taxi driver,went to,pharmacy,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
51-year-old male taxi driver,had,fever,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
male taxi driver,went to,local pharmacy,"On January 20, 2020, a 51-year-old male taxi driver had fever, cough, and myalgia and went to a local pharmacy to get unspecified over-the-counter medications."
Xinyang city,in pneumonia is,critical type,"Objective To report the first case of a neonatal pneumonia with 2019-nCoV infection, and the experience of successfully diagnosis and treatment in late pregnancy woman with novel coronavirus pneumonia (critical type) in Xinyang city."
experience,is in,late pregnancy woman with novel coronavirus pneumonia,"Objective To report the first case of a neonatal pneumonia with 2019-nCoV infection, and the experience of successfully diagnosis and treatment in late pregnancy woman with novel coronavirus pneumonia (critical type) in Xinyang city."
late pregnancy woman,is with,novel coronavirus pneumonia in Xinyang city,"Objective To report the first case of a neonatal pneumonia with 2019-nCoV infection, and the experience of successfully diagnosis and treatment in late pregnancy woman with novel coronavirus pneumonia (critical type) in Xinyang city."
novel coronavirus pneumonia,is in,Xinyang city,"Objective To report the first case of a neonatal pneumonia with 2019-nCoV infection, and the experience of successfully diagnosis and treatment in late pregnancy woman with novel coronavirus pneumonia (critical type) in Xinyang city."
neonatal pneumonia,is with,2019-nCoV infection,"Objective To report the first case of a neonatal pneumonia with 2019-nCoV infection, and the experience of successfully diagnosis and treatment in late pregnancy woman with novel coronavirus pneumonia (critical type) in Xinyang city."
woman,is with,38 weeks,"Methods The successfully diagnosis and treatment of a woman with 38 weeks singleton pregnancy complicated with novel coronavirus pneumonia (critical type), and a case of neonatal pneumonia with 2019-nCoV infection were retrospectively analyzed."
Methods,were,analyzed,"Methods The successfully diagnosis and treatment of a woman with 38 weeks singleton pregnancy complicated with novel coronavirus pneumonia (critical type), and a case of neonatal pneumonia with 2019-nCoV infection were retrospectively analyzed."
Methods,were,retrospectively analyzed,"Methods The successfully diagnosis and treatment of a woman with 38 weeks singleton pregnancy complicated with novel coronavirus pneumonia (critical type), and a case of neonatal pneumonia with 2019-nCoV infection were retrospectively analyzed."
virus,has,case,"The data so far suggest that the virus has a case fatality risk around 1%; this rate would make it many times more severe than typical seasonal influenza, putting it somewhere between the 1957 influenza pandemic (0.6%) and the 1918 influenza pandemic (2%).2"
rate,putting,it,"The data so far suggest that the virus has a case fatality risk around 1%; this rate would make it many times more severe than typical seasonal influenza, putting it somewhere between the 1957 influenza pandemic (0.6%) and the 1918 influenza pandemic (2%).2"
Abnormal respiratory signs,were reported for,2.80%,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
Abnormal signs,were reported for,2.80%,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
Abnormal respiratory signs,were,reported,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
respiratory signs,were,reported,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
Abnormal signs,were,reported,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
signs,were reported for,2.80%,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
signs,were,reported,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
respiratory signs,were reported for,2.80%,"Abnormal respiratory signs (coughing, nasal discharge, or sneezing) were reported for 28/1,015 (2.8%) dogs sampled."
experts,are,severe acute syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,severe acute respiratory syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,acute respiratory syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,severe syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,acute syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,respiratory syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
experts,are,severe respiratory syndrome confident,"severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus."
common presenting symptoms,are,fever,"The most common presenting symptoms are fever, cough, dyspnea, and myalgias and/or fatigue."
multiple ground-glass opacities,is with,patchy infiltration,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,common clinical features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,common features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,clinical features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,common clinical features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,clinical features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,common clinical features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,clinical features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
multiple ground-glass opacities,is in,bilateral lung field,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
patients,shared,common features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,common clinical features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,common features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,clinical features including fever,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
two patients,shared,common features,"The two patients shared common clinical features including fever, cough, and multiple ground-glass opacities in the bilateral lung field with patchy infiltration."
Neoadjuvant therapy,is recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,highly recommended for gastrointestinal cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,recommended for cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is highly recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is highly recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,recommended for gastrointestinal cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is highly recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,highly recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,highly recommended,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,highly recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,highly recommended for cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,recommended,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is highly recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended for cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended for gastrointestinal cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,recommended for cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,recommended,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,recommended for gastrointestinal cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
Neoadjuvant therapy,is,recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
therapy,is,recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage &ge; 2/rectal cancer T stage &ge; 3/unresectable colon cancer).
virus,was ultimately named,SARS-CoV,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
spread,is in,Southeast Asia,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
virus,was,ultimately named,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
virus,was named,SARS-CoV,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
febrile patients,had,syndrome,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
patients,present with,pneumonia,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
patients,had,syndrome,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
febrile patients,present with,pneumonia,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
virus,was,named,"The virus was ultimately named SARS-CoV, as febrile patients had severe acute respiratory syndrome and could present with pneumonia and lower respiratory symptoms such as cough and dyspnea.2 The SARS-CoV outbreak started in Guangdong, China, and spread to many countries in Southeast Asia, North America, Europe, and South Africa."
2020,were,enrolled,"Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to Shanghai Jiao Tong University Affiliated Sixth People's Hospital and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study."
2020,were enrolled in,study,"Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to Shanghai Jiao Tong University Affiliated Sixth People's Hospital and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study."
Ten patients,is with,COVID-19,"Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to Shanghai Jiao Tong University Affiliated Sixth People's Hospital and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study."
Shanghai Jiao Tong University Affiliated Sixth People,to,Hospital,"Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to Shanghai Jiao Tong University Affiliated Sixth People's Hospital and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study."
30 patients,is with,other viral pneumonia,"Ten patients with COVID-19 and 30 patients with other viral pneumonia (non-COVID-19) admitted to Shanghai Jiao Tong University Affiliated Sixth People's Hospital and Jinshan Branch Hospital from January 22 to February 17, 2020 were enrolled in this study."
leukopenia cytopenia,are common in,COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common than those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,common in COVID-19 patients than those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common in COVID-19 patients than those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are more common in,COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common in COVID-19 patients than those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common than those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,common in COVID-19 patients than those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,common in COVID-19 patients than those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are more common In,conclusion,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common than those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are common than,those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common in COVID-19 patients than those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are common than,those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are more common than,those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common in COVID-19 patients than those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are common than,those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,common,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common than those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,more common,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common than those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are common In,conclusion,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are more common than,those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are more common than,those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common in COVID-19 patients than those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,more common in COVID-19 patients than those,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common than those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,more common in COVID-19 patients than those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common in COVID-19 patients than those in non COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion common in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,In conclusion more common in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
leukopenia cytopenia,are,more common in COVID-19 patients than those in COVID-19 patients,"In conclusion, leukopenia, lymphocytopenia and eosinophil cytopenia are more common in COVID-19 patients than those in non- COVID-19 patients."
COVID-19,has spread,due in part,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread,due in part to increased globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread,due to globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly,due in part,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly,due in part to increased globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly Compared with,SARS,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly,due in part,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly,due to globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly Compared with,SARS,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread Compared with,SARS,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread,due,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly,due in part to globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly,due to globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly,due to increased globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly,due in part to globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly,due,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread,due in part to globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly,due to increased globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread rapidly,due in part to increased globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread,due to increased globalization,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
COVID-19,has spread more rapidly,due,"Compared with SARS and MERS, COVID-19 has spread more rapidly, due in part to increased globalization and the focus of the epidemic."
Trauma Surgery Branch,organized,expert consensus,"In order to standardize the emergency treatment and the infection prevention and control of severe trauma patients with hidden infection, suspected or confirmed infection of 2019-nCoV, Trauma Surgery Branch of Chinese Medical Doctors' Association organized this expert consensus."
patients,is with,hidden infection,"In order to standardize the emergency treatment and the infection prevention and control of severe trauma patients with hidden infection, suspected or confirmed infection of 2019-nCoV, Trauma Surgery Branch of Chinese Medical Doctors' Association organized this expert consensus."
patients,had,older ages,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
older ages,higher incidence of,comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
older ages,incidence of,comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
severe/critical patients,had,ages,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
severe/critical patients,had,higher incidence,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
patients,had,ages,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
severe/critical patients,had,older ages,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
older ages,incidence of,comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
severe/critical patients,had,incidence of comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
severe/critical patients,had,incidence,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
patients,had,incidence of comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
patients,had,incidence,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
patients,had,higher incidence of comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
severe/critical patients,had,higher incidence of comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
ages,incidence of,comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
ages,higher incidence of,comorbidities,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
patients,had,higher incidence,"RESULTS: Compared with the ordinary patients, the severe/critical patients had older ages, higher incidence of comorbidities, cough, expectoration, chest pain and dyspnea."
age,clinical factors of were,risk factors,"The clinical factors of age > 50 years old, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia."
age,factors of were,risk factors,"The clinical factors of age > 50 years old, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia."
age,factors of were,risk factors for COVID-19 pneumonia,"The clinical factors of age > 50 years old, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia."
age,clinical factors of were,risk factors for COVID-19 pneumonia,"The clinical factors of age > 50 years old, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia."
age,clinical factors of were,risk factors for severe/critical COVID-19 pneumonia,"The clinical factors of age > 50 years old, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia."
age,factors of were,risk factors for severe/critical COVID-19 pneumonia,"The clinical factors of age > 50 years old, comorbidities, dyspnea, chest pain, cough, expectoration, decreased lymphocytes and increased inflammation indicators were risk factors for severe/critical COVID-19 pneumonia."
23 patients,is with,2019 nCov infection,"Results The 23 patients with 2019 nCov infection consisted of 15 men and 8 women, and the median age was 46.0 (40.5, 52.0) years (27-80 years); 9 of them had basic disease (39%), including hypertension (17%), cardiovascular diseases (17%), diabetes (9%), hypothyroidism (4%) and old tuberculosis (4%)."
hypertension,including disease is,39%,"Results The 23 patients with 2019 nCov infection consisted of 15 men and 8 women, and the median age was 46.0 (40.5, 52.0) years (27-80 years); 9 of them had basic disease (39%), including hypertension (17%), cardiovascular diseases (17%), diabetes (9%), hypothyroidism (4%) and old tuberculosis (4%)."
patients,consisted of,15 men,"Results The 23 patients with 2019 nCov infection consisted of 15 men and 8 women, and the median age was 46.0 (40.5, 52.0) years (27-80 years); 9 of them had basic disease (39%), including hypertension (17%), cardiovascular diseases (17%), diabetes (9%), hypothyroidism (4%) and old tuberculosis (4%)."
23 patients,consisted of,15 men,"Results The 23 patients with 2019 nCov infection consisted of 15 men and 8 women, and the median age was 46.0 (40.5, 52.0) years (27-80 years); 9 of them had basic disease (39%), including hypertension (17%), cardiovascular diseases (17%), diabetes (9%), hypothyroidism (4%) and old tuberculosis (4%)."
symptoms,included,cough,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,70%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,expectoration,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,70%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,17%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,fever,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,fever,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,myalgia,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,26%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,43%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,100%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,dyspnea,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,43%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,expectoration,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,myalgia,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,26%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,dyspnea,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,cough,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
Clinical symptoms,included,17%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
symptoms,included,100%,"Clinical symptoms included: fever (100%), cough (70%), expectoration (43%), myalgia (26%), headache (17%) and dyspnea (17%), and the less common symptoms were diarrhea (4.3%)."
contact,history of are,clinical basis for diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,Epidemic history of are,clinical basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions Epidemic history,are clinical basis for,diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions Epidemic history,are,clinical basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,history of are,basis for diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,Epidemic history of are,clinical basis for diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,Epidemic history of are,basis for diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions Epidemic history,are clinical basis for,diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,history of are,clinical basis for diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions Epidemic history,are basis for,diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,history of are,basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions history,are,clinical basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,Epidemic history of are,basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions Epidemic history,are basis for,diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,Epidemic history of are,clinical basis for diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions history,are clinical basis for,diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,Epidemic history of are,basis for diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions history,are basis for,diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions history,are,basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions Epidemic history,are,basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,history of are,clinical basis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions history,are basis for,diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
contact,history of are,basis for diagnosis of disease,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
Conclusions history,are clinical basis for,diagnosis,"Conclusions Epidemic history of contact, fever, pneumonia signs of chest CT, normal or decreased count of WBC and lymphocytopenia are the clinical basis for diagnosis of the disease."
lung immunopathology,immunization against,syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,severe acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
immunization,induces,lung immunopathology,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
inadequate immunization,induces,lung eosinophilic immunopathology,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,severe respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,severe respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,severe acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,severe syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,severe respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,severe respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,severe acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,severe acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
immunization,induces,lung eosinophilic immunopathology,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,severe syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
inadequate immunization,induces,lung immunopathology,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,severe acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
immunization,induces lung immunopathology upon,infection,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,immunization against,severe syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,severe acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung immunopathology,inadequate immunization against,severe acute syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,severe acute respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
inadequate immunization,induces lung immunopathology upon,infection,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,inadequate immunization against,severe syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
lung eosinophilic immunopathology,immunization against,respiratory syndrome coronavirus,"However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) induces a lung eosinophilic immunopathology upon infection."
mice,immunized after,infection with mouse &#8208;,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,were,however observed,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,however were observed in,lungs of almost all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infection,is with,mouse &#8208;,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,were,however observed,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,were observed in,lungs of all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,were observed in,lungs of almost all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
mice,immunized without,escaped,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,however were observed in,lungs of almost all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,were observed in,lungs of immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,however were observed in,lungs of all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
mice,immunized after,infection,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,were,observed,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,were observed in,lungs of all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,however were observed in,lungs of all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,were,observed,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,were observed in,lungs of immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,were observed in,lungs of almost all immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
infiltrations,however were observed in,lungs of immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
eosinophilic infiltrations,however were observed in,lungs of immunized mice,"All the mice immunized with more than 0.5&#8201;Âµg S protein without adjuvant escaped from SARS after infection with mouse&#8208;adapted SARS&#8208;CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice."
chief complain,were,symptoms,"Different from SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) infection, the initial presentations or the chief complain of some patients with the 2019 novel coronavirus (COVID-19) were gastrointestinal symptoms."
initial presentations chief complain,were,symptoms,"Different from SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) infection, the initial presentations or the chief complain of some patients with the 2019 novel coronavirus (COVID-19) were gastrointestinal symptoms."
initial presentations complain,were,symptoms,"Different from SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) infection, the initial presentations or the chief complain of some patients with the 2019 novel coronavirus (COVID-19) were gastrointestinal symptoms."
presentations complain,were,symptoms,"Different from SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) infection, the initial presentations or the chief complain of some patients with the 2019 novel coronavirus (COVID-19) were gastrointestinal symptoms."
presentations chief complain,were,symptoms,"Different from SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) infection, the initial presentations or the chief complain of some patients with the 2019 novel coronavirus (COVID-19) were gastrointestinal symptoms."
patients,is with,2019 novel coronavirus,"Different from SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) infection, the initial presentations or the chief complain of some patients with the 2019 novel coronavirus (COVID-19) were gastrointestinal symptoms."
diabetes mellitus,were,comorbidities,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
gastrointestinal symptoms,were,common clinical manifestations,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
gastrointestinal symptoms,were,most common clinical manifestations,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
gastrointestinal symptoms,were,common manifestations,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
diabetes mellitus,were,most common comorbidities,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
gastrointestinal symptoms,were,most common manifestations,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
gastrointestinal symptoms,were,clinical manifestations,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
gastrointestinal symptoms,were,manifestations,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
diabetes mellitus,were,common comorbidities,"Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities."
experience,managing,pregnant women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited experience,managing,women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
clinical experience,managing,pregnant women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
pregnant women,is with,COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
clinical experience,managing,pregnant women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited experience,managing,pregnant women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
experience,managing,women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
experience,managing,pregnant women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
case series,is with,confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
experience,managing,women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited clinical experience,managing,women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited experience,managing,pregnant women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited clinical experience,managing,pregnant women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited experience,managing,women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
clinical experience,managing,women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited clinical experience,managing,pregnant women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
clinical experience,managing,women,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
Limited clinical experience,managing,women with COVID-19,"Limited clinical experience in managing pregnant women with COVID-19 and their neonates has been reported from China recently based on a case series of nine pregnancies with confirmed COVID-19 treated in Zhongnan Hospital of Wuhan University and 10 neonates (nine pregnancies) delivered at five different hospitals,11, 12 although many more cases (>100) of suspected or confirmed COVID-19 have been treated and delivered in several hospitals in China according to the news releases and media reports."
infection,occurs in,trimester of pregnancy,"There appears to be some risk of premature rupture of membranes, preterm delivery, fetal tachycardia and fetal distress when the infection occurs in the third trimester of pregnancy."
infection,occurs in,trimester,"There appears to be some risk of premature rupture of membranes, preterm delivery, fetal tachycardia and fetal distress when the infection occurs in the third trimester of pregnancy."
infection,occurs in,third trimester of pregnancy,"There appears to be some risk of premature rupture of membranes, preterm delivery, fetal tachycardia and fetal distress when the infection occurs in the third trimester of pregnancy."
infection,occurs in,third trimester,"There appears to be some risk of premature rupture of membranes, preterm delivery, fetal tachycardia and fetal distress when the infection occurs in the third trimester of pregnancy."
HCoVs,have received attention after,outbreak of respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of severe acute respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of severe acute respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of acute respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention as,pathogens,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of severe syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of acute syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received,attention,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received,attention,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of severe respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention as,pathogens,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention as,important pathogens,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of severe syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of severe respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of acute respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention after,outbreak of severe acute syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of severe acute syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
important pathogens,is in,respiratory tract infection,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of respiratory syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,have received attention as,important pathogens,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
HCoVs,However have received attention after,outbreak of acute syndrome,"However, after the outbreak of the severe acute respiratory syndrome (SARS) and emergence of the Middle East respiratory syndrome (MERS), HCoVs have received worldwide attention as important pathogens in respiratory tract infection."
Background viruses,pose,potential threat,"Background Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety."
Background Emerging viruses,have,have identified,"Background Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety."
Background viruses,have,have identified,"Background Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety."
Background Emerging viruses,pose,potential threat,"Background Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety."
locusts,swarmed into,Ethiopia,"In October 2019, the locusts swarmed south into Ethiopia, Eritrea, and Somalia, and in late December, they spread to Kenya, causing the worst infestation there in 70 years."
locusts,swarmed south In,Oct-19,"In October 2019, the locusts swarmed south into Ethiopia, Eritrea, and Somalia, and in late December, they spread to Kenya, causing the worst infestation there in 70 years."
locusts,swarmed into,Eritrea,"In October 2019, the locusts swarmed south into Ethiopia, Eritrea, and Somalia, and in late December, they spread to Kenya, causing the worst infestation there in 70 years."
locusts,swarmed south into,Ethiopia,"In October 2019, the locusts swarmed south into Ethiopia, Eritrea, and Somalia, and in late December, they spread to Kenya, causing the worst infestation there in 70 years."
locusts,swarmed In,Oct-19,"In October 2019, the locusts swarmed south into Ethiopia, Eritrea, and Somalia, and in late December, they spread to Kenya, causing the worst infestation there in 70 years."
bat CD26s,large diversities in,region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,especially region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities especially in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities especially in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
different species,from CD26s is,bCD26s,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bats,are original source of,MERS-CoV,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,especially region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bCD26s,is in,many species,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,especially region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities especially in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities especially in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
Middle East respiratory syndrome coronavirus,of domain is,RBD,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,especially region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,especially region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities especially in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities especially in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
different species,from CD26s is,bCD26s,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bats,are original source of,MERS-CoV,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,especially region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bCD26s,is in,many species,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities in region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,especially region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities especially in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities especially in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
Middle East respiratory syndrome coronavirus,of domain is,RBD,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,large diversities in,especially region responsible,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,diversities,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,diversities in,region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
bat CD26s,exhibit,large diversities in region,"These results add more evidence to the existing belief that bats are the original source of MERS-CoV and suggest that bCD26s in many species can mediate the entry of the virus, which has significant implications for the surveillance and control of MERS-CoV infection.IMPORTANCE In this study, we found that bat CD26s (bCD26s) from different species exhibit large diversities, especially in the region responsible for binding to the receptor binding domain (RBD) of Middle East respiratory syndrome coronavirus (MERS-CoV)."
tract infection outbreaks,have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe tract infection outbreaks,however have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
tract infection outbreaks,however have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe tract infection outbreaks,however have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe respiratory tract infection outbreaks,have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
pathogenicity,is in,humans,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
respiratory tract infection outbreaks,however have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
respiratory tract infection outbreaks,have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
tract infection outbreaks,have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
respiratory tract infection outbreaks,however have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe tract infection outbreaks,have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe respiratory tract infection outbreaks,however have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
tract infection outbreaks,however have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
respiratory tract infection outbreaks,have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe tract infection outbreaks,have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe respiratory tract infection outbreaks,have caused,pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
Severe respiratory tract infection outbreaks,however have caused,high pathogenicity,"Severe respiratory tract infection outbreaks caused by severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, however, have caused high pathogenicity and mortality rates in humans."
transmission,constitutes,serious threat to health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,threat to,public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
serious threat,incidence of,coronavirus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,constitutes,threat to public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
UK,declares,serious threat,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
threat,incidence of,coronavirus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,constitutes,threat to health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
UK,declares,threat to health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
incidence,constitutes,threat to public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
UK,declares,serious threat to health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
UK,declares,threat,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,constitutes,serious threat,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,constitutes,serious threat to public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
UK,declares,serious threat to public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
incidence,constitutes,serious threat to health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,serious and imminent threat to,public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
incidence,constitutes,threat to health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,constitutes,threat,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
incidence,constitutes,serious threat to public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
incidence,constitutes,threat,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
incidence,constitutes,serious threat,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
UK,declares,threat to public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
serious threat,incidence of,novel coronavirus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,serious threat to,public health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,threat to,health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,serious threat to,health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,serious and imminent threat to,health,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,incidence of,coronavirus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
transmission,incidence of,novel coronavirus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
threat,incidence of,novel coronavirus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected far,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected far from transmission,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
England 's health secretary,enact,regulations,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected as far,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
England 's health secretary,enact regulations,ensure,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected as far from transmission,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
England,has,health secretary,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected as far from transmission of virus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
people,are,protected far from transmission of virus,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
England,'s secretary is,Matt Hancock,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
Merseyside,is in,Milton Keynes,"UK declares â€œserious and imminent threat to public healthâ€The UK government declared that the â€œincidence or transmission of novel coronavirus constitutes a serious and imminent threat to public health.â€ The announcement on 10 February means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that people are â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital in Merseyside and Kents Hill Park in Milton Keynes as isolation facilities."
England 's health secretary,enact,regulations,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected far from transmission,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected far from transmission of virus,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected as far from transmission of virus,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
England 's health secretary,enact regulations,ensure,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected far,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected as far,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
England,has,health secretary,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
England,'s secretary is,Matt Hancock,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected as far from transmission,"The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities."
public,is,protected as far from transmission of virus,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
threat,incidence of,coronavirus 2019-nCoV,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
public,is,protected,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
public,is,protected far,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
public,is,protected as far,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,incidence of,coronavirus 2019-nCoV,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
threat,incidence of,novel coronavirus 2019-nCoV,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,threat to,public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
public,is,protected as far from transmission,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,serious threat to,public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,serious threat to,health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,constitutes,serious threat,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,constitutes,serious threat to health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
public,is,protected far from transmission,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
England,'s secretary is,Matt Hancock,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,constitutes,threat,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,constitutes,serious threat to public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
serious threat,incidence of,novel coronavirus 2019-nCoV,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,threat to,health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
incidence,constitutes,threat,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
incidence,constitutes,serious threat,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
public,is,protected far from transmission of virus,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,serious and imminent threat to,health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,constitutes,threat to public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
England,has,health secretary,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
incidence,constitutes,threat to health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
incidence,constitutes,threat to public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,incidence of,novel coronavirus 2019-nCoV,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
incidence,constitutes,serious threat to health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,constitutes,threat to health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
England 's health secretary,enact,regulations,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
incidence,constitutes,serious threat to public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
transmission,serious and imminent threat to,public health.The announcement,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
serious threat,incidence of,coronavirus 2019-nCoV,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
England 's health secretary,enact regulations,ensure,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
patients,is in,isolation,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
eight people,is in,UK,"The UK government has declared that the incidence or transmission of the novel coronavirus 2019-nCoV constitutes a serious and imminent threat to public health.The announcement means that Englandâ€™s health secretary, Matt Hancock, can enact regulations to ensure that the public is â€œprotected as far as possible from the transmission of the virus.â€ This includes designating Arrowe Park Hospital, Merseyside, and the Kents Hill Park hotel and conference centre, Milton Keynes, as isolation facilities.It also means that NHS staff members have â€œstrengthened powersâ€ to keep patients in isolation if public health professionals believe there to be a â€œreasonable risk an individual may have the virus.â€As at 10 February eight people in the UK had tested positive for 2019-nCoV."
it,stockpile,14 million doses of oseltamivir2006,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
century,of scare is,governments,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
H5N1 avian influenza,is in,2004,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
oseltamivir,reduces,symptoms,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
BMJ,publishes,critical,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
oseltamivir,reduces,complications,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
US,adds oseltamivir to,its stockpile2004,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
have stockpiling,is in,vast quantities.Box 1 Oseltamivir,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
US,adds,oseltamivir,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
Cochrane,update,review,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
oseltamivir,reduces complications in,flu2009,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
it,stockpile,14 million doses,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
Cochrane,update,review of oseltamivir2011,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
First outbreak,is in,humans2005,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
Cochrane,review of,oseltamivir2011,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
oseltamivir,reduces symptoms in,flu2009,"Since the first pandemic scare of this century, H5N1 avian influenza in 2004 (see timeline, box 1), governments have been stockpiling the neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu), in vast quantities.Box 1 Oseltamivir and pandemic flu preparednessâ€”key events 2003â€”US adds oseltamivir to its strategic national stockpile2004â€”First outbreak of H5N1 avian flu in humans2005â€”UK announces it will stockpile 14 million doses of oseltamivir2006â€”Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu2009â€”H1N1 swine flu pandemic declared by WHO2009â€”The BMJ publishes critical Cochrane update review of oseltamivir2011â€”FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data2013â€”GSK and Roche release trial data on zanamivir and oseltamivir2014â€”Cochrane review finds insufficient evidence that oseltamivir reduces lower respiratory complications or impedes transmission2016â€”Generic formulations of oseltamivir become available2017â€”WHO downgrades status of oseltamivir2020â€”Cochrane team member Thomas Jefferson sues Roche in US for wrongfully billing public health authorities for oseltamivir as a pandemic response drugRETURN TO TEXTThe UK, the US, and many other countries hold enough stocks of these antivirals to offer courses of treatment to a quarter of their population."
cases,been reported,usual,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been reported,usual in early phase,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been reported,usual in early phase of disease outbreak,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
patient,is with,confirmed covid-19,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been reported across,25 countries .1,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been reported across,25 other countries .1,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
alarm,was raised as,result,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
infection,is with,severe acute respiratory syndrome coronavirus-2,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
severe pneumonia,is in,patients admitted to hospital .2,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
alarm,was raised as,result of cases,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been reported,usual in phase of disease outbreak,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
alarm,was,raised,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been,reported,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
contact,is with,patient,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
alarm,was raised as,result of most severe cases,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
cases,been reported,usual in phase,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
alarm,was raised as,result of severe cases,"A further 526 laboratory confirmed cases have been reported across 25 other countries.1 As is usual in the early phase of a disease outbreak, the alarm was raised as a result of the most severe cases, and the first reports describe severe pneumonia in patients admitted to hospital.2In a linked paper, Xu and colleagues (doi:10.1136/bmj.m606) report a case series of 62 patients (median age 41 years) admitted to hospital in the Zhejiang province with laboratory confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for covid-19.3 All the patients presented with respiratory symptoms, fever or flu-like illness, or both, and all had travelled to Wuhan or been in contact with a patient with confirmed covid-19 while staying in Wuhan."
patients,is with,covid-19,"The novel coronavirus that has so far spread from China to 26 countries around the world does not seem to be as â€œdeadly as other coronaviruses including SARS and MERS,â€ the World Health Organization has said.At a briefing on 17 February WHOâ€™s director general, Tedros Adhanom Ghebreyesus, said that more than 80% of patients with covid-19 have a â€œmild disease and will recoverâ€ and that it is fatal in 2% of reported cases."
Middle East respiratory syndrome,killed,34%,"In comparison, the 2003 outbreak of severe acute respiratory syndrome (SARS) had a case fatality rate of around 10% (8098 cases and 774 deaths), while Middle East respiratory syndrome (MERS) killed 34% of people with the illness â€¦"
Middle East syndrome,killed,34%,"In comparison, the 2003 outbreak of severe acute respiratory syndrome (SARS) had a case fatality rate of around 10% (8098 cases and 774 deaths), while Middle East respiratory syndrome (MERS) killed 34% of people with the illness â€¦"
Middle East syndrome,killed,34 % of people,"In comparison, the 2003 outbreak of severe acute respiratory syndrome (SARS) had a case fatality rate of around 10% (8098 cases and 774 deaths), while Middle East respiratory syndrome (MERS) killed 34% of people with the illness â€¦"
Middle East respiratory syndrome,killed,34 % of people,"In comparison, the 2003 outbreak of severe acute respiratory syndrome (SARS) had a case fatality rate of around 10% (8098 cases and 774 deaths), while Middle East respiratory syndrome (MERS) killed 34% of people with the illness â€¦"
you need,avoid,assessment of patients with possible covid-19 in primary careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment of patients,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
patients,is with,possible covid-19,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
contact,is with,someone,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
patient,call,NHS 111The guidance,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you,need in,anyone,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,assessment of patients in careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
patients,is in,primary careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
at-risk individuals,contain,spread,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
someone,is with,covid-19,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
individuals,contain,spread of infection,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you,need in,anyone with cough,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
clear protocols,managing,possible cases including isolation procedures,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
protocols,managing,possible cases including isolation procedures,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment of patients in primary careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
protocols,managing,possible cases,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
UK,recorded,its case of respiratory infection,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
at-risk individuals,contain,spread of infection,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
should made,isolate,patient,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment of patients with possible covid-19 in primary careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
it,is,essential,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment of patients with possible covid-19 in careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,assessment,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment of patients with possible covid-19,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
individuals,contain,spread,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
UK,recorded,its case of infection,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,assessment of patients,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
anyone,is with,cough,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
clear protocols,managing,possible cases,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,assessment of patients in primary careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,should,should made,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,assessment of patients with possible covid-19,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
UK,recorded,its case of acute infection,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,assessment of patients with possible covid-19 in careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
UK,recorded,its case,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
you need,avoid,in-person assessment of patients in careGP surgeries,"What you need to knowConsider covid-19 infection in anyone with cough, fever, or breathlessness who has had contact with someone with covid-19, or has returned from a high risk area in the 14 days before the onset of symptomsEvery effort should be made to avoid in-person assessment of patients with possible covid-19 in primary careGP surgeries should plan ahead and develop clear protocols for managing possible cases, including isolation procedures, personal protective equipment, seeking specialist advice, and decontaminationIf covid-19 infection is suspected in someone attending the practice, isolate the patient in a room (away from other patients and staff), close the door, and ask the patient to call NHS 111The guidance may change so it is essential to look at the latest guidance online (box 1)The UK recorded its first confirmed case of acute respiratory infection due to coronavirus disease 2019 (covid-19) on 31 January 2020 and responded by quarantining at-risk individuals to contain the spread of infection."
effusions,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
lung cavitation,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
pleural effusions,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
discrete pulmonary nodules,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
discrete nodules,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
discrete nodules,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
pulmonary nodules,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
discrete pulmonary nodules,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
lung cavitation,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
effusions,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
lymphadenopathy,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
nodules,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
nodules,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
pulmonary nodules,were,absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
lymphadenopathy,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
pleural effusions,were,Notably absent,"Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent."
fibrosis,was,left,"During the absorption period, the lesions disappeared or fibrosis was left behind, with lung structure distortion and bronchiectasis."
lesions,disappeared with,lung structure distortion,"During the absorption period, the lesions disappeared or fibrosis was left behind, with lung structure distortion and bronchiectasis."
lesions,disappeared During,absorption period,"During the absorption period, the lesions disappeared or fibrosis was left behind, with lung structure distortion and bronchiectasis."
fibrosis,was,left behind,"During the absorption period, the lesions disappeared or fibrosis was left behind, with lung structure distortion and bronchiectasis."
conspicuous ground grass opacity lesions,is in,peripheral lungs on CT images combined with normal,Conclusions Patients with fever and/or cough and with conspicuous ground grass opacity lesions in the peripheral and posterior lungs on CT images combined with normal or decreased white blood cells and a history of epidemic exposure are highly suspected of 2019-nCoV pneumonia.
Conclusions Patients,are,suspected,Conclusions Patients with fever and/or cough and with conspicuous ground grass opacity lesions in the peripheral and posterior lungs on CT images combined with normal or decreased white blood cells and a history of epidemic exposure are highly suspected of 2019-nCoV pneumonia.
Patients,is with,fever,Conclusions Patients with fever and/or cough and with conspicuous ground grass opacity lesions in the peripheral and posterior lungs on CT images combined with normal or decreased white blood cells and a history of epidemic exposure are highly suspected of 2019-nCoV pneumonia.
Patients,is with,conspicuous ground grass opacity lesions in peripheral lungs on CT images combined,Conclusions Patients with fever and/or cough and with conspicuous ground grass opacity lesions in the peripheral and posterior lungs on CT images combined with normal or decreased white blood cells and a history of epidemic exposure are highly suspected of 2019-nCoV pneumonia.
new coronavirus pneumonia,of outbreak is,main transmission mode,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
outbreak,focus of,research,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
research,is in,China,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
outbreak,have become,focus,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
outbreak,focus of,research in China,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
Wuhan City,in pneumonia is,NCP,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
new coronavirus pneumonia,is in,Wuhan City,"Since the outbreak of the new coronavirus pneumonia (NCP) in Wuhan City, China, the main transmission mode as well as the diagnosis and treatment of NCP have become a focus of research in China and World Health Organizations."
Hubei province,specialists of,breast diseases,"In the central epidemic area of COVID-19, Hubei province, especially Wuhan, the clinical specialists of breast diseases should consider all of the following factors comprehensively: the prevention of COVID-19, the diagnosis and treatment of breast diseases and the accessibility of medical resources."
International Health Regulations,Committee of,World Health Organization,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
International Health Regulations,declared,outbreak,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
International Health Regulations,declared On,30-Jan-20,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
International Health Regulations,declared outbreak On,30-Jan-20,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were,reported,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
"37,198 confirmed infections",were confirmed .3 in,condition,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were,also reported in 26 countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were reported in,26 countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
"37,198 confirmed infections",were confirmed .3 in,serious condition,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were,also reported,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were,reported in 26 other countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
confirmed infections,were confirmed .3 in,condition,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were reported in,26 other countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were also reported in,26 other countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were reported on,07-Feb-20,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
"37,198 confirmed infections",is in,China,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were,also reported,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
confirmed infections,were confirmed .3 in,serious condition,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were reported in,26 other countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were also reported on,07-Feb-20,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were also reported in,26 other countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were,reported in 26 other countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were,reported,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were,reported in 26 countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were also reported in,26 countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were also reported in,26 countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were,reported in 26 countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were,also reported in 26 other countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were,also reported in 26 countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were also reported on,07-Feb-20,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
0.3,confirmed infections in,China,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID infections,were reported in,26 countries,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
811 deaths,is with,death ratio of 2.1 %,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were reported on,07-Feb-20,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
COVID 19 infections,were,also reported in 26 other countries on 7 February 2020,"On 30 January 2020, the International Health Regulations, Emergency Committee of the World Health Organization (WHO) declared the outbreak â€“ a â€˜public health emergency of international concernâ€™.2 On 8 February 2020 (24:00 GMT?+?8), there were 37,198 confirmed infections in China (including 811 deaths with a death ratio of 2.1%; and 6188 patients were confirmed in serious condition and 28,942 suspected cases).3 The COVID 19 infections were also reported in 26 other countries on 7 February 2020, including Canada, the USA, Australia, India, Sri-Lanka, Cambodia, Thailand, Vietnam, Malaysia, Singapore, Taiwan, the Republic of Korea, Sri Lanka, Japan, Philippines, Nepal, United Arab Emirates, Russia, Italy, Germany, Sweden, Finland, Belgium, Spain, France and the UK.4"
it,is,slightly larger,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is,nm slightly larger than influenza,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is,nm larger than influenza,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is slightly larger than,influenza,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is larger at_time,nm,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is,larger,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is larger than,influenza,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
it,is slightly larger at_time,nm,"At 125?nm, it is slightly larger than influenza, SARS and MERS viruses."
sputum,had,diarrhea,"Among 141 NCP patients, 139 (98.58%) had fever (over 37.5 &deg; C), 106 (75.18%) coughed, 11 (7.80%) had headache, 41 (29.08%) coughed up sputum, 93 (65.96%) had chest distress, and 4 (2.84%) had diarrhea."
fibrosis shadow,is in,5 cases,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
7 cases,in effusion is,4.96%,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
GGO,is with,focal consolidation,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
7 cases,in shadow is,4.96%,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
bilateral pleural effusion,is in,7 cases,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
shadow,is in,7 cases,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
mediastinal hilar lymphadenopathy,is in,4 cases,"HRCT of 141 NCP patients were abnormal, 52 (36.88%) showed ground glass shadow (GGO) and patchy shadow, mainly subpleural distribution; 23 (16.31%) showed GGO with focal consolidation; 27 (19.15%) had small patchy blur; 20 (14.18%) had large patchy consolidation; 48 (34.04%) had bronchovascular bundle thickening and vascular perforator sign; 5 (3.55%) had Air bronchus sign; small nodule shadow in 7 cases (4.96%); fibrosis, grid shadow or strip shadow in 5 cases (3.55%); bilateral pleural effusion in 7 cases (4.96%); mediastinal or bilateral hilar lymphadenopathy in 4 cases (2.84%)."
world,is witnessing,epidemic,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
emerging genetics,suggest,path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
world,is witnessing,epidemic of COVID-19,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,suggest,similar path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,similar path to,those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,suggest,path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,suggest,path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,path to,those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
disease,caused by,novel coronavirus,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,suggest,path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,suggest,similar path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
genetics,suggest,similar path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,path to,those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
emerging genetics,suggest,path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
emerging genetics,suggest,similar path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,suggest,similar path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
genetics,suggest,similar path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,similar path to,those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
genetics,suggest,path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,similar path to,those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
disease,caused by,coronavirus,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,path to,those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,suggest,similar path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
emerging genetics,suggest,path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,similar path to,those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
clinical evidences,suggest,path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,suggest,similar path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,suggest,path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
genetics,suggest,path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
emerging genetics,suggest,similar path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
emerging genetics,suggest,similar path to those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,suggest,path,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,suggest,similar path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
genetics,suggest,path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
genetics,suggest,similar path to those,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
evidences,path to,those of SARS,"As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS."
SARS-HCoV,is in,2002,"It: Two Coronaviruses, HCoV-229E and HCoV-OC43, causing generally mild respiratory tract infections in humans, were described in the XX c. Pandemic Coronaviruses were first discovered as late as in the XXI c.: SARS-HCoV in 2002 â€“ causing severe respiratory tract infections (SARS) in China; MERS-HCoV in 2012 â€“ circulating mostly on the Arabian Peninsula."
MERS-HCoV,is in,2012,"It: Two Coronaviruses, HCoV-229E and HCoV-OC43, causing generally mild respiratory tract infections in humans, were described in the XX c. Pandemic Coronaviruses were first discovered as late as in the XXI c.: SARS-HCoV in 2002 â€“ causing severe respiratory tract infections (SARS) in China; MERS-HCoV in 2012 â€“ circulating mostly on the Arabian Peninsula."
Infection,might manifest,itself,"Infection caused by HCoV-MERS might manifest itself as ARDS, a mild-mannered and asymptomatic disease."
Infection,caused by,HCoV-MERS,"Infection caused by HCoV-MERS might manifest itself as ARDS, a mild-mannered and asymptomatic disease."
Viral pneumonia,was diagnosed at,initial CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,initial CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was,correctly diagnosed,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,initial CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,initial CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
initial CT study,is in,remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,initial CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,initial CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was,diagnosed,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,initial CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
two patients,is with,adenovirus,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was,diagnosed,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,initial CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,initial CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,initial CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was,correctly diagnosed,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,initial CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,initial CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,initial CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,initial CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,CT study in remaining 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,initial CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
remaining 49 patients,is with,COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was correctly diagnosed at,CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,initial CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,CT study,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,initial CT study in 49 patients,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
Viral pneumonia,was diagnosed at,initial CT study in 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was correctly diagnosed at,initial CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
pneumonia,was diagnosed at,initial CT study in remaining 49 patients with COVID-19,Viral pneumonia was correctly diagnosed at the initial CT study in the remaining 49 patients with COVID-19 and two patients with adenovirus.
our aim,is,have reported from other strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar pulmonary syndromes,have,have reported from strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,is,have reported from other strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during severe acute syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
pulmonary syndromes,have,have reported from other strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,is,have reported from strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar syndromes,have,have reported,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
syndromes,have,have reported from strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
syndromes,have,have reported from other strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar pulmonary syndromes,have,have reported from other strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during severe acute respiratory syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar pulmonary syndromes,have,have reported from other strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar pulmonary syndromes,have,have reported from strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar syndromes,have,have reported from other strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,is,have reported from strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during severe respiratory syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,is,have reported,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar pulmonary syndromes,have,have reported,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during severe syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar syndromes,have,have reported from other strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
pulmonary syndromes,have,have reported,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during respiratory syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
syndromes,have,have reported,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
pulmonary syndromes,have,have reported from strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar syndromes,have,have reported from strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
syndromes,have,have reported from other strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
similar syndromes,have,have reported from strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
pulmonary syndromes,have,have reported from strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review,lessons,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during acute respiratory syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
syndromes,have,have reported from strains of coronavirus family,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
pulmonary syndromes,have,have reported from other strains,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
our aim,review lessons from,imaging studies obtained during acute syndrome,"Because similar pulmonary syndromes have been reported from other strains of the coronavirus family, our aim is to review the lessons from imaging studies obtained during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks."
Most patients,is with,COVID-19 pneumonia,"Most patients with COVID-19 pneumonia had typical imaging features, such as ground-glass opacities (GGO) (87 [86.1%]) or mixed GGO and consolidation (65 [64.4%]), vascular enlargement in the lesion (72 [71.3%]), and traction bronchiectasis (53 [52.5%])."
87 GGO,is in,lesion,"Most patients with COVID-19 pneumonia had typical imaging features, such as ground-glass opacities (GGO) (87 [86.1%]) or mixed GGO and consolidation (65 [64.4%]), vascular enlargement in the lesion (72 [71.3%]), and traction bronchiectasis (53 [52.5%])."
Conclusion SARS-CoV-2,was isolated from,putative patients,Conclusion SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever.
Conclusion SARS-CoV-2,was,isolated,Conclusion SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever.
Conclusion SARS-CoV-2,was isolated from,putative patients with unexplained pneumonia,Conclusion SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever.
Conclusion SARS-CoV-2,was isolated from,putative patients with pneumonia,Conclusion SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever.
putative patients,is with,unexplained pneumonia,Conclusion SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever.
symptoms,were,fever,"The early symptoms were fever, sore throat, cough or sputum production, chills, and muscle ache."
early symptoms,were,fever,"The early symptoms were fever, sore throat, cough or sputum production, chills, and muscle ache."
major manifestations,are,fever,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
clinical manifestations,are,fever,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
major manifestations,shortness of,breath,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
major clinical manifestations,is in,coronavirus infections 2019-nCoV,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
major clinical manifestations,are,fever,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
clinical manifestations,shortness of,breath,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
manifestations,are,fever,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
manifestations,shortness of,breath,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
major clinical manifestations,shortness of,breath,"The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia."
infections,identified,included,"The infections identified included: ARI, avian influenza A(H5N1), influenza A(H1N1)pdm09 and Middle East respiratory syndrome coronavirus (MERS-CoV) infection."
comprenaient les infections,respiratoires,la,"Les infections identifiÃ©es comprenaient les infections respiratoires aiguÃ«s (IRA), la grippe aviaire A(H5N1), la grippe A(H1N1)pdm09 et l'infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)."
les infections,respiratoires,la,"Les infections identifiÃ©es comprenaient les infections respiratoires aiguÃ«s (IRA), la grippe aviaire A(H5N1), la grippe A(H1N1)pdm09 et l'infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)."
comprenaient les infections,respiratoires,aiguÃ«s,"Les infections identifiÃ©es comprenaient les infections respiratoires aiguÃ«s (IRA), la grippe aviaire A(H5N1), la grippe A(H1N1)pdm09 et l'infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)."
les infections,respiratoires,IRA,"Les infections identifiÃ©es comprenaient les infections respiratoires aiguÃ«s (IRA), la grippe aviaire A(H5N1), la grippe A(H1N1)pdm09 et l'infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)."
comprenaient les infections,respiratoires,IRA,"Les infections identifiÃ©es comprenaient les infections respiratoires aiguÃ«s (IRA), la grippe aviaire A(H5N1), la grippe A(H1N1)pdm09 et l'infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)."
les infections,respiratoires,aiguÃ«s,"Les infections identifiÃ©es comprenaient les infections respiratoires aiguÃ«s (IRA), la grippe aviaire A(H5N1), la grippe A(H1N1)pdm09 et l'infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)."
Sputum samples,were,diluted,Sputum samples were diluted in 2 mL phosphate buffered saline (PBS).
Sputum samples,were diluted in,2 mL phosphate,Sputum samples were diluted in 2 mL phosphate buffered saline (PBS).
speed,are dramatically exceeding,those of Middle East respiratory syndrome coronavirus,The speed of spread and infectivity of COVID-19 (also known as Wuhan-2019-nCoV) are dramatically exceeding those of the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
speed,are dramatically exceeding,those,The speed of spread and infectivity of COVID-19 (also known as Wuhan-2019-nCoV) are dramatically exceeding those of the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
speed,are exceeding,those of Middle East syndrome coronavirus,The speed of spread and infectivity of COVID-19 (also known as Wuhan-2019-nCoV) are dramatically exceeding those of the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
speed,are exceeding,those of Middle East respiratory syndrome coronavirus,The speed of spread and infectivity of COVID-19 (also known as Wuhan-2019-nCoV) are dramatically exceeding those of the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
speed,are exceeding,those,The speed of spread and infectivity of COVID-19 (also known as Wuhan-2019-nCoV) are dramatically exceeding those of the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
speed,are dramatically exceeding,those of Middle East syndrome coronavirus,The speed of spread and infectivity of COVID-19 (also known as Wuhan-2019-nCoV) are dramatically exceeding those of the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
MERS,are result of,coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
SARS,are,result of coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
causes,Therefore differ,result of coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
COVID-19,are result of,coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
causes,differ dramatically,result of coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
causes,differ,result of coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
MERS,are,result of coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
causes,Therefore differ dramatically,result of coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
SARS,are result of,coronaviral infections,"Therefore, although SARS, MERS, and COVID-19 are all the result of coronaviral infections, the causes of the coronaviruses differ dramatically in their transmissibility."
methanol extract,contains,sitosterol,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
betulin,have,diverse biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
betulin,have,activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indirubin,have,diverse activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
methanol extract,contains,chemical components,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indirubin,have,biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole B,have,diverse activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
tryptanthrin,have,biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
betulin,have,biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole A,have,biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
betulin,have,diverse activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole A,have,activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
tryptanthrin,have,diverse activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole A,have,diverse biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole B,have,diverse biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indirubin,have,diverse biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
tryptanthrin,have,diverse biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole B,have,activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole A,have,diverse activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indirubin,have,activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
tryptanthrin,have,activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
indigodole B,have,biological activities,"The methanol extract of S. cusia leaf contains chemical components such as &beta;-sitosterol, indirubin, tryptanthrin, betulin, indigodole A, and indigodole B that have diverse biological activities."
zoonotic origin,poses,threat to health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
zoonotic origin,poses,major threat to health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,factors contributing to high virulence,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
2019-novel coronavirus,is,highly pathogenic CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,human,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
origin,poses,major threat,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,pathogenic,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,viral factors,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,viral factors contributing to virulence,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,highly pathogenic human CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,viral factors contributing to virulence of 2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
poses,major threat to,health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
zoonotic origin,poses,threat,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,factors contributing to virulence,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
origin,poses,threat to health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
poses,major threat to,public health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,human CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
poses,threat to,health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
origin,poses,major threat to health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
origin,poses,threat to public health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,factors,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
zoonotic origin,poses,major threat to public health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
poses,threat to,public health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,pathogenic CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
2019-novel coronavirus,is,pathogenic human CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
origin,poses,major threat to public health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,highly pathogenic CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,pathogenic human CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,viral factors contributing,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is,known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
2019-novel coronavirus,is,CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,viral factors contributing to high virulence,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
origin,poses,threat,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,viral factors contributing to high virulence of 2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
2019-novel coronavirus,is,highly pathogenic human CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
2019-novel coronavirus,is,pathogenic CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
2019-novel coronavirus,is,human CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,factors contributing,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
zoonotic origin,poses,threat to public health.However,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,factors contributing to virulence of 2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
zoonotic origin,poses,major threat,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
little,is known about,factors contributing to high virulence of 2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
coronavirus,is,CoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are known,respiratory pathogens associated,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are known,respiratory pathogens associated,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,often major virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,have thrust HCoVs due to,their pathogenicity,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,have thrust HCoVs due to,their pathogenicity in humans.The study,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
HCoVs,onset of,2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,often major virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,major virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,contributed to,our understanding of infection pathogenesis,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,major virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are known,pathogens,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,often virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,often virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are known,pathogens associated,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,often major virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,major virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are known,respiratory pathogens,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,have thrust HCoVs due to,their pathogenicity in humans.The recent study,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,contributed extensively to,our understanding,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are known,respiratory pathogens,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,often virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are known,pathogens,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,contributed to,our understanding,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,have thrust HCoVs due to,their high pathogenicity,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,major virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,have thrust,HCoVs,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are,virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,often major virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,virulence factors.Human coronaviruses known,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
viral proteins,are,often virulence factors.Human coronaviruses,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,contributed extensively to,our understanding of infection pathogenesis,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,contributed to,our understanding of infection pathogenesis of 2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
their high pathogenicity,is in,humans.The recent study of HCoVs-host interactions,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
proteins,are known,pathogens associated,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,have thrust HCoVs due to,their high pathogenicity in humans.The study,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
onset,contributed extensively to,our understanding of infection pathogenesis of 2019-nCoV,"2019-novel coronavirus (2019-nCoV) is a highly pathogenic human CoV that first emerged in Wuhan in 2019.2019-nCoV has a zoonotic origin and poses a major threat to public health.However, little is known about the viral factors contributing to the high virulence of 2019-nCoV.Many animal viruses, including CoVs, encode proteins that interfere with host gene expression, including those involved in antiviral immune responses, and these viral proteins are often major virulence factors.Human coronaviruses (HCoVs) are known respiratory pathogens associated with a range of respiratory infection.In the past 17 years, the onset of 2019-nCoV, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogenicity in humans.The recent study of HCoVs-host interactions has contributed extensively to our understanding of infection pathogenesis of 2019-nCoV.This review discuss various host physiopathologic mechanism, such as apoptosis, innate immunity, endoplasmic reticulum (ER) stress response, mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-&kappa;B) pathway that may be modulated by HCoVs and provides evidence for the intensive investigate of 2019-nCoV infection."
Psychological impact,was assessed by,Impact of Event health status,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
Psychological impact,was assessed by,Impact of Event Scale-Revised health status,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
impact,was assessed by,Impact,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
impact,was assessed by,Impact of Event health status,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
Psychological impact,was assessed by,Impact,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
impact,was assessed by,Impact of Event Scale-Revised health status,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
assessed,was assessed by,Depression,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
Psychological impact,was,assessed,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
impact,was,assessed,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
assessed,was,assessed,"Psychological impact was assessed by the Impact of Event Scale-Revised (IES-R), and mental health status was assessed by the Depression, Anxiety and Stress Scale (DASS-21)."
Female gender,were,significantly associated,"Female gender, student status, specific physical symptoms (e.g., myalgia, dizziness, coryza), and poor self-rated health status were significantly associated with a greater psychological impact of the outbreak and higher levels of stress, anxiety, and depression (p &lt; 0.05)."
gender,were,associated,"Female gender, student status, specific physical symptoms (e.g., myalgia, dizziness, coryza), and poor self-rated health status were significantly associated with a greater psychological impact of the outbreak and higher levels of stress, anxiety, and depression (p &lt; 0.05)."
Female gender,were,associated,"Female gender, student status, specific physical symptoms (e.g., myalgia, dizziness, coryza), and poor self-rated health status were significantly associated with a greater psychological impact of the outbreak and higher levels of stress, anxiety, and depression (p &lt; 0.05)."
gender,were,significantly associated,"Female gender, student status, specific physical symptoms (e.g., myalgia, dizziness, coryza), and poor self-rated health status were significantly associated with a greater psychological impact of the outbreak and higher levels of stress, anxiety, and depression (p &lt; 0.05)."
infection,of intervals is,SI,"We used the serial intervals (SI) of infection caused by two other well-known coronaviruses (CoV), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) CoVs, as approximations of the unknown SI for 2019-nCoV to estimate R0."
serial intervals,estimate,R0,"We used the serial intervals (SI) of infection caused by two other well-known coronaviruses (CoV), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) CoVs, as approximations of the unknown SI for 2019-nCoV to estimate R0."
48-year-old male,is with,CMV pneumonia secondary to 2019-nCoV infection,Method Clinical data of two patients with 2019-nCoV infection after renal transplantationin Jan 2020 Renmin Hospital of Wuhan Universiyt were retrospectively analyzed.Case 1 was a 48-year-old male with CMV pneumonia secondary to 2019-nCoV infection at 4 months after transplantation.
two patients,is with,2019-nCoV infection,Method Clinical data of two patients with 2019-nCoV infection after renal transplantationin Jan 2020 Renmin Hospital of Wuhan Universiyt were retrospectively analyzed.Case 1 was a 48-year-old male with CMV pneumonia secondary to 2019-nCoV infection at 4 months after transplantation.
cefoperazone sulbactam sodium,regimens including,arbidol tablets,"Treatment regimens: cefoperazone sulbactam sodium + linezolid to resist infection, gamma globulin to enhance immunity function, methylprednisolone to control inflammatory response, antiviral regimens including arbidol tablets + lopina-velitonavir tablets."
top four,are fever Among,symptom composition of 45 fatality cases collected from released official reports,"Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain."
top four,are fever Among,symptom composition,"Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain."
top four,are fever Among,symptom composition of 45 fatality cases,"Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain."
top four,are,fever,"Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain."
top four,are fever Among,symptom composition of 45 fatality cases collected from official reports,"Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain."
top four,are fever Among,symptom composition of 45 fatality cases collected,"Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain."
major comorbidities,include,heart disease,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,chronic bronchitis,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,infarction,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,bronchitis,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,coronary heart disease,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,hypertension,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,chronic bronchitis,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,diabetes,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,bronchitis,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,infarction,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,cerebral infarction,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,heart disease,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,cerebral infarction,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,coronary heart disease,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
comorbidities,include,hypertension,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
major comorbidities,include,diabetes,"The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis."
infection,is with,novel coronavirus,"To understand the time-dependent risk of infection on a cruise ship, the Diamond Princess, I estimated the incidence of infection with novel coronavirus (COVID-19)."
COVID-19,is compared with,two coronavirus epidemics in terms of number of reported infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two coronavirus epidemics in terms of number of human infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics in terms of number of reported human infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,SARS,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
two related coronavirus epidemics,is in,terms of number of reported human infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two coronavirus epidemics in terms of number of reported human infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics in terms of number of infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
terms,in epidemics is,SARS,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,approved,vaccine,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two coronavirus epidemics in terms,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics in terms of number of human infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two coronavirus epidemics,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is,compared,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics in terms,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics in terms of number,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two related coronavirus epidemics in terms of number of reported infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two coronavirus epidemics in terms of number,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
COVID-19,is compared with,two coronavirus epidemics in terms of number of infections,"COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine."
virus,is,virulent,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine diarrhea virus,is,highly virulent re-emerging coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine epidemic diarrhea virus,is,virulent re-emerging enteric coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine epidemic diarrhea virus,is,highly virulent re-emerging coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine epidemic diarrhea virus,is,re-emerging coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine epidemic diarrhea virus,is,highly virulent re-emerging enteric coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine diarrhea virus,is,re-emerging coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine diarrhea virus,is,virulent re-emerging coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine diarrhea virus,is,re-emerging enteric coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
virus,is,enteric,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine epidemic diarrhea virus,is,re-emerging enteric coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine diarrhea virus,is,virulent re-emerging enteric coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine epidemic diarrhea virus,is,virulent re-emerging coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Porcine diarrhea virus,is,highly virulent re-emerging enteric coronavirus,"Porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets."
Hubei province,specialists of,breast diseases,"In the central epidemic area of COVID-19, Hubei province, especially Wuhan, the clinical specialists of breast diseases should consider all of the following factors comprehensively: the prevention of COVID-19, the diagnosis and treatment of breast diseases and the accessibility of medical resources."
Results,is in,still hospital for COVID-19,"Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators."
two,were,cured,"Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators."
Feb-02,2020 to,Feb 9 2020,"Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators."
four patients,is in,our department,"Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators."
update ofprotective measures,is in,our department,"Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators."
patients,were diagnosed between,January 25th in 21 hospitals in 17 cities,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
21 hospitals,is in,17 cities of six provinces of Shaanxi,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
patients,were diagnosed between,January 25th,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
patients,were,diagnosed,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
patients,were diagnosed between,January 25th in 21 hospitals in 17 cities of six provinces of Shaanxi,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
Shaanxi,of provinces is,autonomous region,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
patients,were diagnosed between,January,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
patients,were diagnosed between,January 25th in 21 hospitals in 17 cities of six provinces,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
patients,were diagnosed between,January 25th in 21 hospitals,"The patients were diagnosed between January 25th, 2020 and February 21st, 2020 in 21 hospitals in 17 cities of six provinces(autonomous region) of Shaanxi, Gansu, Ningxia, Hebei, Henan and Shandong."
common symptom,was,fever,"The most common symptom was fever (n=20, 65%), including 1 case of high fever, 9 cases of moderate fever, 10 cases of low fever."
common symptom,was fever including,1 case of fever,"The most common symptom was fever (n=20, 65%), including 1 case of high fever, 9 cases of moderate fever, 10 cases of low fever."
common symptom,was fever including,1 case of high fever,"The most common symptom was fever (n=20, 65%), including 1 case of high fever, 9 cases of moderate fever, 10 cases of low fever."
common symptom,was fever including,1 case,"The most common symptom was fever (n=20, 65%), including 1 case of high fever, 9 cases of moderate fever, 10 cases of low fever."
symptoms,included,cough,"The fever of fifteen cases lasted for â‰¤3 d, while in other 5 cases lasted > 3 d. Other symptoms included cough (n=14, 45%), fatigue (n=3, 10%) and diarrhea (n=3, 9%)."
Other symptoms,included,cough,"The fever of fifteen cases lasted for â‰¤3 d, while in other 5 cases lasted > 3 d. Other symptoms included cough (n=14, 45%), fatigue (n=3, 10%) and diarrhea (n=3, 9%)."
Other symptoms,included,diarrhea,"The fever of fifteen cases lasted for â‰¤3 d, while in other 5 cases lasted > 3 d. Other symptoms included cough (n=14, 45%), fatigue (n=3, 10%) and diarrhea (n=3, 9%)."
symptoms,included,fatigue,"The fever of fifteen cases lasted for â‰¤3 d, while in other 5 cases lasted > 3 d. Other symptoms included cough (n=14, 45%), fatigue (n=3, 10%) and diarrhea (n=3, 9%)."
symptoms,included,diarrhea,"The fever of fifteen cases lasted for â‰¤3 d, while in other 5 cases lasted > 3 d. Other symptoms included cough (n=14, 45%), fatigue (n=3, 10%) and diarrhea (n=3, 9%)."
headache,were,rare,"Pharyngalgia, runny nose, dizziness, headache and vomiting were rare."
dizziness,were,rare,"Pharyngalgia, runny nose, dizziness, headache and vomiting were rare."
vomiting,were,rare,"Pharyngalgia, runny nose, dizziness, headache and vomiting were rare."
nose,were,rare,"Pharyngalgia, runny nose, dizziness, headache and vomiting were rare."
runny nose,were,rare,"Pharyngalgia, runny nose, dizziness, headache and vomiting were rare."
Pharyngalgia,were,rare,"Pharyngalgia, runny nose, dizziness, headache and vomiting were rare."
paper,reviewed,diseases,"Through literature review, this paper reviewed the oral psychosomatic diseases closely related to patients' psychological state, such as oral mucosal disease, temporomandibular joint disease, bruxism, periodontal disease and so on."
paper,reviewed diseases Through,literature review,"Through literature review, this paper reviewed the oral psychosomatic diseases closely related to patients' psychological state, such as oral mucosal disease, temporomandibular joint disease, bruxism, periodontal disease and so on."
groups,Common symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
two groups,clinical symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
two groups,Common clinical symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
groups,clinical symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
groups,Common clinical symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
groups,symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
two groups,Common symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
two groups,symptoms of were,fever,"Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs.52.17%) , cough (80.64% vs.95.65%) , fatigue (61.30% vs.56.52%) , chest distress (77.42% vs.73.91%) ."
symptoms,were,headache,"Some other symptoms were headache, myalgia, dyspnea, diarrhea, nausea and vomiting."
other symptoms,were,headache,"Some other symptoms were headache, myalgia, dyspnea, diarrhea, nausea and vomiting."
two groups,laboratory characteristics of were,lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
two groups,laboratory and radiological characteristics of were,mainly lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
groups,characteristics of were,lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
two groups,laboratory and radiological characteristics of were,lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
groups,laboratory and radiological characteristics of were,lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
two groups,characteristics of were,mainly lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
two groups,characteristics of were,lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
two groups,laboratory characteristics of were,mainly lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
groups,laboratory and radiological characteristics of were,mainly lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
groups,laboratory characteristics of were,lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
groups,characteristics of were,mainly lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
groups,laboratory characteristics of were,mainly lymphopenia,"The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement."
number,were,reported,"A high number of cases were reported in Xinyang (269 cases, 21.26%) , Zhengzhou (156 cases, 12.33%) , Nanyang (155 cases, 12.25%) , Zhumadian (139 cases, 10.99%) , followed by Shangqiu (91 cases, 7.19%) , Zhoukou (76 cases, 6.01%) ."
number,were reported in,Xinyang,"A high number of cases were reported in Xinyang (269 cases, 21.26%) , Zhengzhou (156 cases, 12.33%) , Nanyang (155 cases, 12.25%) , Zhumadian (139 cases, 10.99%) , followed by Shangqiu (91 cases, 7.19%) , Zhoukou (76 cases, 6.01%) ."
high number,were reported in,Xinyang,"A high number of cases were reported in Xinyang (269 cases, 21.26%) , Zhengzhou (156 cases, 12.33%) , Nanyang (155 cases, 12.25%) , Zhumadian (139 cases, 10.99%) , followed by Shangqiu (91 cases, 7.19%) , Zhoukou (76 cases, 6.01%) ."
high number,were,reported,"A high number of cases were reported in Xinyang (269 cases, 21.26%) , Zhengzhou (156 cases, 12.33%) , Nanyang (155 cases, 12.25%) , Zhumadian (139 cases, 10.99%) , followed by Shangqiu (91 cases, 7.19%) , Zhoukou (76 cases, 6.01%) ."
symptoms,were fever Among,605 patients,"Among 605 patients, the symptoms were fever (553 cases, 91.4%) , debilitation (44 cases, 7.3%) , cough (110 cases, 18.2%) , expectoration (19 cases, 3.1%) , chills (6 cases, 1.0%) , shiver (7 cases, 1.2%) , running nose (21 cases, 3.5%) , stuffy noses (8 cases, 1.3%) , throat dryness and sore (24 cases, 4.0%) , headache (21 cases, 3.5%) , chest pain (6 cases, 1.0%) , anhelation (18 cases, 3.0%) , and gastrointestinal symptom (21 cases, 3.5%) ."
symptoms,were,fever,"Among 605 patients, the symptoms were fever (553 cases, 91.4%) , debilitation (44 cases, 7.3%) , cough (110 cases, 18.2%) , expectoration (19 cases, 3.1%) , chills (6 cases, 1.0%) , shiver (7 cases, 1.2%) , running nose (21 cases, 3.5%) , stuffy noses (8 cases, 1.3%) , throat dryness and sore (24 cases, 4.0%) , headache (21 cases, 3.5%) , chest pain (6 cases, 1.0%) , anhelation (18 cases, 3.0%) , and gastrointestinal symptom (21 cases, 3.5%) ."
patients cough,agitated during,procedure,"Midazolam, Propofol and Morphine or fentanyl were used for sedation and analgesia, avoiding patients cough and agitated during the procedure."
Midazolam,were,used for sedation,"Midazolam, Propofol and Morphine or fentanyl were used for sedation and analgesia, avoiding patients cough and agitated during the procedure."
Midazolam,were,used,"Midazolam, Propofol and Morphine or fentanyl were used for sedation and analgesia, avoiding patients cough and agitated during the procedure."
pulmonary thromboembolism,is in,patients with sudden onset of oxygenation deterioration,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of thromboembolism in patients with onset,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
patients,is with,sudden onset of oxygenation deterioration,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of pulmonary thromboembolism in patients with sudden onset,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of thromboembolism in patients with sudden onset of oxygenation deterioration,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of pulmonary thromboembolism in patients with sudden onset of oxygenation deterioration,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of thromboembolism in patients with sudden onset,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,is,necessary,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of pulmonary thromboembolism in patients with onset of oxygenation deterioration,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of pulmonary thromboembolism in patients,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of thromboembolism in patients with onset of oxygenation deterioration,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of thromboembolism,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
patients,in thromboembolism is,PTE,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of pulmonary thromboembolism in patients with onset,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of pulmonary thromboembolism,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
It,consider,possibility of thromboembolism in patients,"It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure."
recommendations,is in,adults based opinions of front-line clinical experts involved,"With the deeper cognition of COVID-19 and accumulation of clinical experience, we proposed the recommendations for pulmonary rehabilitation of COVID-19 in adults based on the opinions of front-line clinical experts involved in the management of this epidemic and a review of the relevant literature and evidences: 1. for the inpatients with COVID-19, pulmonary rehabilitation would relieve the symptoms of dyspnea, anxiety, and depression; eventually improve physical function and the quality of life; 2."
inpatients,is with,COVID-19,"With the deeper cognition of COVID-19 and accumulation of clinical experience, we proposed the recommendations for pulmonary rehabilitation of COVID-19 in adults based on the opinions of front-line clinical experts involved in the management of this epidemic and a review of the relevant literature and evidences: 1. for the inpatients with COVID-19, pulmonary rehabilitation would relieve the symptoms of dyspnea, anxiety, and depression; eventually improve physical function and the quality of life; 2."
groups,thickening of,septum,"For imaging features, both groups had ground-glass opacity and thickening of interlobular septum, but the ratio of central and gradient distribution was higher in patients with heart failure than that in patients with COVID-19 (4/7 vs. 1/12, P=0.04)."
groups,thickening of,interlobular septum,"For imaging features, both groups had ground-glass opacity and thickening of interlobular septum, but the ratio of central and gradient distribution was higher in patients with heart failure than that in patients with COVID-19 (4/7 vs. 1/12, P=0.04)."
significant differences,is in,chest CT features such enlargement of pulmonary veins,"There are significant differences in chest CT features, such as enlargement of pulmonary veins, lesions distribution and morphology between heart failure and COVID-19."
causes,include,acid accumulation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
Aggravating causes,include,events,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
Aggravating causes,include,inflammation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
causes,include,fulminant inflammation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
causes,include,thrombotic events,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
Aggravating causes,include,fulminant inflammation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
Aggravating causes,include,thrombotic events,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
causes,include,lactic acid accumulation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
Aggravating causes,include,acid accumulation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
Aggravating causes,include,lactic acid accumulation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
causes,include,events,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
causes,include,inflammation,"Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events."
cardiovascular damage,determine,correlation of serum natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,NT-proBNP,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
impact,was,evaluated,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal pro natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum pro B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal pro B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
patients,is with,COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
correlation,is with,severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal pro peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
impact,was,also evaluated,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation with,severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum pro B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum pro peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum pro natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation with,severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal B-type peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro B-type natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
determine,correlation of,serum N-terminal pro B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro B-type natriuretic peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal pro peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro B-type peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal peptide,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro B-type peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal natriuretic peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum N-terminal peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal pro B-type natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum N-terminal peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
damage,determine,correlation of serum pro peptide with severity of COVID-19,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
cardiovascular damage,determine,correlation of serum pro natriuretic peptide with severity,"Objective: To evaluate the cardiovascular damage of patients with COVID-19, and determine the correlation of serum N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) with the severity of COVID-19, and the impact of concomitant cardiovascular disease on severity of COVID-19 was also evaluated."
regression,were,used,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
univariate logistic regression,were,used,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
logistic regression,analyze,correlation of past history including hypertension,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
univariate regression,were,used,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
logistic regression,were,used,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
logistic regression,analyze,correlation of past history,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
regression,analyze,correlation,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
regression,analyze,correlation of past history including hypertension,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
regression,analyze,correlation of past history,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
logistic regression,analyze,correlation,"Both univariate and multivariate logistic regression were used to analyze the correlation of past medical history including hypertension, diabetes and coronary heart disease (CHD) , as well as the levels of serum NT-proBNP and cTnI to the disease severity of COVID-19 patients."
hs-CRP,were,correlated,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
elevated hs-CRP,were,correlated,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
elevated hs-CRP,were,significantly correlated with disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
hs-CRP,were,significantly correlated with critical disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
elevated hs-CRP,were,significantly correlated,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
hs-CRP,were,significantly correlated,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
hs-CRP,were,significantly correlated with disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
elevated hs-CRP,were,significantly correlated with critical disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
elevated hs-CRP,were,correlated with disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
elevated hs-CRP,were,correlated with critical disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
hs-CRP,were,correlated with critical disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
hs-CRP,were,correlated with disease status,"Univariate logistic regression analysis showed that age, male, elevated NT-proBNP, elevated cTnI, elevated hs-CRP, elevated serum creatinine, hypertension, and CHD were significantly correlated with critical disease status(all P<0.05)."
past history,are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
clinical disease status,is in,patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
increased level,are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
patients,is with,COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past history,are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two independent determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past medical history of are,two determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
level,are,two independent determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants of disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,increased level of are,two determinants,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two independent determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
cTnI,level of are,two determinants of disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
CHD,past history of are,two determinants of clinical disease status in patients with COVID-19,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two determinants of disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants of clinical disease status in patients,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
past medical history,are,two independent determinants of clinical disease status,The past medical history of CHD and increased level of cTnI are two independent determinants of clinical disease status in patients with COVID-19.
unexplained pneumonia,has appeared in,Wuhan City,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
pneumonia,has appeared in,Wuhan City,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
new type,was,confirmed,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
new type,was confirmed as,COVID-19,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
unexplained pneumonia,has appeared Since,Dec-19,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
pneumonia,has appeared Since,Dec-19,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
unexplained pneumonia,has appeared in,Hubei Province,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
type,was,confirmed,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
type,was confirmed as,COVID-19,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
pneumonia,has appeared in,Hubei Province,"Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19."
appropriate treatment methods,minimize,effect of epidemic on tumor treatment,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,adverse effect of epidemic on tumor treatment,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,diagnosis of,patients with tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,diagnosis of,patients,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
patients,is with,limited medical resources,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,diagnosis of,patients with malignant tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,accurate diagnosis of,patients with hepatobiliary malignant tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,effect of epidemic,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,should,should adopted,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,effect,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
provided,support for,patients with resources,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
patients,is with,hepatobiliary malignant tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,adverse effect on tumor treatment,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment strategy,be,should changed,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
provided,support for,patients with limited resources,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,effect on tumor treatment,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,accurate diagnosis of,patients with hepatobiliary tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
provided,support for,patients with medical resources,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,accurate diagnosis of,patients with malignant tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
provided,support for,patients with limited medical resources,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,adverse effect of epidemic,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
provided,support for,patients,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,accurate diagnosis of,patients with tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,accurate diagnosis of,patients,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,diagnosis of,patients with hepatobiliary tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
appropriate treatment methods,minimize,adverse effect,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
treatment,diagnosis of,patients with hepatobiliary malignant tumors,"In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment."
patients,is in,terms of clinical symptoms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,are,difficult,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients with COVID-19,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
patients,is with,COVID-19,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients in terms of clinical symptoms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients in terms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients with COVID-19 in terms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients with COVID-19 in terms of symptoms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients in terms of symptoms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
Lung cancer patients,differentiate from,patients with COVID-19 in terms of clinical symptoms,"Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients."
pulmonary infiltrates,is in,cancer patients,Objective: To investigate the principles of differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of novel coronavirus (2019-nCoV) by analyzing one case of lymphoma who presented pulmonary ground-glass opacities (GGO) after courses of chemotherapy.
pulmonary infiltrates,is in,cancer patients,Conclusions: The 2019 novel coronavirus disease (COVID-19) complicates the clinical scenario of pulmonary infiltrates in cancer patients.
clinical manifestations,included,cough,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main clinical manifestations,included,15.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
clinical manifestations,included,15.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main clinical manifestations,included,diarrhea,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
manifestations,included,fever,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main manifestations,included,cough,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
clinical manifestations,included,35.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main clinical manifestations,included,35.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
manifestations,included,95.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main manifestations,included,15.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main manifestations,included,fever,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main manifestations,included,95.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
manifestations,included,15.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
manifestations,included,diarrhea,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
manifestations,included,35.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
manifestations,included,cough,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main manifestations,included,35.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main clinical manifestations,included,95.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
clinical manifestations,included,95.00%,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
clinical manifestations,included,diarrhea,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main clinical manifestations,included,cough,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main manifestations,included,diarrhea,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
main clinical manifestations,included,fever,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
clinical manifestations,included,fever,"The main clinical manifestations included fever (95.00%), cough (35.00%), and diarrhea (15.00%)."
severe anxiety,incidence of were,2.17 % respectively,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
incidence,were,2.17 % respectively,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
anxiety,incidence of were,2.17%,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
severe anxiety,incidence of were,2.17%,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
incidence,were,2.17%,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
anxiety,incidence of were,2.17 % respectively,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
them,Among % is,5/230,"Among them, the incidence of severe anxiety, moderate anxiety and mild anxiety were 2.17% (5/230), 4.78% (11/230) and 16.09% (37/230), respectively."
actual practice situation,is in,our hospital,"Referring to the ""Diagnosis and Treatment Scheme for NCP (Trial Version 4 and 5)"" and combining the actual practice situation in our hospital with the ""Summary of New Coronavirus Files of Shanghai Renji Hospital"", we summarize how to carry out the clinical practice of colorectal surgery under the situation of the prevention and control of the NCP epidemiology, meanwhile under such situation aiming the procedure of diagnose and treatment for emergency patients with colorectal tumor, we share the experiences of the diagnosis of colorectal tumor, the management of patients with colorectal cancer who are scheduled to be admitted for surgery, the protection of wards, the perioperative management."
patients,is with,colorectal cancer,"Referring to the ""Diagnosis and Treatment Scheme for NCP (Trial Version 4 and 5)"" and combining the actual practice situation in our hospital with the ""Summary of New Coronavirus Files of Shanghai Renji Hospital"", we summarize how to carry out the clinical practice of colorectal surgery under the situation of the prevention and control of the NCP epidemiology, meanwhile under such situation aiming the procedure of diagnose and treatment for emergency patients with colorectal tumor, we share the experiences of the diagnosis of colorectal tumor, the management of patients with colorectal cancer who are scheduled to be admitted for surgery, the protection of wards, the perioperative management."
emergency patients,is with,colorectal tumor,"Referring to the ""Diagnosis and Treatment Scheme for NCP (Trial Version 4 and 5)"" and combining the actual practice situation in our hospital with the ""Summary of New Coronavirus Files of Shanghai Renji Hospital"", we summarize how to carry out the clinical practice of colorectal surgery under the situation of the prevention and control of the NCP epidemiology, meanwhile under such situation aiming the procedure of diagnose and treatment for emergency patients with colorectal tumor, we share the experiences of the diagnosis of colorectal tumor, the management of patients with colorectal cancer who are scheduled to be admitted for surgery, the protection of wards, the perioperative management."
protective measures,summarizing guidelines in,recent years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,recent years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing,research progress,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,recent years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
treatment strategies,improve,treatment strategies,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,recent years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,recent years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,recent years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing,guidelines,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,recent years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,recent years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
recent years,is in,fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,recent years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,recent years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,recent years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,recent years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,recent years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing guidelines in,years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing guidelines in,recent years in fields,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing,research progress,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,years in fields of cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
measures,summarizing research progress in,recent years,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing,guidelines,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
protective measures,summarizing research progress in,recent years in fields of colorectal cancer disease screening,"By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies(including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia."
surveillance,preventing,possible rebound of epidemic,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,strengthening,control,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,quarantining,source of infection,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,quarantining,source of infection,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,quarantining,source,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,optimizing,management,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,speeding up,diagnosis of cases,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,tightening,control,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,optimizing,management of close contacts,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
optimizing,management of,contacts,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,preventing,possible rebound,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,speeding up,diagnosis of suspected cases,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,speeding up,diagnosis,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,tightening,prevention,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,tightening,prevention,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,speeding up,diagnosis of suspected cases,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,preventing,possible rebound,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,tightening,prevention of cluster outbreaks,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,quarantining,source,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,optimizing,management of close contacts,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,optimizing,management,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,tightening,control,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,optimizing,management of contacts,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,strengthening,control,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
people,return to,work,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,tightening,prevention of cluster outbreaks,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,strengthening,community prevention,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,preventing,possible rebound of epidemic,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,speeding up,diagnosis,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
people,return to,work from Chinese Spring Festival holiday,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
surveillance,optimizing,management of contacts,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
control,prevention of,cluster outbreaks,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,strengthening,community prevention,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
optimizing,management of,close contacts,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
people,return to,work from Spring Festival holiday,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
quarantining,source of,infection,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
epidemic surveillance,speeding up,diagnosis of cases,"Strategies for prevention and control of NCP include improving epidemic surveillance, quarantining the source of infection, speeding up the diagnosis of suspected cases, optimizing the management of close contacts, tightening prevention and control of cluster outbreaks and hospital infection, preventing possible rebound of the epidemic after people return to work from the Chinese Spring Festival holiday, and strengthening community prevention and control."
clinical features,include,pulmonary infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
infiltration,revealed by,X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,inflammatory pulmonary infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,coughing,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,pulmonary infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,inflammatory pulmonary infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,fever,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,pulmonary infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,inflammatory infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,pulmonary infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,inflammatory pulmonary infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,inflammatory infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,inflammatory infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,fever,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
inflammatory pulmonary infiltration,revealed by,X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,pulmonary infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,shortness,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,coughing,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,inflammatory pulmonary infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,shortness of breath,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,inflammatory infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,inflammatory pulmonary infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,shortness,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
inflammatory infiltration,revealed by,X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,inflammatory infiltration revealed by X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,pulmonary infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,shortness of breath,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,inflammatory infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
clinical features,include,infiltration revealed,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
pulmonary infiltration,revealed by,X ray,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
features,include,inflammatory pulmonary infiltration,"The clinical features include fever, coughing, shortness of breath, and inflammatory pulmonary infiltration revealed by X ray."
drugs,commonly used in,practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
Antiviral drugs,commonly used in,practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
drugs,used in,practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
Antiviral drugs,used in,practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
drugs,commonly used in,clinical practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
Antiviral drugs,commonly used in,clinical practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
drugs,used in,clinical practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
Antiviral drugs,used in,clinical practice,"Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc."
ribavirin,are,invalid,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
acyclovir,are,invalid,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
ribavirin,are invalid for,2019-nCoV,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
ganciclovir,are,invalid for 2019-nCoV,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
ganciclovir,are,invalid,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
acyclovir,are invalid for,2019-nCoV,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
ganciclovir,are invalid for,2019-nCoV,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
acyclovir,are,invalid for 2019-nCoV,"), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended."
Drugs,are effective for,2019-nCoV,"Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-Î², convalescent plasma, and monoclonal antibodies."
Drugs,are,effective,"Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-Î², convalescent plasma, and monoclonal antibodies."
Drugs,are possibly effective for,2019-nCoV,"Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-Î², convalescent plasma, and monoclonal antibodies."
Drugs,are,possibly effective,"Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-Î², convalescent plasma, and monoclonal antibodies."
cough,may,may helpful for early detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful for early detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful for detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful for early detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
cough,may,may helpful for early detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful for early detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful for early detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful for early detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
cough,may,may helpful for detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
cough,may,may helpful for detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful for detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful for detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
cough,may,may helpful for early detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful for early detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful for detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
cough,may,may helpful,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
cough,may,may helpful for detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful for early detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful for detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful for detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful for early detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful for early detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful for detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful for detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful for early detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful for detection of novel coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful for detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful for detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
myalgia,may,may helpful,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful for early detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
Fever,may,may helpful for detection of coronavirus pneumonia,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
dyspnea,may,may helpful for early detection,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
imagings,may,may helpful,"Fever, cough, myalgia, weakness, dyspnea and imagings may be helpful for the early detection of novel coronavirus pneumonia."
pulmonary rehabilitation methods,is in,principle of 4S,"The article provides the pulmonary rehabilitation (PR) methods in the principle of 4S (simple, safe, satisfy, save) for patients with pneumonia caused by the novel coronavirus, shows how to establish a ventilative and convectional PR environment to prevent the spread of virus through droplets, how to guide the patients to carry out PR, how to carry out respiratory muscle training, effective cough, expectoration, sneeze, general exercise, digestive function rehabilitation and psychological rehabilitation, and how to clean and disinfect the PR environment."
patients,is with,pneumonia caused by novel coronavirus,"The article provides the pulmonary rehabilitation (PR) methods in the principle of 4S (simple, safe, satisfy, save) for patients with pneumonia caused by the novel coronavirus, shows how to establish a ventilative and convectional PR environment to prevent the spread of virus through droplets, how to guide the patients to carry out PR, how to carry out respiratory muscle training, effective cough, expectoration, sneeze, general exercise, digestive function rehabilitation and psychological rehabilitation, and how to clean and disinfect the PR environment."
article,provides,rehabilitation methods,"The article provides the pulmonary rehabilitation (PR) methods in the principle of 4S (simple, safe, satisfy, save) for patients with pneumonia caused by the novel coronavirus, shows how to establish a ventilative and convectional PR environment to prevent the spread of virus through droplets, how to guide the patients to carry out PR, how to carry out respiratory muscle training, effective cough, expectoration, sneeze, general exercise, digestive function rehabilitation and psychological rehabilitation, and how to clean and disinfect the PR environment."
blood test,showed,blood cell count,"(2) The blood test of the patients showed normal or decreased white blood cell count (23/29), decreased lymphocyte count (20/29), increased hypersensitive C reactive protein (hs-CRP) (27/29), and normal procalcitonin."
blood test,showed,normal blood cell count,"(2) The blood test of the patients showed normal or decreased white blood cell count (23/29), decreased lymphocyte count (20/29), increased hypersensitive C reactive protein (hs-CRP) (27/29), and normal procalcitonin."
blood test,showed,23/29,"(2) The blood test of the patients showed normal or decreased white blood cell count (23/29), decreased lymphocyte count (20/29), increased hypersensitive C reactive protein (hs-CRP) (27/29), and normal procalcitonin."
blood test,showed,white blood cell count,"(2) The blood test of the patients showed normal or decreased white blood cell count (23/29), decreased lymphocyte count (20/29), increased hypersensitive C reactive protein (hs-CRP) (27/29), and normal procalcitonin."
blood test,showed,normal white blood cell count,"(2) The blood test of the patients showed normal or decreased white blood cell count (23/29), decreased lymphocyte count (20/29), increased hypersensitive C reactive protein (hs-CRP) (27/29), and normal procalcitonin."
Combination,is,recommended,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,be,confirmed,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
Combination,is recommended by,Revised Edition,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
Combination,is recommended because of,effect on MERS,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,be confirmed by,trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,needs,confirmed by randomized controlled trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,be confirmed by,randomized controlled trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,needs,confirmed,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,be confirmed by,controlled trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,needs,confirmed by randomized trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,be confirmed by,randomized trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,needs,confirmed by controlled trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
Combination,is recommended because of,effect,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
Combination,is recommended by,5 th edition National Health Commission 's Regimen,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
edition National Health Commission,'s Regimen is,Revised Edition,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,needs,confirmed by trial,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
Combination,is recommended by,Edition,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
effectiveness,be confirmed by,RCT,"Combination of Ribavirin and Interferon-Î± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable."
dry cough,is in,5 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
manifestations,were fever in,8 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
clinical manifestations,were,fever,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
clinical manifestations,were fever in,pharyngalgia,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
clinical manifestations,were fever in,pharyngalgia in 4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
manifestations,blocked in,01-Sep,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
4 cases,fatigue in,4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
fever,is in,8 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
pharyngalgia,is in,4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
manifestations,were fever in,pharyngalgia,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
8 cases,cough in,5 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
4 cases,soreness in,4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
fatigue,is in,4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
body soreness,is in,4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
manifestations,were fever in,pharyngalgia in 4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
8 cases,pharyngalgia in,4 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
clinical manifestations,blocked in,1 case,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
clinical manifestations,were fever in,8 cases,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
manifestations,blocked in,1 case,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
clinical manifestations,blocked in,01-Sep,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
manifestations,were,fever,"The clinical manifestations were fever in 8 cases (8/9) , dry cough in 5 cases (5/9) , pharyngalgia in 4 cases (4/9) , fatigue in 4 cases (4/9) , body soreness in 4 cases (4/9) , and blocked or watery nose in 1 case (1/9) ."
Severe respiratory infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can rapidly progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can rapidly progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory failure,is with,high lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can progress to,respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute respiratory infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can rapidly progress to,acute failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe respiratory infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
acute respiratory infection diseases,can rapidly progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can progress to,acute respiratory failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
respiratory infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can rapidly progress to,failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe infection diseases,can progress to,acute failure with lethality,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
Severe acute infection diseases,can progress to,failure,"Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality."
outbreak,can lead to,patients developing into distress syndrome,The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS).
outbreak,can lead to,patients developing into respiratory distress syndrome,The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS).
outbreak,can lead to,patients,The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS).
outbreak,can lead to,patients developing into acute distress syndrome,The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS).
outbreak,can lead to,patients developing into acute respiratory distress syndrome,The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS).
outbreak,can lead to,patients developing,The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS).
average contact time,was,"2 1.5,2.7 h.Clinical symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,was,"2 1.5,2.7 symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,were,fever,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,were fever in,76.67%,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,was,"2 1.5,2.7 h.Clinical symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cough,is in,25 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,was,"2 1.5,2.7 symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,was,"2 1.5,2.7 h.Clinical symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,were fever in,headache in 16 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,was,"2 1.5,2.7 symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,were fever in,headache,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,was,"2 1.5,2.7 h.Clinical symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,was,"2 1.5,2.7 symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,were fever in,headache,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,was,"2 1.5,2.7 h.Clinical symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,were,fever,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
dyspnea,is in,14 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
21patients,in fatigue is,70%,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,was,"2 1.5,2.7 symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact times,was,"2 1.5,2.7 h.Clinical symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,were,fever,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,were fever in,headache in 16 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,was,"2 1.5,2.7 symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact times,was,"2 1.5,2.7 h.Clinical symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
23 patients,headache in,petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
fatigue,is in,21patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,was,"2 1.5,2.7 symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,were fever in,76.67%,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
fever,is in,23 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,were fever in,76.67%,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
headache,is in,petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,were fever in,23 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact times,was,"2 1.5,2.7 symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,were fever in,headache in 16 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,were fever in,23 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,were fever in,headache,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,were fever in,76.67%,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,were fever in,23 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,were,fever,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact times,was,"2 1.5,2.7 h.Clinical symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,were fever in,headache in 16 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact times,was,"2 1.5,2.7 h.Clinical symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact times,was,"2 1.5,2.7 symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact times,was,"2 1.5,2.7 symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,were fever in,headache,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
cumulative contact time,was,"2 1.5,2.7 h.Clinical symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,was,"2 1.5,2.7 symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact time,were fever in,23 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
contact times,was,"2 1.5,2.7 symptoms of patients","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average contact time,was,"2 1.5,2.7 h.Clinical symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
average cumulative contact time,was,"2 1.5,2.7 h.Clinical symptoms","The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
L,is in,22 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
5 patients,in D-dimer is,> 0.5 mg/l,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
abnormal liver function,is in,7 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
12 petients,function in,7 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
blood test,revealed,WBC,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
12 petients,D-dimer in,5 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
12 petients,damage in,5 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
L,is in,8 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
L,is in,4 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
elevated D-dimer,is in,5 patients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
myocardial damage,is in,5 petients,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
Routine blood test,revealed,WBC,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
disease.Lymphocyte count,during Ã— is,9,"The average contact times were 12 (7,16) and the average cumulative contact time was 2 (1.5,2.7) h.Clinical symptoms of these patients were fever in 23 patients (76.67%) , headache in 16 petients (53.33%) , fatigue or myalgia in 21patients (70%) , nausea, vomiting or diarrhea in 9 petients (30%) , cough in 25 petients (83.33%) , and dyspnea in 14 petients (46.67%) .Routine blood test revealed WBC <4.0Ã—10(9)/L in 8 petients (26.67%) , (4-10) Ã—10(9)/L in 22 petients (73.33%) , and WBC>4.0Ã—10(9)/L in 4 petients (13.33%) during the disease.Lymphocyte count <1.0Ã—10(9)/L occurred in 12 petients (40%),abnormal liver function in 7 petients (23.33%) ,myocardial damage in 5 petients(16.67%), elevated D-dimer (>0.5mg/l) in 5 patients (16.67%)."
albumin,showed,bilateral multiple mottling,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,mainly showed,interstitial changes.According,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
proportion,were increased in,patients infected in period,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,changes.According,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,were,decreased.Chest CT,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
count,is in,peripheral blood,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
CT,showed,bilateral pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,ground-glass opacity.Compared with patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,ground-glass,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
decreased.Chest CT,showed,bilateral pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,ground-glass opacity.Compared with patients infected in protected period,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,mottling,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,mainly showed,changes.According,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
decreased.Chest CT,showed,pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,bilateral pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
11 patients,showed,Unilateral pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,mainly showed,shadows,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
patients,showed,pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,mainly showed shadows to,imaging examination,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,ground-glass opacity.Compared with patients infected in period,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed changes.According to,imaging examination,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,were,CT,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
patients,showed,Unilateral pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,ground-glass opacity.Compared,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
proportion,were,increased,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,multiple mottling,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
D-dimer,were,significantly increased in severe patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,mainly showed changes.According to,imaging examination,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
CT,showed,pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,bilateral mottling,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
11 patients,showed,19 patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
lymphocyte count,were,decreased.Chest CT,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed shadows to,imaging examination,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
11 patients,showed,pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,pneumonia,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
D-dimer,were,increased,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
D-dimer,were,significantly increased in patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
D-dimer,were,significantly increased,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
lymphocyte count,were,significantly decreased.Chest CT,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,ground-glass opacity.Compared with patients infected,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
proportion,were increased in,patients infected in unprotected period,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
11 patients,showed,63.33%,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
patients,showed,19 patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,mainly showed,patchy shadows,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,interstitial changes.According,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,patchy shadows,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
D-dimer,were,increased in patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,were,significantly decreased.Chest CT,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
D-dimer,were,increased in severe patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
lymphocyte count,were,CT,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
patients,showed,63.33%,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
proportion,were increased in,patients infected,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
proportion,were increased in,patients,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
albumin,showed,shadows,"Compared with normal patients, the average exposure times, cumulative exposure time, BMI, Fever time, white blood cell count, liver enzyme, LDH, myoenzyme and D-dimer were significantly increased in severe patients, while the lymphocyte count and albumin levels in peripheral blood were significantly decreased.Chest CT mainly showed patchy shadows and interstitial changes.According to imaging examination, 11 patients (36.67%) showed Unilateral pneumonia and 19 patients (63.33%) showed bilateral pneumonia,4 patients (13.33%) showed bilateral multiple mottling and ground-glass opacity.Compared with the patients infected in the protected period, the proportion of severe infection and bilateral pneumonia were both increased in the patients infected in unprotected period."
patients had,is,important,"Severe patients had BMI increased, heating time prolonged , white blood cell count, lymphocyte count, D-dimer and albumin level significantly changed and were prone to be complicated with liver damage and myocardial damage.Strict protection measures is important to prevent infection for medical workers."
Severe patients had,prevent,infection,"Severe patients had BMI increased, heating time prolonged , white blood cell count, lymphocyte count, D-dimer and albumin level significantly changed and were prone to be complicated with liver damage and myocardial damage.Strict protection measures is important to prevent infection for medical workers."
Severe patients had,is,important,"Severe patients had BMI increased, heating time prolonged , white blood cell count, lymphocyte count, D-dimer and albumin level significantly changed and were prone to be complicated with liver damage and myocardial damage.Strict protection measures is important to prevent infection for medical workers."
patients had,prevent,infection,"Severe patients had BMI increased, heating time prolonged , white blood cell count, lymphocyte count, D-dimer and albumin level significantly changed and were prone to be complicated with liver damage and myocardial damage.Strict protection measures is important to prevent infection for medical workers."
multicenter collaboration group,developed,expert consensus,"In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion."
collaboration group,developed,expert consensus,"In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion."
patients,is with,novel coronavirus pneumonia,"In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion."
chloroquine,is in,treatment of novel coronavirus pneumonia,"In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion."
use,is in,patients with novel coronavirus pneumonia,"In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion."
chloroquine phosphate tablet,mg per,day,"It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine."
chloroquine phosphate tablet,mg for,10 days,"It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine."
patients,is with,coronavirus disease 2019,"Objective: To explore and analyze the possible mechanism of liver injury in patients with coronavirus disease 2019 (novel coronavirus pneumonia, NCP)."
liver injury,is in,patients with coronavirus disease 2019,"Objective: To explore and analyze the possible mechanism of liver injury in patients with coronavirus disease 2019 (novel coronavirus pneumonia, NCP)."
Four cases,were,combined,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
case,was simultaneously combined with,high blood pressure,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
Four cases,were combined with,one underlying disease,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
case,was,simultaneously combined,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
cases,were,combined,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
Four cases,were combined with,one disease,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
case,was combined with,blood pressure,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
cases,were combined with,one disease,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
case,was combined with,high blood pressure,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
cases,were combined with,one underlying disease,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
case,was,combined,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
case,was simultaneously combined with,blood pressure,"Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor."
novel coronavirus pneumonia,is,more likely,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be caused by,drug reactions in severe patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,is,likely,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,is,more likely,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be,caused,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be caused by,adverse drug reactions,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be caused by,drug reactions in severe patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
adverse drug reactions,is in,severe patients receiving,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be,caused,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be caused by,drug reactions,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be caused by,adverse drug reactions in patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be caused by,adverse drug reactions in severe patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be caused by,drug reactions in patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,be caused by,adverse drug reactions in severe patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be caused by,adverse drug reactions,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be caused by,drug reactions in patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be caused by,drug reactions,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
coronavirus pneumonia,is,likely,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
novel coronavirus pneumonia,be caused by,adverse drug reactions in patients,Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.
Neoadjuvant therapy,is recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,highly recommended for gastrointestinal cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,recommended for cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is highly recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is highly recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,recommended for gastrointestinal cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is highly recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,highly recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is recommended at,stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,highly recommended,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is recommended at,advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended for cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is highly recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,highly recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,highly recommended for cancer at advanced stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,recommended,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is,highly recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is highly recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
Neoadjuvant therapy,is recommended for,gastrointestinal cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is recommended for,cancer,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
therapy,is,recommended for gastrointestinal cancer at stages,Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage â‰¥ 2/rectal cancer T stage â‰¥ 3/unresectable colon cancer).
lung cancer patients,are,susceptible,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are,susceptible to infection than healthy individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are more susceptible than,individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are more susceptible to,infection,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are,more susceptible,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are susceptible to,infection,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are,more susceptible to infection than individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are susceptible than,healthy individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are,susceptible to infection than individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are more susceptible than,healthy individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are susceptible than,individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
lung cancer patients,are,more susceptible to infection than healthy individuals,"Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals."
men,is with,underlying diseases including diabetes,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
most,were men with,comorbidities,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
most,were men with,diseases including diabetes,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
infected patients,most of were,men,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
patients,most of were,men with diseases including diabetes,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
most,were men with,diseases,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
infected patients,most of were,men with diseases,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
most,were,men,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
patients,most of were,men,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
infected patients,most of were,men with diseases including diabetes,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
patients,most of were,men with diseases,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
diabetes,including diseases is,comorbidities,"Preliminary clinical features indicated that most of the infected patients were men with underlying diseases (comorbidities) including diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, malignancy and chronic liver disease[6]."
Patient,presented with,fever,"Patient presented with fever, cough, myalgia, sputum production, headache, haemoptysis, diarrhea and dyspnea[6]."
lopinavir/ritonavir,is used for,possible treatment of 2019-nCoV infection,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present widely used for possible treatment in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present used for possible treatment of 2019-nCoV infection in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
possible treatment,is in,countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is used for,possible treatment of 2019-nCoV infection in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present used for possible treatment in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present used for possible treatment,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present widely used for possible treatment,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is widely used for,possible treatment of 2019-nCoV infection,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,used,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is widely used for,possible treatment in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is used for,possible treatment,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is used At,present,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present widely used for possible treatment of 2019-nCoV infection in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is widely used for,possible treatment of 2019-nCoV infection in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is widely used for,possible treatment,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present used for possible treatment of 2019-nCoV infection,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is widely used At,present,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,widely used,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is used for,possible treatment in countries,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
lopinavir/ritonavir,is,At present widely used for possible treatment of 2019-nCoV infection,"At present, lopinavir/ritonavir is widely used for possible treatment of 2019-nCoV infection in countries that the emerging infection exists."
people,are,susceptible,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
SARS-CoV-2 infection patients,also become,source,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread including,children.The main source,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread including,children.The source,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
SARS-CoV-2 infection patients,become,source,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread to,its infectivity,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
SARS-CoV-2 infection patients,source of,infection,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
people,are,generally susceptible,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
SARS-CoV-2 infection patients,also become,source of infection,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread to,its strong infectivity,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread to,children.Due,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread including,children.The source of infection,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
outbreak,has spread including,children.The main source of infection,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
SARS-CoV-2 infection patients,become,source of infection,"An outbreak of pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection has spread to children.Due to its strong infectivity, people are generally susceptible, including children.The main source of infection is the SARS-CoV-2 infection patients, asymptomatic infection may also become the source of infection."
therapies,involving,combination of medicine,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,published articles including,drug treatment options,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
efficacy,is in,treatment of COVID-19,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
therapies,involving,combination,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,articles including,drug treatment options for SARS-CoV-2,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,articles for,health emergencies,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
therapies,involving,combination of Chinese medicine,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
involving,combination of,Chinese medicine,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,articles including,drug treatment options,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,published articles including,drug treatment options for SARS-CoV-2,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,published articles for,health emergencies,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,articles for,public health emergencies,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
involving,combination of,medicine,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
issue,published articles for,public health emergencies,"This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies."
clinical studies,test safety in,treatment in China,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
results,have,have achieved,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
studies,test safety in,treatment of coronavirus disease 2019,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
clinical studies,test safety in,treatment of coronavirus disease 2019 in China,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
promising results,have,have achieved,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
studies,test,safety,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
results,have,have achieved thus far,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
results,have,have achieved far,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
studies,test safety in,treatment of coronavirus disease 2019 in China,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
clinical studies,test safety in,treatment of coronavirus disease 2019,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
studies,test safety in,treatment,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
studies,test safety in,treatment in China,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
promising results,have,have achieved thus far,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
treatment,is in,China,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
studies,test,their efficacy,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
promising results,have,have achieved far,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
clinical studies,test,safety,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
clinical studies,test,their efficacy,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
clinical studies,test safety in,treatment,"Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far."
institution,is in,China,"The cases reported to date suggest that most are older adults; it is currently unclear whether comorbidities reflect the age group affected or whether they are risk factors for severe disease.4, 5 Early studies using data before the institution of public health interventions in China suggest that SARSâ€CoVâ€2 is as transmissible as SARS coronavirus and probably more transmissible than influenza viruses.6, 7 The timing of infectiousness relative to symptom onset is a particularly important parameter with implications for public health control."
important parameter,is with,implications for public health control,"The cases reported to date suggest that most are older adults; it is currently unclear whether comorbidities reflect the age group affected or whether they are risk factors for severe disease.4, 5 Early studies using data before the institution of public health interventions in China suggest that SARSâ€CoVâ€2 is as transmissible as SARS coronavirus and probably more transmissible than influenza viruses.6, 7 The timing of infectiousness relative to symptom onset is a particularly important parameter with implications for public health control."
cases,reported to,date,"The cases reported to date suggest that most are older adults; it is currently unclear whether comorbidities reflect the age group affected or whether they are risk factors for severe disease.4, 5 Early studies using data before the institution of public health interventions in China suggest that SARSâ€CoVâ€2 is as transmissible as SARS coronavirus and probably more transmissible than influenza viruses.6, 7 The timing of infectiousness relative to symptom onset is a particularly important parameter with implications for public health control."
influenza viruses .6,timing of,infectiousness,"The cases reported to date suggest that most are older adults; it is currently unclear whether comorbidities reflect the age group affected or whether they are risk factors for severe disease.4, 5 Early studies using data before the institution of public health interventions in China suggest that SARSâ€CoVâ€2 is as transmissible as SARS coronavirus and probably more transmissible than influenza viruses.6, 7 The timing of infectiousness relative to symptom onset is a particularly important parameter with implications for public health control."
importance,is,also reinforced,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
importance,is reinforced by,report,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
23 confirmed cases,is in,Australia,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
incubation period,is,6 days,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
mean incubation period,is,6 days,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
importance,is also reinforced by,report,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
importance,is,reinforced,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
superspreading events,feature of,previous coronavirus outbreaks .10,"While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of â€œsuperspreadingâ€ events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVIDâ€19 in Australia, across five jurisdictions."
criteria,are studies,aim,"The criteria for inclusion are:(1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4)data from multiple reports but originated from one study, where we extract information from all reports; (5)guidelines, includes: national or academic guidelines/experts &lsquo;consensus."
studies,is with,diagnosis criteria meeting,"The criteria for inclusion are:(1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4)data from multiple reports but originated from one study, where we extract information from all reports; (5)guidelines, includes: national or academic guidelines/experts &lsquo;consensus."
outcome,one at,least,"The criteria for inclusion are:(1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4)data from multiple reports but originated from one study, where we extract information from all reports; (5)guidelines, includes: national or academic guidelines/experts &lsquo;consensus."
clinical outcome,one at,least,"The criteria for inclusion are:(1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4)data from multiple reports but originated from one study, where we extract information from all reports; (5)guidelines, includes: national or academic guidelines/experts &lsquo;consensus."
criteria,are,studies,"The criteria for inclusion are:(1) studies that aim to compare LPV/r and placebo/standard for SARS, MERS; (2) studies that include at least one clinical outcome; (3) studies with diagnosis criteria meeting WHO requirement on SARS or MERS; (4)data from multiple reports but originated from one study, where we extract information from all reports; (5)guidelines, includes: national or academic guidelines/experts &lsquo;consensus."
mortality,early use of,LPV/r regimen,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
use,reduce,mortality,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
early use,reduce,mortality of SARS,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
mortality,use of,LPV/r regimen,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
early use,reduce,steroids dosing,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
use,reduce,mortality of SARS,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
early use,reduce,mortality,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
use,reduce,steroids dosing,"The results of included studies indicate the early use of LPV/r regimen can reduce the mortality of SARS and MERS, and reduce steroids dosing."
present guidance,summarizes,current strategies on pre-diagnosis,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
triage,is in,common fever,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
present guidance,summarizes,strategies,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
guidance,summarizes,current strategies,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
present guidance,summarizes,strategies on pre-diagnosis,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
guidance,summarizes,strategies on pre-diagnosis,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
guidance,summarizes,strategies,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
s fever,is in,outpatient department,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
guidance,summarizes,current strategies on pre-diagnosis,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
present guidance,summarizes,current strategies,"The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children&prime;s fever in outpatient department during the novel coronavirus pneumonia epidemic period."
mortality,is higher in,elderly individuals,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
case fatality rate,is,4.30%,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
mortality,is,higher,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
patients,is with,chronic conditions including patients,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
mortality,is higher in,individuals,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
patients,is with,coronary artery disease,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
case fatality rate,is in,patients infected with SARC-CoV-2,"The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension."
mortality rate,However is lower than,that of coronaviruses diseases,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,is,However lower,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,is lower than,that,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,is lower than,that of other coronaviruses diseases,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,is,lower,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,is lower than,that of coronaviruses diseases,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,However is lower than,that of other coronaviruses diseases,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
mortality rate,However is lower than,that,"However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola."
Residents,had,higher awareness rate,"Residents had higher awareness rate of cough (99.5%, n= 3 997) and fever(96.0%, n= 3 857) symptoms, the transmission by droplets (99.5%, n= 3 995), aerosol transmission (81.1%, n= 3 258), and contact transmission (92.3%, n= 3 708), but lower awareness of symptoms os muscle pain or fatigue (62.7%, n= 2 518)."
Residents,had,awareness rate of cough,"Residents had higher awareness rate of cough (99.5%, n= 3 997) and fever(96.0%, n= 3 857) symptoms, the transmission by droplets (99.5%, n= 3 995), aerosol transmission (81.1%, n= 3 258), and contact transmission (92.3%, n= 3 708), but lower awareness of symptoms os muscle pain or fatigue (62.7%, n= 2 518)."
Residents,had,awareness rate,"Residents had higher awareness rate of cough (99.5%, n= 3 997) and fever(96.0%, n= 3 857) symptoms, the transmission by droplets (99.5%, n= 3 995), aerosol transmission (81.1%, n= 3 258), and contact transmission (92.3%, n= 3 708), but lower awareness of symptoms os muscle pain or fatigue (62.7%, n= 2 518)."
Residents,had,fever symptoms,"Residents had higher awareness rate of cough (99.5%, n= 3 997) and fever(96.0%, n= 3 857) symptoms, the transmission by droplets (99.5%, n= 3 995), aerosol transmission (81.1%, n= 3 258), and contact transmission (92.3%, n= 3 708), but lower awareness of symptoms os muscle pain or fatigue (62.7%, n= 2 518)."
Residents,had,higher awareness rate of cough,"Residents had higher awareness rate of cough (99.5%, n= 3 997) and fever(96.0%, n= 3 857) symptoms, the transmission by droplets (99.5%, n= 3 995), aerosol transmission (81.1%, n= 3 258), and contact transmission (92.3%, n= 3 708), but lower awareness of symptoms os muscle pain or fatigue (62.7%, n= 2 518)."
cases,were,multiple lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
8 cases,were,1 lesion,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
cases,were,1 lesion,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
cases,were,lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
cases,were,lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
93 cases,were,multiple lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
cases,were,distributed,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
5 cases,were,2 lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
12 cases,were,lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
cases,were,nodular lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
41 cases,were,distributed,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
cases,were,2 lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
12 cases,were,nodular lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
93 cases,were,lesions,"41 cases (38.7%) were distributed at the same time; 8 cases (7.5%) were 1 lesion, 5 cases (4.7%) were 2 lesions, 93 cases (87.8%) were multiple lesions, and 12 cases were nodular lesions (11.3%)."
ground-glass lesions,of cases is,cases,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
94 cases,cases of,cord-like lesions,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
cord-like lesions,of cases is,15 cases,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
cases,cases of,coexisting lesions,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
cord-like lesions,of cases is,6.60%,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
enlarged mediastinal lymph nodes,with cases is,22.60%,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
24 cases,is with,enlarged mediastinal lymph nodes,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
ground-glass lesions,of cases is,88.70%,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
coexisting lesions,of cases is,14.20%,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
pleural effusion,with cases is,2.80%,"94 cases of ground-glass lesions (88.7%), 7 cases of cord-like lesions (6.6%), 15 cases (14.2%) of coexisting lesions of two or more forms; 10 cases (9.4%) involving one lung lobe There were 96 cases (90.6%) involving two or more lung lobes; 24 cases (22.6%) with enlarged mediastinal lymph nodes (19 cases over 60 years old, accounting for 79.2%); 3 cases with pleural effusion (2.8 %), 1 case had pericardial effusion (0.9%), and 2 cases had pleural involvement / thickening (1.9%)."
it,causes,Coronavirus Disease 2019,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Severe Acute Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Severe Respiratory Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Severe Acute Respiratory Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Acute Respiratory Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,SARS-CoV-2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Acute Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Respiratory Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
International Committee,named,virus Severe Syndrome Coronavirus 2,"The International Committee on Viral Classification named the virus 'Severe Acute Respiratory Syndrome Coronavirus 2' (SARS-CoV-2), and the WHO named the pneumonia it causes 'Coronavirus Disease 2019' (COVID-19)."
diarrhea,surgical or other wound with,fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
contact,is expected with,items,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical invasive wound with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,diarrhea,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,surgical wound,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
virus,could spread for,purposes of research,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,invasive wound with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,invasive wound with fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,wound with oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
contact,is,when expected,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,surgical invasive wound with oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,wound with fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
surgical invasive wound,is with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical wound with,fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical or other wound with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical invasive wound with,fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,wound,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,invasive wound with oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical or other invasive wound with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,surgical wound with oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical wound with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
contact,is,expected,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,surgical wound with fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,surgical or other invasive wound with,fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,wound with,fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
virus,could spread for,purposes,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,invasive wound,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,surgical invasive wound,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,invasive wound with,fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
diarrhea,wound with,oozing fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
patient,has,surgical invasive wound with fluid,"These measures include 1) wearing an efficient mask (an N95 mask); 2) always performing hand hygiene before and after examining a patient; (3) wearing sterile gloves when entering a patient&rsquo;s room and touching a patient; (4) wearing a gown when contact is expected with items and environmental surfaces surrounding a patient or when the patient is incontinent or has diarrhea or a surgical or other invasive wound with oozing fluid; 5) cleaning and disinfecting ophthalmic equipment and correctly handling medical waste after examination to prevent transmission to patients who are subsequently examined; 6) wearing goggles and a disposable mask to cover the front and sides of the face before touching a patient, as the virus could spread through the ocular surface; 7) performing the relevant screening for novel coronavirus pneumonia for regular patients who have conjunctivitis and respiratory symptoms at the same time; 8) prohibiting the use of infected patients as potential donors for corneal transplants and temporarily adding donor SARS-CoV-2 screening to the medical standard of the eye bank during the outbreak; and 9) for the purposes of scientific research, diagnosis, and other special needs, packing, shipping, and transporting collected specimens according to the relevant dangerous biological goods regulations."
effect,preventive effect for,staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
curative effect,preventive effect for,Chinese staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
effect,preventive effect for,Chinese staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
effect,effect for,Chinese staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
effect,effect for,staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
curative effect,effect for,Chinese staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
curative effect,effect for,staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
curative effect,preventive effect for,staff,"To observe the curative effect of TCM syndrome differentiation and treatment for novel coronavirus pneumonia (novel coronavirus pneumonia, NCP) patients and the preventive effect for Chinese medical staff."
patients,confirmed with,NCP,"After taking traditional Chinese medicine, 16 out of 25 NCP suspected patients with phlegm heat stagnating lung syndrome were discharged to home for isolation observation, 4 patients hospitalized for observation, and 5 patients confirmed with NCP."
patients,taking,medicine,"After taking traditional Chinese medicine, 16 out of 25 NCP suspected patients with phlegm heat stagnating lung syndrome were discharged to home for isolation observation, 4 patients hospitalized for observation, and 5 patients confirmed with NCP."
patients,taking,traditional Chinese medicine,"After taking traditional Chinese medicine, 16 out of 25 NCP suspected patients with phlegm heat stagnating lung syndrome were discharged to home for isolation observation, 4 patients hospitalized for observation, and 5 patients confirmed with NCP."
patients,taking,traditional medicine,"After taking traditional Chinese medicine, 16 out of 25 NCP suspected patients with phlegm heat stagnating lung syndrome were discharged to home for isolation observation, 4 patients hospitalized for observation, and 5 patients confirmed with NCP."
patients,taking,Chinese medicine,"After taking traditional Chinese medicine, 16 out of 25 NCP suspected patients with phlegm heat stagnating lung syndrome were discharged to home for isolation observation, 4 patients hospitalized for observation, and 5 patients confirmed with NCP."
suspected patients,is with,phlegm heat stagnating,"After taking traditional Chinese medicine, 16 out of 25 NCP suspected patients with phlegm heat stagnating lung syndrome were discharged to home for isolation observation, 4 patients hospitalized for observation, and 5 patients confirmed with NCP."
angiotensin converting enzyme,of allele is,D allele,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
study,has suggested,that deletion allele,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
recent study,has suggested,that deletion allele of angiotensin enzyme,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
recent study,has suggested,that deletion allele,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
study,has suggested,that deletion allele of angiotensin converting enzyme,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
hypoxemia,is in,SARS patients,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
recent study,has suggested,that deletion allele of angiotensin converting enzyme,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
study,has suggested,that deletion allele of angiotensin enzyme,A recent study has suggested that the deletion allele (D allele) of the angiotensin converting enzyme (ACE) gene is associated with hypoxemia in SARS patients.
viral infections,are characterized by,infiltration including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration including activated neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration including activated neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration of leukocytes including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration of leukocytes including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are,characterized,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are,characterized,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration including activated neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration of leukocytes,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
BACKGROUND,characterized by,infiltration of leukocytes including activated neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration of leukocytes including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration including activated neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are,characterized,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration of leukocytes including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration of leukocytes,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration including activated neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are,characterized,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration of leukocytes,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration including activated neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration including activated neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration of leukocytes including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration of leukocytes including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration of leukocytes including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory infections,are characterized by,infiltration including neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
infections,are characterized by,infiltration,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration of leukocytes,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
viral infections,are characterized by,infiltration of leukocytes including neutrophils,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
Respiratory viral infections,are characterized by,infiltration including activated neutrophils into lung,"BACKGROUND: Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease."
BACKGROUND,described During,acute phase of severe acute respiratory syndrome,"BACKGROUND: During the acute phase of severe acute respiratory syndrome (SARS), mononuclear cells infiltration, alveolar cell desquamation and hyaline membrane formation have been described, together with dysregulation of plasma cytokine levels."
BACKGROUND,described together with,dysregulation of plasma cytokine levels,"BACKGROUND: During the acute phase of severe acute respiratory syndrome (SARS), mononuclear cells infiltration, alveolar cell desquamation and hyaline membrane formation have been described, together with dysregulation of plasma cytokine levels."
Pulse steroid therapy,were,two factors associated with delayed resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
Pulse steroid therapy,were,two independent factors associated with delayed resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
Pulse steroid therapy,were,two independent factors associated with resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two independent factors,associated with,delayed resolution pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two independent factors,is in,non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two factors,associated with,delayed resolution pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two factors,associated with,resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two independent factors,associated with,resolution pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two independent factors,associated with,delayed resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two factors,associated with,delayed resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two factors,associated with,resolution pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution of pneumonitis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution of pneumonitis in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with delayed resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution of pneumonitis in non-randomized analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors associated with delayed resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with resolution in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors associated with resolution of pneumonitis in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two factors in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
prolonged fever,were,two independent factors associated with delayed resolution of pneumonitis in non-randomized retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with delayed resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
two independent factors,associated with,resolution,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two factors associated with resolution in analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
fever,were,two independent factors in retrospective analysis,"Pulse steroid therapy and prolonged fever were two independent factors associated with delayed resolution of pneumonitis, in this non-randomized, retrospective analysis."
Severe Acute Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Acute Respiratory Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Respiratory Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Severe Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Acute Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Severe Acute Respiratory Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Severe Acute Respiratory Syndrome coronavirus,cause of,life-threatening atypical pneumonia,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
Severe Respiratory Syndrome coronavirus,induces,parenchyma cells,"Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), cause of the life-threatening atypical pneumonia, infects many organs, such as lung, liver and immune organ, and induces parenchyma cells apoptosis and necrosis."
infected person,expels,microorganisms,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
person,expels microorganisms to,surrounding environment,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
person,expels,pathogenic microorganisms,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
infected person,expels microorganisms to,surrounding environment,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
infected person,expels microorganisms to,environment,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
infected person,expels,pathogenic microorganisms,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
person,expels microorganisms to,environment,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
person,expels,microorganisms,BACKGROUND: Infectious respiratory diseases are transmitted to non-infected subjects when an infected person expels pathogenic microorganisms to the surrounding environment when coughing or sneezing.
mechanism,may explain,autoimmunity,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,autoimmunity including type II diabetes,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,forms,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,so-called viral autoimmunity including type II diabetes,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,so-called viral autoimmunity,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,forms of obesity,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,viral autoimmunity including type II diabetes,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,so-called autoimmunity including type II diabetes,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,so-called autoimmunity,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
mechanism,may explain,viral autoimmunity,"This mechanism â€“ ""Viral Receptor Disease (VRD)"" â€“ may explain so-called ""viral autoimmunity"", some classical autoimmune disorders and other diseases, including type II diabetes mellitus, and some forms of obesity."
receptor disease,is,hypothesis,"Viral receptor disease is a unifying hypothesis that may also explain some diseases with well-established, but multi-factorial and apparently unrelated aetiologies â€“ like coronary artery and other vascular diseases â€“ in addition to diseases like schizophrenia that are poorly understood and lack plausible, coherent, pathogenic explanations."
diseases,is with,well-established,"Viral receptor disease is a unifying hypothesis that may also explain some diseases with well-established, but multi-factorial and apparently unrelated aetiologies â€“ like coronary artery and other vascular diseases â€“ in addition to diseases like schizophrenia that are poorly understood and lack plausible, coherent, pathogenic explanations."
Viral receptor disease,is,hypothesis,"Viral receptor disease is a unifying hypothesis that may also explain some diseases with well-established, but multi-factorial and apparently unrelated aetiologies â€“ like coronary artery and other vascular diseases â€“ in addition to diseases like schizophrenia that are poorly understood and lack plausible, coherent, pathogenic explanations."
Viral receptor disease,is,unifying hypothesis,"Viral receptor disease is a unifying hypothesis that may also explain some diseases with well-established, but multi-factorial and apparently unrelated aetiologies â€“ like coronary artery and other vascular diseases â€“ in addition to diseases like schizophrenia that are poorly understood and lack plausible, coherent, pathogenic explanations."
receptor disease,is,unifying hypothesis,"Viral receptor disease is a unifying hypothesis that may also explain some diseases with well-established, but multi-factorial and apparently unrelated aetiologies â€“ like coronary artery and other vascular diseases â€“ in addition to diseases like schizophrenia that are poorly understood and lack plausible, coherent, pathogenic explanations."
disease,is,unifying,"Viral receptor disease is a unifying hypothesis that may also explain some diseases with well-established, but multi-factorial and apparently unrelated aetiologies â€“ like coronary artery and other vascular diseases â€“ in addition to diseases like schizophrenia that are poorly understood and lack plausible, coherent, pathogenic explanations."
Pneumothorax,complicates,management of acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
patients,is in,isolation intensive care unit,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,SARS,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of ventilated acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated severe acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of mechanically ventilated acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of mechanically ventilated syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,complicates,management of ventilated severe acute syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of acute respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,mechanically ventilated severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of severe syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,often complicates,management of severe respiratory syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
Pneumothorax,management of,ventilated syndrome,INTRODUCTION: Pneumothorax often complicates the management of mechanically ventilated severe acute respiratory syndrome (SARS) patients in the isolation intensive care unit (ICU).
our results,suggest,similarities to syndrome,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection characteristically seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection characteristically seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome characteristically seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities characteristically seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome characteristically seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities characteristically seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection characteristically seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome characteristically seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection characteristically seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection characteristically seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
similarities,seen in,children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
similarities,characteristically seen in,children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection characteristically seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome characteristically seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome of SARS-CoV infection seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
similarities,seen in,young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
similarities,characteristically seen in,young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome characteristically seen in young children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome seen,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities characteristically seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to milder syndrome characteristically seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
our results,suggest,similarities to syndrome of SARS-CoV infection seen in children,"CONCLUSIONS: SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children."
unidentified environmental reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
natural transmission,is in,sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
natural transmission,is in,sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission of prion diseases in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
unidentified environmental reservoir,contributes to,natural transmission of prion diseases,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
environmental reservoir,contributes to,natural transmission in sheep,"An unidentified environmental reservoir of infectivity contributes to the natural transmission of prion diseases (transmissible spongiform encephalopathies [TSEs]) in sheep, deer, and elk."
symptoms,warrant,change in medical management,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
change,is in,medical management,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
exacerbation,is,event defined in terms of subjective descriptors,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
exacerbation,is,event defined in terms of descriptors,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
exacerbation,is,event,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
symptoms,warrant,change,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
symptoms,warrant,change in management,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
exacerbation,is,event defined in terms,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
exacerbation,is,event defined,"An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management."
Respiratory virus infection,is,risk factor for development,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
Respiratory virus infection,is,risk factor for development of asthma,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
bronchiolitis,is in,infants,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
Respiratory syncytial virus infection,is,risk factor,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
virus infection,is,risk factor,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
Respiratory syncytial virus infection,is,risk factor for development of asthma,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
syncytial virus infection,is,risk factor for development,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
syncytial virus infection,is,risk factor for development of asthma,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
virus infection,is,risk factor for development of asthma,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
Respiratory virus infection,is,risk factor,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
syncytial virus infection,is,risk factor,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
virus infection,is,risk factor for development,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
Respiratory syncytial virus infection,is,risk factor for development,BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma.
FPS,were,examined,"Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined."
they,were,treated,"Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined."
they,were treated Following,infection,"Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined."
they,were treated with,FP,"Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined."
FPS,were,intranasally examined,"Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined."
they,were,Following infection treated with FP,"Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined."
fluticasone,decreasing airway hyperreactivity in,mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing,airway hyperreactivity,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing inflammation in,allergen-sensitized RSV-infected mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing,inflammation,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
combination,is with,salmeterol,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing airway hyperreactivity than,either,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing inflammation in,allergen-sensitized mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,is in,combination with salmeterol,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing airway hyperreactivity in,RSV-infected mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing airway hyperreactivity in,allergen-sensitized RSV-infected mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing inflammation in,mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing airway hyperreactivity in,allergen-sensitized mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,is,effective,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing inflammation than,either,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing airway hyperreactivity than,either alone,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing inflammation than,either alone,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
fluticasone,decreasing inflammation in,RSV-infected mice,"CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice."
biological markers,involved in,diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,identify,biological markers involved in diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,has,has used,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,has,has successfully used,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,identify,biological markers involved,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,identify,markers involved,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,identify,biological markers involved in diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
biological markers,involved in,autoimmune diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,identify,markers involved,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
markers,involved in,autoimmune diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,identify,biological markers,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
markers,involved in,diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,identify,markers involved in diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,identify,markers involved in diseases,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,identify,biological markers,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,has,has successfully used,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
Immunonic data,identify,markers,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,identify,biological markers involved,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,has,has used,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
data,identify,markers,"Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodeficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines."
administration,altered,homoestasis,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
homoestasis,administration to,HSV-2 mice,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
administration,altered,homoestasis of IFNs host response,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
IFN response,represents,host defense event against infection,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
treatment,is with,meliacine,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
IFN response,represents,early host defense event,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
IFN response,represents,host defense event against viral infection,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
herpetic infection,is in,female mice infected intravaginally with HSV-2,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
homoestasis,administration to,HSV-2 infected mice,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
IFN response,represents,early host defense event against infection,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
homoestasis,administration of,meliacine,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
IFN response,represents,host defense event,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
IFN response,represents,early host defense event against viral infection,"Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response."
may potential therapeutic target,is in,RA treatment,These findings suggest that CD147 may be one of the important factors in progressive joint destruction of RA and that CD147 may be a potential therapeutic target in RA treatment.
important factors,is in,progressive joint destruction of RA,These findings suggest that CD147 may be one of the important factors in progressive joint destruction of RA and that CD147 may be a potential therapeutic target in RA treatment.
analysis,may pave,way to development of therapeutics,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of innovative highly needed therapeutics,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of innovative needed therapeutics,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of innovative needed therapeutics in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of innovative therapeutics in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
lung epithelial function,is in,host response,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
development,is in,pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of innovative therapeutics,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of needed therapeutics,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of needed therapeutics in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of highly needed therapeutics,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of highly needed therapeutics in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of innovative highly needed therapeutics in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development of therapeutics in pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
host response,is in,pneumonia,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
analysis,may pave,way to development,The analysis of lung epithelial function in the host response in pneumonia may pave the way to the development of innovative highly needed therapeutics in pneumonia in addition to antibiotics.
evidence,was detected in,4 individuals,"Serologic evidence of SARS-CoV infection was detected in 4 individuals, including 2 non-clinical workers, who had not previously been identified as SARS cases; none reported having had fever or cough."
evidence,was,detected,"Serologic evidence of SARS-CoV infection was detected in 4 individuals, including 2 non-clinical workers, who had not previously been identified as SARS cases; none reported having had fever or cough."
Serologic evidence,was detected in,4 individuals,"Serologic evidence of SARS-CoV infection was detected in 4 individuals, including 2 non-clinical workers, who had not previously been identified as SARS cases; none reported having had fever or cough."
Serologic evidence,was,detected,"Serologic evidence of SARS-CoV infection was detected in 4 individuals, including 2 non-clinical workers, who had not previously been identified as SARS cases; none reported having had fever or cough."
little,is known regarding,human patterns,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,patterns relevant,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,mixing patterns relevant,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human mixing patterns relevant to spread of infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,mixing patterns relevant to spread of close-contact infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human mixing patterns,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,patterns relevant to spread of close-contact infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is,known,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human patterns relevant,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human patterns relevant to spread of close-contact infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human patterns relevant to spread of infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,mixing patterns relevant to spread of infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,patterns,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human mixing patterns relevant to spread of close-contact infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human mixing patterns relevant,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,patterns relevant to spread,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human mixing patterns relevant to spread,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,mixing patterns,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,mixing patterns relevant to spread,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,patterns relevant to spread of infections,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
little,is known regarding,human patterns relevant to spread,"Surprisingly little is known regarding the human mixing patterns relevant to the spread of close-contact infections, such as measles, influenza and meningococcal disease."
plasma,is in,SARS patients,"METHODS AND FINDINGS: In response to the WHO request we conducted a systematic review of the published literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN), intravenous immunoglobulin (IVIG), and SARS convalescent plasma from both in vitro studies and in SARS patients."
many patients,making,search for new therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,search for new therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search for therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search for new therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search for therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,respond adequately to,treatments,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search for new therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,search for,therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search for new therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search for therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,search for,new therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,respond adequately to,treatments,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,search for therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,search for,new therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search for new therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search for therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
recent successes,is with,biological agents,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search for therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,search for therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search for therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
BACKGROUND,fail Despite,recent successes with biological agents as therapy for autoimmune inflammatory diseases such rheumatoid arthritis,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,continued search for,therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search for therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,continued search for,therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,search for,therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,continued search for,new therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,continued search for,new therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,continued search for,new therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,continued search for,therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,continued search for new therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,search for new therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,search for therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,search for,new therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,respond to,treatments,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
making,search for,therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search for therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search for new therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search for therapies important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,making,search for new therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search for new therapies extremely important,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,continued search for new therapies,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
many patients,making,search,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
patients,respond to,treatments,"BACKGROUND: Despite recent successes with biological agents as therapy for autoimmune inflammatory diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these treatments, making a continued search for new therapies extremely important."
reactive oxygen species,promote,inflammation,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
hypothesis,was,Recently challenged,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
polymorphisms,increase,disease severity in mouse arthritis models,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
hypothesis,was,challenged,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
polymorphisms,is in,Ncf1,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
prevailing hypothesis,was,challenged,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
prevailing hypothesis,was,Recently challenged,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
polymorphisms,were,when shown,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
polymorphisms,increase,disease severity,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
disease severity,is in,mouse arthritis models,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
oxygen species,promote,inflammation,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
polymorphisms,were,shown,"Recently, the prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to increase disease severity in mouse and rat arthritis models."
discovered pathway,leading to,inflammatory disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,introduces class for,treatment,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,leading to,autoimmune inflammatory disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
discovered pathway,leading to,autoimmune inflammatory disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
discovered pathway,leading to,disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
discovered pathway,leading to,autoimmune disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,leading to,inflammatory disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,introduces,novel class,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,introduces,novel class of therapeutics,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,Treatment with,ROS-promoting substances,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,introduces,class,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
discovered pathway,Treatment with,ROS-promoting substances,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,is with,ROS-promoting substances such phytol,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,Treatment with,substances,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,leading to,disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,Treatment of,arthritis,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
discovered pathway,Treatment with,substances,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
discovered pathway,Treatment of,arthritis,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
pathway,leading to,autoimmune disease,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,introduces,class of therapeutics,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Treatment,introduces class for,treatment of RA,CONCLUSIONS: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
influenza,is in,United States,"METHODS AND FINDINGS: We measured rate of inter-regional spread and timing of influenza in the United States for nine seasons, from 1996 to 2005 using weekly influenza and pneumonia mortality from the Centers for Disease Control and Prevention."
present day transmission scenarios,constitutes,weakness in current preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in current preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in current preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in current global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in current preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in current global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in current preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in current global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in current global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in current preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in current global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in current preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in current global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in current preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in current global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in current global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in current global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in current global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in current global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
air transportation,is,one feature,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in current preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in current global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
most,reckoned by,World Health Organization,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in global preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,weakness in preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in global preparedness plan against pandemic flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness in current preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in current preparedness plan against flu,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
present day transmission scenarios,constitutes,major weakness in preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in global preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,weakness,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
day transmission scenarios,constitutes,major weakness in current preparedness plan,"Given that air transportation is the one feature that most differentiates present day transmission scenarios from those in 1918, our present inability to prevent spread of influenza by international air travel, as reckoned by the World Health Organization, constitutes a major weakness in the current global preparedness plan against pandemic flu."
Covariates,associated with,transmission,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,positively associated with,transmission,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,associated with,transmission univariate analysis,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,positively associated at,p,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
transmission,is in,univariate analysis,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,associated with,transmission analysis,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,positively associated with,transmission analysis,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
isolation,to delay is,need for oxygen,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
oxygen,shortness of,breath,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
delay,need for,oxygen,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
isolation,Day of,illness,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,associated at,p,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
Covariates,positively associated with,transmission univariate analysis,"Covariates positively associated with transmission in univariate analysis at p < 0.05 included delay to isolation (Day 7 of illness or later), admission to a non-isolation facility, pre-existing chronic respiratory disease and immunosuppressive disease, need for oxygen, shortness of breath, vomiting, and higher lactate dehydrogenase levels and higher neutrophil counts."
BACKGROUND,was identified In,acute respiratory syndrome coronavirus,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
BACKGROUND,was identified In,severe acute respiratory syndrome coronavirus,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
BACKGROUND,identified as,etiological agent of severe acute respiratory syndrome,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
BACKGROUND,identified In,2003,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
disease,characterized by,pneumonia,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
BACKGROUND,was identified In,severe respiratory syndrome coronavirus,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
disease,characterized by,severe pneumonia,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
BACKGROUND,was identified In,respiratory syndrome coronavirus,"BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death."
MR score,was for,best rapid prediction,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,prediction of intra-amniotic infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,rapid prediction,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,best prediction,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,prediction,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,prediction of infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,best rapid prediction of intra-amniotic infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,best prediction of infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,rapid prediction of intra-amniotic infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,best prediction of intra-amniotic infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,compared with,other laboratory tests,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,compared with,laboratory tests used,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,rapid prediction of infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,compared with,laboratory tests,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,compared with,other laboratory tests routinely used,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,compared with,other laboratory tests used,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,compared with,laboratory tests routinely used,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
MR score,was for,best rapid prediction of infection,"When compared with other laboratory tests routinely used to diagnose amniotic fluid inflammation and infection, the MR score had the highest accuracy to detect inflammation (white blood cell count > 100 cells/mm(3)), whereas the combination of Gram stain and MR score was best for rapid prediction of intra-amniotic infection (positive amniotic fluid culture)."
following plants,are,used,"The following plants are used for abscesses: Berberis aquifolium/Mahonia aquifolium Echinacea purpurea, Symphytum officinale, Bovista pila, Bovista plumbea, Achillea millefolium and Usnea longissima."
plants,are used for,abscesses,"The following plants are used for abscesses: Berberis aquifolium/Mahonia aquifolium Echinacea purpurea, Symphytum officinale, Bovista pila, Bovista plumbea, Achillea millefolium and Usnea longissima."
following plants,are used for,abscesses,"The following plants are used for abscesses: Berberis aquifolium/Mahonia aquifolium Echinacea purpurea, Symphytum officinale, Bovista pila, Bovista plumbea, Achillea millefolium and Usnea longissima."
plants,are,used,"The following plants are used for abscesses: Berberis aquifolium/Mahonia aquifolium Echinacea purpurea, Symphytum officinale, Bovista pila, Bovista plumbea, Achillea millefolium and Usnea longissima."
Curcuma longa L.,are,used,"Curcuma longa L., Salix scouleriana and Salix lucida are used for caprine arthritis and caprine arthritis encephalitis.Euphrasia officinalis and Matricaria chamomilla are used for eye problems."
Curcuma longa L.,are used for,caprine arthritis,"Curcuma longa L., Salix scouleriana and Salix lucida are used for caprine arthritis and caprine arthritis encephalitis.Euphrasia officinalis and Matricaria chamomilla are used for eye problems."
used,are used for,eye problems,"Curcuma longa L., Salix scouleriana and Salix lucida are used for caprine arthritis and caprine arthritis encephalitis.Euphrasia officinalis and Matricaria chamomilla are used for eye problems."
used,are,used,"Curcuma longa L., Salix scouleriana and Salix lucida are used for caprine arthritis and caprine arthritis encephalitis.Euphrasia officinalis and Matricaria chamomilla are used for eye problems."
Wounds,are,treated with Bovista spp.,"Wounds and injuries are treated with Bovista spp., Usnea longissima, Calendula officinalis, Arnica sp., Malva sp., Prunella vulgaris, Echinacea purpurea, Berberis aquifolium/Mahonia aquifolium, Achillea millefolium, Capsella bursa-pastoris, Hypericum perforatum, Lavandula officinalis, Symphytum officinale and Curcuma longa."
Wounds,are,treated,"Wounds and injuries are treated with Bovista spp., Usnea longissima, Calendula officinalis, Arnica sp., Malva sp., Prunella vulgaris, Echinacea purpurea, Berberis aquifolium/Mahonia aquifolium, Achillea millefolium, Capsella bursa-pastoris, Hypericum perforatum, Lavandula officinalis, Symphytum officinale and Curcuma longa."
following plants,are,used,"The following plants are used for diarrhea and scours: Plantago major, Calendula officinalis, Urtica dioica, Symphytum officinale, Pinus ponderosa, Potentilla pacifica, Althaea officinalis, Anethum graveolens, Salix alba and Ulmus fulva."
following plants,are used for,diarrhea,"The following plants are used for diarrhea and scours: Plantago major, Calendula officinalis, Urtica dioica, Symphytum officinale, Pinus ponderosa, Potentilla pacifica, Althaea officinalis, Anethum graveolens, Salix alba and Ulmus fulva."
plants,are,used,"The following plants are used for diarrhea and scours: Plantago major, Calendula officinalis, Urtica dioica, Symphytum officinale, Pinus ponderosa, Potentilla pacifica, Althaea officinalis, Anethum graveolens, Salix alba and Ulmus fulva."
plants,are used for,diarrhea,"The following plants are used for diarrhea and scours: Plantago major, Calendula officinalis, Urtica dioica, Symphytum officinale, Pinus ponderosa, Potentilla pacifica, Althaea officinalis, Anethum graveolens, Salix alba and Ulmus fulva."
Mastitis,is treated with,Achillea millefolium,"Mastitis is treated with Achillea millefolium, Arctium lappa, Salix alba, Teucrium scorodonia and Galium aparine."
Mastitis,is,treated,"Mastitis is treated with Achillea millefolium, Arctium lappa, Salix alba, Teucrium scorodonia and Galium aparine."
Ketosis,is treated with,Gaultheria shallon,"Ketosis is treated with Gaultheria shallon, Vaccinium sp., and Symphytum officinale."
Ketosis,is,treated,"Ketosis is treated with Gaultheria shallon, Vaccinium sp., and Symphytum officinale."
Plants,is with,high validity for wounds,"Plants with high validity for wounds and injuries included Hypericum perforatum, Malva parviflora and Prunella vulgaris."
Plants,included,Prunella vulgaris,"Plants with high validity for wounds and injuries included Hypericum perforatum, Malva parviflora and Prunella vulgaris."
Plants,included,Hypericum perforatum,"Plants with high validity for wounds and injuries included Hypericum perforatum, Malva parviflora and Prunella vulgaris."
Plants,included,Malva parviflora,"Plants with high validity for wounds and injuries included Hypericum perforatum, Malva parviflora and Prunella vulgaris."
Anxiety,are,well treated with Melissa officinalis,Anxiety and pain are well treated with Melissa officinalis and Nepeta caesarea.
Anxiety,are,well treated,Anxiety and pain are well treated with Melissa officinalis and Nepeta caesarea.
Anxiety,are,treated,Anxiety and pain are well treated with Melissa officinalis and Nepeta caesarea.
Anxiety,are,treated with Melissa officinalis,Anxiety and pain are well treated with Melissa officinalis and Nepeta caesarea.
Severe syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
large outbreak,is in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused outbreak in,2003,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,large outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,caused,outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,large outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe respiratory syndrome,large outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,outbreak of,pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe syndrome,caused,outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,large outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,caused,outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,large outbreak of pneumonia,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory syndrome,outbreak in,Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,outbreak,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
respiratory syndrome,outbreak in,China,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
syndrome,caused,large outbreak in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute respiratory syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
Severe acute syndrome,caused,large outbreak of pneumonia in Beijing,"BACKGROUND: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia in Beijing, China, in 2003."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
acute respiratory tract infections,is in,Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
"2,135 patients",is with,acute respiratory tract infections in Brisbane,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
PCR primers,resulted in,detection of 43 additional specimens,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
Screening,using,WU virus,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
specific PCR primers,resulted in,detection,"Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virusâ€“specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus."
healthy volunteers,were,evaluated,"METHODS: Brazilian ATL patients (78 cutaneous, CL, and 58 mucosal leishmaniasis, ML) and 609 healthy volunteers were evaluated."
volunteers,were,evaluated,"METHODS: Brazilian ATL patients (78 cutaneous, CL, and 58 mucosal leishmaniasis, ML) and 609 healthy volunteers were evaluated."
discovery,resulted in,search,This discovery resulted in a search for NADPH oxidase-activating substances as a potential new approach to treat autoimmune disorders such as rheumatoid arthritis (RA).
discovery,resulted in,search for NADPH oxidase-activating substances,This discovery resulted in a search for NADPH oxidase-activating substances as a potential new approach to treat autoimmune disorders such as rheumatoid arthritis (RA).
discovery,resulted in,search for NADPH substances,This discovery resulted in a search for NADPH oxidase-activating substances as a potential new approach to treat autoimmune disorders such as rheumatoid arthritis (RA).
perception,needing,help prepare,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
risk,perception of was,important predictor having considered,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
perception,was important predictor,both having considered,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
perception,was most important predictor,both having considered,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
risk,perception of was,most important predictor having considered,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
perception,was predictor,both having considered,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
risk,perception of was,predictor having considered,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
help,prepare for,pandemic,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
perception,needing,help prepare for pandemic,"Beliefs about the severity of pandemic influenza and the ability to respond were significant independent predictors of having a plan for pandemic influenza, and the perception of the risk of pandemic influenza was the most important predictor of both having considered the impact of, and needing help to prepare for a pandemic."
assay,detect,four pathogens,"The assay was developed to detect four bacterial pathogens (Bordetella pertussis, Streptococcus pyogenes, Chlamydia pneumoniae and Mycoplasma pneumoniae) and 9 viral pathogens (adenovirus 4, coronavirus OC43, 229E and HK, influenza A and B, parainfluinza types 1, 2, and 3 and respiratory syncytial virus."
assay,detect,four bacterial pathogens,"The assay was developed to detect four bacterial pathogens (Bordetella pertussis, Streptococcus pyogenes, Chlamydia pneumoniae and Mycoplasma pneumoniae) and 9 viral pathogens (adenovirus 4, coronavirus OC43, 229E and HK, influenza A and B, parainfluinza types 1, 2, and 3 and respiratory syncytial virus."
assay,detect,9 viral pathogens,"The assay was developed to detect four bacterial pathogens (Bordetella pertussis, Streptococcus pyogenes, Chlamydia pneumoniae and Mycoplasma pneumoniae) and 9 viral pathogens (adenovirus 4, coronavirus OC43, 229E and HK, influenza A and B, parainfluinza types 1, 2, and 3 and respiratory syncytial virus."
assay,was,developed,"The assay was developed to detect four bacterial pathogens (Bordetella pertussis, Streptococcus pyogenes, Chlamydia pneumoniae and Mycoplasma pneumoniae) and 9 viral pathogens (adenovirus 4, coronavirus OC43, 229E and HK, influenza A and B, parainfluinza types 1, 2, and 3 and respiratory syncytial virus."
assay,detect,9 pathogens,"The assay was developed to detect four bacterial pathogens (Bordetella pertussis, Streptococcus pyogenes, Chlamydia pneumoniae and Mycoplasma pneumoniae) and 9 viral pathogens (adenovirus 4, coronavirus OC43, 229E and HK, influenza A and B, parainfluinza types 1, 2, and 3 and respiratory syncytial virus."
seriousness,is with,estimated 50,"BACKGROUND: Despite the seriousness of dengue-related disease, with an estimated 50â€“100 million cases of dengue fever and 250,000â€“500,000 cases of dengue hemorrhagic fever/dengue shock syndrome each year, a clear understanding of dengue pathogenesis remains elusive."
NF-ÎºB,initiated,responses,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
response,is in,dengue patient blood samples,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
dengue viral replication,is in,cell line infection models,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
NF-ÎºB,initiated,IFN,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
NF-ÎºB,initiated,type I interferon,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
NF-ÎºB,initiated,ubiquitin proteasome pathway,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
NF-ÎºB,initiated,immune responses,"METHODOLOGY/PRINCIPAL FINDINGS: Using microarray and high throughput quantitative PCR method to monitor the host response to dengue viral replication in cell line infection models and in dengue patient blood samples, we identified differentially expressed genes along three major pathways; NF-ÎºB initiated immune responses, type I interferon (IFN) and the ubiquitin proteasome pathway."
reliability,is in,context of four heavily studied viral infections,"In this study we have determined the reliability of 10 housekeeping genes in context of four heavily studied viral infections; human immunodeficiency virus type 1, herpes simplex virus type 1, cytomegalovirus and varicella zoster virus infections using a variety of cell types and virus strains."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be targeted as,as influenza viruses,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
continued epidemiologic surveillance,reformulations of,norovirus vaccines,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
reformulations,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
vaccines,be,targeted,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential in control of future outbreaks,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
surveillance,will,will essential,"The continuing evolution of new replacement strains suggests that, as with influenza viruses, vaccines could be targeted that protect against norovirus infections, and that continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential in the control of future outbreaks."
their causative agents,are,For majority RNA viruses,"For the overwhelming majority, their causative agents are RNA viruses which include but are not limited to HIV, Influenza, SARS, Ebola, Dengue, and Hantavirus."
their agents,are,For majority RNA viruses,"For the overwhelming majority, their causative agents are RNA viruses which include but are not limited to HIV, Influenza, SARS, Ebola, Dengue, and Hantavirus."
their causative agents,are,RNA viruses,"For the overwhelming majority, their causative agents are RNA viruses which include but are not limited to HIV, Influenza, SARS, Ebola, Dengue, and Hantavirus."
their agents,are,RNA viruses,"For the overwhelming majority, their causative agents are RNA viruses which include but are not limited to HIV, Influenza, SARS, Ebola, Dengue, and Hantavirus."
their agents,are,For overwhelming majority RNA viruses,"For the overwhelming majority, their causative agents are RNA viruses which include but are not limited to HIV, Influenza, SARS, Ebola, Dengue, and Hantavirus."
Dengue encephalitis virus,is in,Asia,"Increasing cases of Dengue and Japanese encephalitis virus in Asia, frequent outbreaks of Yellow fever virus in Africa and South America, and the ongoing spread of West Nile virus throughout the Americas, show the geographical burden of flavivirus diseases."
frequent outbreaks,is in,Africa,"Increasing cases of Dengue and Japanese encephalitis virus in Asia, frequent outbreaks of Yellow fever virus in Africa and South America, and the ongoing spread of West Nile virus throughout the Americas, show the geographical burden of flavivirus diseases."
Increasing cases,show,burden,"Increasing cases of Dengue and Japanese encephalitis virus in Asia, frequent outbreaks of Yellow fever virus in Africa and South America, and the ongoing spread of West Nile virus throughout the Americas, show the geographical burden of flavivirus diseases."
cases,show,burden,"Increasing cases of Dengue and Japanese encephalitis virus in Asia, frequent outbreaks of Yellow fever virus in Africa and South America, and the ongoing spread of West Nile virus throughout the Americas, show the geographical burden of flavivirus diseases."
HIV infection,is in,humans,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,serves as,natural model,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes disease in,domestic cat,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes disease in,Felis catus,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes mortality in,domestic cat,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,serves as,model for HIV infection,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes mortality in,Felis catus,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,serves as,model,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes,AIDS-like disease,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes mortality in,cat,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,serves as,natural model for HIV infection,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes disease in,cat,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,serves as,model for HIV infection in humans,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes,disease,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,causes,mortality,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
FIV infection,serves as,natural model for HIV infection in humans,FIV infection causes AIDS-like disease and mortality in the domestic cat (Felis catus) and serves as a natural model for HIV infection in humans.
SJL/J mice,immunize with,PDC-E2,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,mitochondrial autoantigen of PBC,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,major mitochondrial autoantigen,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,major mitochondrial autoantigen of PBC,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,major autoantigen,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
development,is in,portal tracts,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,mitochondrial autoantigen,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,pyruvate dehydrogenase complex,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
pyruvate dehydrogenase complex,autoantigen of,PBC,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,autoantigen,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,autoantigen of PBC,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
SJL/J mice,immunize with,major autoantigen of PBC,"Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis."
mild pain,were frequent among,Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
reactions,were,During study similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
fever,were more frequent among,Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
induration,was,however frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
reactions,were generally similar for,vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
reactions,were,During observer-blind study similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
fever,were,more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
fever,were frequent among,Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
induration,however was frequent among,Subunit group,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
injection-site induration,was,frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
pain,were more frequent among,Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
pain,were,frequent among Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
mild pain,were more frequent among,Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
mild pain,were,more frequent among Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
pain,were frequent among,Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
injection-site induration,was more frequent among,Subunit group,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
reactions,were,During observer-blind study generally similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
injection-site induration,was,however frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
injection-site induration,was,however more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
induration,however was more frequent among,Subunit group,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
reactions,were similar for,vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
mild pain,were,frequent among Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
local reactions,were,During observer-blind study generally similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
induration,was,however more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
induration,was,frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
mild pain,were,more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
reactions,were,During study generally similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
local reactions,were,During study generally similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
induration,was,more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
injection-site induration,was,more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
pain,were,frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
local reactions,were,During study similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
local reactions,were,During observer-blind study similar for vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
pain,were,more frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
local reactions,were generally similar for,vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
local reactions,were similar for,vaccines 1 22 days post-vaccination,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
fever,were,frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
pain,were,more frequent among Sub/MF59 â„¢ recipients,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
mild pain,were,frequent,"During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1â€“22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59â„¢ recipients (P â‰¤ 0.005)."
its role,is in,prognosis of patients with lung interstitial fibrosis,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
patients,is with,lung interstitial fibrosis,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
study,investigate,relationship between tumor necrosis factor with occurrence of SARS-CoV infection,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
study,investigate,relationship,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
tumor necrosis factor,is with,occurrence of SARS-CoV infection,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
study,investigate,relationship between tumor necrosis factor with occurrence,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
study,investigate,relationship between tumor necrosis factor,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
occurrence,with factor is,TNF,This study was to investigate the relationship between tumor necrosis factor (TNF)-Î± gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.
two case-case studies,is in,discharged SARS patients,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,were carried out in,two studies in discharged SARS patients,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,is with,interstitial lung fibrosis,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,were carried out in,two case-case studies,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,were carried out in,two studies in SARS patients,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,were carried out in,two case-case studies in SARS patients,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,were carried out in,two case-case studies in discharged SARS patients,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
Relationships,were carried out in,two studies,Relationships of TNF-Î± gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients.
potential effect,was,captured,The potential effect of hepatitis A prevalence in the US on hepatitis A prevalence in Canada was captured through a term representing infection of Canadians due to travel in the US.
potential effect,is in,US on hepatitis A prevalence,The potential effect of hepatitis A prevalence in the US on hepatitis A prevalence in Canada was captured through a term representing infection of Canadians due to travel in the US.
potential effect,was captured through,term,The potential effect of hepatitis A prevalence in the US on hepatitis A prevalence in Canada was captured through a term representing infection of Canadians due to travel in the US.
US,is in,Canada,The potential effect of hepatitis A prevalence in the US on hepatitis A prevalence in Canada was captured through a term representing infection of Canadians due to travel in the US.
representing,infection of,Canadians,The potential effect of hepatitis A prevalence in the US on hepatitis A prevalence in Canada was captured through a term representing infection of Canadians due to travel in the US.
potential effect,was captured through,term due,The potential effect of hepatitis A prevalence in the US on hepatitis A prevalence in Canada was captured through a term representing infection of Canadians due to travel in the US.
cationic copolymers,are,regarded,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are regarded as,agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are regarded as,effective agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are regarded as,agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are regarded as,agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are regarded as,agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
cationic copolymers,are regarded as,effective agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
cationic copolymers,are regarded as,effective agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are regarded as,effective agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are regarded as,agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are,regarded,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
cationic copolymers,are regarded as,agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are regarded as,effective agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
cationic copolymers,are regarded as,agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
cationic copolymers,are regarded as,agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are regarded as,effective agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
cationic copolymers,are regarded as,effective agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are regarded as,effective agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are regarded as,effective agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are regarded as,effective agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are regarded as,agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
enhanced delivery,is in,various applications,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are,regarded,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are regarded as,effective agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are regarded as,effective agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are regarded as,agents,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
copolymers,are,regarded,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic cationic copolymers,are regarded as,agents for delivery,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
Synthetic copolymers,are regarded as,agents for delivery of acids,Synthetic cationic copolymers of poly(ethylene imine) (PEI) and poly(ethylene glycol) (PEG) are regarded as effective agents for enhanced delivery of nucleic acids in various applications.
LC-CD133,showed,significant resistance,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,highly co-expressed,drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,co-expressed,multiple marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,showed,significant resistance to chemotherapy agents,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore highly co-expressed,drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,co-expressed,marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,co-expressed,multiple drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,highly co-expressed,marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore co-expressed,drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,highly co-expressed,multiple marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore highly co-expressed,marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore highly co-expressed,multiple marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,highly co-expressed,multiple drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore co-expressed,multiple drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,showed,resistance,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore co-expressed,marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore co-expressed,multiple marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,co-expressed,drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,showed,resistance to chemotherapy agents,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
LC-CD133,Furthermore highly co-expressed,multiple drug-resistant marker ABCG2,"Furthermore, LC-CD133(+), unlike LC-CD133(âˆ’), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy."
viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,However was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,However found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,However was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,However found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,However was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,However found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,However was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,However found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,However was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,However found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist in,years,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,persist,continuing,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was,found,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
example,was found,suggesting,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
influenza A viruses,continuing,circulate sub-clinically at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate sub-clinically,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,continuing,circulate sub-clinically at levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
viruses,perhaps continuing,circulate at low levels between seasons,"However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged."
nebulised heparin,damage from,deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
nebulised heparin,limit damage in,alveolar space,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,limit,damage,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
nebulised heparin,damage from,fibrin deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
nebulised heparin,limit,damage from fibrin deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
nebulised heparin,limit,damage,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,limit damage in,alveolar space,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,damage from,deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,damage from,fibrin deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
nebulised heparin,limit,damage from deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,limit,damage from fibrin deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
nebulised heparin,limit damage in,space,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,limit,damage from deposition,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
heparin,limit damage in,space,INTRODUCTION: Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation.
Fatal respiratory disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal respiratory disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal respiratory disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is characterized by,lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
respiratory disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human respiratory disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal respiratory disease,is characterized by,severe lung pathology,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal respiratory disease,is characterized by,lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal respiratory disease,is characterized by,lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human respiratory disease,is characterized by,severe lung pathology including pulmonary edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal human disease,is characterized by,severe lung pathology including edema,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal respiratory disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
human disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
Fatal disease,is,characterized,"Fatal human respiratory disease associated with the 1918 pandemic influenza virus and potentially pandemic H5N1 viruses is characterized by severe lung pathology, including pulmonary edema and extensive inflammatory infiltrate."
cells,play role in,acute lung inflammation,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,rapid cell recruitment,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
cells,play role in,acute lung inflammation associated,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,cell recruitment into lungs,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
cells,play role in,acute lung inflammation associated with HP influenza virus infection,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,rapid cell recruitment of macrophages into lungs,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
cells,play role in,lung inflammation,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,cell recruitment,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,rapid cell recruitment into lungs,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,cell recruitment of macrophages,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
cells,play role in,lung inflammation associated,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
cells,play,role,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads,suggesting,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,rapid cell recruitment of macrophages,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
cells,play role in,lung inflammation associated with HP influenza virus infection,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,leads to,cell recruitment of macrophages into lungs,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
infection,is with,HP influenza viruses such H5N1,"These results together show that infection with HP influenza viruses such as H5N1 and the 1918 pandemic virus leads to a rapid cell recruitment of macrophages and neutrophils into the lungs, suggesting that these cells play a role in acute lung inflammation associated with HP influenza virus infection."
case,is in,44-year old Caucasian woman complicated with pneumonia requiring,We report a case of systemic lupus erythematosus (SLE) in a 44-year old Caucasian woman complicated with pneumonia and severe respiratory failure requiring ICU treatment and mechanical ventilation.
Symptoms,developed in,SLE course,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed after,stop in immunosupresant therapy,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed in,generally well controlled SLE course,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed after,sudden stop in immunosupresant therapy,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
sudden stop,is in,immunosupresant therapy,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed in,generally controlled SLE course,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed in,controlled SLE course,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed after,sudden stop,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed after,stop,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
Symptoms,developed in,well controlled SLE course,"Symptoms developed in a generally well controlled SLE course after sudden stop in immunosupresant therapy (methotrexate, cyclosporin and methylprednisolone)."
diagnosis,requires,exclusion,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
diagnosis,requires,exclusion of pneumonia,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
diagnosis,requires,exclusion of pneumonia induced,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
Differential diagnosis,requires,exclusion of pneumonia induced,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
Differential diagnosis,requires,exclusion of pneumonia,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
Differential diagnosis,requires,exclusion,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
diagnosis,requires,exclusion of pneumonia induced by pathogens,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
Differential diagnosis,requires,exclusion of pneumonia induced by pathogens,Differential diagnosis requires exclusion of pneumonia induced by pathogens such as Pneumocystis jirovevecii (carinii) and Mycobacterium sp.
dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disease,is,fatal,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disease,is,fatal,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disease,is,fatal,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disease,is,fatal,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disease,is,fatal,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,is,disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,is,fatal disorder,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
dilatation disease,threatening worldwide,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
Proventricular dilatation disease,threatening,psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
fatal disorder,threatening,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
disorder,threatening worldwide,domesticated psittacine birds,BACKGROUND: Proventricular dilatation disease (PDD) is a fatal disorder threatening domesticated and wild psittacine birds worldwide.
%,level of,change,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
23.80%,had made,level,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
23.80%,had made,level of change,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,were,very or concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
45.50%,were,very or concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,were,or extremely concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
45.50%,were,concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
45.50%,were,or concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,were,very or extremely concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,had made level to,way,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
23.80%,had made level to,way,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
45.50%,were,or extremely concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,had made,level of change,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,were,or concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
45.50%,were,very or extremely concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,had made,level,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
23.80%,level of,change,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
%,were,concerned,Overall 14.9% of the state population thought pandemic influenza was very or extremely likely to occur; 45.5% were very or extremely concerned that they or their family would be affected by pandemic influenza if it occurred; and 23.8% had made some level of change to the way they live their life because of the possibility of pandemic influenza.
Hepatitis C Virus,progresses in,individuals,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses in,individuals co-infected,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses in,individuals co-infected with Human Immunodeficiency Virus-1,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses rapidly in,individuals co-infected with Human Immunodeficiency Virus-1,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses more rapidly,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
mechanisms,are,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
immunologic mechanisms,are,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses rapidly in,individuals,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses rapidly,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses more rapidly in,individuals co-infected with Human Immunodeficiency Virus-1,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses rapidly in,individuals co-infected,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses rapidly in,individuals co-infected with Immunodeficiency Virus-1,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses more rapidly in,individuals co-infected with Immunodeficiency Virus-1,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
underlying mechanisms,are,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
underlying immunologic mechanisms,are,unknown,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses more rapidly in,individuals,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses in,individuals co-infected with Immunodeficiency Virus-1,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
Hepatitis C Virus,progresses more rapidly in,individuals co-infected,"BACKGROUND AND AIMS: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown."
bystander role,accumulation of,functional HIV-specific T-cells,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
accumulation,is in,liver,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
accumulation,inducing,progression of liver disease,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
bystander role,accumulation of,HIV-specific T-cells,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
bystander role,accumulation during,HCV/HIV co-infection,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
accumulation,inducing,progression,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
accumulation,inducing,faster progression,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
accumulation,inducing,faster progression of liver disease,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
bystander role,accumulation in,liver,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
bystander role,accumulation of,T-cells,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
bystander role,accumulation of,functional T-cells,CONCLUSION: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a bystander role for HIV in inducing faster progression of liver disease.
TNF-Î±,is involved in,pathogenesis of hantavirus-caused fever with syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hantavirus-caused hemorrhagic fever,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of fever with renal syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hemorrhagic fever with syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of fever,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of fever with syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hantavirus-caused fever with renal syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hemorrhagic fever,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hantavirus-caused hemorrhagic fever with syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hemorrhagic fever with renal syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is,involved,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
TNF-Î±,is involved in,pathogenesis of hantavirus-caused fever,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
hantavirus-caused hemorrhagic fever,is with,renal syndrome,Since TNF-Î± is involved in the pathogenesis of hantavirus-caused hemorrhagic fever with renal syndrome (HFRS) we investigated its effects on HFRS-causing hantavirus-infected cells.
low,admitted for,AECOPD,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low among COPD patients admitted,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low among COPD patients admitted to ICU,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low admitted to ICU for AECOPD,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
low,admitted to,ICU,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low admitted for AECOPD,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low among COPD patients admitted for AECOPD,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low among COPD patients admitted to ICU for AECOPD,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
40%,is with,PCT,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low admitted to ICU,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is,low admitted,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
likelihood,is low among,COPD patients,CONCLUSION: The likelihood of bacterial infection is low among COPD patients admitted to ICU for AECOPD (40% with PCT < 0.1 Î¼g/L) suggesting a possible inappropriate use of antibiotics.
54 year old male patient,is in,Kampar,"Here we report yet another Melaka-like reovirus (named Kampar virus) isolated from the throat swab of a 54 year old male patient in Kampar, Perak, Malaysia who was suffering from high fever, acute respiratory disease and vomiting at the time of virus isolation."
Human cells,were cultured in,absence,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
cells,activated by,monoclonal antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human cells,were,cultured,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human immunocompetent cells,were cultured in,absence of cadmium,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human immunocompetent cells,activated by,antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
cells,were,cultured,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human cells,activated by,antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
immunocompetent cells,were cultured in,absence of cadmium,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
immunocompetent cells,were,cultured,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human cells,were cultured in,absence of cadmium,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human cells,activated by,monoclonal antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human immunocompetent cells,were cultured in,absence,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
immunocompetent cells,were cultured in,absence,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
immunocompetent cells,activated by,monoclonal antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
cells,activated by,antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human immunocompetent cells,were,cultured,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
Human immunocompetent cells,activated by,monoclonal antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
cells,were cultured in,absence,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
cells,were cultured in,absence of cadmium,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
immunocompetent cells,activated by,antibodies,"METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride."
intranasal infection,results in,nonlethal infection characterized,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,nonlethal infection characterized by titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,nonlethal infection,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,nonlethal infection characterized,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,infection characterized,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,infection characterized by titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,infection characterized by titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,nonlethal infection characterized by titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,infection characterized by high titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,nonlethal infection characterized by high titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,is with,rMA15,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,infection,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,infection characterized,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,nonlethal infection,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,nonlethal infection characterized by titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,nonlethal infection characterized by high titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,nonlethal infection characterized by high titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,nonlethal infection characterized by high titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results In,contrast,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results In,contrast,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,infection characterized by high titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,infection,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,infection characterized by high titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
infection,results in,infection characterized by titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,infection characterized by high titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,nonlethal infection characterized by titer replication within lungs,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
intranasal infection,results in,infection characterized by titer replication,"In contrast, intranasal infection of young 10-week-old C57BL/6 mice with rMA15 results in a nonlethal infection characterized by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body weight, thus providing a useful model to identify host mediators of protection."
genome microarrays,reflected,effects,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,innate response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,innate immune response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,innate response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,innate immune response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,innate immune response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,immune response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
inflammation,effects on,host cell protein processing,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,immune response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
pro-inflammation,is in,Alzheimer 's disease,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
genome microarrays,reflected,effects on host cell protein processing,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,immune response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
genome microarrays,reflected,inflammation,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
Full genome microarrays,reflected,effects,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
Full genome microarrays,reflected,effects on host cell protein processing,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,innate response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,innate response,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
Alzheimer,in,disease,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
oxidized LDL receptor,mediates,response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,immune response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
Full genome microarrays,reflected,inflammation,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
LDL receptor,mediates,innate immune response to beta amyloid,"Full genome microarrays of brains reflected inflammation causing neuronal damage (Gfap), effects on host cell protein processing (ubiquitin ligase), synapse remodeling (Complement 1q), and also increased expression of PD-1L (a ligand that allows persistent LCMV brain infection) and CD 36 (a fatty acid translocase and oxidized LDL receptor that mediates innate immune response to beta amyloid which is associated with pro-inflammation in Alzheimer's disease)."
acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
CONCLUSION,is In,outbred mice,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
abnormalities,secondary to,inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
neurologic abnormalities,secondary to,inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,neurologic abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
abnormalities,secondary to,inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
acquired T. gondii infection,causes,neurologic abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult acquired T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic adult T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
neurologic abnormalities,secondary to,inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult acquired T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,neurologic abnormalities,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic T. gondii infection,causes,abnormalities secondary,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
chronic acquired T. gondii infection,causes,abnormalities secondary to inflammation,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
adult T. gondii infection,causes,neurologic abnormalities secondary to inflammation of brain parenchyma,"CONCLUSION: In outbred mice, chronic, adult acquired T. gondii infection causes neurologic and behavioral abnormalities secondary to inflammation and loss of brain parenchyma."
neurodegeneration,persistence of,parasite in brain,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause inflammation in,genetically susceptible hosts,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause inflammation in,hosts,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause,inflammation,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause,neurodegeneration,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
parasite,is in,brain,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause inflammation in,susceptible hosts,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause neurodegeneration in,susceptible hosts,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause neurodegeneration in,genetically susceptible hosts,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
neurodegeneration,persistence of,parasite,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
persistence,can cause neurodegeneration in,hosts,This mouse model of chronic T. gondii infection raises questions of whether persistence of this parasite in brain can cause inflammation or neurodegeneration in genetically susceptible hosts.
BACKGROUND,become Since,9/11 attack,"BACKGROUND: Since the 9/11 attack and severe acute respiratory syndrome (SARS), the development of qualified and able public health leaders has become a new urgency in building the infrastructure needed to address public health emergencies."
Equine herpesvirus type 1,member of,Alphaherpesvirinae,"BACKGROUND: Equine herpesvirus type 1 (EHV-1), a member of the Alphaherpesvirinae, is spread via nasal secretions and causes respiratory disease, neurological disorders and abortions."
mortality,has,has ascribed,"Influenza-related mortality has been variously ascribed to an ineffective host response that fails to limit viral replication, an excessive host inflammatory response that results in lung injury and impairment of gas exchange, or to bacterial superinfection."
mortality,has,has ascribed to host response,"Influenza-related mortality has been variously ascribed to an ineffective host response that fails to limit viral replication, an excessive host inflammatory response that results in lung injury and impairment of gas exchange, or to bacterial superinfection."
inflammation,is,major cause,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is major cause in,influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is,major cause of mortality in influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is major cause of,mortality,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is major cause in,influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is,cause,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is cause in,influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is major cause of,mortality,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
immune resistance,be,effectively stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is cause of,mortality,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
innate immune resistance,be,effectively stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
immune resistance,be,stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is,major cause of mortality in influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is,cause of mortality in influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
innate resistance,be,stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
innate resistance,be,effectively stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
resistance,be,stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is cause in,influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
resistance,be,effectively stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is cause of,mortality,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is,cause,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
ineffective inflammation,is,major cause,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
major cause,is in,influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
inflammation,is,cause of mortality in influenza pneumonia,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
innate immune resistance,be,stimulated,"CONCLUSIONS: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia."
mice,is with,human lung cancer xenografts,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
targeting peptide,was,When coupled to liposomes,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
targeting peptide,was coupled to,liposomes,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
peptide,was,When coupled to liposomes,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
peptide,was,coupled,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
targeting peptide,was,coupled,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
peptide,was,When coupled,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
peptide,was coupled to,liposomes,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
targeting peptide,was,When coupled,"When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased."
targeting liposomes,increased drug accumulation compared with,drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased,drug accumulation in tumor tissues,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes drugs,resulting from,higher concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased,drug accumulation in tumor tissues,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes free drugs,resulting from,higher concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes free drugs,resulting from,concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes drugs,resulting from,concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation by,5.7-fold,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation by,5.7-fold,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased,drug accumulation,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation by,5.7-fold,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased,drug accumulation in tumor tissues,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes free drugs,resulting from,higher concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes free drugs,resulting from,concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes free drugs,resulting from,higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes drugs,resulting from,higher concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased,drug accumulation in tumor tissues,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,free drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes free drugs,resulting from,concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes free drugs,resulting from,higher concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased,drug accumulation,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes drugs,resulting from,higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes drugs,resulting from,concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,increased drug accumulation compared with,free drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased,drug accumulation,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes drugs,resulting from,concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes drugs,resulting from,higher concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes drugs,resulting from,concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,free drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes drugs,resulting from,higher concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs resulting from concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs resulting from higher concentration of bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation by,5.7-fold,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
drug accumulation,is in,tumor tissues,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased,drug accumulation,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,Furthermore increased drug accumulation compared with,drugs resulting from concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes free drugs,resulting from,higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting from higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes drugs,resulting from,concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes free drugs,resulting from,higher concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting from concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes,Furthermore increased drug accumulation compared with,drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes drugs,resulting from,higher concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,drugs resulting,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes drugs,resulting from,concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes free drugs,resulting from,concentration bioavailable doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
liposomes free drugs,resulting from,concentration,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes,increased drug accumulation compared with,free drugs resulting from higher concentration of doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
targeting liposomes free drugs,resulting from,concentration doxorubicin,"Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin."
common clinical features,were fever Among,patients,"Among the patients, the most common clinical features were fever (100%), arthralgia (90%), rash (50%) and conjunctivitis (40%)."
patients,Among fever is,100%,"Among the patients, the most common clinical features were fever (100%), arthralgia (90%), rash (50%) and conjunctivitis (40%)."
common clinical features,were,fever,"Among the patients, the most common clinical features were fever (100%), arthralgia (90%), rash (50%) and conjunctivitis (40%)."
viral detection,is in,nasopharyngeal samples collected during seasonal influenza virus,"We applied a â€œnext-generationâ€ parallel sequencing platform for viral detection in nasopharyngeal and fecal samples collected during seasonal influenza virus (Flu) infections and norovirus outbreaks from 2005 to 2007 in Osaka, Japan."
viral detection,is in,nasopharyngeal samples collected during seasonal influenza virus,"We applied a â€œnext-generationâ€ parallel sequencing platform for viral detection in nasopharyngeal and fecal samples collected during seasonal influenza virus (Flu) infections and norovirus outbreaks from 2005 to 2007 in Osaka, Japan."
viral detection,is in,nasopharyngeal samples collected during seasonal influenza virus,"We applied a â€œnext-generationâ€ parallel sequencing platform for viral detection in nasopharyngeal and fecal samples collected during seasonal influenza virus (Flu) infections and norovirus outbreaks from 2005 to 2007 in Osaka, Japan."
viral detection,is in,nasopharyngeal samples collected during seasonal influenza virus,"We applied a â€œnext-generationâ€ parallel sequencing platform for viral detection in nasopharyngeal and fecal samples collected during seasonal influenza virus (Flu) infections and norovirus outbreaks from 2005 to 2007 in Osaka, Japan."
viral detection,is in,nasopharyngeal samples collected during seasonal influenza virus,"We applied a â€œnext-generationâ€ parallel sequencing platform for viral detection in nasopharyngeal and fecal samples collected during seasonal influenza virus (Flu) infections and norovirus outbreaks from 2005 to 2007 in Osaka, Japan."
RVFV,causes,severe hemorrhagic illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,is,transmitted,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,causes,hemorrhagic illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,causes fever among,humans,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,causes,severe illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,fever of,abortions,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,causes,fever,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,causes illness among,humans,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
abortions,is in,livestock,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,is transmitted by,mosquitoes,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,causes,illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
RVFV,fever of,abortions in livestock,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and high rates of abortions in livestock."
mutations,have,have linked with disorders,"The mutations in genes encoding for sodium channel proteins have been linked with several inherited genetic disorders such as febrile epilepsy, Brugada syndrome, ventricular fibrillation, long QT syndrome, or channelopathy associated insensitivity to pain."
mutations,have,have linked with genetic disorders,"The mutations in genes encoding for sodium channel proteins have been linked with several inherited genetic disorders such as febrile epilepsy, Brugada syndrome, ventricular fibrillation, long QT syndrome, or channelopathy associated insensitivity to pain."
mutations,have,have linked,"The mutations in genes encoding for sodium channel proteins have been linked with several inherited genetic disorders such as febrile epilepsy, Brugada syndrome, ventricular fibrillation, long QT syndrome, or channelopathy associated insensitivity to pain."
mutations,is in,genes encoding for sodium channel proteins,"The mutations in genes encoding for sodium channel proteins have been linked with several inherited genetic disorders such as febrile epilepsy, Brugada syndrome, ventricular fibrillation, long QT syndrome, or channelopathy associated insensitivity to pain."
Association,has,has detected with AIDs including rheumatoid arthritis,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Association,has,has detected with AIDs including arthritis,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Association,has,has detected with AIDs,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Association,has,has detected with several AIDs,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Association,has,has detected with several AIDs including rheumatoid arthritis,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Association,has,has detected,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Association,has,has detected with several AIDs including arthritis,"Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Gravesâ€™ disease."
Glu47,is involved in,binding,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
important residue,is in,S3 subsite,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is,residue,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
binding,is with,P3Lys of octapeptide,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is residue in,S3 subsite,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is,important,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is involved in,binding with P3Lys,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is,important residue,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is involved in,binding with P3Lys of octapeptide,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is important residue in,S3 subsite,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
Glu47,is,involved,The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite and is involved in binding with P3Lys of the octapeptide.
importance,prevalence of,seven viral,"METHODOLOGY/ PRINCIPAL FINDINGS: We systematically analyzed the prevalence and importance of seven viral, one protozoan (Cytauxzoon felis), and several bacterial (e.g., hemotropic mycoplasma) infections in 77 of approximately 200 remaining free-ranging Iberian lynxes of the DoÃ±ana and Sierra Morena areas, in Southern Spain, between 2003 and 2007."
immunodeficiency virus,was found in,Iberian lynxes,"With the exception of feline immunodeficiency virus (FIV), evidence of infection by all tested feline pathogens was found in Iberian lynxes."
feline immunodeficiency virus,evidence of,infection by tested feline pathogens,"With the exception of feline immunodeficiency virus (FIV), evidence of infection by all tested feline pathogens was found in Iberian lynxes."
immunodeficiency virus,was,found,"With the exception of feline immunodeficiency virus (FIV), evidence of infection by all tested feline pathogens was found in Iberian lynxes."
feline immunodeficiency virus,was found in,Iberian lynxes,"With the exception of feline immunodeficiency virus (FIV), evidence of infection by all tested feline pathogens was found in Iberian lynxes."
feline immunodeficiency virus,was,found,"With the exception of feline immunodeficiency virus (FIV), evidence of infection by all tested feline pathogens was found in Iberian lynxes."
Highlighted areas,include,contribution of early life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
Highlighted areas,include,contribution of severe early life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
Highlighted areas,include,contribution of life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
areas,include,contribution of life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
areas,include,contribution of severe life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
Highlighted areas,include,contribution,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
Highlighted areas,include,contribution of severe life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
areas,include,contribution of severe early life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
severe viral infections,is in,infancy,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
areas,include,contribution,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
differences,is in,innate immune system cytokine responses to viral infection between asthmatic subjects,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
areas,include,contribution of early life,"Highlighted areas include the contribution of severe early life viral infections to asthma inception, genetic determinants of severe viral infections in infancy, the differences in innate and adaptive immune system cytokine responses to viral infection between asthmatic and nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced illness."
duplicated copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
mechanisms,be employed by,other bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
similar mechanisms,be,employed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
similar mechanisms,be employed by,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
mechanisms,be employed by,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
mechanisms,be,employed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
similar mechanisms,be employed by,other bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
mechanisms,be employed by,other bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
similar mechanisms,be,employed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
similar mechanisms,be employed by,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are,observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
mechanisms,be employed by,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed in,bacteria from hot springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
mechanisms,be,employed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are observed in,bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are also observed,suggesting,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar duplicated copies,are observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
duplicated copies,are,also observed,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
similar mechanisms,be employed by,other bacteria,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
Similar copies,are also observed in,bacteria from springs,"Similar duplicated copies of argB are also observed in bacteria from hot springs such as Thermus thermophilus, Deinococcus geothermalis, Deinococcus radiodurans, and Roseiflexus castenholzii, suggesting that similar mechanisms for temperature adaptation may be employed by other bacteria."
review,examines,data related to role of viruses in development,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
data,related to,role viruses development,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data related to role in development of thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are,cited,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data related to role of viruses,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data related to role of viruses in development of thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
role,is in,development of thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
data,related to,role development thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
data,related to,role development,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are,cited,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
data,related to,role,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data related to role,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are,frequently cited,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
data,related to,role viruses development thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data related,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,major environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,major environmental factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
data,related to,role viruses,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
review,examines,data related to role in development,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,major environmental factor involved in thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are,frequently cited,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are frequently cited as,environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are frequently cited as,major environmental factor,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
infections,are cited as,factor involved in subacute thyroiditis,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
Viral infections,are cited as,environmental factor involved,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis.
retroviruses,is in,Graves 's disease,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
Graves,in,disease,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
retroviruses,is in,subacute thyroiditis,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
subacute thyroiditis,in retroviruses is,HFV,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
Hashimoto,in,thyroiditis,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
HTLV-1,is in,Hashimoto 's thyroiditis,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
Asymptomatic UTI,was characterized by,response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
UTI,was characterized by,minimal immune response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
UTI,was,characterized,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
UTI,was characterized by,response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
Asymptomatic UTI,was characterized by,minimal response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
Asymptomatic UTI,was,characterized,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
UTI,was characterized by,immune response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
Asymptomatic UTI,was characterized by,immune response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
Asymptomatic UTI,was characterized by,minimal immune response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
UTI,was characterized by,minimal response,"Asymptomatic UTI was characterized by a minimal immune response that was predominantly monocytic and lymphocytic, with limited lesions, and elevated urinary levels of IFN-Î³, IL-18 and MCP-1 (P â‰¤ 0.02)."
IHC,antigens of,IBV,"Using IHC, antigens of IBV were detected in nasal epithelium, trachea, lung, spleen, myocardial vasculature, liver, gastrointestinal tract, kidney, skin, sclera of the eye, spinal cord, as well as in brain neurons of the inoculated embryos."
GlÃ¤sser,has,disease,"BACKGROUND: Haemophilus parasuis (HPS) is an important swine pathogen that causes GlÃ¤sser's disease, which is characterized by fibrinous polyserositis, meningitis and arthritis."
parasuis,is,important,"BACKGROUND: Haemophilus parasuis (HPS) is an important swine pathogen that causes GlÃ¤sser's disease, which is characterized by fibrinous polyserositis, meningitis and arthritis."
infection,results in,production,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
neutrophil recruitment,is in,response to PVM infection,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
acute infection,results in,production of chemokine,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
acute infection,results in,local production of chemokine,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
acute infection,is with,respiratory pathogen,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
acute infection,results in,production,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
infection,results in,production of chemokine,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
infection,results in,local production of chemokine,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
acute infection,results in,local production,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
infection,results in,local production,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
respiratory pathogen,virus of,mice,"BACKGROUND: We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice."
regression,explore,risk factors,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
logistic regression,was,conducted,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
regression,was,conducted,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
HCWs,were defined as,case group,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
regression,explore,risk factors for SARS infection,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
HCWs,were,defined,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
SARS infection,is in,HCWs,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
HCWs,were,respectively defined,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
logistic regression,explore,risk factors for SARS infection in HCWs,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
HCWs,were respectively defined as,case group,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
logistic regression,explore,risk factors,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
regression,explore,risk factors for SARS infection in HCWs,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
logistic regression,explore,risk factors for SARS infection,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
HCWs,is with,IgG against SARS,"The HCWs with IgG against SARS and those without IgG against SARS were respectively defined as the ""case group"" and the ""control group"", and logistic regression was conducted to explore the risk factors for SARS infection in HCWs."
incidence,was,and positively associated,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
number,caring for,SARS cases,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
air ventilation,is in,wards,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,associated,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
number,caring for,serious SARS cases,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,significantly and positively associated with,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
results,adjusting for,age,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,and associated,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,significantly and associated,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,and associated with,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
face-to-face interaction,is with,SARS patients,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,significantly and associated with,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,significantly and positively associated,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,associated with,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
incidence,was,and positively associated with,"RESULTS: After adjusting for age, gender, marital status, educational level, professional title, and the department in which an individual worked, the results of a multivariate logistic regression analysis indicated that incidence of SARS among HCWs was significantly and positively associated with: performing tracheal intubations for SARS patients, methods used for air ventilation in wards, avoiding face-to-face interaction with SARS patients, the number of pairs of gloves worn by HCWs, and caring for serious SARS cases."
disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive pulmonary disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive pulmonary disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive pulmonary disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
pulmonary disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
pulmonary disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic pulmonary disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
disease,is,treatable,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive pulmonary disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic pulmonary disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
pulmonary disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic pulmonary disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive pulmonary disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
pulmonary disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive disease,is,disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic obstructive pulmonary disease,is,treatable disease state characterised,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
Chronic pulmonary disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive pulmonary disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
disease,is,disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
obstructive pulmonary disease,is,treatable disease state,"Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state, characterised by progressive airflow limitation that is not fully reversible."
COPD,is disease of,lungs,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is now,disease of lungs,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is now,primarily disease of lungs,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is now,primarily disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
COPD,is,disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
COPD,is,disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is,primarily disease of lungs,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
COPD,is,systemic,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
COPD,is,primarily disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is,disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
COPD,is primarily disease of,lungs,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is,primarily disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
COPD,is,systemic disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is,disease of lungs,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
appreciation,is now,disease,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
disease,manifestations of are,lung,"Although COPD is primarily a disease of the lungs there is now an appreciation that many of the manifestations of disease are outside the lung, leading to the notion that COPD is a systemic disease."
diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine vector-borne diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several vector-borne diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
vector-borne diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
vector-borne diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine vector-borne diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several vector-borne diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine vector-borne diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine vector-borne diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine vector-borne diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several vector-borne diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine vector-borne diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine vector-borne diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
vector-borne diseases,have,have identified in canids,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several vector-borne diseases,have,have identified in canids including visceral leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
canine vector-borne diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine diseases,have,have identified,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
vector-borne diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
Several canine diseases,have,have identified in canids including leishmaniosis,"Several canine vector-borne diseases or antibodies to these pathogens have been identified in wild canids including visceral leishmaniosis, Lyme disease, heartworm, hepatozoonosis and anaplasmosis to name a few."
had,catastrophic consequences for,hemophilia patients,"However, the transmission of hepatitis B in the 1970s and of hepatitis C and HIV in the 1980s through plasma-derived factor VIII concentrates had catastrophic consequences for hemophilia patients."
had,consequences for,hemophilia patients,"However, the transmission of hepatitis B in the 1970s and of hepatitis C and HIV in the 1980s through plasma-derived factor VIII concentrates had catastrophic consequences for hemophilia patients."
induced additional chemical shifts,is in,ETM,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind in,contrast,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind at C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen of channel,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was,found,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind at,C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind inside,lumen of channel,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind inside,lumen,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen at C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen of channel at C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
induced additional chemical shifts,is in,ETM,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind in,contrast,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind at C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen of channel,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was,found,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind at,C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind inside,lumen of channel,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,bind inside,lumen,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen at C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind inside lumen of channel at C-terminal,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
drug HMA,was found,bind,"The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM."
Dysfunction,perturbs,regulation,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
mucus transport,leading to,volume,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
mucus transport,leading to,reduced volume,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
Dysfunction mucus,plugging of,airways,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
mucus,plugging of,airways,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
leading,decreased,mucus transport,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
mucus transport,leading to,volume of airway surface liquid,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
mucus transport,leading to,reduced volume of airway surface liquid,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
Dysfunction,is in,cystic fibrosis,"Dysfunction of CFTR in cystic fibrosis (CF) airway epithelium perturbs the normal regulation of ion transport, leading to a reduced volume of airway surface liquid (ASL), mucus dehydration, decreased mucus transport, and mucus plugging of the airways."
Herpes simplex virus type-1,cause,tract infections in patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections in ill patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections in critically ill patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
infections,is in,critically ill patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections in critically ill patients in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections in ill patients in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in critically ill patients in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,tract infections in patients in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in critically ill patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in ill patients in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in patients in individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
Herpes simplex virus type-1,cause,respiratory tract infections in ill patients,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
infections,is in,individuals,BACKGROUND: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract infections in critically ill patients or in individuals that are immunocompromised.
systematic data,is available on,role under maintenance regimen,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available,has investigated by interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
outpatients,is with,autoimmune disease,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is,available,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available,has investigated,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
its role,has,has investigated,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available on,role under maintenance regimen,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available,has investigated by prospective interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available on,role under maintenance regimen of immunosuppression,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available,has investigated by studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available,has investigated,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available on,role of HSV-1,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
its role,has,has investigated by prospective interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available on,role of HSV-1,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available on,role of HSV-1,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available on,role under maintenance regimen,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available,has investigated,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available,has investigated by studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available,has investigated by studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available on,role,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available on,role under maintenance regimen,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is,available,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available on,role,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available,has investigated by prospective studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is,available,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available,has investigated by prospective interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available on,role under maintenance regimen of immunosuppression,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available on,role of HSV-1,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available,has investigated,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available,has investigated by interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available on,role,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available,has investigated by prospective interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
its role,has,has investigated by interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available on,role,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available,has investigated by interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
systematic data,is available,has investigated by prospective studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available on,role of HSV-1 under maintenance regimen,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available,has investigated by studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
its role,has,has investigated by studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is available,has investigated by interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available,has investigated by prospective studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available,has investigated by prospective studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
role,is in,outpatients with autoimmune disease,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
its role,has,has investigated by prospective studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available on,role under maintenance regimen of immunosuppression,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little systematic data,is available,has investigated by prospective interventional studies,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available on,role of HSV-1 under maintenance regimen,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
little data,is,available,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
data,is available on,role under maintenance regimen of immunosuppression,"While its role during critical illness has been investigated by prospective interventional studies, comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients with autoimmune disease under a maintenance regimen of immunosuppression."
~ 1400 patients,is with,rheumatoid arthritis,"METHODS: We retrospectively reviewed the charts of ~1400 patients with rheumatoid arthritis, vasculitis, and systemic lupus erythematosus (SLE) that were followed at the outpatient clinic of a German University hospital during the years 2000â€“2007."
63 patients,is with,rheumatoid arthritis,"RESULTS: 63 patients with rheumatoid arthritis, vasculitis, or SLE were admitted to a ward and diagnosed to have pneumonia/pneumonitis."
Cells,were treated,determine,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
Cells,determine,effect on COX-2,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
Cells,determine,effect,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
Cells,determine,effect of PIN1 depletion on COX-2,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
Cells,were,treated,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
Cells,were treated with,LPS/IFN,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
Cells,determine,effect of PIN1 depletion,"Cells were treated with LPS/IFN, calpain inhibitors (carbobenzoxy-valinyl-phenylalaninal (zVF), PD150606), cycloheximide and COX inhibitors to determine the effect of PIN1 depletion on COX-2 and calpain."
other members,causing infection including,monkeypox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several other members,causing infection including,monkeypox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
other members,causing,human infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
members,causing,human infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
members,causing,infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several members,are capable In addition to,smallpox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several members,causing infection including,monkeypox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several other members,causing,infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several members,causing,human infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
members,are,capable,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several other members,are,capable,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several other members,causing,human infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
other members,are capable In addition to,smallpox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several members,causing,infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
other members,are,capable,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
members,are capable In addition to,smallpox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
other members,causing,infection,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several members,are,capable,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
members,causing infection including,monkeypox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
several other members,are capable In addition to,smallpox,"In addition to smallpox, several other members of the genus are capable of causing human infection, including monkeypox, cowpox, and other zoonotic rodent-borne poxviruses."
Infection,results in,spectrum of clinical illness,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of clinical illness ranging,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of illness ranging from infection,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of illness ranging from asymptomatic infection,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of illness ranging,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of clinical illness ranging from infection,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of illness,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
Infection,results in,spectrum of clinical illness ranging from asymptomatic infection,"Infection results in a spectrum of clinical illness ranging from asymptomatic infection, undifferentiated fever, dengue fever, dengue haemorrhagic fever (DHF) to dengue shock syndrome (DSS)."
infections,is with,asthma,"Though viral respiratory tract infections are reported triggers for exacerbations, information on these infections with asthma is sparse in Caribbean territories."
exacerbations,information on,infections with asthma,"Though viral respiratory tract infections are reported triggers for exacerbations, information on these infections with asthma is sparse in Caribbean territories."
tract infections,are,reported,"Though viral respiratory tract infections are reported triggers for exacerbations, information on these infections with asthma is sparse in Caribbean territories."
respiratory tract infections,are,reported,"Though viral respiratory tract infections are reported triggers for exacerbations, information on these infections with asthma is sparse in Caribbean territories."
viral respiratory tract infections,are,reported,"Though viral respiratory tract infections are reported triggers for exacerbations, information on these infections with asthma is sparse in Caribbean territories."
viral tract infections,are,reported,"Though viral respiratory tract infections are reported triggers for exacerbations, information on these infections with asthma is sparse in Caribbean territories."
cysteine proteases,are involved in,infectious process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are involved in,process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cathepsin B treatment,overcome,block of infection observed in presence,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cathepsin B treatment,overcome,block of infection observed in presence of furin inhibition,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are,involved,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
need,is in,HPV16 infection using,We confirmed the need for cathepsin B in HPV16 infection using cathepsin B null mouse embryonic fibroblasts.
Cl,blocks,trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated by,cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,mediated,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,in part mediated by cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated in,part,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
cysteine proteases,are involved in,infectious process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are involved in,process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are,involved,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
need,is in,HPV16 infection using,We confirmed the need for cathepsin B in HPV16 infection using cathepsin B null mouse embryonic fibroblasts.
Cl,blocks,trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated by,cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,mediated,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,in part mediated by cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated in,part,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
cysteine proteases,are involved in,infectious process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are involved in,process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are,involved,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
need,is in,HPV16 infection using,We confirmed the need for cathepsin B in HPV16 infection using cathepsin B null mouse embryonic fibroblasts.
Cl,blocks,trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated by,cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,mediated,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,in part mediated by cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated in,part,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
cysteine proteases,are involved in,infectious process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are involved in,process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are,involved,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
need,is in,HPV16 infection using,We confirmed the need for cathepsin B in HPV16 infection using cathepsin B null mouse embryonic fibroblasts.
Cl,blocks,trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated by,cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,mediated,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,in part mediated by cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated in,part,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
cysteine proteases,are involved in,infectious process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are involved in,process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are,involved,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
need,is in,HPV16 infection using,We confirmed the need for cathepsin B in HPV16 infection using cathepsin B null mouse embryonic fibroblasts.
Cl,blocks,trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated by,cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,mediated,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,in part mediated by cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated in,part,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
cysteine proteases,are involved in,infectious process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are involved in,process,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
cysteine proteases,are,involved,"We also demonstrate that cysteine proteases are involved in the infectious process, and that cathepsin B treatment of viral particles was shown to overcome the block of infection observed in the presence of furin inhibition."
need,is in,HPV16 infection using,We confirmed the need for cathepsin B in HPV16 infection using cathepsin B null mouse embryonic fibroblasts.
Cl,blocks,trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated by,cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,mediated,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is,in part mediated by cysteine proteases,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,infectious viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
data,is mediated in,part,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,intracellular trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,blocks,trafficking of viral particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
Cl,intracellular trafficking of,infectious particles,"CONCLUSION: We present data that suggest HPV16 infection is in part mediated by cysteine proteases, and that NH(4)Cl blocks the intracellular trafficking of infectious viral particles."
handwashing,was regarded as,feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded by,our participants,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded Of,behaviours likely,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
Handwashing,useful target for,health promotion,"CONCLUSION: Handwashing could prove a useful target for health promotion, but interventions to promote infection control may need to address a number of factors identified within this study as potential barriers to carrying out infection control behaviours."
Handwashing,target for,health promotion,"CONCLUSION: Handwashing could prove a useful target for health promotion, but interventions to promote infection control may need to address a number of factors identified within this study as potential barriers to carrying out infection control behaviours."
handwashing,was regarded as,feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded by,our participants,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded Of,behaviours likely,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than cough than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as more feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as feasible than cough,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,more feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded by our participants as more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,regarded by our participants as more feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was regarded as,feasible,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than social distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
handwashing,was,Of behaviours likely regarded as more feasible than cough than distancing,"Of the behaviours likely to influence infection transmission, handwashing was regarded by our participants as more feasible than cough and sneeze hygiene and more acceptable than social distancing."
Handwashing,useful target for,health promotion,"CONCLUSION: Handwashing could prove a useful target for health promotion, but interventions to promote infection control may need to address a number of factors identified within this study as potential barriers to carrying out infection control behaviours."
Handwashing,target for,health promotion,"CONCLUSION: Handwashing could prove a useful target for health promotion, but interventions to promote infection control may need to address a number of factors identified within this study as potential barriers to carrying out infection control behaviours."
emergencies,may require,treatment,"These emergenciesâ€”which include malignant spinal cord compression, brain metastases, superior vena cava obstruction, and uncontrolled tumour hemorrhage â€”may require treatment outside of hospital hours, particularly on weekends and hospital holidays."
emergencies,may require,treatment particularly on weekends,"These emergenciesâ€”which include malignant spinal cord compression, brain metastases, superior vena cava obstruction, and uncontrolled tumour hemorrhage â€”may require treatment outside of hospital hours, particularly on weekends and hospital holidays."
emergencies,may require,treatment on weekends,"These emergenciesâ€”which include malignant spinal cord compression, brain metastases, superior vena cava obstruction, and uncontrolled tumour hemorrhage â€”may require treatment outside of hospital hours, particularly on weekends and hospital holidays."
%,were treated on,Saturday,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
68%,were,treated,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
%,were treated Of,cohort,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
%,were,treated,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
68%,were,Of cohort treated on Saturday,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
%,were,Of cohort treated on Saturday,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
68%,were treated Of,cohort,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
68%,were treated on,Saturday,"Of this cohort, 68% were treated on both Saturday and Sunday, 22% on Saturday alone, and 10% on Sunday alone."
patient infection rate,accounted for,68.40%,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient infection rate,followed by,urinary tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient nosocomial infection rate,accounted for,68.40%,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient infection rate,followed by,urinary tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient infection rate,followed by,tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient infection rate,followed by,tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient nosocomial infection rate,accounted for,most of infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient infection rate,accounted for,68.40%,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient nosocomial infection rate,accounted for,most,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient infection rate,accounted for,most,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient nosocomial infection rate,accounted for,most of infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
infections,of most is,68.40%,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient infection rate,accounted for,most of infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient infection rate,accounted for,most of infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient nosocomial infection rate,accounted for,most,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient infection rate,accounted for,most,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient nosocomial infection rate,accounted for,68.40%,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient nosocomial infection rate,followed by,urinary tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient nosocomial infection rate,followed by,tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
overall patient nosocomial infection rate,followed by,tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
patient nosocomial infection rate,followed by,urinary tract infections,"RESULTS: Among 1980 patients admitted over the period of time, the overall patient nosocomial infection rate was 26.8% or 51.0 per 1000 patient days., Lower respiratory tract infections (LRTI) accounted for most of the infections (68.4%), followed by urinary tract infections (UTI, 15.9%), bloodstream (BSI, 5.9%), and gastrointestinal tract (GI, 2.5%) infections."
differences,is in,distribution of infection sites,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
rate,was in,ICU of tertiary hospital in China,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
high rate,was in,ICU of tertiary hospital in China,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
rate,was in,ICU,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
high rate,was in,ICU of hospital,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
high rate,was in,ICU,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
rate,was through,year 2003 2007,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
high rate,was in,ICU of tertiary hospital,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
rate,was in,ICU of tertiary hospital,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
tertiary hospital,is in,China,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
rate,was in,ICU of hospital in China,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
high rate,was through,year 2003 2007,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
rate,was in,ICU of hospital,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
high rate,was in,ICU of hospital in China,"CONCLUSION: There was a high and relatively stable rate of nosocomial infections in the ICU of a tertiary hospital in China through year 2003â€“2007, with some differences in the distribution of the infection sites, and pathogen and antibiotic susceptibility profiles from those reported from the Western countries."
number,was modelled as,function of laboratory-confirmed positive tests,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was,modelled,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of tests,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of positive tests,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of positive tests for influenza,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of laboratory-confirmed positive tests for influenza,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of tests for influenza,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
trend,using,Poisson regression,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of laboratory-confirmed tests for influenza,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
number,was modelled as,function of laboratory-confirmed tests,"METHODS AND FINDINGS: The weekly number of influenza-negative tests from 1999 to 2006 was modelled as a function of laboratory-confirmed positive tests for influenza, respiratory syncytial virus (RSV), adenovirus and parainfluenza viruses, seasonality, and trend using Poisson regression."
liquorice,acts like,hyperaldosteronism,"When imbibed, liquorice acts like hyperaldosteronism which presents with typical symptoms including high blood pressure, low blood potassium, and muscle pain and weakness."
paramyxoviruses,are responsible for,infections,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,resulting in,airway inflammation of chronic diseases,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,acute infections in children,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,resulting in,airway inflammation of diseases,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,acute respiratory infections in children,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,acute infections,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,resulting in,airway inflammation,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,resulting in,airway inflammation of diseases like asthma,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are,responsible,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
acute respiratory infections,is in,children,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,respiratory infections,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,acute respiratory infections,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,resulting in,airway inflammation of chronic diseases like asthma,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,infections in children,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
paramyxoviruses,are responsible for,respiratory infections in children,"A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma."
patients,is with,Tourette syndrome,"METHODS: Whole-genome Affymetrix Human 2.0 Plus arrays were examined from 526 samples of males and females ages 2 to 78, including control subjects and patients with Tourette syndrome, stroke, migraine, muscular dystrophy, and autism."
METHODS,examined from,526 samples of males including control subjects,"METHODS: Whole-genome Affymetrix Human 2.0 Plus arrays were examined from 526 samples of males and females ages 2 to 78, including control subjects and patients with Tourette syndrome, stroke, migraine, muscular dystrophy, and autism."
patients,is with,epithelial ovarian carcinoma,"BACKGROUND: The general enhanced expression of Î±(1)-antichymotrypsin (ACT), clusterin (CLU), Î±(1)-antitrypsin (AAT), haptoglobin Î²-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported."
expression,was,reported,"BACKGROUND: The general enhanced expression of Î±(1)-antichymotrypsin (ACT), clusterin (CLU), Î±(1)-antitrypsin (AAT), haptoglobin Î²-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported."
general enhanced expression,was,reported,"BACKGROUND: The general enhanced expression of Î±(1)-antichymotrypsin (ACT), clusterin (CLU), Î±(1)-antitrypsin (AAT), haptoglobin Î²-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported."
general enhanced expression,is in,sera of patients with epithelial ovarian carcinoma,"BACKGROUND: The general enhanced expression of Î±(1)-antichymotrypsin (ACT), clusterin (CLU), Î±(1)-antitrypsin (AAT), haptoglobin Î²-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported."
enhanced expression,was,reported,"BACKGROUND: The general enhanced expression of Î±(1)-antichymotrypsin (ACT), clusterin (CLU), Î±(1)-antitrypsin (AAT), haptoglobin Î²-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported."
general expression,was,reported,"BACKGROUND: The general enhanced expression of Î±(1)-antichymotrypsin (ACT), clusterin (CLU), Î±(1)-antitrypsin (AAT), haptoglobin Î²-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported."
presence,assures,recurrence of lung damage,The presence of antigenically disparate pulmonary viruses and the emergence of novel viruses assures the recurrence of lung damage with infection and resolution of each primary viral infection.
presence,assures recurrence with,infection of primary viral infection,The presence of antigenically disparate pulmonary viruses and the emergence of novel viruses assures the recurrence of lung damage with infection and resolution of each primary viral infection.
presence,assures,recurrence,The presence of antigenically disparate pulmonary viruses and the emergence of novel viruses assures the recurrence of lung damage with infection and resolution of each primary viral infection.
phenotype,increased severity without,evidence for enhanced neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity without,evidence for enhanced neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,was,rather manifested,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity without,evidence,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,increased severity of,demyelination,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity without,evidence for infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,was rather manifested in,onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity without,evidence,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,was manifested in,onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,was rather manifested in,onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,was manifested in,earlier onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity without,evidence for infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,was,manifested,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity in,brain stem,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity without,evidence for neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,was rather manifested in,earlier onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,was,manifested,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity without,evidence for enhanced infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,increased severity without,evidence,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity of,demyelination,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,was rather manifested in,earlier onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity without,evidence for enhanced infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
increased severity,is in,brain stem,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,severity without,evidence for enhanced neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity without,evidence for enhanced neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,was,rather manifested,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity without,evidence for neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,was manifested in,onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity of,demyelination,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,increased severity in,brain stem,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,was manifested in,earlier onset,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,increased severity without,evidence for neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity without,evidence,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity without,evidence for enhanced infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity of,demyelination,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,increased severity without,evidence for infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity in,brain stem,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
unique phenotype,increased severity without,evidence for infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity without,evidence for neuronal infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,severity in,brain stem,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
phenotype,increased severity without,evidence for enhanced infection,The unique phenotype of infected RL(âˆ’/âˆ’) mice was rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord without evidence for enhanced neuronal infection.
Patients,were,identified,"Patients with incident severe gallstone disease (acute cholecystitis, biliary pancreatitis, acute cholangitis) and gallstone-related procedures (elective and non-elective cholecystectomy, endoscopic retrograde cholangiopancreatography [ERCP]) that led to hospital admission were identified using ICD-9-CM diagnostic and procedure codes."
Patients,using,ICD-9-CM codes,"Patients with incident severe gallstone disease (acute cholecystitis, biliary pancreatitis, acute cholangitis) and gallstone-related procedures (elective and non-elective cholecystectomy, endoscopic retrograde cholangiopancreatography [ERCP]) that led to hospital admission were identified using ICD-9-CM diagnostic and procedure codes."
Patients,is with,incident severe gallstone disease,"Patients with incident severe gallstone disease (acute cholecystitis, biliary pancreatitis, acute cholangitis) and gallstone-related procedures (elective and non-elective cholecystectomy, endoscopic retrograde cholangiopancreatography [ERCP]) that led to hospital admission were identified using ICD-9-CM diagnostic and procedure codes."
substantial change,is in,incidence of acute cholecystitis,"For those aged â‰¥60, incidences of biliary pancreatitis, acute cholangitis, and hospital admission for gallstone receiving ERCP increased significantly without substantial change in the incidence of acute cholecystitis and despite a decreased rate of elective cholecystectomy."
incidences,increased For,aged â‰¥ 60,"For those aged â‰¥60, incidences of biliary pancreatitis, acute cholangitis, and hospital admission for gallstone receiving ERCP increased significantly without substantial change in the incidence of acute cholecystitis and despite a decreased rate of elective cholecystectomy."
incidences,increased For,â‰¥ 60,"For those aged â‰¥60, incidences of biliary pancreatitis, acute cholangitis, and hospital admission for gallstone receiving ERCP increased significantly without substantial change in the incidence of acute cholecystitis and despite a decreased rate of elective cholecystectomy."
slide surfaces,were examined,chelated Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
Two slide surfaces,were examined,chelated Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
slide surfaces,were examined,Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
Two slide surfaces,were examined,Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
slide surfaces,were examined,chelated Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
Two slide surfaces,were examined,chelated Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
slide surfaces,were examined,Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
Two slide surfaces,were examined,Cu,"RESULTS: Two slide surfaces were examined, chelated Cu(2+ )slides suspended on a polyethylene glycol (PEG) coating and chelated Ni(2+ )slides immobilized on a support without PEG coating."
Dependovirus,associated with,latent infection,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,associated with,latent infection in geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,is,Dependovirus associated with infection in geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,is,Dependovirus,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Dependovirus,associated with,latent infection geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,associated with,infection in geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Dependovirus,associated with,infection geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,is,Dependovirus associated with infection,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,is,Dependovirus associated with latent infection in geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
latent infection,is in,geese,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,associated with,latent infection,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Dependovirus,associated with,infection,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,is,Dependovirus associated,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,associated with,infection,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
Goose parvovirus,is,Dependovirus associated with latent infection,BACKGROUND: Goose parvovirus (GPV) is a Dependovirus associated with latent infection and mortality in geese.
bacterial infection,is in,chronic obstructive pulmonary disease,"In this study, we describe PCT levels overtime and their relationship with bacterial infection in chronic obstructive pulmonary disease (COPD) critically ill patients with pneumonia."
ill patients,is with,pneumonia,"In this study, we describe PCT levels overtime and their relationship with bacterial infection in chronic obstructive pulmonary disease (COPD) critically ill patients with pneumonia."
their relationship,is with,bacterial infection in chronic obstructive pulmonary disease,"In this study, we describe PCT levels overtime and their relationship with bacterial infection in chronic obstructive pulmonary disease (COPD) critically ill patients with pneumonia."
bacterial infection,is in,severe COPD patients with pneumonia,CONCLUSION: Based on these results we suggest that a PCT level cut off > 0.1 Î¼g/L may be more appropriate than 0.25 Î¼g/L (previously proposed for non severe lower respiratory tract infection) to predict the probability of a bacterial infection in severe COPD patients with pneumonia.
PCT level,cut off,> 0.1 Î¼g/L,CONCLUSION: Based on these results we suggest that a PCT level cut off > 0.1 Î¼g/L may be more appropriate than 0.25 Î¼g/L (previously proposed for non severe lower respiratory tract infection) to predict the probability of a bacterial infection in severe COPD patients with pneumonia.
severe COPD patients,is with,pneumonia,CONCLUSION: Based on these results we suggest that a PCT level cut off > 0.1 Î¼g/L may be more appropriate than 0.25 Î¼g/L (previously proposed for non severe lower respiratory tract infection) to predict the probability of a bacterial infection in severe COPD patients with pneumonia.
studies,testing,strategies,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
Further studies,are needed in,COPD patients with severe pneumonia,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
Further studies,are,needed,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
studies,testing,antibiotic strategies,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
Further studies,testing,strategies,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
COPD patients,is with,severe pneumonia,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
Further studies,testing,antibiotic strategies,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
Further studies,are needed in,COPD patients,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
studies,are needed in,COPD patients,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
studies,are,needed,Further studies testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
P aeruginosa,were indistinguishable by,molecular typing,P aeruginosa from sputum and paired cough aerosols were indistinguishable by molecular typing.
P aeruginosa,were indistinguishable by,typing,P aeruginosa from sputum and paired cough aerosols were indistinguishable by molecular typing.
P aeruginosa,were,indistinguishable,P aeruginosa from sputum and paired cough aerosols were indistinguishable by molecular typing.
P aeruginosa,were,cultivated,"P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range."
P aeruginosa,were,cultivated from particles in size range,"P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range."
P aeruginosa,were cultivated in,size range,"P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range."
P aeruginosa,were,cultivated from respiratory particles in size range,"P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range."
P aeruginosa,were cultivated from,particles,"P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range."
P aeruginosa,were cultivated from,respiratory particles,"P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range."
patients,produce,viable aerosols,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,aerosols of,P aeruginosa,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,is with,CF,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
suggesting,potential for,transmission,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,suggesting,potential for airborne transmission,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,produce,aerosols,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,produce,aerosols of P aeruginosa,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,produce aerosols,coughing,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,produce,viable aerosols of P aeruginosa,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,suggesting,potential,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
suggesting,potential for,airborne transmission,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,viable aerosols of,P aeruginosa,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
patients,suggesting,potential for transmission,"CONCLUSION: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission."
changes,is in,pork consumption RESULTS,"Measures assessed changes in transport usage, purchase of preparatory goods for a pandemic, perceived risk groups, indicators of anxiety, assessed estimated mortality rates for seasonal flu, effectiveness of seasonal flu vaccination, and changes in pork consumption RESULTS: 26% of the respondents were 'very concerned' about being a flu victim (42% Malaysians, 5% Europeans, p < .001)."
changes,is in,usage,"Measures assessed changes in transport usage, purchase of preparatory goods for a pandemic, perceived risk groups, indicators of anxiety, assessed estimated mortality rates for seasonal flu, effectiveness of seasonal flu vaccination, and changes in pork consumption RESULTS: 26% of the respondents were 'very concerned' about being a flu victim (42% Malaysians, 5% Europeans, p < .001)."
Measures,assessed,changes in transport usage,"Measures assessed changes in transport usage, purchase of preparatory goods for a pandemic, perceived risk groups, indicators of anxiety, assessed estimated mortality rates for seasonal flu, effectiveness of seasonal flu vaccination, and changes in pork consumption RESULTS: 26% of the respondents were 'very concerned' about being a flu victim (42% Malaysians, 5% Europeans, p < .001)."
Measures,assessed,changes,"Measures assessed changes in transport usage, purchase of preparatory goods for a pandemic, perceived risk groups, indicators of anxiety, assessed estimated mortality rates for seasonal flu, effectiveness of seasonal flu vaccination, and changes in pork consumption RESULTS: 26% of the respondents were 'very concerned' about being a flu victim (42% Malaysians, 5% Europeans, p < .001)."
64%,greatly underestimated mortality rates In,data,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,underestimated mortality rates In,data collected only in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
data,collected in,Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,underestimated mortality rates In,data,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,greatly underestimated mortality rates In,data collected in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,greatly underestimated mortality rates In,data collected only in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,underestimated mortality rates In,data collected only in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,underestimated mortality rates In,data collected in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,greatly underestimated mortality rates In,data,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,underestimated mortality rates In,data collected,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,greatly underestimated mortality rates In,data collected in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,greatly underestimated mortality rates In,data collected,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,greatly underestimated mortality rates In,data collected,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
data,collected in,only Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
%,greatly underestimated mortality rates In,data collected only in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,underestimated mortality rates In,data collected in Europe,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,underestimated mortality rates In,data collected,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
64%,underestimated mortality rates In,data,"In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu."
Initial responses,large differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
Initial responses,differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
responses,regional differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
responses,differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
Initial responses,large regional differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
Initial responses,regional differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
responses,large regional differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
responses,large differences in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
large regional differences,is in,anxiety,"CONCLUSION: Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food."
clinical feature,is,pulmonary fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
typical clinical feature,is,pulmonary fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
feature,is,fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
typical clinical feature,is,fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
typical feature,is,pulmonary fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
typical feature,is,fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
feature,is,pulmonary fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
clinical feature,is,fibrosis,A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure.
large gap,still remains In,aftermath of SARS epidemic,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,still remains In,aftermath,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
large gap,still remains,has made,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
large gap,remains in,our knowledge,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
large gap,remains,has made,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
SARS-CoV,interacts at,onset of infection,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,remains in,our knowledge,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
SARS-CoV,interacts at,onset,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,still remains In,aftermath of SARS epidemic,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,still remains,has made,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,remains In,aftermath,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
SARS-CoV,interacts with,host cell,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,remains,has made,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
large gap,remains In,aftermath,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
large gap,remains In,aftermath of SARS epidemic,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
large gap,still remains In,aftermath,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
gap,remains In,aftermath of SARS epidemic,"In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection."
principal component analysis,Intriguingly revealed,clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,strong clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,strong clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,strong clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,strong clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,strong clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,strong clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,strong clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,strong clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,strong clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,strong clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,strong clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,strong clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,clustering about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,strong clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,strong clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,Intriguingly revealed,strong clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,Intriguingly revealed,clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
component analysis,revealed,strong clustering,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,clustering of anxiety about swine flu,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
principal component analysis,revealed,clustering of anxiety,"Intriguingly, principal component analysis revealed strong clustering of anxiety about swine flu, bird flu and terrorism."
evidence,ingestion of,virus-contaminated foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated as,source,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated as,source of infection in instances,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,ingestion of,foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated ingestion as,source,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated as,source of infection,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated ingestion as,source,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated ingestion as,source of infection,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated as,source of infection in instances,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
infection,is in,instances,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated,ingestion of virus-contaminated foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated as,source,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated ingestion as,source of infection in instances,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,ingestion of,virus-contaminated foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated,ingestion of virus-contaminated foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated ingestion as,source of infection,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated ingestion as,source of infection in instances,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated,ingestion,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated,ingestion of foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated,ingestion,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,ingestion of,foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
Epidemiological evidence,has implicated,ingestion of foods,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
evidence,has implicated as,source of infection,"Epidemiological evidence has implicated ingestion of virus-contaminated foods as the source of infection in some instances and our data suggests that viremia, secondary to, for example, gastro-intestinal infection, can potentially lead to infection of the lung."
common febrile diseases,is in,Africa,"Maria Yazdanbakhsh and Peter Kremsner argue that there needs to be better awareness, surveillance, and clinical management of common febrile diseases in Africa, especially influenza."
infected-mice,showed,pneumonia with infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,diffuse pneumonia with inflammatory infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical diffuse pneumonia with inflammatory infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,diffuse pneumonia,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical pneumonia,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical pneumonia on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,diffuse pneumonia with infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,pneumonia on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical pneumonia with inflammatory infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,diffuse pneumonia with infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical diffuse pneumonia on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,pneumonia with inflammatory infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
typical diffuse pneumonia,is with,inflammatory cellular infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,pneumonia with infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical diffuse pneumonia,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical diffuse pneumonia with inflammatory infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical diffuse pneumonia with infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical pneumonia with inflammatory infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,pneumonia,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical diffuse pneumonia with infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,pneumonia with inflammatory infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical pneumonia with infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed pneumonia At,stage,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,diffuse pneumonia on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed pneumonia At,acute stage,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,typical pneumonia with infiltration on day 7,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
infected-mice,showed,diffuse pneumonia with inflammatory infiltration,"At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation."
apoD deposition,is,detectable,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,atherosclerotic lesions of humans with disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,lesions of humans with disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,atherosclerotic lesions of humans with established disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,atherosclerotic lesions,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,lesions,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,lesions of humans with established cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,atherosclerotic lesions of humans,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,lesions of humans with established cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,atherosclerotic lesions of humans with disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,lesions of humans,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,atherosclerotic lesions of humans with established cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,lesions,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
humans,is with,established cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,lesions of humans with disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,lesions of humans with cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is,detectable,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,lesions of humans with established disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,lesions of humans,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
mice,is with,premature atherosclerosis,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,lesions of humans with established disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,atherosclerotic lesions of humans,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,atherosclerotic lesions,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,atherosclerotic lesions of humans with established disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,atherosclerotic lesions of humans with cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,lesions of humans with cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Increased apoD deposition,is detectable in,atherosclerotic lesions of humans with established cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
apoD deposition,is detectable in,atherosclerotic lesions of humans with cardiovascular disease,Increased apoD deposition is detectable in atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Initial infection experiments,demonstrated,degrees of infection efficiency between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,varying degrees between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,degrees,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,varying degrees of infection efficiency,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated degrees,possible,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
it,infect cells in,tissue types,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,degrees between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated degrees,possible,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,varying degrees,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,varying degrees of infection efficiency,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,degrees of infection efficiency between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,varying degrees of infection efficiency between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,varying degrees between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,degrees of infection efficiency,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
it,was,possible,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,varying degrees of infection efficiency between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,degrees,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,degrees between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,varying degrees between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,degrees of infection efficiency between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,varying degrees of infection efficiency between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,degrees between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,varying degrees between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,degrees of infection efficiency,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,varying degrees,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,degrees of infection efficiency between cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,is with,cloned using,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
Initial infection experiments,demonstrated,varying degrees of infection efficiency between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
infection experiments,demonstrated,degrees between different cell lines,"Initial infection experiments with both cloned and uncloned cell lines using Hendra and Nipah viruses demonstrated varying degrees of infection efficiency between the different cell lines, although it was possible to infect cells in all tissue types."
aurintricarboxylic acid,inhibitor of,nucleic acid processing enzymes,"METHODOLOGY/PRINCIPAL FINDINGS: We investigated the potential of aurintricarboxylic acid (ATA), a potent inhibitor of nucleic acid processing enzymes, to protect Madin-Darby canine kidney cells from influenza infection."
cells,were,simultaneously treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were,when treated with ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were,treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were,when treated with ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were,when simultaneously treated with ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were treated with,ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were,when treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were,simultaneously treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were simultaneously treated with,ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were,treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were,when simultaneously treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were,when treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were treated with,ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were simultaneously treated with,ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
infected cells,were,when simultaneously treated with ATA,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
cells,were,when simultaneously treated,"Finally, we observed additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-influenza drug that inhibits M2-ion channels of influenza A virus."
agent,was identified in,152 samples,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
additional agent,was identified in,76%,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
Streptococcus pneumoniae,including samples is,76%,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
agent,was identified in,152 samples including Streptococcus pneumoniae,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
agent,was,identified,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
B n,=,1,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
additional agent,was,identified,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
agent,was identified in,76%,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
additional agent,was identified in,152 samples including Streptococcus pneumoniae,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
additional agent,was identified in,152 samples,"At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (nâ€Š=â€Š62); Haemophilus influenzae (nâ€Š=â€Š104); human respiratory syncytial virus A (nâ€Š=â€Š11) and B (nâ€Š=â€Š1); human rhinovirus A (nâ€Š=â€Š1) and B (nâ€Š=â€Š4); human coronaviruses 229E (nâ€Š=â€Š1) and OC43 (nâ€Š=â€Š2); Klebsiella pneumoniae (nâ€Š=â€Š2); Acinetobacter baumannii (nâ€Š=â€Š2); Serratia marcescens (nâ€Š=â€Š1); and Staphylococcus aureus (nâ€Š=â€Š35) and methicillin-resistant S. aureus (MRSA, nâ€Š=â€Š6)."
Streptococcus pneumoniae,is cause of,community,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
pneumoniae,is,common,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
BACKGROUND,is cause of,community,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
Streptococcus pneumoniae,is,common cause,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
Streptococcus pneumoniae,is,cause,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
BACKGROUND,is common cause of,community,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
BACKGROUND,is,cause,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
BACKGROUND,is,common cause,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
Streptococcus pneumoniae,is common cause of,community,BACKGROUND: Streptococcus pneumoniae is a common cause of community acquired pneumonia and bacteremia.
replacement,was,Surprisingly tolerated,"Surprisingly, replacement of a glycine residue, situated close to the aromatic domain, with a lysine residue was tolerated, whereas the introduction of a lysine adjacent to the glycine, was not."
glycine residue,is with,lysine residue,"Surprisingly, replacement of a glycine residue, situated close to the aromatic domain, with a lysine residue was tolerated, whereas the introduction of a lysine adjacent to the glycine, was not."
replacement,was,tolerated,"Surprisingly, replacement of a glycine residue, situated close to the aromatic domain, with a lysine residue was tolerated, whereas the introduction of a lysine adjacent to the glycine, was not."
presence,provides,opportunity for therapeutic interventions at molecular biology level,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides opportunity In,particular for temporal lobe epilepsy,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides opportunity In,particular for lobe epilepsy,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity for interventions,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides opportunity In,particular for mesial lobe epilepsy,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity at molecular biology level,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity for therapeutic interventions,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides opportunity In,particular,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity for interventions at molecular biology level,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides opportunity In,particular for mesial temporal lobe epilepsy,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity at biology level,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity for interventions at biology level,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
presence,provides,opportunity for therapeutic interventions at biology level,"In particular for mesial temporal lobe epilepsy, the presence of a latency period between the first manifestation of seizures to chronic epilepsy provides the opportunity for therapeutic interventions at the molecular biology level."
infection,is with,nvH1N1,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
typical innate response,infection with,nvH1N1,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
innate response,infection with,nvH1N1,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,severe disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,severe disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,mild patients,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,severe disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,severe disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,severe disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,severe disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,severe disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,severe disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,mild patients,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,severe disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
response,infection with,nvH1N1,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,mild patients,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,severe disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
mild patients,disease with,respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,disease,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,severe disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,innate response in,severe disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,response in,disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
typical response,infection with,nvH1N1,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical innate response in,disease with involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,mild patients,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
infection,typical response in,disease with respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
typical innate response,is in,mild patients,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
severe disease,is with,respiratory involvement,"CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases."
emergence,is with,pandemic potential such severe acute respiratory syndrome coronavirus,"The emergence of viral respiratory pathogens with pandemic potential, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza A H5N1, urges the need for deciphering their pathogenesis to develop new intervention strategies."
SARS-CoV infection,causes,lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
advanced age,with syndrome is,ARDS,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,acute lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,ALI,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
life-threatening acute respiratory distress syndrome,is with,advanced age correlating positively,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
emergence,is with,pandemic potential such severe acute respiratory syndrome coronavirus,"The emergence of viral respiratory pathogens with pandemic potential, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza A H5N1, urges the need for deciphering their pathogenesis to develop new intervention strategies."
SARS-CoV infection,causes,lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
advanced age,with syndrome is,ARDS,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,acute lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,ALI,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
life-threatening acute respiratory distress syndrome,is with,advanced age correlating positively,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
emergence,is with,pandemic potential such severe acute respiratory syndrome coronavirus,"The emergence of viral respiratory pathogens with pandemic potential, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza A H5N1, urges the need for deciphering their pathogenesis to develop new intervention strategies."
SARS-CoV infection,causes,lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
advanced age,with syndrome is,ARDS,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,acute lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,ALI,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
life-threatening acute respiratory distress syndrome,is with,advanced age correlating positively,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
emergence,is with,pandemic potential such severe acute respiratory syndrome coronavirus,"The emergence of viral respiratory pathogens with pandemic potential, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza A H5N1, urges the need for deciphering their pathogenesis to develop new intervention strategies."
SARS-CoV infection,causes,lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
advanced age,with syndrome is,ARDS,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,acute lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,ALI,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
life-threatening acute respiratory distress syndrome,is with,advanced age correlating positively,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
emergence,is with,pandemic potential such severe acute respiratory syndrome coronavirus,"The emergence of viral respiratory pathogens with pandemic potential, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza A H5N1, urges the need for deciphering their pathogenesis to develop new intervention strategies."
SARS-CoV infection,causes,lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
advanced age,with syndrome is,ARDS,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,acute lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,ALI,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
life-threatening acute respiratory distress syndrome,is with,advanced age correlating positively,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
emergence,is with,pandemic potential such severe acute respiratory syndrome coronavirus,"The emergence of viral respiratory pathogens with pandemic potential, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza A H5N1, urges the need for deciphering their pathogenesis to develop new intervention strategies."
SARS-CoV infection,causes,lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
advanced age,with syndrome is,ARDS,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,acute lung injury,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
SARS-CoV infection,causes,ALI,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
life-threatening acute respiratory distress syndrome,is with,advanced age correlating positively,SARS-CoV infection causes acute lung injury (ALI) that may develop into life-threatening acute respiratory distress syndrome (ARDS) with advanced age correlating positively with adverse disease outcome.
threat,posed by,occurrences infections,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences infections H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
urgent need,is emphasized by,resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences infections pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
need,is,emphasized,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
urgent need,is,emphasized,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
urgent medical need,is emphasized by,widespread resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences highly pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
urgent medical need,is,emphasized,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections highly pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences infections pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
occurrences,is with,highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
urgent medical need,is emphasized by,resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
need,is emphasized by,resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
need,is emphasized by,widespread resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
urgent need,is emphasized by,widespread resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections highly pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences infections highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
medical need,is emphasized by,resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences highly pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences infections highly pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
medical need,is emphasized by,widespread resistance,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections highly pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections highly pathogenic avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
medical need,is,emphasized,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences infections avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences human infections pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
pandemic threat,posed by,occurrences infections pathogenic H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
threat,posed by,occurrences human infections avian H5N1 viruses,"BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic."
mg/kg CR6261,evidenced by,weight loss,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,administered after,therapeutically 1 day,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,administered after,1 day,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,blunted,disease,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,reduced,lung loads,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,reduced,lung loads,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,reduced,lung viral loads,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,blunted,disease,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,evidenced by,decreased weight loss,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,prevented death in,animals,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,prevented death in,animals,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,evidenced by,weight loss,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,evidenced by,decreased weight loss,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,reduced,lung viral loads,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
mg/kg CR6261,administered after,1 day,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
30 mg/kg CR6261,administered after,therapeutically 1 day,"When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage."
majority,are,resistant,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
Worldwide,are,resistant,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
majority,are resistant to,oseltamivir,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
majority,are resistant to,neuraminidase inhibitor,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
majority,are resistant to,most widely prescribed neuraminidase inhibitor,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
majority,are resistant to,widely prescribed neuraminidase inhibitor,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
Worldwide,are resistant to,adamantanes,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
majority,are resistant to,prescribed neuraminidase inhibitor,"Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI)."
oseltamivir influenza viruses,using,infection model,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir oseltamivir-resistant influenza viruses,using,infection model,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir oseltamivir-resistant influenza viruses,using,in infection model in MDCK cells,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
in infection model,is in,MDCK cells,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir influenza viruses,using,in infection model in MDCK cells,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
Amantadine,were,tested against amantadine,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
Amantadine,were,tested,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir influenza viruses,using,infection model in MDCK cells,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir oseltamivir-resistant influenza viruses,using,infection model in MDCK cells,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir influenza viruses,using,in infection model,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
oseltamivir oseltamivir-resistant influenza viruses,using,in infection model,"Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells."
TCAD regimen,is synergistic against,resistant viruses,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,composed of,amantadine,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is highly synergistic against,resistant viruses,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is highly synergistic against,viruses including 2009 H1N1,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is synergistic against,viruses including 2009 H1N1,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is,synergistic,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is,highly synergistic,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is synergistic against,viruses,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is highly synergistic against,viruses,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is synergistic against,resistant viruses including 2009 H1N1,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
TCAD regimen,is highly synergistic against,resistant viruses including 2009 H1N1,"Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1."
Karen Edmond,highlight,approaches,Karen Edmond and Anita Zaidi highlight new approaches that could reduce the burden of neonatal sepsis worldwide.
Anita Zaidi,highlight,new approaches,Karen Edmond and Anita Zaidi highlight new approaches that could reduce the burden of neonatal sepsis worldwide.
Karen Edmond,highlight,new approaches,Karen Edmond and Anita Zaidi highlight new approaches that could reduce the burden of neonatal sepsis worldwide.
Anita Zaidi,highlight,approaches,Karen Edmond and Anita Zaidi highlight new approaches that could reduce the burden of neonatal sepsis worldwide.
Murine coronavirus,provides animal models for,study of nervous system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of nervous system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of central nervous system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of central system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of central system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides,animal models,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of nervous system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of central nervous system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides,animal models,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of nervous system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of central system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of central system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
coronavirus,provides animal models for,study of central nervous system disease including encephalitis,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,infection of,mouse,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Murine coronavirus,provides animal models for,study of central nervous system disease,"Murine coronavirus, mouse hepatitis virus (MHV) infection of the mouse, provides animal models for the study of central nervous system disease, including encephalitis and demyelinating diseases such as Multiple Sclerosis and for hepatitis."
Bio T DNA assay,was developed,detect,"The â€œBio Tâ€ DNA assay was developed to detect: Variola major (VM), Bacillus anthracis (BA), Yersinia pestis (YP), Francisella tularensis (FT) and Varicella zoster virus (VZV)."
Bio T DNA assay,was,developed,"The â€œBio Tâ€ DNA assay was developed to detect: Variola major (VM), Bacillus anthracis (BA), Yersinia pestis (YP), Francisella tularensis (FT) and Varicella zoster virus (VZV)."
Bio T RNA assay,detect,Ebola,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,Lassa fever virus,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,virus,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,Ebola virus,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,Lassa,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,was,developed,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,Hantavirus Sin Nombre species,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,dengue virus,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,Rift Valley fever,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,serotypes 1,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
Bio T RNA assay,detect,HSN,"The â€œBio Tâ€ RNA assay (mRT-PCR-EHA) was developed to detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus Sin Nombre species (HSN) and dengue virus (serotypes 1â€“4)."
LOD,was,âˆ¼ 1 Ã— 10,"The LOD for dengue whole organisms was âˆ¼1Ã—10(âˆ’4) dilution for dengue 1 and 2, 1Ã—10(4) LD(50)/mL and 1Ã—10(2) LD(50)/mL for dengue 3 and 4."
dengue 1,for dilution is,1 Ã— 10,"The LOD for dengue whole organisms was âˆ¼1Ã—10(âˆ’4) dilution for dengue 1 and 2, 1Ã—10(4) LD(50)/mL and 1Ã—10(2) LD(50)/mL for dengue 3 and 4."
BA,"2,3,4 for",BA,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
two assays,sensitivities of were,100 % for FT,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
assays,surrogate sensitivities of were,100 % for FT,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
FT,for % is,95 % CI 83 100,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
BA,"for 2,3,4 is",95 % CI 75 100,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
two assays,surrogate sensitivities of were,100%,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
assays,sensitivities of were,100 % for FT,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
assays,sensitivities of were,100%,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
two assays,surrogate sensitivities of were,100 % for FT,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
assays,surrogate sensitivities of were,100%,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
two assays,sensitivities of were,100%,"The surrogate sensitivities of these two assays were 100% (95%CI 83â€“100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 and 95% (95%CI 75â€“100) for BA (pX01) and dengue 1 using spiked clinical specimens."
activity,was,Further metal ion,"Further, this activity was metal ion dependent and was inhibited by adenosine 5â€² (Î², Î³ imido) triphosphate, an ATP analog."
activity,was,metal ion,"Further, this activity was metal ion dependent and was inhibited by adenosine 5â€² (Î², Î³ imido) triphosphate, an ATP analog."
activity,was,ion,"Further, this activity was metal ion dependent and was inhibited by adenosine 5â€² (Î², Î³ imido) triphosphate, an ATP analog."
activity,was,Further ion,"Further, this activity was metal ion dependent and was inhibited by adenosine 5â€² (Î², Î³ imido) triphosphate, an ATP analog."
pandemic 2009 influenza,were,incorporated into QSS 2009,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
pandemic 2009 influenza,were,incorporated with responses,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
pandemic influenza,were,incorporated into QSS 2009 with responses,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
pandemic influenza,were,incorporated into QSS 2009,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
pandemic influenza,were,incorporated,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
pandemic influenza,were,incorporated with responses,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
pandemic 2009 influenza,were,incorporated,"Four questions related to respondents' anticipated compliance with a physician's advice to stay home if they had a common cold, seasonal influenza, pandemic (H1N1) 2009 influenza or avian influenza were incorporated into QSS 2009, with responses recorded using a balanced Likert scale ranging from ""very unlikely"" to ""very likely."""
HCW,transmit HCV to,patient,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCW,transmit,HCV,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCV infections,be,serious,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCW,transmit HIV to,patient,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCW,transmit,HIV,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,received,information,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,received information from,courses,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,worked,hours,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,worked,fewer hours,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,worked per,week,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,worked hours per,week,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
HCWs,received information from,educational courses,"RESULTS: HCWs who know the risk of acquiring Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) from a patient were in practice from less years, worked fewer hours per week, knew that a HCW can transmit HCV and HIV to a patient, knew that HCV and HIV infections can be serious, and have received information from educational courses and scientific journals."
RVFV,causes,severe hemorrhagic illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
it,causes,abortion rates,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,is,transmitted,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,causes,hemorrhagic illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,causes fever among,humans,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,causes,severe illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,causes,fever,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,causes illness among,humans,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
it,causes abortion rates in,livestock,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
it,causes,fever,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
it,causes fever in,livestock,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
it,causes,high abortion rates,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,is transmitted by,mosquitoes,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
RVFV,causes,illness,"RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, while in livestock it causes fever and high abortion rates."
Severe acute respiratory syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase diffuse damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,often caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase alveolar damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
respiratory syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,caused,severe end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase diffuse damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,organizing,phase damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe acute syndrome coronavirus infection,often caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,caused,end stage lung disease,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase diffuse alveolar damage,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
acute respiratory syndrome coronavirus infection,organizing,phase alveolar damage in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe respiratory syndrome coronavirus infection,organizing,phase diffuse damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
Severe syndrome coronavirus infection,organizing,phase damage especially in elderly,"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly."
infection,is with,Urbani,"In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice."
infection,resulted In,contrast to most models of viral pathogenesis,"In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice."
infection,resulted in,disease outcomes,"In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice."
infection,resulted in,clinical disease outcomes,"In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice."
infection,resulted In,contrast to models of viral pathogenesis,"In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice."
health impact,causes,headache,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
health impact,causes,nausea,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,headache,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,rash,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
Chikungunya virus,is,pathogen,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,myalgia,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,is in,humans,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
health impact,causes,vomiting,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
virus,is,emerging,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
health impact,causes,fever disease,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
health impact,causes,myalgia,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,nausea,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,arthralgia,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,fever disease,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
health impact,causes,rash,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
health impact,causes,arthralgia,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
virus,is,mosquito-borne,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
major health impact,causes,vomiting,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
Chikungunya virus,is,mosquito-borne emerging pathogen,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
Chikungunya virus,is,mosquito-borne pathogen,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
Chikungunya virus,is,emerging pathogen,"Chikungunya virus is a mosquito-borne emerging pathogen that has a major health impact in humans and causes fever disease, headache, rash, nausea, vomiting, myalgia, and arthralgia."
potential,seroprevalence of,B19V,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,unexpectedly high seroprevalence of,parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,seroprevalence of,human parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,high seroprevalence of,B19V,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in countries in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in malaria-endemic countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in certain malaria-endemic countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in certain countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,high seroprevalence of,B19V,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in certain malaria-endemic countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,high seroprevalence of,human parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,seroprevalence of,parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,seroprevalence of,parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in malaria-endemic countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
BACKGROUND,observed in,certain malaria-endemic countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in certain countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in certain countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
BACKGROUND,have,have observed in certain countries in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
BACKGROUND,have,have observed in countries in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,unexpectedly high seroprevalence of,human parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in malaria-endemic countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,high seroprevalence of,human parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in certain malaria-endemic countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,unexpectedly high seroprevalence of,B19V,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,unexpectedly high seroprevalence of,human parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in certain countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in malaria-endemic countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in malaria-endemic countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in certain countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,unexpectedly high seroprevalence of,B19V,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
BACKGROUND,have,have observed in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in malaria-endemic countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in countries in parallel with use as treatment,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,high seroprevalence of,parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in certain malaria-endemic countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,seroprevalence of,human parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,unexpectedly high seroprevalence of,parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in certain malaria-endemic countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
pathogenic potential,seroprevalence of,B19V,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
parallel,is with,local use of chloroquine as first-line treatment for malaria,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in countries in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
potential,high seroprevalence of,parvovirus B19,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in certain malaria-endemic countries,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
high seroprevalence,have,have observed in parallel with use,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in certain countries in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
seroprevalence,have,have observed in parallel,BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria.
course,are,unknown,BACKGROUND: The clinical course of human papillomavirus (HPV) associated with Bowenoid papulosis and condyloma acuminatum of anogenital tumors are still unknown.
course,are,still unknown,BACKGROUND: The clinical course of human papillomavirus (HPV) associated with Bowenoid papulosis and condyloma acuminatum of anogenital tumors are still unknown.
clinical course,are,still unknown,BACKGROUND: The clinical course of human papillomavirus (HPV) associated with Bowenoid papulosis and condyloma acuminatum of anogenital tumors are still unknown.
clinical course,are,unknown,BACKGROUND: The clinical course of human papillomavirus (HPV) associated with Bowenoid papulosis and condyloma acuminatum of anogenital tumors are still unknown.
Neisseria gonorrhoeae,possess,well-characterized adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
N. meningitidis,possess,well-characterized CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Neisseria gonorrhoeae,possess,well-characterized CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Moraxella catarrhalis,possess,adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Moraxella catarrhalis,possess adhesins In,particular,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
influenzae,possess,well-characterized adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Moraxella catarrhalis,possess,CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
influenzae,possess adhesins In,particular,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
N. meningitidis,possess adhesins In,particular,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Moraxella catarrhalis,possess,well-characterized CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Haemophilus influenzae,possess,well-characterized CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Haemophilus influenzae,possess,well-characterized adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Haemophilus influenzae,possess adhesins In,particular,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
N. meningitidis,possess,well-characterized adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
influenzae,possess,well-characterized CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Neisseria gonorrhoeae,possess,CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Neisseria gonorrhoeae,possess adhesins In,particular,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Haemophilus influenzae,possess,adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
influenzae,possess,adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
influenzae,possess,CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Haemophilus influenzae,possess,CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Neisseria gonorrhoeae,possess,adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
N. meningitidis,possess,adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
N. meningitidis,possess,CEACAM1-binding adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
Moraxella catarrhalis,possess,well-characterized adhesins,"In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins."
ultrasound,of time is,OR 1.40,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,pattern of,liver unique to S. japonicum,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,was associated with,infection at time,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,was associated,adjusting,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,was associated,adjusting for age,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,associated with,infection status,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,was associated with,infection,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,was associated,adjusting for age,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,adjusting for,age,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,was,associated,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,was associated,adjusting,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,was associated with,infection,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,was associated with,infection at time,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,was,associated,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,adjusting for,age,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,associated with,prior infection status,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
fibrosis,associated with,infection status,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
Parenchymal fibrosis,associated with,prior infection status,"Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03â€“1.90) and infection intensity (test for trend, pâ€Š=â€Š0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted OR 1.84, 95% CI: 1.30â€“2.60; test for trend: p<0.001 respectively), despite prompt treatment of infections."
study,Additionally demonstrates,infection of peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of primary peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of primary peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of primary peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of primary peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of primary cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of primary cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of primary cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of primary cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of primary peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of primary peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of primary cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection of cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,trypsin-independent infection,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of primary cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of primary cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of primary cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,trypsin-independent infection of primary peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,Additionally demonstrates,infection of primary peripheral cells,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
study,demonstrates,infection of peripheral cells by rotavirus,"Additionally, this study demonstrates trypsin-independent infection of primary peripheral cells by rotavirus, which may allow for the establishment of extraintestinal viremia and antigenemia."
mouth disease,have,life-threatening manifestations,"Hand, foot and mouth disease (HFMD), a common contagious disease that usually affects children, is normally mild but can have life-threatening manifestations."
skin pigmentation,were,associated with two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,significant p < reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,significant p two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,significant two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
supplementation,is with,vitamin D,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,p reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,significant reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,p two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,significant p reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,significant reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,significant p reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,p reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,p < reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p < reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,significant p two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,found,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
significant p < two-fold reduction,is in,risk developing,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
marked reduction,is in,percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,p < two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p < reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,p < two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < two-fold reduction with marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,marked reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant p two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,found,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p two-fold reduction with reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,significant p < reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,p < reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,p two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,significant two-fold reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with p < reduction with reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with two-fold reduction with marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p two-fold reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were,associated with significant two-fold reduction with reduction in percentages of days,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with significant p reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were,associated with p < reduction with marked reduction,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
skin pigmentation,were associated with,marked reduction in percentages,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Light skin pigmentation,were associated with,marked reduction in percentages of days ill,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,caused thereby during,fall,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,acute viral tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,viral tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,burden of,illness,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,acute tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,acute respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,caused during,fall in zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,viral respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,caused during,fall,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,caused during,fall in temperate zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,caused thereby during,fall in temperate zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,caused during,fall in zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,acute viral tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,caused thereby during,fall in zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,acute viral respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,caused thereby during,fall in temperate zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,acute tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,caused thereby during,fall,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,caused thereby during,fall in zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,viral tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,incidence of,tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,viral respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,acute respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
Maintenance,caused during,fall,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,caused during,fall in temperate zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
fall,is in,temperate zones,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
burden,incidence of,acute viral respiratory tract infections,"Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. CONCLUSIONS/SIGNIFICANCE: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones."
severity,incidence of,infections including influenza in subpopulations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
infections,is in,subpopulations with lower 25-hydroxyvitamin D concentrations such pregnant women,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in population in subpopulations with 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in general population in subpopulations with 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in general population in subpopulations with lower 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in population in subpopulations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in general population,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in population in subpopulations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in population in subpopulations with 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in population in subpopulations with lower 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
infections,is in,general population,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in general population in subpopulations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
findings,provide,direction for,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in subpopulations with lower 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in subpopulations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in population,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in subpopulations with lower 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in general population,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in general population in subpopulations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in general population in subpopulations with lower 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
findings,call for,future studies,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in subpopulations with 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in general population in subpopulations with 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in population in subpopulations with lower 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
findings,provide,direction,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections including influenza in population,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
severity,incidence of,infections in subpopulations with 25-hydroxyvitamin D concentrations,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
subpopulations,is with,lower 25-hydroxyvitamin D concentrations such pregnant women,"The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese."
hope,was,significant,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
p,=,0.05,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
Baseline hope,was,predictor,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
Baseline hope,was predictor of,resilience outcome trajectory for depression,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
Baseline hope,was significant predictor of,resilience outcome trajectory for depression,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
Baseline hope,was,significant predictor,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
Baseline hope,was predictor of,resilience outcome trajectory,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
Baseline hope,was significant predictor of,resilience outcome trajectory,"Baseline hope was a significant predictor of a resilience outcome trajectory for depression (B = -0.24, p < 0.01 for depression); and anxiety (B = -0.11, p = 0.05 for anxiety)."
plants DNA,especially exploring,aspiration pneumonia,"CONCLUSIONS/SIGNIFICANCE: Our study shows that plants DNA may be identified in the BAL fluid of pneumonia patients, especially when exploring aspiration pneumonia, but the significance of the presence of plant DNA and its role in the pathogenesis of pneumonia is unknown and remains to be investigated."
plants DNA,exploring,aspiration pneumonia,"CONCLUSIONS/SIGNIFICANCE: Our study shows that plants DNA may be identified in the BAL fluid of pneumonia patients, especially when exploring aspiration pneumonia, but the significance of the presence of plant DNA and its role in the pathogenesis of pneumonia is unknown and remains to be investigated."
rIDE,increasing,stability,The ability of rIDE to enhance infectivity of cell-free VZV over a wide range of incubation times and temperatures suggests that rIDE may be useful for increasing the stability of varicella or zoster vaccines.
rIDE,be,useful,The ability of rIDE to enhance infectivity of cell-free VZV over a wide range of incubation times and temperatures suggests that rIDE may be useful for increasing the stability of varicella or zoster vaccines.
rIDE,increasing,stability of varicella,The ability of rIDE to enhance infectivity of cell-free VZV over a wide range of incubation times and temperatures suggests that rIDE may be useful for increasing the stability of varicella or zoster vaccines.
analyse,systematically relationship between,gene expression profiles,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
Solexa/Illumina,has,digital gene expression,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
analyse,relationship after,N-PRRSV infection,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
analyse,relationship between,gene expression profiles,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
analyse,systematically relationship after,N-PRRSV infection,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
Solexa/Illumina,'s expression is,DGE,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
analyse,systematically relationship between,pulmonary gene expression profiles,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
analyse,relationship between,pulmonary gene expression profiles,"Here we report on the first genome-wide host transcriptional responses to classical North American type PRRSV (N-PRRSV) strain CH 1a infection using Solexa/Illumina's digital gene expression (DGE) system, a tag-based high-throughput transcriptome sequencing method, and analyse systematically the relationship between pulmonary gene expression profiles after N-PRRSV infection and infection pathology."
51 spots,were,identified,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
spots,were,identified,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
51 spots,corresponding to,42 proteins,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
spots,corresponding by,MS/MS analysis,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
spots,were identified Among,selected protein spots,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
spots,were identified Among,protein spots,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
51 spots,corresponding by,MS/MS analysis,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
spots,corresponding to,42 proteins,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
51 spots,were identified Among,selected protein spots,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
51 spots,were identified Among,protein spots,"Among the selected protein spots, 51 spots were identified corresponding to 42 proteins by MS/MS analysis; most of them were matched to orthologous proteins of Gallus gallus, Anas platyrhynchos or other avian species, including alpha-enolase, lamin A, aconitase 2, cofilin-2 and annexin A2, etc."
patients,were older compared with,those,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,were,older,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,white blood cell,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,is with,segmental/lobar pneumonia,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,fever duration,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,longer fever duration,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,lower blood cell,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,lower white blood cell,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,WBC,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
patients,had,blood cell,"The patients with segmental/lobar pneumonia were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with those with bronchopneumonia."
severe hemorrhagic colitis,is in,humans,"BACKGROUND: Escherichia coli serogroup O157:H7 has emerged as an important zoonotic bacterial pathogen, causing a range of symptoms from self-limiting bloody diarrhea to severe hemorrhagic colitis and hemolytic-uremic syndrome in humans."
screening tests,rely on,crude,"For serodiagnosis of echinococcosis, especially cystic disease, most screening tests rely on crude or purified Echinococcus granulosus hydatid cyst fluid."
infections,may result in,generation,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
Mixed infections,may result in,generation of persistent chlamydial infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
infections,may result in,generation of chlamydial infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
infections,may result in,generation of persistent infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
Mixed infections,may result in,generation of persistent infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
Mixed infections,may result in,generation of infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
Mixed infections,may result in,generation of chlamydial infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
Mixed infections,is with,Chlamydia,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
Mixed infections,may result in,generation,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
infections,may result in,generation of persistent chlamydial infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
infections,may result in,generation of infections,Mixed infections with Chlamydia and porcine epidemic diarrhea virus (PEDV) may result in generation of persistent chlamydial infections.
dual infection,is in,Vero cells,"To test this hypothesis, an in vitro model of dual infection with cell culture-adapted PEDV and Chlamydia abortus or Chlamydia pecorum in Vero cells was established."
model,was,established,"To test this hypothesis, an in vitro model of dual infection with cell culture-adapted PEDV and Chlamydia abortus or Chlamydia pecorum in Vero cells was established."
dual infection,is with,cell culture-adapted PEDV,"To test this hypothesis, an in vitro model of dual infection with cell culture-adapted PEDV and Chlamydia abortus or Chlamydia pecorum in Vero cells was established."
in model,was,established,"To test this hypothesis, an in vitro model of dual infection with cell culture-adapted PEDV and Chlamydia abortus or Chlamydia pecorum in Vero cells was established."
TEM examinations,revealed,inclusions,"TEM examinations of mixed infections with Chlamydia abortus and Chlamydia pecorum revealed aberrant chlamydial inclusions containing reticulate-like, pleomorphic ABs, which were up to 2 Î¼m in diameter."
2 Î¼m,is in,diameter,"TEM examinations of mixed infections with Chlamydia abortus and Chlamydia pecorum revealed aberrant chlamydial inclusions containing reticulate-like, pleomorphic ABs, which were up to 2 Î¼m in diameter."
TEM examinations,revealed,aberrant chlamydial inclusions,"TEM examinations of mixed infections with Chlamydia abortus and Chlamydia pecorum revealed aberrant chlamydial inclusions containing reticulate-like, pleomorphic ABs, which were up to 2 Î¼m in diameter."
TEM examinations,revealed,aberrant inclusions,"TEM examinations of mixed infections with Chlamydia abortus and Chlamydia pecorum revealed aberrant chlamydial inclusions containing reticulate-like, pleomorphic ABs, which were up to 2 Î¼m in diameter."
TEM examinations,revealed,chlamydial inclusions,"TEM examinations of mixed infections with Chlamydia abortus and Chlamydia pecorum revealed aberrant chlamydial inclusions containing reticulate-like, pleomorphic ABs, which were up to 2 Î¼m in diameter."
mixed infections,is with,Chlamydia abortus,"TEM examinations of mixed infections with Chlamydia abortus and Chlamydia pecorum revealed aberrant chlamydial inclusions containing reticulate-like, pleomorphic ABs, which were up to 2 Î¼m in diameter."
inducing,apoptosis of,tumor cells,Lycorine can suppress leukemia growth and reduce cell survival and inducing apoptosis of tumor cells.
Lycorine,inducing,apoptosis of tumor cells,Lycorine can suppress leukemia growth and reduce cell survival and inducing apoptosis of tumor cells.
Lycorine,inducing,apoptosis,Lycorine can suppress leukemia growth and reduce cell survival and inducing apoptosis of tumor cells.
Lycorine,reduce,cell survival,Lycorine can suppress leukemia growth and reduce cell survival and inducing apoptosis of tumor cells.
Lycorine,can suppress,leukemia growth,Lycorine can suppress leukemia growth and reduce cell survival and inducing apoptosis of tumor cells.
R06E cells,produced,viral titers,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
R06E cells,produced,viral titers comparable,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
R06E cells,produced,titers,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
R06E cells,produced,titers comparable to VeroE6 cells,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
R06E cells,produced,titers comparable,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
titers,comparable to,VeroE6 cells,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
viral titers,comparable to,VeroE6 cells,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
R06E cells,produced,viral titers comparable to VeroE6 cells,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
infection,is with,Ebola,"METHODOLOGY/PRINCIPAL FINDINGS: Upon infection with Ebola or Marburg viruses, R06E cells produced viral titers comparable to VeroE6 cells, as shown by TCID(50) analysis."
common organ dysfunctions,included,septic shock,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,renal failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,altered status,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,respiratory failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,acute renal failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,acute respiratory failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,mental status,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,shock,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,status,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,acute failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
common organ dysfunctions,included,acute failure,"The most common organ dysfunctions included acute respiratory failure, altered mental status, septic shock, and acute renal failure."
Diabetes level,were,risk factors,"Diabetes [odds ratio (OR) 8.830, 95% confidence interval [CI] 2.041 to 38.201, p = 0.004) and lactate dehydrogenase (LDH) level (OR 1.240, 95% CI 1.025 to 1.500, p = 0.027) were independent risk factors of hospital death, as were septic shock and altered mental status."
Diabetes level,were,shock,"Diabetes [odds ratio (OR) 8.830, 95% confidence interval [CI] 2.041 to 38.201, p = 0.004) and lactate dehydrogenase (LDH) level (OR 1.240, 95% CI 1.025 to 1.500, p = 0.027) were independent risk factors of hospital death, as were septic shock and altered mental status."
differences,problems for,European strategies,"CONCLUSION: These differences could create problems for European strategies if an evolving influenza pandemic results in more serious public health challenges or, indeed, if a novel disease other than influenza emerges with pandemic potential."
differences,problems for,strategies,"CONCLUSION: These differences could create problems for European strategies if an evolving influenza pandemic results in more serious public health challenges or, indeed, if a novel disease other than influenza emerges with pandemic potential."
evolving influenza pandemic results,is in,challenges,"CONCLUSION: These differences could create problems for European strategies if an evolving influenza pandemic results in more serious public health challenges or, indeed, if a novel disease other than influenza emerges with pandemic potential."
stathmin phosphorylation profile,was modified in,response,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
stathmin phosphorylation profile,was modified in,response to bortezomib treatment,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
regulation,participated in,response induced,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
stathmin phosphorylation profile,was,modified,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
regulation,participated in,response,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
regulation,participated in,response induced by bortezomib,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
regulation,participated in,cellular response induced,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
regulation,participated in,cellular response,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
regulation,participated in,cellular response induced by bortezomib,Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib.
presence,is in,highly purified PRRSV virions,"The presence of five selected cellular proteins (i.e., Î²-actin, Tubulin, Annexin A2, heat shock protein Hsp27, and calcium binding proteins S100) in the highly purified PRRSV virions was validated by Western blot and immunogold labeling assays."
bacteremia patients,infected with,resistant strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,antibiotic strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
Antibiotics,may provide relief to,patients,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
Antibiotics,may provide,little immediate relief,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,resistant strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
Antibiotics,may provide,relief,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,antibiotic strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,antibiotic resistant strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,antibiotic resistant strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,antibiotic strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,antibiotic resistant strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
Antibiotics,may provide,immediate relief,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,antibiotic strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,antibiotic resistant strain plague,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
bacteremia patients,infected with,resistant strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
Antibiotics,may provide,little relief,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
high bacteremia patients,infected with,resistant strain,Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected with an antibiotic resistant strain of plague.
Differential diagnose,was,hindered,BACKGROUND: Differential diagnose of Japanese encephalitis virus (JEV) infection from other flavivirus especially West Nile virus (WNV) and Dengue virus (DV) infection was greatly hindered for the serological cross-reactive.
diagnose,was,hindered,BACKGROUND: Differential diagnose of Japanese encephalitis virus (JEV) infection from other flavivirus especially West Nile virus (WNV) and Dengue virus (DV) infection was greatly hindered for the serological cross-reactive.
Helicobacter cetorum,is in,Helicobacter pylori/Helicobacter acinonychis complex,"Based on detection of both rRNA and protein-coding transcripts, we identified two new proteobacterial species; a Helicobacter closely related to Helicobacter cetorum in the Helicobacter pylori/Helicobacter acinonychis complex and an Acinetobacter related to Acinetobacter schindleri."
adults,is with,seasonal influenza,"CONCLUSIONS: In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy."
adults,is with,seasonal influenza,"CONCLUSIONS: In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy."
Mice,were infected with,JEV followed by administration,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by intraperitoneal administration daily,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by administration daily,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were,infected,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by administration of Morpholinos,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by intraperitoneal administration of Morpholinos daily,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by intraperitoneal administration,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by administration of Morpholinos daily,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed by intraperitoneal administration of Morpholinos,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,JEV followed,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
Mice,were infected with,GP78 strain,METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with JEV (GP78 strain) followed by intraperitoneal administration of Morpholinos (5 mg/kg body weight) daily for up to five treatments.
sufficiency,assess,anxiety,"We aimed to assess HCWs concerns and anxiety, perceived sufficiency of information, and intended behavior during the recent A/H1N1 influenza pandemic and their associations with psychological distress."
perceived sufficiency,assess,HCWs concerns,"We aimed to assess HCWs concerns and anxiety, perceived sufficiency of information, and intended behavior during the recent A/H1N1 influenza pandemic and their associations with psychological distress."
sufficiency,assess,HCWs concerns,"We aimed to assess HCWs concerns and anxiety, perceived sufficiency of information, and intended behavior during the recent A/H1N1 influenza pandemic and their associations with psychological distress."
their associations,is with,psychological distress,"We aimed to assess HCWs concerns and anxiety, perceived sufficiency of information, and intended behavior during the recent A/H1N1 influenza pandemic and their associations with psychological distress."
perceived sufficiency,assess,anxiety,"We aimed to assess HCWs concerns and anxiety, perceived sufficiency of information, and intended behavior during the recent A/H1N1 influenza pandemic and their associations with psychological distress."
most,failed,septicaemia,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,eggs associated with organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
eggs nestlings,associated with,multiple organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,eggs,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
eggs nestlings,associated with,internal organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
eggs nestlings,associated with,organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,eggs associated with multiple organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
eggs nestlings,associated with,multiple internal organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,especially septicaemia,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,septicaemia by swine pathogens,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
eggs,septicaemia by,swine pathogens,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,especially septicaemia by swine pathogens,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,eggs associated with internal organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,eggs associated with multiple internal organ damage,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
most,failed,eggs associated,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
livestock pathogens,causing,disease,"We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease."
domestic cat,has offered potential in,description of over 250 disease models,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
domestic cat,has offered,potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
domestic cat,has offered potential in,description,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
domestic cat,has offered,enormous genomic potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered,enormous potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered,genomic potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
domestic cat,has offered,enormous potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
domestic cat,has offered,genomic potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered,enormous genomic potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered potential in,description of over 250 disease models,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered potential in,description,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered,potential,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
cat,has offered potential in,description of over 250 hereditary disease models,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
domestic cat,has offered potential in,description of over 250 hereditary disease models,"BACKGROUND: The domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditary disease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- FeLV, feline coronavirus -- FECV, feline immunodeficiency virus - FIV) that are homologues to human scourges (cancer, SARS, and AIDS respectively)."
homes,is with,respiratory infections,We report the results of quantitative meta-analyses of published studies that examined the association of dampness or mold in homes with respiratory infections and bronchitis.
association,is in,homes with respiratory infections,We report the results of quantitative meta-analyses of published studies that examined the association of dampness or mold in homes with respiratory infections and bronchitis.
random effects models,from ORs is,95 % CIs,"ORs (95% CIs) from random effects models using studies adjusting for major confounding variables were, for bronchitis, 1.45 (1.32-1.59); for respiratory infections, 1.44 (1.31-1.59); for respiratory infections excluding nonspecific upper respiratory infections, 1.50 (1.32-1.70), and for respiratory infections in children or infants, 1.48 (1.33-1.65)."
infections,for infections is,1.44 1.31-1.59,"ORs (95% CIs) from random effects models using studies adjusting for major confounding variables were, for bronchitis, 1.45 (1.32-1.59); for respiratory infections, 1.44 (1.31-1.59); for respiratory infections excluding nonspecific upper respiratory infections, 1.50 (1.32-1.70), and for respiratory infections in children or infants, 1.48 (1.33-1.65)."
respiratory infections,is in,children,"ORs (95% CIs) from random effects models using studies adjusting for major confounding variables were, for bronchitis, 1.45 (1.32-1.59); for respiratory infections, 1.44 (1.31-1.59); for respiratory infections excluding nonspecific upper respiratory infections, 1.50 (1.32-1.70), and for respiratory infections in children or infants, 1.48 (1.33-1.65)."
children,in infections is,1.48,"ORs (95% CIs) from random effects models using studies adjusting for major confounding variables were, for bronchitis, 1.45 (1.32-1.59); for respiratory infections, 1.44 (1.31-1.59); for respiratory infections excluding nonspecific upper respiratory infections, 1.50 (1.32-1.70), and for respiratory infections in children or infants, 1.48 (1.33-1.65)."
associations,were,confirmed,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
associations,were confirmed as,causal,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent,proportion,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent,proportion of infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent,proportion of respiratory infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent,substantial proportion of respiratory infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent,substantial proportion of infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent,proportion,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent,proportion of infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent,substantial proportion of respiratory infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,is in,buildings,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent proportion,confirmed,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent,substantial proportion,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent,substantial proportion,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
control,would prevent proportion,confirmed,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent,substantial proportion of infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
effective control,would prevent,proportion of respiratory infections,"If these associations were confirmed as causal, effective control of dampness and mold in buildings would prevent a substantial proportion of respiratory infections."
GI conditions,included,6.90%,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
GI conditions,included,diarrhea,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
GI conditions,included,2.30%,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
GI conditions,included,acute diarrhea,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
GI conditions,included,bacterial acute diarrhea,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
GI conditions,included,giardiasis,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
GI conditions,included,bacterial diarrhea,"GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%)."
febrile systemic illnesses,is with,identified pathogens,"Among febrile systemic illnesses with identified pathogens, malaria (5.4%) accounted for most cases followed by dengue (1.9%) and others including chikungunya, rickettsial diseases, leptospirosis, brucellosis, Epstein Barr virus infections, tick-borne encephalitis (TBE) and viral hepatitis."
cutaneous larva migrans,requiring,rabies post-exposure prophylaxis,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
cutaneous larva migrans,requiring,rabies prophylaxis,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
larva migrans,requiring,rabies prophylaxis also,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
cutaneous larva migrans,requiring,rabies prophylaxis also,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
larva migrans,requiring,rabies prophylaxis,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
larva migrans,requiring,rabies post-exposure prophylaxis also,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
cutaneous larva migrans,requiring,rabies post-exposure prophylaxis also,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
conditions,were,dominated,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
larva migrans,requiring,rabies post-exposure prophylaxis,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
Dermatological conditions,were,dominated,"Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy."
Respiratory illness,included,112 cases of tuberculosis including cases of multi-drug resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases of tuberculosis,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases including cases of multi-drug resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases including cases of resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases of tuberculosis including cases of resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases including cases of resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases including cases,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases of tuberculosis including cases of resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases of tuberculosis including cases,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases including cases,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases of tuberculosis including cases,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases of tuberculosis including cases of multi-drug resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases of tuberculosis,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Respiratory illness,included,112 cases including cases of multi-drug resistant,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
illness,included,112 cases,"Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease."
Purpose,was,identified for diagnoses in immigrants from Africa,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was identified in,immigrants from sub-Saharan Africa,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was,identified,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was,identified for diagnoses in immigrants,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was identified for,several diagnoses,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was identified in,immigrants,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was identified for,diagnoses,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was,identified for several diagnoses in immigrants from Africa,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was identified in,immigrants from Africa,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Chagas disease,is in,immigrant travellers from South America,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was,identified for several diagnoses in immigrants,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Purpose,was,identified for diagnoses in immigrants from sub-Saharan Africa,Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa.
Leptospirosis,is,zoonotic,"Leptospirosis is a widespread zoonotic infection that primarily affects residents of tropical regions, but causes infections in animals and humans in temperate regions as well."
Leptospirosis,is,widespread,"Leptospirosis is a widespread zoonotic infection that primarily affects residents of tropical regions, but causes infections in animals and humans in temperate regions as well."
Leptospirosis,can vary in,severity,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
Leptospirosis,can vary from,mild non-specific illness,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
widespread damage,failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
Leptospirosis,can vary from,mild illness,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
endothelial damage,multi-organ failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
Leptospirosis,can vary from,illness to disease,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
widespread damage,multi-organ failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
Leptospirosis,can vary from,mild illness to disease,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
Leptospirosis,can vary from,non-specific illness,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
endothelial damage,failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
widespread endothelial damage,multi-organ failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
widespread endothelial damage,failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
Leptospirosis,can vary from,illness,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
damage,failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
damage,multi-organ failure,hemorrhage,"Leptospirosis can vary in severity from a mild, non-specific illness to severe disease that includes multi-organ failure and widespread endothelial damage and hemorrhage."
antibiotic therapy,is with,lisinopril,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing,therapy,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing,antibiotic therapy,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing,antibiotic therapy with lisinopril,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing therapy with,endothelial protective activities,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing,therapy with lisinopril,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing therapy with,activities,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing therapy with,endothelial activities,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
severity,supplementing therapy with,protective activities,"In addition, supplementing antibiotic therapy with lisinopril or derivatives with endothelial protective activities may decrease the severity of leptospirosis."
edema,is,significant,"â€”Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening."
edema,is,problem,"â€”Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening."
edema,is,worldwide,"â€”Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening."
Pulmonary edema,manifestation of,left ventricular heart failure,"â€”Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening."
Pulmonary edema,is,problem,"â€”Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening."
edema,is,medical,"â€”Pulmonary edema, a major manifestation of left ventricular heart failure, renal insufficiency, shock, diffuse alveolar damage and lung hypersensitivity states, is a significant medical problem worldwide and can be life-threatening."
HR,contain,major differences,"The current HR(2005) contain major differences compared to earlier versions, including: substantial shifts from containment at the border to containment at the source of the event; shifts from a rather small disease list (smallpox, plague, cholera, and yellow fever) required to be reported, to all public health threats; and shifts from preset measures to tailored responses with more flexibility to deal with the local situations on the ground."
HR,contain,differences,"The current HR(2005) contain major differences compared to earlier versions, including: substantial shifts from containment at the border to containment at the source of the event; shifts from a rather small disease list (smallpox, plague, cholera, and yellow fever) required to be reported, to all public health threats; and shifts from preset measures to tailored responses with more flexibility to deal with the local situations on the ground."
current HR,contain,major differences,"The current HR(2005) contain major differences compared to earlier versions, including: substantial shifts from containment at the border to containment at the source of the event; shifts from a rather small disease list (smallpox, plague, cholera, and yellow fever) required to be reported, to all public health threats; and shifts from preset measures to tailored responses with more flexibility to deal with the local situations on the ground."
tailored responses,is with,more flexibility deal,"The current HR(2005) contain major differences compared to earlier versions, including: substantial shifts from containment at the border to containment at the source of the event; shifts from a rather small disease list (smallpox, plague, cholera, and yellow fever) required to be reported, to all public health threats; and shifts from preset measures to tailored responses with more flexibility to deal with the local situations on the ground."
current HR,contain,differences,"The current HR(2005) contain major differences compared to earlier versions, including: substantial shifts from containment at the border to containment at the source of the event; shifts from a rather small disease list (smallpox, plague, cholera, and yellow fever) required to be reported, to all public health threats; and shifts from preset measures to tailored responses with more flexibility to deal with the local situations on the ground."
genotyping analysis,is in,Taiwanese cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility through genotyping analysis in Taiwanese cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility through genotyping analysis,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to dengue fever through genotyping analysis in Taiwanese cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to dengue fever,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to fever through genotyping analysis in cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to fever,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was,associated,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to dengue fever through genotyping analysis,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility through genotyping analysis in cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to fever through genotyping analysis in Taiwanese cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to fever through genotyping analysis,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
rs4804803 SNP,was associated with,susceptibility to dengue fever through genotyping analysis in cohort,METHODS AND FINDINGS: We studied whether the rs4804803 SNP was associated with a susceptibility to dengue fever (DF) and/or dengue hemorrhagic fever (DHF) through genotyping analysis in a Taiwanese cohort.
illness,is common in,influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,more common than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,common than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is,common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is common in,influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,common in influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is more common in,influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,more common than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is,more common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is,more common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are,afebrile,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is more common than,influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,common than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,more common in influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,common in influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,more common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
many influenza infections,are afebrile,more common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is,common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is common than,influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,more common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are,afebrile,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is more common than,influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is,common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,more common in influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is,more common in influenza infections than influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is more common in,influenza infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
influenza infections,are afebrile,more common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is common than,influenza B infections,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
febrile illness,is,common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
illness,is,more common,"Although febrile illness is more common in influenza A infections than influenza B infections, many influenza A infections are afebrile."
Herpes simplex,produces,Alzheimer disease,Herpes simplex is implicated in Alzheimer's disease and viral infection produces Alzheimer's disease like pathology in mice.
Herpes simplex,is,implicated,Herpes simplex is implicated in Alzheimer's disease and viral infection produces Alzheimer's disease like pathology in mice.
pathology,is in,mice,Herpes simplex is implicated in Alzheimer's disease and viral infection produces Alzheimer's disease like pathology in mice.
Herpes simplex,is implicated in,in Alzheimer disease,Herpes simplex is implicated in Alzheimer's disease and viral infection produces Alzheimer's disease like pathology in mice.
pharynx swabs,showed,14 amplifications for adenovirus,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
21 pharynx swabs,showed,14 amplifications for adenovirus,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
21 pharynx swabs,showed,14 positive amplifications,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
pharynx swabs,showed,14 positive amplifications,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
pharynx swabs,showed,14 amplifications,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
three co-infections,is with,respiratory syncytial virus,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
pharynx swabs,showed,14 positive amplifications for adenovirus,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
21 pharynx swabs,showed,14 positive amplifications for adenovirus,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
21 pharynx swabs,showed,14 amplifications,"RESULTS: Two strains of adenovirus and two strains of enterovirus were isolated, the 21 pharynx swabs showed 14 positive amplifications for adenovirus; three co-infections with respiratory syncytial virus, two positive for rhinovirus, one positive for parainfluenza 3, and four negative."
Patients,gave,pharyngeal swabs,"Patients from the ED (emergency department) with flu-like symptoms (sore throat, cough, rhinorhea, or nasal congestion) and fever >37.5Â°C were admitted in the Unit of Infectious diseases and gave pharyngeal or nasopharyngeal swabs."
Patients,is with,flu-like symptoms,"Patients from the ED (emergency department) with flu-like symptoms (sore throat, cough, rhinorhea, or nasal congestion) and fever >37.5Â°C were admitted in the Unit of Infectious diseases and gave pharyngeal or nasopharyngeal swabs."
strategies,disable,innate system,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,system,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,immune system,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,immune system for replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,innate immune system,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,innate immune system for productive replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,system for replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,innate system for productive replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,innate system for replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,innate immune system for replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,system for productive replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
strategies,disable,immune system for productive replication,BACKGROUND: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of infection.
Cephalosporins,can,can used in patients allergic to penicillin with exception,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients with exception of type I hypersensibility,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,been,proposed,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients allergic,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients allergic to penicillin,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
patients allergic,is with,exception of type I hypersensibility,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients allergic with exception,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients with exception,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,been,also proposed,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients allergic with exception of type I hypersensibility,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
Cephalosporins,can,can used in patients allergic to penicillin with exception of type I hypersensibility,Cephalosporins can be used in patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat the relapses.
nasopharynx,is ecological niche for,many commensal bacteria,"The nasopharynx is the ecological niche for many commensal bacteria and for potential respiratory or invasive pathogens like Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis."
nasopharynx,is niche for,commensal bacteria,"The nasopharynx is the ecological niche for many commensal bacteria and for potential respiratory or invasive pathogens like Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis."
nasopharynx,is ecological niche for,commensal bacteria,"The nasopharynx is the ecological niche for many commensal bacteria and for potential respiratory or invasive pathogens like Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis."
nasopharynx,is niche for,many commensal bacteria,"The nasopharynx is the ecological niche for many commensal bacteria and for potential respiratory or invasive pathogens like Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis."
Proteobacteria,is with,Moraxella,"The 5 most predominant phyla were Proteobacteria (64%), Firmicutes (21%), Bacteroidetes (11%), Actinobacteria (3%) and Fusobacteria (1,4%) with Moraxella, Haemophilus, Streptococcus, Flavobacteria, Dolosigranulum, Corynebacterium and Neisseria as predominant genera."
predominant genera,as Proteobacteria is,64%,"The 5 most predominant phyla were Proteobacteria (64%), Firmicutes (21%), Bacteroidetes (11%), Actinobacteria (3%) and Fusobacteria (1,4%) with Moraxella, Haemophilus, Streptococcus, Flavobacteria, Dolosigranulum, Corynebacterium and Neisseria as predominant genera."
Moraxella,with Proteobacteria is,64%,"The 5 most predominant phyla were Proteobacteria (64%), Firmicutes (21%), Bacteroidetes (11%), Actinobacteria (3%) and Fusobacteria (1,4%) with Moraxella, Haemophilus, Streptococcus, Flavobacteria, Dolosigranulum, Corynebacterium and Neisseria as predominant genera."
Proteobacteria,of predominance is,relative abundance,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
Microbiota profiles,varied with,season,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
91%,is in,fall/winter,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
19%,is in,fall/winter,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
75%,is in,spring,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
Microbiota profiles,varied strongly with,season,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
14%,is in,spring,"Microbiota profiles varied strongly with season, with in fall/winter a predominance of Proteobacteria (relative abundance (% of all sequences): 75% versus 51% in spring) and Fusobacteria (absolute abundance (% of children): 14% versus 2% in spring), and in spring a predominance of Bacteroidetes (relative abundance: 19% versus 3% in fall/winter, absolute abundance: 91% versus 54% in fall/winter), and Firmicutes."
ILIs,were,defined,"ILIs were defined as body temperature â‰¥38Â°C and cough and at least two of the following symptoms: sore throat, rhinorrhea, headache and muscular pain, for a maximum duration of 3 days."
ILIs,were defined as,body temperature â‰¥ 38,"ILIs were defined as body temperature â‰¥38Â°C and cough and at least two of the following symptoms: sore throat, rhinorrhea, headache and muscular pain, for a maximum duration of 3 days."
Streptococcus suis infection,is,increasing health problem across South East Asia,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
adults,is in,Vietnam,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
infection,is,public,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,increasing public health problem,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,increasing public health problem across South East Asia,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
infection,is,increasing,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,public health problem across South East Asia,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
common cause,is in,adults,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,public health problem,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,increasing health problem,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,health problem across South East Asia,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
Streptococcus suis infection,is,health problem,"BACKGROUND: Streptococcus suis infection, an emerging zoonosis, is an increasing public health problem across South East Asia and the most common cause of acute bacterial meningitis in adults in Vietnam."
infection,resulted in,lung lesions consistent with bronchointerstitial pneumonia of varying severity blunting,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions consistent,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions consistent with bronchointerstitial pneumonia of severity blunting,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions consistent with pneumonia of severity blunting,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions consistent with pneumonia blunting,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions consistent with bronchointerstitial pneumonia blunting,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
infection,resulted in,lung lesions consistent with pneumonia of varying severity blunting,"Histologically, the infection resulted in lung lesions consistent with bronchointerstitial pneumonia of varying severity and nasal turbinates with blunting or loss of cilia of the epithelium lining the nasal septa."
detection,is in,EBC swabs,"RESULTS: Viral screening resulted in the detection of 4 different viruses in EBC and/or nasal swabs: Rhinovirus, Human Respiratory Syncytial Virus B, Influenza A and Influenza B. Rhinovirus was detected in 6 EBCs and 1 EBC was Influenza B positive."
detected,was positive,Influenza B,"RESULTS: Viral screening resulted in the detection of 4 different viruses in EBC and/or nasal swabs: Rhinovirus, Human Respiratory Syncytial Virus B, Influenza A and Influenza B. Rhinovirus was detected in 6 EBCs and 1 EBC was Influenza B positive."
Influenza B. Rhinovirus,was,detected,"RESULTS: Viral screening resulted in the detection of 4 different viruses in EBC and/or nasal swabs: Rhinovirus, Human Respiratory Syncytial Virus B, Influenza A and Influenza B. Rhinovirus was detected in 6 EBCs and 1 EBC was Influenza B positive."
Influenza B. Rhinovirus,was,detected in 6 EBCs,"RESULTS: Viral screening resulted in the detection of 4 different viruses in EBC and/or nasal swabs: Rhinovirus, Human Respiratory Syncytial Virus B, Influenza A and Influenza B. Rhinovirus was detected in 6 EBCs and 1 EBC was Influenza B positive."
treatment,is with,DMXAA,We determined that treatment with DMXAA generates significant therapeutic effects against TC-1 tumors but does not enhance the antigen-specific immune responses in tumor bearing mice.
effects,treatment with,DMXAA,We determined that treatment with DMXAA generates significant therapeutic effects against TC-1 tumors but does not enhance the antigen-specific immune responses in tumor bearing mice.
antigen-specific immune responses,is in,tumor bearing mice,We determined that treatment with DMXAA generates significant therapeutic effects against TC-1 tumors but does not enhance the antigen-specific immune responses in tumor bearing mice.
significant effects,treatment with,DMXAA,We determined that treatment with DMXAA generates significant therapeutic effects against TC-1 tumors but does not enhance the antigen-specific immune responses in tumor bearing mice.
important complication,is In,Plasmodium falciparum malaria endemic areas,BACKGROUND: In Plasmodium falciparum malaria endemic areas placental malaria (PM) is an important complication of malaria.
hepatitis B virus,is major factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
liver,resulting in,hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major etiological factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
virus,is,major,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is etiological factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
virus,is,etiological,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is etiological factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major etiological factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is etiological factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
liver,resulting in,carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is etiological factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major etiological factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is etiological factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major etiological factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major etiological factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,etiological factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,etiological factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major etiological factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major etiological factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major etiological factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major etiological factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,etiological factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,etiological factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major etiological factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is etiological factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is etiological factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is factor to,liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is etiological factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,etiological factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major etiological factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major etiological factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major etiological factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is etiological factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is etiological factor to,liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,etiological factor of inflammation to liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,etiological factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,etiological factor of inflammation to liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major etiological factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major etiological factor to,liver resulting,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,etiological factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,etiological factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major etiological factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is major factor of,inflammation,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major etiological factor of inflammation to liver resulting in hepatocellular carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
BACKGROUND,is,major etiological factor,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major etiological factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is major factor to,liver,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hepatitis B virus,is,major etiological factor of inflammation to liver resulting in carcinoma,BACKGROUND: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver resulting in hepatocellular carcinoma.
hospitalized patients,is with,acute lower respiratory illness,"METHODS: From September 1, 2003â€“August 31, 2005, we tested hospitalized patients with acute lower respiratory illness and outpatient controls without fever or respiratory symptoms for HRVs with polymerase chain reaction and molecularly-typed select HRVs."
HRVs,is with,polymerase chain reaction,"METHODS: From September 1, 2003â€“August 31, 2005, we tested hospitalized patients with acute lower respiratory illness and outpatient controls without fever or respiratory symptoms for HRVs with polymerase chain reaction and molecularly-typed select HRVs."
deafness,are,features of Usher syndrome in humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
degeneration,are features of,Usher syndrome,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
deafness,are features of,Usher syndrome in humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
retinal degeneration,are features of,Usher syndrome,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
Syndromal deafness,are,features of Usher syndrome,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
Syndromal deafness,are,features of Usher syndrome in humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
deafness,are,features of Usher syndrome,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
Syndromal deafness,are features of,Usher syndrome in humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
Syndromal deafness,are,features,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
retinal degeneration,are,features,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
Syndromal deafness,are features of,Usher syndrome,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
retinal degeneration,are features of,Usher syndrome in humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
degeneration,are,features,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
degeneration,are features of,Usher syndrome in humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
Usher syndrome,is in,humans,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
deafness,are,features,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
deafness,are features of,Usher syndrome,Syndromal deafness as well as retinal degeneration are features of the Usher syndrome in humans.
supportive care,are,treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
care,are,main treatment for influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
supportive care,are main treatment for,influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
neuraminidase inhibitors,are,treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
care,are,main treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
care,are,treatment for influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
supportive care,are,treatment for influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
supportive care,are,main treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
neuraminidase inhibitors,are main treatment for,influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
course,be influenced by,agents,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
neuraminidase inhibitors,are treatment for,influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
course,be,influenced,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
course,be favorably influenced by,agents,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
care,are,treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
neuraminidase inhibitors,are,main treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
care,are main treatment for,influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
course,be,favorably influenced,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
data,suggest,treatment for influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
data,suggest,main treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
supportive care,are,main treatment for influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
data,suggest,main treatment for influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
care,are treatment for,influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
data,suggest,treatment,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
supportive care,are treatment for,influenza,"While supportive care and neuraminidase inhibitors are the main treatment for influenza, data from observational and interventional studies suggest that the course of influenza can be favorably influenced by agents not classically considered as influenza treatments."
nonrestorative sleep,is with,associated REM-related apneas/hypopneas,"RESULTS: Chronic post-SARS is characterized by persistent fatigue, diffuse myalgia, weakness, depression, and nonrestorative sleep with associated REM-related apneas/hypopneas, an elevated sleep EEG cyclical alternating pattern, and alpha EEG sleep anomaly."
Post,had,symptoms of pre fatigue,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
patients,is with,FMS,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
SARS patients,had,symptoms of pre fatigue,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
SARS patients,had,symptoms,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
SARS patients,had,symptoms of fatigue,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
Post,had,symptoms,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
Post,had,symptoms of fatigue,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
patients,is with,chronic fatigue syndrome,"Post- SARS patients had symptoms of pre and post-sleep fatigue and post sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with chronic fatigue syndrome."
coronavirus strain,was isolated from,brain tissues of ten piglets,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
One coronavirus strain,was,isolated from brain tissues of ten piglets with manifestations of vomiting in Jilin province in China,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
One coronavirus strain,was,isolated from brain tissues with evident clinical manifestations of vomiting,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
One coronavirus strain,was,isolated from brain tissues of ten piglets with evident manifestations of vomiting in Jilin province in China,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
One coronavirus strain,was isolated with,evident manifestations of vomiting in Jilin province,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
One coronavirus strain,was,isolated from brain tissues of ten piglets with evident clinical manifestations,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
One coronavirus strain,was,isolated from brain tissues of ten piglets with manifestations of vomiting,"One coronavirus strain was isolated from brain tissues of ten piglets with evident clinical manifestations of vomiting, diarrhea and dyskinesia in Jilin province in China."
Major pathological changes,included,cortical hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Major pathological changes,included,meningeal hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Major changes,included,cortical hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Major pathological changes,included,meningeal hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
changes,included,hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
pathological changes,included,hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
changes,included,hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
changes,included,hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
pathological changes,included,meningeal hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Major changes,included,hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
changes,included,meningeal hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
pathological changes,included,meningeal hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Major pathological changes,included,hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Major changes,included,meningeal hyperemia,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
changes,included,cortical hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
pathological changes,included,cortical hemorrhage,"Major pathological changes included meningeal hyperemia, meningeal hemorrhage and cortical hemorrhage."
Nipah virus,was,first recognized in 1998 in disease outbreak associated with febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with highly lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with highly lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with highly lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with highly lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with highly lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with highly lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
respiratory disease,is in,pigs,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with highly lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with highly lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,1998,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with highly lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with highly lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with lethal febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with highly lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
lethal febrile encephalitis,is in,humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with febrile encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with highly lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,1998,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with highly lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with highly lethal encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with highly lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was recognized in,disease outbreak associated with lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,first recognized in 1998 in disease outbreak associated with highly lethal febrile encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was first recognized in,disease outbreak associated with lethal encephalitis,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
Nipah virus,was,recognized in 1998 in disease outbreak associated with encephalitis in humans,Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs.
enzyme-ligand complexes,were,derived by docking Imipenem to NDM-1 receptor,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
two enzyme-ligand complexes,were derived by,docking Imipenem,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
enzyme-ligand complexes,were derived by,respectively docking Imipenem,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
two enzyme-ligand complexes,were derived to,NDM-1 receptor,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
two enzyme-ligand complexes,were,derived by respectively docking Imipenem to NDM-1 receptor,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
two enzyme-ligand complexes,were,derived,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
enzyme-ligand complexes,were derived by,docking Imipenem,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
enzyme-ligand complexes,were,derived,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
two enzyme-ligand complexes,were,derived by docking Imipenem to NDM-1 receptor,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
enzyme-ligand complexes,were,derived by respectively docking Imipenem to NDM-1 receptor,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
enzyme-ligand complexes,were derived to,NDM-1 receptor,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
two enzyme-ligand complexes,were derived by,respectively docking Imipenem,"With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor."
manifestation,was based on,discharge diagnosis from hospital,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
Clinical manifestation,was,based,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
hospital,is with,four conditions predominating,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
Clinical manifestation,was based on,discharge diagnosis,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
Clinical manifestation,was based on,discharge diagnosis from hospital,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
manifestation,was,based,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
manifestation,was based on,discharge diagnosis,"Clinical manifestation of ARI was based on discharge diagnosis from hospital with four conditions predominating: bronchiolitis, pneumonia, episodic viral wheeze/asthma and upper respiratory tract infection."
50 % reduction,is in,binding,ABBREVIATIONS: Armstrong 53b (Arm53b); baculovirus Autographa californica GP64 (GP64); charge-coupled device (CCD); dystroglycan (DG); feline immunodeficiency virus (FIV); glycoprotein precursor (GP-C); firefly luciferase (Luc); lymphocytic choriomeningitis virus (LCMV); nuclear targeted Î²-galactosidase (ntLacZ); optical density (OD); PBS/0.1% (w/v) Tween-20 (PBST); relative light units (RLU); Rous sarcoma virus (RSV); transducing units per milliliter (TU/ml); vesicular stomatitis virus (VSV-G); wheat germ agglutinin (WGA); 50% reduction in binding (C(50)).
Hepatitis virus,is agent of,type viral hepatitis,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
Hepatitis virus,is,agent,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
Hepatitis virus,is causative agent of,type hepatitis,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
Hepatitis virus,is agent of,type hepatitis,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
BACKGROUND,is,causative agent,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
Hepatitis virus,is,causative agent,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
BACKGROUND,is,agent,"BACKGROUND: Hepatitis A virus is the causative agent of type A viral hepatitis, which causes occasional acute hepatitis."
Lithium chloride,has,has found,"Lithium chloride (LiCl) has been found to be effective against several DNA viruses, such as Herpes simplex virus and vaccinia virus."
LiCl,acted on,initial stage,The time-of-addition effect of the drug on TGEV infection indicated that LiCl acted on the initial and late stage of TGEV infection.
LiCl,acted on,initial stage of TGEV infection,The time-of-addition effect of the drug on TGEV infection indicated that LiCl acted on the initial and late stage of TGEV infection.
LiCl,acted on,stage of TGEV infection,The time-of-addition effect of the drug on TGEV infection indicated that LiCl acted on the initial and late stage of TGEV infection.
LiCl,acted on,stage,The time-of-addition effect of the drug on TGEV infection indicated that LiCl acted on the initial and late stage of TGEV infection.
1a,of pseudoparticles is,HCVpp,"To investigate the antiviral effect of LA (Chloroquine and NH(4)Cl) on pH dependent endocytosis, HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells."
liver cells,were infected in,presence of different concentrations of Chloroquine,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp in presence of concentrations of Chloroquine,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp in presence of different concentrations of Chloroquine,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were infected with,HCVpp,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were infected in,presence of concentrations of Chloroquine,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp of 3a in presence of different concentrations,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp in presence of different concentrations,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were infected in,presence,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp in presence,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp of 3a in presence,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were infected in,presence of different concentrations,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
luciferase activity,was,determined,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp of 3a in presence of different concentrations of Chloroquine,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
luciferase activity,using,luminometer,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were infected in,presence of concentrations,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp of 3a in presence of concentrations,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp of 3a in presence of concentrations of Chloroquine,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were infected with,HCVpp of 3a,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
liver cells,were,infected with HCVpp in presence of concentrations,"For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer."
Patients,absence during,hospital admission,"Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission."
Patients,absence of,infection,"Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission."
Patients,were grouped into,four cohorts,"Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission."
Patients,absence during,same hospital admission,"Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission."
Patients,were,grouped,"Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission."
Patients,had,risk of mortality RR 6.58,"Patients who had both viral and bacterial infections during the same hospitalization had the greatest risk of mortality RR 6.58, 95% CI (5.47, 7.91); multi-organ failure RR 8.25, 95% CI (7.50, 9.07); and septic shock RR 271.2, 95% CI (188.0, 391.3)."
Patients,had,risk,"Patients who had both viral and bacterial infections during the same hospitalization had the greatest risk of mortality RR 6.58, 95% CI (5.47, 7.91); multi-organ failure RR 8.25, 95% CI (7.50, 9.07); and septic shock RR 271.2, 95% CI (188.0, 391.3)."
important role,is in,host response to influenza A virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is,associated,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
important role,is in,host response to influenza A virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is,associated,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
important role,is in,host response to influenza A virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is,associated,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
important role,is in,host response to influenza A virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is,associated,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
important role,is in,host response to influenza A virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is,associated,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of different danger-associated molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of danger-associated patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion of patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of different molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,secretion of molecular patterns,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role for,DAMPs,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
suggesting,important role in,host response to influenza virus infection,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
influenza virus infection,is associated with,robust secretion,"Finally, we show that influenza A virus infection is associated with robust secretion of different danger-associated molecular patterns (DAMPs) suggesting an important role for DAMPs in host response to influenza A virus infection."
it,reduce,morbidity,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
trial,is designed,determine,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
placebo-controlled trial,is,designed,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,illness in Indigenous infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,respiratory illness in Australian Indigenous infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,illness in Australian Indigenous infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
placebo-controlled trial,is in,Indigenous infants hospitalised with bronchiolitis,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,illness in infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
trial,is,designed,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,respiratory illness,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,illness in Australian infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,respiratory illness in Indigenous infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
placebo-controlled trial,is designed,determine,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce,short-term morbidity,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
respiratory illness,is in,Australian Indigenous infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,respiratory illness in infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,respiratory illness in Australian infants,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
it,reduce morbidity from,illness,"Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness."
oil,were,examined,"Essential oil of star anise as well as phenylpropanoids and sesquiterpenes, for example, trans-anethole, eugenol, Î²-eudesmol, farnesol, Î²-caryophyllene and Î²-caryophyllene oxide, which are present in many essential oils, were examined for their antiviral activity against herpes simplex virus type 1 (HSV-1) in vitro."
Essential oil,were,examined,"Essential oil of star anise as well as phenylpropanoids and sesquiterpenes, for example, trans-anethole, eugenol, Î²-eudesmol, farnesol, Î²-caryophyllene and Î²-caryophyllene oxide, which are present in many essential oils, were examined for their antiviral activity against herpes simplex virus type 1 (HSV-1) in vitro."
crystal structure,causing Streptococcus suis in,complex with zinc,METHODOLOGY/PRINCIPAL FINDINGS: Here we determined the crystal structure of SsTroA from a highly pathogenic streptococcal toxic shock syndrome (STSS)-causing Streptococcus suis in complex with zinc.
crystal structure,causing Streptococcus suis in,complex,METHODOLOGY/PRINCIPAL FINDINGS: Here we determined the crystal structure of SsTroA from a highly pathogenic streptococcal toxic shock syndrome (STSS)-causing Streptococcus suis in complex with zinc.
crystal structure,causing,Streptococcus suis,METHODOLOGY/PRINCIPAL FINDINGS: Here we determined the crystal structure of SsTroA from a highly pathogenic streptococcal toxic shock syndrome (STSS)-causing Streptococcus suis in complex with zinc.
complex,is with,zinc,METHODOLOGY/PRINCIPAL FINDINGS: Here we determined the crystal structure of SsTroA from a highly pathogenic streptococcal toxic shock syndrome (STSS)-causing Streptococcus suis in complex with zinc.
histopathology,represent,end stage phenomenon,"The histopathology of DAD is considered to represent end stage phenomenon in acutely behaving interstitial pneumonias, such as acute interstitial pneumonia (AIP) and acute exacerbations of idiopathic pulmonary fibrosis (IPF)."
histopathology,represent end stage phenomenon,behaving,"The histopathology of DAD is considered to represent end stage phenomenon in acutely behaving interstitial pneumonias, such as acute interstitial pneumonia (AIP) and acute exacerbations of idiopathic pulmonary fibrosis (IPF)."
histopathology,is,considered,"The histopathology of DAD is considered to represent end stage phenomenon in acutely behaving interstitial pneumonias, such as acute interstitial pneumonia (AIP) and acute exacerbations of idiopathic pulmonary fibrosis (IPF)."
separating,perkinsids from,core dinoflagellates,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support with,lineage positioned,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of marine alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of uncharacterized marine alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of numerous uncharacterized marine alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support with,Perkinsozoa,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
lineages,separating,perkinsids,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand,support,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of numerous marine alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support with,independent lineage,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of numerous uncharacterized alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
lineages,separating,perkinsids from core dinoflagellates,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support with,independent lineage positioned,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support with,lineage,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of numerous alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of uncharacterized alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
results,expand support along with,presence of alveolate group,"These results, along with the presence of the numerous uncharacterized â€˜marine alveolate group I' and Perkinsus-like lineages separating perkinsids from core dinoflagellates, expand support for the affiliation of the genus Perkinsus with an independent lineage (Perkinsozoa) positioned between the phyla of Apicomplexa and Dinoflagellata."
meta-analysis,confirmed,significant heterogeneity,"As for long-term effects, phase and amplitude terms of pneumococcal and influenza seasonal sine waves were not correlated and meta-analysis confirmed significant heterogeneity of influenza, but not pneumococcal phase terms."
meta-analysis,confirmed,heterogeneity,"As for long-term effects, phase and amplitude terms of pneumococcal and influenza seasonal sine waves were not correlated and meta-analysis confirmed significant heterogeneity of influenza, but not pneumococcal phase terms."
RVFV infection,usually causes,illness,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
number,progress to,disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
number,however progress to,disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
RVFV infection,causes,illness,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
small number,however progress to,disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
small number,however progress to,neurological disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
small number,progress to,disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
number,progress to,neurological disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
RVFV infection,is in,humans,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
number,however progress to,neurological disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
small number,progress to,neurological disorders,"RVFV infection in humans usually causes a self-limiting, acute and febrile illness; however, a small number of cases progress to neurological disorders, partial or complete blindness, hemorrhagic fever, or thrombosis."
ADAM10,was,shown,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
ADAM10,was shown,important for replication of HIV-1,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
Cells,harboring,disrupted ADAM10,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
ADAM10,was shown,important for replication,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
ADAM10,was shown,important,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
allele,survived,reovirus infection,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
ADAM10,was shown by,RNA interference,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
Cells,harboring,ADAM10,"Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1."
disease form,is associated with,specific Streptococcus suis serotype 2,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
new disease form,is,associated,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
new disease form,is associated with,Streptococcus suis serotype 2,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
new disease form,is associated with,specific Streptococcus suis serotype 2,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
disease form,is,associated,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
disease form,is associated with,SS2,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
new disease form,is associated with,SS2,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
disease form,is associated with,Streptococcus suis serotype 2,BACKGROUND: Our previous studies revealed that a new disease form of streptococcal toxic shock syndrome (STSS) is associated with specific Streptococcus suis serotype 2 (SS2) strains.
Moraxella catarrhalis,are primary pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are primary bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
primary pathogens,predict,ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
primary pathogens,predict,clinical ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
pathogens,predict,ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are primary bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,bacterial pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are primary bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,primary bacterial pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
primary bacterial pathogens,predict,clinical ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,primary bacterial pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,primary pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are primary pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,primary pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,primary bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are primary bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are,primary bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,bacterial pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
primary bacterial pathogens,predict,ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,bacterial pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
pathogens,predict,clinical ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are primary pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are primary pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are,primary pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are,pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,primary pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
bacterial pathogens,predict,clinical ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,primary bacterial pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,primary pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Haemophilus influenzae,are,primary pathogens of otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are bacterial pathogens of,otitis media,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Streptococcus pneumoniae,are,primary bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,primary bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
Moraxella catarrhalis,are,bacterial pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
bacterial pathogens,predict,ear state,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
influenzae,are,primary pathogens,"Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the primary bacterial pathogens of otitis media and their loads predict clinical ear state."
respiratory viruses,were,common,"RESULTS: M. catarrhalis (96%), H. influenzae (91%), S. pneumoniae (89%) and respiratory viruses (59%) were common; including rhinovirus (HRV) (38%), polyomavirus (HPyV) (14%), adenovirus (HAdV) (13%), bocavirus (HBoV) (8%) and coronavirus (HCoV) (4%)."
respiratory viruses,were,common including rhinovirus,"RESULTS: M. catarrhalis (96%), H. influenzae (91%), S. pneumoniae (89%) and respiratory viruses (59%) were common; including rhinovirus (HRV) (38%), polyomavirus (HPyV) (14%), adenovirus (HAdV) (13%), bocavirus (HBoV) (8%) and coronavirus (HCoV) (4%)."
attention,developing,holistic framework,"Building on the undoubted success of quantitative modelling of the epidemiology and control of human and animal diseases such as AIDS, influenza, foot-and-mouth disease and BSE, attention needs to be paid to developing a more holistic framework that captures the role of the underlying drivers of disease risks, from demography and behaviour to land use and climate change."
attention,developing,more holistic framework,"Building on the undoubted success of quantitative modelling of the epidemiology and control of human and animal diseases such as AIDS, influenza, foot-and-mouth disease and BSE, attention needs to be paid to developing a more holistic framework that captures the role of the underlying drivers of disease risks, from demography and behaviour to land use and climate change."
attention,developing,framework,"Building on the undoubted success of quantitative modelling of the epidemiology and control of human and animal diseases such as AIDS, influenza, foot-and-mouth disease and BSE, attention needs to be paid to developing a more holistic framework that captures the role of the underlying drivers of disease risks, from demography and behaviour to land use and climate change."
Bats,are natural reservoirs for,spectrum of infectious diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of zoonotic diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious zoonotic diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are,natural reservoirs,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of zoonotic diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious zoonotic diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of zoonotic diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious zoonotic diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious zoonotic diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious zoonotic diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious zoonotic diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of zoonotic diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious zoonotic diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of zoonotic diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of diseases,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of infectious diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of zoonotic diseases including henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of zoonotic diseases including emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are natural reservoirs for,spectrum of diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are,reservoirs,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious zoonotic diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of infectious diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Bats,are reservoirs for,spectrum of zoonotic diseases including recently emerged henipaviruses,Bats are natural reservoirs for a spectrum of infectious zoonotic diseases including the recently emerged henipaviruses (Hendra and Nipah viruses).
Community-acquired adenovirus pneumonia,requiring,ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
adenovirus pneumonia,requiring,ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
adenovirus pneumonia,often requiring,mechanical ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
adenovirus pneumonia,often requiring,ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
adenovirus pneumonia,requiring,mechanical ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
Community-acquired adenovirus pneumonia,often requiring,mechanical ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
Community-acquired adenovirus pneumonia,is in,immunocompetent adult civilians,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
Community-acquired adenovirus pneumonia,requiring,mechanical ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
Community-acquired adenovirus pneumonia,often requiring,ventilation,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
CONCLUSIONS,presents as,non-specific acute febrile respiratory illness followed by abrupt onset of respiratory failure,"CONCLUSIONS: Community-acquired adenovirus pneumonia in immunocompetent adult civilians presents as a non-specific acute febrile respiratory illness followed by the abrupt onset of respiratory failure, often requiring mechanical ventilation."
technology,could,could used more widely in patients with respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,has,potential utility,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used in patients with acute illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,has,potential utility for rationalization of use of antibiotics,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used widely,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used widely in patients with acute illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used in patients with acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used widely in patients with respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used in patients with respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used in patients with respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,has,potential utility for rationalization of use,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used in patients with acute illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used widely in patients with acute illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,has,potential utility for rationalization,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
patients,is with,acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used widely in patients with acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used widely,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used widely in patients with illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used in patients with illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used in patients,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used widely in patients,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used more widely in patients,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used in patients with illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used widely in patients with illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used in patients,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used widely in patients with acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used widely in patients,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used more widely in patients with illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used more widely in patients with illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,has,potential utility,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used more widely in patients with acute illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used more widely,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used more widely in patients,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,has,potential utility for rationalization of use of antibiotics,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used widely in patients with respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,has,potential utility for rationalization of use,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,has,potential utility for rationalization,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
potential utility,improving,infection control measures,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used more widely in patients with acute illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used more widely,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used in patients with acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used more widely in patients with respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
technology,could,could used more widely in patients with acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
new technology,could,could used more widely in patients with acute respiratory illness,The new technology could be used more widely in patients with acute respiratory illness and has potential utility for rationalization of the use of antibiotics and improving infection control measures.
lichen planus,decreases,quality of life,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
it,uncomfortable feeling in,mouth,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
Oral lichen planus,quality of,life,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
lichen planus,quality of,life,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
it,can cause pain during,eating,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
lichen planus,decreases,quality,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
it,feeling in,mouth,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
Oral lichen planus,decreases,quality,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
Oral lichen planus,decreases,quality of life,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
it,can cause,spontaneous pain,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
uncomfortable feeling,is in,mouth,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
it,can cause,pain,BACKGROUND: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during eating and tooth-brushing and an uncomfortable feeling in the mouth.
VAS scores,were significantly increased after,30 days,"VAS scores of dry mouth, breath odor, oral freshness, and sleep disorder were significantly increased 30 days after application of REFRECARE-H(Â® )(P = 0.01, P = 0.05, P = 0.03, P = 0.04)."
VAS scores,were increased after,30 days,"VAS scores of dry mouth, breath odor, oral freshness, and sleep disorder were significantly increased 30 days after application of REFRECARE-H(Â® )(P = 0.01, P = 0.05, P = 0.03, P = 0.04)."
VAS scores,were,significantly increased,"VAS scores of dry mouth, breath odor, oral freshness, and sleep disorder were significantly increased 30 days after application of REFRECARE-H(Â® )(P = 0.01, P = 0.05, P = 0.03, P = 0.04)."
VAS scores,were,increased,"VAS scores of dry mouth, breath odor, oral freshness, and sleep disorder were significantly increased 30 days after application of REFRECARE-H(Â® )(P = 0.01, P = 0.05, P = 0.03, P = 0.04)."
prevalent viruses,is in,H1N1v negative single infections,"The most prevalent viruses in H1N1v negative single infections were rhinovirus (62.6%), followed by parainfluenza viruses (24.2%) and adenovirus (5.3%)."
rhinovirus,followed by,parainfluenza viruses,"The most prevalent viruses in H1N1v negative single infections were rhinovirus (62.6%), followed by parainfluenza viruses (24.2%) and adenovirus (5.3%)."
score,score compared with,antidepressants,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,score compared with,antidepressants,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,score compared with,antidepressants alone,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,combined with,antidepressants,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,score of,HAMD,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was effective score in,comprehensive effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was effective score in,comprehensive effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
score,score compared with,antidepressants alone,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was more effective score in,comprehensive effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was more effective score in,comprehensive effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was effective score in,effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was effective score in,effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was more effective score in,effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,was more effective score in,effect,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
Xiaoyaosan,score of,SDS,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
score,score of,HAMD,"The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone."
NDM-1 enzyme,was potent,mostly susceptible,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was highly potent,susceptible,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was potent,susceptible to tigecycline,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was potent,mostly susceptible to tigecycline,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was,potent,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,degrade,carbapenem antibiotics,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was,highly potent,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was highly potent,mostly susceptible to tigecycline,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was highly potent,susceptible to tigecycline,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was potent,susceptible,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
NDM-1 enzyme,was highly potent,mostly susceptible,"We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1."
key component,is in,non-vesicular ER to trans-Golgi trafficking of ceramide,"In contrast, we show that C. trachomatis co-opts CERT, a lipid transfer protein that is a key component in non-vesicular ER to trans-Golgi trafficking of ceramide (the precursor for SM), for C. trachomatis replication."
C. trachomatis,co-opts,lipid transfer protein,"In contrast, we show that C. trachomatis co-opts CERT, a lipid transfer protein that is a key component in non-vesicular ER to trans-Golgi trafficking of ceramide (the precursor for SM), for C. trachomatis replication."
C. trachomatis,co-opts CERT for,C. trachomatis replication,"In contrast, we show that C. trachomatis co-opts CERT, a lipid transfer protein that is a key component in non-vesicular ER to trans-Golgi trafficking of ceramide (the precursor for SM), for C. trachomatis replication."
C. trachomatis,co-opts,CERT,"In contrast, we show that C. trachomatis co-opts CERT, a lipid transfer protein that is a key component in non-vesicular ER to trans-Golgi trafficking of ceramide (the precursor for SM), for C. trachomatis replication."
C. trachomatis,recruits,its ER binding partner,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
C. trachomatis,recruits,CERT,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
C. trachomatis,recruits CERT to,inclusion,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
proteins,establish,on-site SM factory,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
proteins,establish SM factory at,inclusion,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
C. trachomatis,recruits,SM synthases,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
proteins,establish,on-site SM biosynthetic factory,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
C. trachomatis,recruits,VAP-A,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
proteins,establish,SM factory,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
C. trachomatis,recruits SM synthases to,inclusion,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
proteins,establish,SM biosynthetic factory,"We demonstrate that C. trachomatis recruits CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins establish an on-site SM biosynthetic factory at or near the inclusion."
infectious diseases,are,increasingly identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
Vector-borne infectious diseases,are,increasingly identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
diseases,are,identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
Vector-borne diseases,are,identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
infectious diseases,are,identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
Vector-borne diseases,are,increasingly identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
Vector-borne infectious diseases,are,identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
diseases,are,increasingly identified,"Vector-borne infectious diseases, such as malaria, dengue, chikungunya, and West Nile fevers are increasingly identified as major global human health threats in developing and developed countries."
French territories,faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French territories,Recently faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
large-scale outbreaks,epidemic in,one island,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
overseas territories,Recently faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
outbreaks,epidemic of,chikungunya fever,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
outbreaks,epidemic in,one Caribbean island,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
outbreaks,epidemic in,one island,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
large-scale outbreaks,epidemic in,one Caribbean island,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
overseas territories,faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
territories,Recently faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
chikungunya fever,of epidemic is,Martinique,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French territories,Recently faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
overseas territories,faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
overseas territories,Recently faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
large-scale outbreaks,epidemic in,La Re union,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French territories,faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French overseas territories,faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French overseas territories,Recently faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
territories,Recently faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
territories,faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French overseas territories,faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
large-scale outbreaks,epidemic of,chikungunya fever,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
outbreaks,epidemic in,La Re union,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
French overseas territories,Recently faced,large-scale outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
La Re union,in epidemic is,Martinique,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
territories,faced,outbreaks,"Recently, French overseas territories faced large-scale outbreaks: an epidemic of chikungunya fever in La Reâ€² union and Mayotte (2005â€“2006) and four successive outbreaks of dengue fever in one Caribbean island, Martinique (1995â€“2007)."
notorious,are,dengue,"The most notorious are dengue, yellow fever, ebola, marburg, Rift Valley fever and chikungunya viruses."
virus,has,has also detected,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
virus,has,has also detected in children,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
virus,has,has detected in children,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
systemic infections,complicated by,pericarditis,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
children,is with,bronchitis,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
virus,has,has detected,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
virus,has,has detected in children with bronchitis,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
infections,complicated by,pericarditis,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
virus,has,has also detected in children with bronchitis,"The virus has also been detected in children with bronchitis, bronchiolitis, pneumonia, otitis media, sinusitis and systemic infections complicated by pericarditis."
virus,is,major,"BACKGROUND: Hepatitis C virus is a major cause of chronic liver diseases which can lead to permanent liver damage, hepatocellular carcinoma and death."
available treatment,is with,interferon,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
treatment,has limited,benefits,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
available treatment,has limited,benefits,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
benefits,due to,effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
benefits,due to,adverse side effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
available treatment,has limited,benefits due to adverse effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
treatment,has limited,benefits due to adverse effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
available treatment,has limited,benefits due to side effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
available treatment,has limited,benefits due to effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
treatment,has limited,benefits due,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
available treatment,has limited,benefits due to adverse side effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
treatment,has limited,benefits due to effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
benefits,due to,adverse effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
treatment,has limited,benefits due to side effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
treatment,has limited,benefits due to adverse side effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
available treatment,has limited,benefits due,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
benefits,due to,side effects,"The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression, fatigue, and ""flu-like"" symptoms."
reactions,were,reported,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were,reported,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
3.80%,fatigue in,3.70%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
reactions,were reported in,headache in 3.1 %,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
reactions,were reported in,fatigue,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
reactions,were reported in,3.8 % in 3.7 %,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
reactions,were reported in,fatigue in 3.7 %,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were reported in,3.8 % in 3.7 %,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
headache,is in,3.10%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
3.70%,in % is,headache,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
reactions,were reported in,3.80%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were reported in,fatigue in 3.7 %,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were reported in,headache in 3.1 %,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
reactions,were reported in,headache,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were reported in,3.80%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
3.80%,is in,3.70%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were reported in,fatigue,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Local reactions,were reported in,headache,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
fatigue,is in,3.70%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
3.80%,headache in,3.10%,"Local reactions were reported in 3.8%, myalgia and arthralgia in 3.7%, fatigue in 3.7%, headache in 3.1%."
Individuals,is with,pH1N1,"Individuals with pH1N1, compared to other viruses, were more likely to present with fever (92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14% & 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values<0.05)."
Individuals,were,likely,"Individuals with pH1N1, compared to other viruses, were more likely to present with fever (92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14% & 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values<0.05)."
Individuals,were,more likely,"Individuals with pH1N1, compared to other viruses, were more likely to present with fever (92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14% & 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values<0.05)."
Individuals,present with,fever,"Individuals with pH1N1, compared to other viruses, were more likely to present with fever (92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14% & 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values<0.05)."
proportion,were treated with,antibiotics,A high proportion of patients were treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.
high proportion,were treated with,antibiotics,A high proportion of patients were treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.
proportion,were,treated,A high proportion of patients were treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.
high proportion,were,treated,A high proportion of patients were treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.
Severe respiratory disease,revealing,potential link with disease,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
respiratory disease,revealing,potential link with disease,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,revealing,potential link with severe disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,revealing,potential pathogenic link with severe disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,revealing,potential link with disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,disease caused by other influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,revealing,potential pathogenic link with disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe respiratory disease,revealing,potential pathogenic link with disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,caused by,pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
disease,revealing,potential link with severe disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,severe disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe respiratory disease,revealing,potential pathogenic link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,revealing,potential link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,disease caused by other influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,severe disease caused by other influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,severe disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,disease,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
respiratory disease,caused by,pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
potential pathogenic link,is with,severe disease caused by other influenza subtypes such H5N1,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
disease,revealing,potential pathogenic link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe respiratory disease,caused by,2009 pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
respiratory disease,revealing,potential pathogenic link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
respiratory disease,revealing,potential link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,severe disease,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
disease,revealing,potential link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe respiratory disease,revealing,potential link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
disease,caused by,2009 pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
disease,caused by,pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,revealing,potential pathogenic link,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,severe disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,disease,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,severe disease,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
respiratory disease,caused by,2009 pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential link with,disease caused by influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe respiratory disease,caused by,pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,severe disease caused by other influenza subtypes,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
Severe disease,caused by,2009 pandemic influenza virus,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
revealing,potential pathogenic link with,severe disease caused,"CONCLUSIONS: Severe respiratory disease caused by the 2009 pandemic influenza virus is characterized by the existence of a direct association between viral replication and host cytokine response, revealing a potential pathogenic link with the severe disease caused by other influenza subtypes such as H5N1."
NK cell responses,are,However documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
human NK cell responses,are,documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
human NK cell responses,is in,acute influenza infection including infection with 2009 pandemic H1N1 influenza virus,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
human NK cell responses,are,poorly documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
human NK cell responses,are,However documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
human NK cell responses,are,However poorly documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
NK cell responses,are,poorly documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
NK cell responses,are,However poorly documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
infection,is with,2009 pandemic H1N1 influenza virus,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
NK cell responses,are,documented,"However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented."
antibiotic treatment,is,discouraged,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
Indiscriminative antibiotic treatment,is,discouraged,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,antibiotic treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,antibiotic treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,systemic antibiotic treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,systemic treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,systemic treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,systemic antibiotic treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,antibiotic treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,antibiotic treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,systemic treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,antibiotic treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
treatment,is,discouraged,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
Indiscriminative treatment,is,discouraged,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,systemic treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,antibiotic treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,systemic treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,systemic treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,systemic antibiotic treatment,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
calves,can benefit from,systemic antibiotic treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,systemic antibiotic treatment for prevention of septicaemia,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
ill calves,can benefit from,systemic antibiotic treatment for prevention,"Indiscriminative antibiotic treatment of uncomplicated diarrhoea is discouraged, whereas systemically ill calves can benefit from systemic antibiotic treatment for the prevention of septicaemia or concurrent diseases."
disease,is,in Americas manifest as cardiopulmonary compromise with case-fatality ratios,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise with case-fatality ratios between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise with ratios for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,manifest,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise with case-fatality ratios for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for most common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise with ratios for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise with ratios between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise with case-fatality ratios for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise with ratios for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
persistent infections,is in,their reservoir hosts,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for most common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for most common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,hantavirus syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
common viral serotypes,for compromise is,hantavirus cardiopulmonary syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,hantavirus cardiopulmonary syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
case-fatality ratios,with compromise is,hantavirus cardiopulmonary syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest in,Americas,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for most common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
Hantaviruses,cause,infections,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest in,Americas,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,manifest,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,hantavirus cardiopulmonary syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
30%,between compromise is,hantavirus cardiopulmonary syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for most common serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as cardiopulmonary compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,hantavirus syndrome,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for most common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise for viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for common viral serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,cardiopulmonary compromise for common viral serotypes,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is manifest as,compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as compromise,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
human disease,is,in Americas manifest as compromise for serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,cardiopulmonary compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is manifest as,compromise for most common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
disease,is,in Americas manifest as cardiopulmonary compromise for common serotypes between 30 %,"Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%."
Phylogenetically,is with,Betacoronavirus consisting of subgroups,"Phylogenetically, three genera, Alphacoronavirus, Betacoronavirus and Gammacoronavirus, with Betacoronavirus consisting of subgroups A, B, C and D, exist."
Betacoronavirus,with Phylogenetically is,three genera,"Phylogenetically, three genera, Alphacoronavirus, Betacoronavirus and Gammacoronavirus, with Betacoronavirus consisting of subgroups A, B, C and D, exist."
Betacoronavirus,with Phylogenetically is,Alphacoronavirus,"Phylogenetically, three genera, Alphacoronavirus, Betacoronavirus and Gammacoronavirus, with Betacoronavirus consisting of subgroups A, B, C and D, exist."
diseases,have,have associated,"A number of diseases have been associated with the virus including adult T-cell leukemia (ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-I uveitis, and HTLV-I-associated infective dermatitis."
pathogens,were,ranked,"Twenty-six pathogens were ranked in the highest priority group; among those were pathogens with internationally recognised importance (e.g., Human Immunodeficiency Virus, Mycobacterium tuberculosis, Influenza virus, Hepatitis C virus, Neisseria meningitides), pathogens frequently causing large outbreaks (e.g., Campylobacter spp."
those,among pathogens is,pathogens frequently causing,"Twenty-six pathogens were ranked in the highest priority group; among those were pathogens with internationally recognised importance (e.g., Human Immunodeficiency Virus, Mycobacterium tuberculosis, Influenza virus, Hepatitis C virus, Neisseria meningitides), pathogens frequently causing large outbreaks (e.g., Campylobacter spp."
pathogens,is with,internationally recognised importance,"Twenty-six pathogens were ranked in the highest priority group; among those were pathogens with internationally recognised importance (e.g., Human Immunodeficiency Virus, Mycobacterium tuberculosis, Influenza virus, Hepatitis C virus, Neisseria meningitides), pathogens frequently causing large outbreaks (e.g., Campylobacter spp."
recognised importance,with pathogens is,pathogens frequently causing,"Twenty-six pathogens were ranked in the highest priority group; among those were pathogens with internationally recognised importance (e.g., Human Immunodeficiency Virus, Mycobacterium tuberculosis, Influenza virus, Hepatitis C virus, Neisseria meningitides), pathogens frequently causing large outbreaks (e.g., Campylobacter spp."
Other pathogens,included,Helicobacter pylori,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
Other pathogens,included,Varicella zoster virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
Other pathogens,included,Respiratory Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
pathogens,included,Varicella zoster virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
pathogens,included,Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
pathogens,included,Syncytial Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
pathogens,included,Respiratory Syncytial Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
pathogens,included,Respiratory Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
Other pathogens,included,Syncytial Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
pathogens,included,Helicobacter pylori,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
Other pathogens,included,Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
Other pathogens,included,Respiratory Syncytial Virus,"Other pathogens in the highest priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and Hantavirus."
Recombinant IFNs,are used for,treatment,"Recombinant IFNs are used for the treatment of hepatitis C virus infection, multiple sclerosis, and certain malignancies."
IFNs,are used for,treatment,"Recombinant IFNs are used for the treatment of hepatitis C virus infection, multiple sclerosis, and certain malignancies."
Recombinant IFNs,are,used,"Recombinant IFNs are used for the treatment of hepatitis C virus infection, multiple sclerosis, and certain malignancies."
IFNs,are,used,"Recombinant IFNs are used for the treatment of hepatitis C virus infection, multiple sclerosis, and certain malignancies."
IFNs,are used for,treatment of hepatitis C virus infection,"Recombinant IFNs are used for the treatment of hepatitis C virus infection, multiple sclerosis, and certain malignancies."
Recombinant IFNs,are used for,treatment of hepatitis C virus infection,"Recombinant IFNs are used for the treatment of hepatitis C virus infection, multiple sclerosis, and certain malignancies."
foot disease,illustrate,framework,"Avian influenza, salmonella, and foot and mouth disease are presented to illustrate the framework."
Avian influenza,are,presented,"Avian influenza, salmonella, and foot and mouth disease are presented to illustrate the framework."
influenza,are,presented,"Avian influenza, salmonella, and foot and mouth disease are presented to illustrate the framework."
incidence,is in,PEMF group,"RESULTS: The incidence of osteonecrosis in the PEMF group (29%) was significantly lower than that observed in the MPSL group (75%), while no osteonecrosis was observed in the PS group."
osteonecrosis,of incidence is,29%,"RESULTS: The incidence of osteonecrosis in the PEMF group (29%) was significantly lower than that observed in the MPSL group (75%), while no osteonecrosis was observed in the PS group."
PEMF group,in incidence is,29%,"RESULTS: The incidence of osteonecrosis in the PEMF group (29%) was significantly lower than that observed in the MPSL group (75%), while no osteonecrosis was observed in the PS group."
it,protected,90%,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,When given at 56 days prior,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was given prior at,56 days,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,When given at 56 days,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,When given prior to infection,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,given prior,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,When given at 56 days prior to infection,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,given at 56 days prior to infection,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,When given,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,given prior to infection,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
it,protected,90 % of animals,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,given,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was,When given prior,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
prophylactic treatment,was given at,56 days,"When the prophylactic treatment was given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between 1â€“49 days pre-infection), with minimal weight loss occurring during infection."
high lethality,is in,primates,Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates.
Zaire ebolavirus infections,are,associated,Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates.
Zaire ebolavirus infections,are associated with,lethality in primates,Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates.
Zaire ebolavirus infections,are associated with,lethality,Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates.
Zaire ebolavirus infections,are associated with,high lethality in primates,Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates.
Zaire ebolavirus infections,are associated with,high lethality,Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates.
cases,have,During outbreak have observed,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
cases,have,During outbreak have observed in infants,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
severe cases,have,During outbreak have observed in infants,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
cases,have,have observed in infants,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
severe cases,have,have observed in infants,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
severe cases,have,During outbreak have observed,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
cases,have,have observed,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
severe cases,have,have observed,"During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants."
response,is in,cells,"Administration of E protein in trans reduced the stress response in cells infected with rSARS-CoV-Î”E or with respiratory syncytial virus, or treated with drugs, such as tunicamycin and thapsigargin that elicit cell stress by different mechanisms."
Antiviral activity,were,hardly noticed,"Antiviral activity of antioxidants such as NAC, pyrrolidine dithiocarbamate (PDTC), and the vitamin E derivative, trolox, were hardly noticed."
activity,were,hardly noticed,"Antiviral activity of antioxidants such as NAC, pyrrolidine dithiocarbamate (PDTC), and the vitamin E derivative, trolox, were hardly noticed."
activity,were,noticed,"Antiviral activity of antioxidants such as NAC, pyrrolidine dithiocarbamate (PDTC), and the vitamin E derivative, trolox, were hardly noticed."
Antiviral activity,were,noticed,"Antiviral activity of antioxidants such as NAC, pyrrolidine dithiocarbamate (PDTC), and the vitamin E derivative, trolox, were hardly noticed."
Overexpression,enhanced,induction of interleukin 2 compatible with late-stage immunopathogenicity,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,increased,signalling,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
enhanced,induction of,interleukin 2,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,enhanced,induction of interleukin 2 compatible with immunopathogenicity,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
enhanced,induction of,interleukin 2 compatible,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
enhanced,induction of,interleukin 2 compatible with late-stage immunopathogenicity,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,enhanced,induction of interleukin 2,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,enhanced,induction of interleukin 2 compatible,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,enhanced,induction,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,is with,live SARS-CoV,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Overexpression,strongly increased,signalling,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
enhanced,induction of,interleukin 2 compatible with immunopathogenicity,"Overexpression of NSP1 and infection with live SARS-CoV strongly increased signalling through the Calcineurin/NFAT pathway and enhanced the induction of interleukin 2, compatible with late-stage immunopathogenicity and long-term cytokine dysregulation as observed in severe SARS cases."
Participants,quoted,loss of weight as basic symptoms,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
pain,loss as,basic symptoms of TB,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss of weight as basic symptoms of TB,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss as basic symptoms,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss of weight as symptoms of TB,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,chest pain,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss of weight as symptoms,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss as basic symptoms of TB,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss as symptoms of TB,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss of weight,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
pain,loss of,weight,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
Participants,quoted,loss as symptoms,"Participants quoted chest pain, cough, haemoptysis, loss of appetite, loss of weight, weakness and sweating as basic symptoms of TB."
compounds,were,tested,"The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro)."
data,open,new insights for treatment,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,new insights for pharmacological treatment,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,new insights,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,pathophysiological relevance for,AnxA1,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,insights for pharmacological treatment,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,pathophysiological relevance for,AnxA1 in lung inflammation,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,insights for treatment of lung fibrosis,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,relevance for,AnxA1,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,insights,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,new insights for pharmacological treatment of lung fibrosis,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,relevance for,endogenous AnxA1,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,relevance for,endogenous AnxA1 in lung inflammation,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,new insights for treatment of lung fibrosis,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,relevance for,AnxA1 in lung inflammation,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
endogenous AnxA1,is in,lung inflammation,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,insights for pharmacological treatment of lung fibrosis,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,pathophysiological relevance for,endogenous AnxA1,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,pathophysiological relevance for,endogenous AnxA1 in lung inflammation,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
data,open,insights for treatment,"CONCLUSION: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of lung fibrosis."
infection,induces,neurological complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,induces,severe neurological complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,occasionally induces,severe complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,occasionally induces,neurological complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,induces,severe complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,induces,complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,occasionally induces,complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
infection,occasionally induces,severe neurological complications,"Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this infection occasionally induces severe neurological complications."
mice,were infected with,moderate dose of EV71,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were,infected,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were infected with,dose,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were infected with,moderate dose,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were infected with,dose of EV71,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were,When infected,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were,When infected with moderate dose,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were,When infected with moderate dose of EV71,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were,When infected with dose,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
mice,were,When infected with dose of EV71,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
lycorine treatment,was,able,"When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from paralysis."
Early signs,include,respiratory rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,increased rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,respiratory rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,respiratory rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,fever,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,increased respiratory rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,respiratory rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,increased respiratory rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,respiratory rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,increased rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,increased rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,increased respiratory rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,increased respiratory rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,increased respiratory rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,fever,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,increased rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,increased respiratory rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,respiratory rate followed,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,rate,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
Early signs,include,increased rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
signs,include,increased rate followed by depression,"Early signs of pneumonia include increased respiratory rate and fever, followed by depression."
respiratory disease,leading to,failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
disease,leading to,failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
respiratory disease,leading to,respiratory failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
progressive respiratory disease,leading to,respiratory failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
progressive disease,leading to,failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
disease,leading to,respiratory failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
signs,were,consistent,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
signs,were consistent In,our cases,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
progressive disease,leading to,respiratory failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
progressive respiratory disease,leading to,failure,"In our cases all the signs and symptoms, including vomiting, progressive respiratory disease leading to respiratory failure, refractory hypoxemia, leukopenia, lymphopenia, thrombocytopenia, and elevated levels of creatine kinase and hepatic aminotransferases, were consistent with critical illness due to 2009 H1N1 virus infection."
NIV,is in,patients with confirmed diagnosis of influenza AH1N1,"METHODS: Describe the respiratory profile, the mortality rate, and the benefit of using NIV in patients with confirmed diagnosis of influenza AH1N1 who were admitted in the ICU during the year 2009."
patients,is with,confirmed diagnosis of influenza AH1N1,"METHODS: Describe the respiratory profile, the mortality rate, and the benefit of using NIV in patients with confirmed diagnosis of influenza AH1N1 who were admitted in the ICU during the year 2009."
activation,has emerged as,contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,major contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,major contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,major contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,major contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,major contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,major contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,major contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,major contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,major contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,major contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,major contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,major contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,major contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,contributor to pathogeneses of disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has emerged as,contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,major contributor to pathogeneses,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,contributor to pathogeneses of neurodegenerative disorders,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has emerged as,contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,major contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
activation,has recently emerged as,contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
Aberrant activation,has recently emerged as,major contributor,Aberrant activation of caspase-6 has recently emerged as a major contributor to the pathogeneses of neurodegenerative disorders such as Alzheimer's and Huntington disease.
luteolin,profoundly reduced HIV-1 infection In,study,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,reduced HIV-1 infection In,study,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,profoundly reduced,HIV-1 infection,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,profoundly reduced In,study,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,reduced,HIV-1 infection in reporter cells,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
HIV-1 infection,is in,reporter cells,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,reduced In,study,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,profoundly reduced,HIV-1 infection in reporter cells,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
luteolin,reduced,HIV-1 infection,"In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes."
chronic liver disease,is in,United States,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is cause of,liver disease in United States,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is cause of,chronic liver disease in United States,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is cause of,chronic liver disease,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is major cause of,chronic liver disease,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is major cause of,chronic liver disease in United States,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is major cause of,liver disease,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is major cause of,liver disease in United States,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
infection,is,major,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is,major cause,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is,cause,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
HCV infection,is cause of,liver disease,HCV infection is a major cause of chronic liver disease and liver cancer in the United States.
Severe clinical cases,are characterized by,hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
cases,are characterized by,acute hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe cases,are characterized by,acute hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe clinical cases,are,characterized,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
cases,are,characterized,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe cases,are,characterized,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
clinical cases,are characterized by,hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
cases,are characterized by,hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
cases,are characterized by,hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
clinical cases,are characterized by,hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe clinical cases,are characterized by,acute hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe clinical cases,are characterized by,hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
clinical cases,are,characterized,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe clinical cases,are characterized by,acute hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe cases,are characterized by,acute hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
cases,are characterized by,acute hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe cases,are characterized by,hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
acute hepatitis,is with,hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
Severe cases,are characterized by,hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
clinical cases,are characterized by,acute hepatitis,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
clinical cases,are characterized by,acute hepatitis with hemorrhage,"Severe clinical cases are characterized by acute hepatitis with hemorrhage, meningoencephalitis and/or retinitis."
hypouricaemia,is,form of hypouricaemia associated with handling of acid,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is,inherited form of hypouricaemia associated with abnormal handling of acid,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is,form of hypouricaemia associated with abnormal renal handling of uric acid,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is,form associated with handling,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic renal hypouricaemia,is,form of hypouricaemia associated with abnormal renal handling,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic renal hypouricaemia,is form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
renal hypouricaemia,is,form of hypouricaemia associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
hypouricaemia,is inherited form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic renal hypouricaemia,is,form associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is,form associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
renal hypouricaemia,is,form associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is,form of hypouricaemia associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
hypouricaemia,is,form associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is inherited form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic renal hypouricaemia,is,form of hypouricaemia associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
hypouricaemia,is form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
hypouricaemia,is,form of hypouricaemia associated,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
renal hypouricaemia,is,form,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
renal hypouricaemia,is form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
renal hypouricaemia,is inherited form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
hypouricaemia,is,form,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic renal hypouricaemia,is,form,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic renal hypouricaemia,is inherited form of,hypouricaemia,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
Idiopathic hypouricaemia,is,form,"Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid."
wasting,resulting in,hypouricaemia,There is excessive urinary wasting of uric acid resulting in hypouricaemia.
excessive urinary wasting,resulting in,hypouricaemia,There is excessive urinary wasting of uric acid resulting in hypouricaemia.
excessive wasting,resulting in,hypouricaemia,There is excessive urinary wasting of uric acid resulting in hypouricaemia.
urinary wasting,resulting in,hypouricaemia,There is excessive urinary wasting of uric acid resulting in hypouricaemia.
Macedonian patients,is with,hypouricaemia,"Here we have identified Macedonian and British patients with hypouricaemia, who presented with a variety of renal symptoms and signs including renal stone disease, hematuria, pyelonephritis and nephrocalcinosis."
H5N1 viruses,are circulating in,parts,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,caused,infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,are circulating in,parts of Asia,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,caused,infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,caused,infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,caused,infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,caused,human infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,are circulating in,parts,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,caused,infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,caused,human infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,caused,infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,caused,infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,caused,infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,caused,human infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,caused,human infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,caused,human infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,caused,infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,caused,human infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,caused,infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,caused,human infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,caused,infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,are circulating in,parts of Asia,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,are circulating in,parts,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,caused,human infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,caused,infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
human infections,is with,high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,caused,human infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,caused,infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,caused,infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic avian influenza A H5N1 viruses,are circulating in,parts of Asia,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,are circulating in,parts,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,caused,infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,caused,human infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,caused,human infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,caused,human infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,caused,human infections with mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,caused,human infections,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
avian influenza A H5N1 viruses,are circulating in,parts,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
influenza A H5N1 viruses,are circulating in,parts of Asia,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
pathogenic influenza A H5N1 viruses,are circulating in,parts of Asia,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
H5N1 viruses,caused,human infections with high mortality rate,"Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate."
Carbohydrate Metabolism,Metabolism of,Other Amino Acids,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was,developed,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed based on,information of chemical-chemical interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Metabolism of,Cofactors,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Metabolism of,Terpenoids,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed based on,information of interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed In,study,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed based on,information,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed based on,information of chemical-chemical interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed In,study,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed based on,information of interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed based on,information,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Biosynthesis of,Other Secondary Metabolites,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was,developed,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Metabolism of,Other Amino Acids,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was,developed,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed based on,information of chemical-chemical interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Metabolism of,Cofactors,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Metabolism of,Terpenoids,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed based on,information of interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed In,study,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed based on,information,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed based on,information of chemical-chemical interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was developed In,study,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed based on,information of interactions,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
method,was developed based on,information,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Carbohydrate Metabolism,Biosynthesis of,Other Secondary Metabolites,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
novel method,was,developed,"In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism."
Acute distress syndrome,was considered,cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was,considered,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
main cause,is in,critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was,considered,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
ill patients,is with,2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was,considered,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause of death in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was,considered,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death in ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,cause of death in critically ill patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause of death in patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause of death in critically ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,main cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
respiratory distress syndrome,was considered,main cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,main cause of death,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute respiratory distress syndrome,was considered,cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
distress syndrome,was considered,cause in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,cause of death in patients with 2009 H1N1 infection,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Acute distress syndrome,was considered,main cause in ill patients,BACKGROUND: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection.
Mice,infected with,SD/09 virus,"Mice infected with SD/09 virus showed typical ARDS symptoms characterized by 60% lethality on days 8â€“10 post-inoculation, highly edematous lungs, inflammatory cellular infiltration, alveolar and interstitial edema, lung hemorrhage, progressive and severe hypoxemia, and elevated levels of proinflammatory cytokines and chemokines."
Mice,showed,ARDS symptoms,"Mice infected with SD/09 virus showed typical ARDS symptoms characterized by 60% lethality on days 8â€“10 post-inoculation, highly edematous lungs, inflammatory cellular infiltration, alveolar and interstitial edema, lung hemorrhage, progressive and severe hypoxemia, and elevated levels of proinflammatory cytokines and chemokines."
Cough,was,associated,"Cough was significantly associated with Influenza A virus infection (Ï‡2, p<0.001)."
Cough,was,significantly associated,"Cough was significantly associated with Influenza A virus infection (Ï‡2, p<0.001)."
Cough,was significantly associated with,Influenza virus infection,"Cough was significantly associated with Influenza A virus infection (Ï‡2, p<0.001)."
Cough,was associated with,Influenza virus infection,"Cough was significantly associated with Influenza A virus infection (Ï‡2, p<0.001)."
little,However is known about,transcripts,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
little,is known about,transcripts,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
non-coding transcripts,agents of,Bovine Respiratory Disease,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
Histophilus somni,in transcripts is,causative agents of Bovine Respiratory Disease,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
little,is,However known,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
non-coding transcripts,is in,Histophilus somni,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
little,is,known,"However, very little is known about non-coding transcripts in Histophilus somni, one of the causative agents of Bovine Respiratory Disease (BRD) as well as bovine infertility, abortion, septicemia, arthritis, myocarditis, and thrombotic meningoencephalitis."
symptoms,were cough In,HCoV-HKU1-infected patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
clinical symptoms,were,cough,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
cough,is In,HCoV-HKU1-infected patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
predominant clinical symptoms,were cough In,patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
symptoms,were,cough,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
clinical symptoms,were cough In,HCoV-HKU1-infected patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
predominant clinical symptoms,were,cough,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
predominant clinical symptoms,were cough In,HCoV-HKU1-infected patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
clinical symptoms,were cough In,patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
predominant symptoms,were cough In,patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
predominant symptoms,were cough In,HCoV-HKU1-infected patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
predominant symptoms,were,cough,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
symptoms,were cough In,patients,"In HCoV-HKU1-infected patients, the predominant clinical symptoms were cough, fever, and expectoration."
cough,is In,HCoV-NL63-infected patients,"In HCoV-NL63-infected patients they were cough, fever, and rhinorrhea."
therapies,based on,RAS,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
therapies,are,used,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
Pharmacological therapies,based on,renin angiotensin system,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
Pharmacological therapies,are,used,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
Pharmacological therapies,are,used extensively,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
therapies,based on,renin angiotensin system,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
Pharmacological therapies,based on,RAS,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
therapies,are,used extensively,"Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high."
group,could,could investigated further,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,common mechanisms of inhibition of dengue virus replication,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,could,could investigated,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,mechanisms of inhibition of virus replication,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,mechanisms of inhibition of dengue virus replication,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,mechanisms of inhibition,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,common mechanisms of inhibition,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,common mechanisms,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,mechanisms,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
group,discover,common mechanisms of inhibition of virus replication,"This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of inhibition of dengue virus replication."
other viruses,are cause in,months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are cause of,respiratory symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are cause in,months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are cause of,symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are,cause of respiratory symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are,cause,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are,cause of respiratory symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are,cause of respiratory symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are cause of,symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are cause in,months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are,cause of symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are cause in,months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are,cause,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are,cause,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are,cause of symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are cause of,respiratory symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
cause,is in,months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are cause of,symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are cause in,months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are cause in,months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are,cause of respiratory symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are,cause of symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are cause of,respiratory symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are,cause of symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are cause of,respiratory symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are,cause of respiratory symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are cause of,symptoms,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are,cause,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are cause in,months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are,cause of symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are,cause of respiratory symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
respiratory viruses,are,cause of symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other respiratory viruses,are cause in,months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are,cause of symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
other viruses,are,cause of respiratory symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are,cause of respiratory symptoms in months,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
viruses,are,cause of symptoms in months following influenza vaccination,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
influenza vaccine,is,safe,We proposed an educational prospective study to demonstrate to HCWs that influenza vaccine is safe and that other respiratory viruses (RV) are the cause of respiratory symptoms in the months following influenza vaccination.
acute hepatitis,is in,developing countries,BACKGROUND: The National Institutes of Health classified Hepatitis E as an emerging disease since Hepatitis E Virus (HEV) is the major cause of acute hepatitis in developing countries.
intervention,is in,PRIMIT trial,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
objective,examine,potential mediators,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
moderators,potential mediators of,outcomes,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,more frequent hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,frequent hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage hand-washing in,home,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,is in,PRIMIT trial,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
objective,examine,potential mediators,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
moderators,potential mediators of,outcomes,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,more frequent hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,frequent hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage hand-washing in,home,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,is in,PRIMIT trial,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
objective,examine,potential mediators,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
moderators,potential mediators of,outcomes,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,more frequent hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage,frequent hand-washing,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
intervention,encourage hand-washing in,home,"OBJECTIVE: The objective of our study was to evaluate whether a Web-based intervention can encourage more frequent hand-washing in the home, and to examine potential mediators and moderators of outcomes, as a necessary first step before testing effects of the intervention on infection rates in the PRIMIT trial (PRimary care trial of a website based Infection control intervention to Modify Influenza-like illness and respiratory infection Transmission)."
viruses,are agents of,dengue fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are causative agents of,DF,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are agents of,dengue fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are causative agents of,dengue fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are agents of,DF,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are,agents,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are agents of,fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are causative agents of,fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are,causative agents,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are causative agents of,fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are causative agents of,DF,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
viruses,are,causative agents,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are causative agents of,dengue fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are agents of,fever,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are agents of,DF,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Dengue viruses,are,agents,Dengue viruses (DENV) are the causative agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
Zoonotic infections,pose,constant threats,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
Zoonotic infections,remain,disease type,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
Zoonotic infections,pose,threats to residents,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
Zoonotic infections,remain,disease type among infected individuals,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,pose,threats,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,pose,threats to residents,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
Zoonotic infections,pose,constant threats to residents,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
Zoonotic infections,pose,threats,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,remain,disease type among individuals,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,remain,disease type,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,pose,constant threats to residents,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,remain,disease type among infected individuals,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
infections,pose,constant threats,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
Zoonotic infections,remain,disease type among individuals,"Zoonotic infections, such as severe acute respiratory syndrome (SARS), rabies and influenza, pose constant threats to Chinese residents and remain the most deadly disease type among the infected individuals."
20,had,B infection,"In 2009/10 all 41 index cases had a influenza A (H1N1) pdm09 infection, in 2010/11 24 had an A (H1N1) pdm09 and 20 had a B infection."
patients,of lavage is,BAL,"During a three-year period, we tested the bronchoalveolar lavage (BAL) of patients with ventilator-associated pneumonia, community-acquired pneumonia, non-ventilator ICU pneumonia and aspiration pneumonia, and compared the results with those from patients without pneumonia (controls)."
patients,is with,ventilator-associated pneumonia,"During a three-year period, we tested the bronchoalveolar lavage (BAL) of patients with ventilator-associated pneumonia, community-acquired pneumonia, non-ventilator ICU pneumonia and aspiration pneumonia, and compared the results with those from patients without pneumonia (controls)."
results,is with,those from patients without pneumonia,"During a three-year period, we tested the bronchoalveolar lavage (BAL) of patients with ventilator-associated pneumonia, community-acquired pneumonia, non-ventilator ICU pneumonia and aspiration pneumonia, and compared the results with those from patients without pneumonia (controls)."
pathogens,can,can detected,Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary microbiota.
pathogens,can,can detected as commonly in controls,Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary microbiota.
pathogens,can,can detected as commonly in controls as in pneumonia patients,Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary microbiota.
pathogens,can,can detected as in controls as in pneumonia patients,Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary microbiota.
as controls,is in,as pneumonia patients,Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary microbiota.
pathogens,can,can detected as in controls,Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary microbiota.
prevalence,is,11.00%,"The prevalence of coronary artery abnormality (CAA) is 11.0% and results in cardiac sequelae, such as myocardial infarction or coronary aneurysm, which are the most serious complications in KD."
serious complications,is in,KD,"The prevalence of coronary artery abnormality (CAA) is 11.0% and results in cardiac sequelae, such as myocardial infarction or coronary aneurysm, which are the most serious complications in KD."
artery abnormality,prevalence of is,11.00%,"The prevalence of coronary artery abnormality (CAA) is 11.0% and results in cardiac sequelae, such as myocardial infarction or coronary aneurysm, which are the most serious complications in KD."
prevalence,results in,cardiac sequelae,"The prevalence of coronary artery abnormality (CAA) is 11.0% and results in cardiac sequelae, such as myocardial infarction or coronary aneurysm, which are the most serious complications in KD."
coronary artery abnormality,prevalence of is,11.00%,"The prevalence of coronary artery abnormality (CAA) is 11.0% and results in cardiac sequelae, such as myocardial infarction or coronary aneurysm, which are the most serious complications in KD."
prevalence,results in,sequelae,"The prevalence of coronary artery abnormality (CAA) is 11.0% and results in cardiac sequelae, such as myocardial infarction or coronary aneurysm, which are the most serious complications in KD."
chemokine,serve as,potential new marker,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
study,sheds,light,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
study,sheds light on,NiV pathogenesis,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
study,sheds,new light,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
chemokine,serve as,potential marker for lethal NiV encephalitis,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
chemokine,serve as,potential new marker for NiV encephalitis,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
chemokine,serve as,potential marker,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
chemokine,serve as,potential marker for NiV encephalitis,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
chemokine,serve as,potential new marker for lethal NiV encephalitis,"This study sheds new light on NiV pathogenesis, indicating the role of CXCL10 during the course of infection and suggests that this chemokine may serve as a potential new marker for lethal NiV encephalitis."
additional examples,relating to,monitoring fungal pathogens,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
Particular emphasis,is,placed,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
Particular emphasis,is placed on,detection,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
additional examples,relating to,monitoring,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
placed,are,provided,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
examples,relating to,monitoring pathogens,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
emphasis,is,placed,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
examples,relating to,monitoring,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
emphasis,is placed on,detection,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
additional examples,relating to,monitoring pathogens,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
emphasis,is placed on,detection of pathogens,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
examples,relating to,monitoring fungal pathogens,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
Particular emphasis,is placed on,detection of pathogens,"Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided."
Emerging viruses,have,enormous potential spread rapidly,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
viruses,have,potential spread,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
Emerging viruses,have,potential spread rapidly,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
Emerging viruses,have,enormous potential spread,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
viruses,have,potential spread rapidly,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
viruses,have,enormous potential spread rapidly,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
Emerging viruses,have,potential spread,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
viruses,have,enormous potential spread,"Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly."
Viral Hemorrhagic Fevers,are,fundamental,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
Hemorrhagic Fevers,are,fundamental,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
Fevers,are,fundamental,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
SARS,avoiding,outbreaks,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
SARS,are,fundamental,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
SARS,avoiding,nosocomial outbreaks,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
Viral Fevers,are,fundamental,Viral Hemorrhagic Fevers and SARS) are fundamental for avoiding nosocomial outbreaks.
hypotension,increased odds of,testing dengue-positive associated,"Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
hypotension,odds of,testing dengue-positive associated,"Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
hypotension,increased odds of,testing dengue-positive associated with fever,"Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
hypotension,odds of,testing dengue-positive,"Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
hypotension,odds of,testing dengue-positive associated with fever,"Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
increased odds,â‰¤,"150,000 cells/mL","Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
odds,â‰¤,"150,000 cells/mL","Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
hypotension,increased odds of,testing dengue-positive,"Multivariable GEE models showed increased odds of testing dengue-positive associated with fever, headache, retro-orbital pain, myalgia, arthralgia, rash, petechiae, positive tourniquet test, vomiting, leukopenia, platelets â‰¤150,000 cells/mL, poor capillary refill, cold extremities and hypotension."
infection control program,prevent,outbreaks,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent,nosocomial outbreaks,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,academic hospital,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,hospital,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent,outbreaks of H1N1,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,"2,600-bed hospital","METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent,nosocomial outbreaks of H1N1,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,"2,600-bed academic hospital","METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,"2,600-bed tertiary-care academic hospital","METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,"2,600-bed tertiary-care hospital","METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,tertiary-care academic hospital,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
infection control program,prevent outbreaks at,tertiary-care hospital,"METHODOLOGY/PRINCIPAL FINDINGS: An infection control program was implemented to survey and prevent nosocomial outbreaks of H1N1 (2009) influenza at a 2,600-bed, tertiary-care academic hospital."
contact infection rates,were higher than,that,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,highlighting,need for public education,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,highlighting,need for education,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,highlighting need in addition to,hospital infection control,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,were,significantly higher,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,highlighting,need for education of influenza transmission,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,highlighting,need,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,were,higher,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,highlighting,need for public education of influenza transmission,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,highlighting,need for education,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,highlighting need in addition to,hospital infection control,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,highlighting,need,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,highlighting,need for education of influenza transmission,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,were significantly higher than,that of patient contact,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,were higher than,that,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,were significantly higher than,that,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,were significantly higher than,that,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,highlighting,need for public education of influenza transmission,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,were higher than,that of patient contact,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
Unspecified contact infection rates,were,significantly higher,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,highlighting,need for public education,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,were,higher,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,were higher than,that of patient contact,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
contact infection rates,were significantly higher than,that of patient contact,"Unspecified contact infection rates were significantly higher than that of patient contact and household contact infection, highlighting the need for public education of influenza transmission in addition to hospital infection control."
chloride conductance,mediated by,cystic fibrosis transmembrane conductance regulator,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
ion currents,were,chloride conductance mediated,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
ion currents,were,chloride conductance mediated by fibrosis transmembrane conductance regulator,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
chloride conductance,mediated by,fibrosis transmembrane conductance regulator,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
ion currents,activated by,adenosine,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
ion currents,were,chloride conductance,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
ion currents,were,chloride conductance mediated by cystic fibrosis transmembrane conductance regulator,"The ion currents activated by adenosine were chloride conductance mediated by cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel."
AR,is,major receptor responsible,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
AR,is,major,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
AR,is,responsible,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
A AR,is,major receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
A AR,is,receptor responsible,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,inhibitor for,2B adenosine receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
AR,is,receptor responsible,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
A AR,is,major receptor responsible,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,abolished,adenosine-stimulated chloride transport,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
AR,is,receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
A AR,is,receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,abolished,chloride transport,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,specific inhibitor for,A,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,largely abolished,adenosine-stimulated chloride transport,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,inhibitor for,A,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,inhibitor for,A 2B adenosine receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
AR,is,major receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,specific inhibitor for,2B adenosine receptor,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
Alloxazine,largely abolished,chloride transport,"Alloxazine, a specific inhibitor for A(2B) adenosine receptor (A(2B)AR), largely abolished the adenosine-stimulated chloride transport, suggesting that A(2B)AR is a major receptor responsible for regulating the chloride transport of the cells."
ethanol exposure,dysregulates,chloride transport in airways,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
ethanol exposure,dysregulates,CFTR-mediated chloride transport in airways,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
ethanol exposure,dysregulates chloride transport by,suppression,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
ethanol exposure,dysregulates chloride transport by,suppression of adenosine-A,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
ethanol exposure,dysregulates,CFTR-mediated chloride transport,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
ethanol exposure,dysregulates,chloride transport,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
CFTR-mediated chloride transport,is in,airways,"These results imply that ethanol exposure dysregulates CFTR-mediated chloride transport in airways by suppression of adenosine-A(2B)AR-cAMP signaling pathway, which might contribute to alcohol-associated lung infections."
Chlorine,is,pulmonary,BACKGROUND: Chlorine is a known pulmonary irritant gas that may cause acute damage in the respiratory system.
Chlorine,is,known,BACKGROUND: Chlorine is a known pulmonary irritant gas that may cause acute damage in the respiratory system.
acute damage,is in,respiratory system,BACKGROUND: Chlorine is a known pulmonary irritant gas that may cause acute damage in the respiratory system.
Chlorine,is,irritant,BACKGROUND: Chlorine is a known pulmonary irritant gas that may cause acute damage in the respiratory system.
vomiting hyperemia,symptoms for,second group,"The presenting symptoms were cough, nausea, and vomiting and conjunctiva hyperemia for the first group, first groups symptoms plus dyspnea for the second group."
presenting symptoms,were,cough,"The presenting symptoms were cough, nausea, and vomiting and conjunctiva hyperemia for the first group, first groups symptoms plus dyspnea for the second group."
symptoms,were,cough,"The presenting symptoms were cough, nausea, and vomiting and conjunctiva hyperemia for the first group, first groups symptoms plus dyspnea for the second group."
groups symptoms,were for,third group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
chest tightness,were for,third group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
palpitation,were for,third group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
Second groups symptoms,were for,third group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
palpitation,were for,group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
groups symptoms,were for,group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
chest tightness,were for,group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
Second groups symptoms,were for,group,"Second groups symptoms plus palpitation, weakness and chest tightness were for the third group."
Annex,facilitating,decisions,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
88%,reported Among,quantitative survey respondents,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
%,reported Among,survey respondents,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex 2,facilitating,decisions,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex,was,useful,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
88%,excellent/good,knowledge,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex,facilitating,decisions regarding notifiability of potential PHEICs,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex,was,always/usually useful,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
%,excellent/good,knowledge,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
%,excellent/good,knowledge of Annex 2,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
88%,excellent/good,knowledge of Annex 2,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex 2,was,useful,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex,facilitating,decisions regarding notifiability,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
%,using,Annex 2,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
77%,using,Annex 2,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex 2,facilitating,decisions regarding notifiability of potential PHEICs,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
88%,reported Among,survey respondents,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex 2,was,always/usually useful,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
%,reported Among,quantitative survey respondents,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
Annex 2,facilitating,decisions regarding notifiability,"Among quantitative survey respondents, 88% reported having excellent/good knowledge of Annex 2; 77% reported always/usually using Annex 2 for assessing potential PHEICs; 76% indicated their country had some legal, regulatory or administrative provisions for using Annex 2; 95% indicated Annex 2 was always/usually useful for facilitating decisions regarding notifiability of potential PHEICs."
dry air,be,related,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
cold air,be related to,influenza mortality,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
cold air,be,related,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
cold dry air,be related to,influenza mortality,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
cold dry air,be,related,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
dry air,be related to,influenza mortality,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
air,be,related,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
research,supports,contention,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
air,be related to,influenza mortality,"This research supports the contention that cold, dry air may be related to influenza mortality and suggests that warning systems could provide enough lead time to be effective in mitigating the effects."
pathogenic potential,is in,wild non-domestic Felidae species,"Here we review recent genetic advances that have questioned traditional wisdom regarding the origins of virulent Feline infectious peritonitis (FIP) diseases, the pathogenic potential of Feline Immunodeficiency Virus (FIV) in wild non-domestic Felidae species, and the restriction of Feline Leukemia Virus (FeLV) mediated immune impairment to domestic cats rather than other Felidae species."
high HBoV load,could,could agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV load,could,could etiologic agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV viral load,could,could etiologic agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV viral load,could,could etiologic agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV viral load,could,could etiologic agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV load,could,could etiologic agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV viral load,could,could etiologic agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV load,could,could agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV viral load,could,could agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV viral load,could,could agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV load,could,could etiologic agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV viral load,could,could agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
load,be,etiologic,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV load,could,could agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV viral load,could,could agent,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
HBoV load,could,could agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
high HBoV load,could,could etiologic agent for LRTI,"A high HBoV viral load could be an etiologic agent for LRTI, which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization."
cells,have,far have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
Huh7 cells,have,have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
cells,have,have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
Huh7 cells,have,far have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
cells,have,thus far have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
Huh7 cells,have,thus have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
Huh7 cells,have,thus far have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
cells,have,thus have found,"BACKGROUND: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV."
Buruli ulcer,has emerged as,public health problem in communities,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
several rural communities,is in,sub-Saharan Africa,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,health problem in several rural communities,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
important public health problem,is in,several rural communities,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,health problem,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,important health problem in several communities in sub-Saharan Africa,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,important public health problem in several communities in sub-Saharan Africa,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,important public health problem in communities,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,important public health problem in several rural communities,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,important health problem,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,public health problem,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
Buruli ulcer,has emerged as,important public health problem,BACKGROUND: Buruli ulcer (BU) caused by Mycobacterium ulcerans (M. ulcerans) has emerged as an important public health problem in several rural communities in sub-Saharan Africa.
its expression,is,where decreased,"Consequently, it has a beneficial role in many diseases such as hypertension, diabetes, and cardiovascular disease where its expression is decreased."
pneumonia,findings of,> 16 y,"METHODS: We evaluated the epidemiologic characteristics of patients infected with the 2009 H1N1 influenza A virus (4,463 patients, age range from 2 mo to 86 y), and the clinical and laboratory findings of 373 inpatients (80/217 children, â‰¤ 15 y, had pneumonia and 36/156 adults, > 16 y, had pneumonia) in a single hospital during the epidemic."
pneumonia,clinical and laboratory findings of,> 16 y,"METHODS: We evaluated the epidemiologic characteristics of patients infected with the 2009 H1N1 influenza A virus (4,463 patients, age range from 2 mo to 86 y), and the clinical and laboratory findings of 373 inpatients (80/217 children, â‰¤ 15 y, had pneumonia and 36/156 adults, > 16 y, had pneumonia) in a single hospital during the epidemic."
"4,463 patients",range from,2 mo to 86 y,"METHODS: We evaluated the epidemiologic characteristics of patients infected with the 2009 H1N1 influenza A virus (4,463 patients, age range from 2 mo to 86 y), and the clinical and laboratory findings of 373 inpatients (80/217 children, â‰¤ 15 y, had pneumonia and 36/156 adults, > 16 y, had pneumonia) in a single hospital during the epidemic."
pneumonia,clinical findings of,> 16 y,"METHODS: We evaluated the epidemiologic characteristics of patients infected with the 2009 H1N1 influenza A virus (4,463 patients, age range from 2 mo to 86 y), and the clinical and laboratory findings of 373 inpatients (80/217 children, â‰¤ 15 y, had pneumonia and 36/156 adults, > 16 y, had pneumonia) in a single hospital during the epidemic."
genes,have,have implicated,Many genes have been implicated in schizophrenia as have viral prenatal or adult infections and toxoplasmosis or Lyme disease.
Many genes,have,have implicated,Many genes have been implicated in schizophrenia as have viral prenatal or adult infections and toxoplasmosis or Lyme disease.
genes,have,have implicated in schizophrenia,Many genes have been implicated in schizophrenia as have viral prenatal or adult infections and toxoplasmosis or Lyme disease.
Many genes,have,have implicated in schizophrenia,Many genes have been implicated in schizophrenia as have viral prenatal or adult infections and toxoplasmosis or Lyme disease.
such proteins,explaining,immune activation in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,immune activation in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,are,immunogenic,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,activation,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,preponderance of,immune-related gene variants in schizophrenia genome,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,preponderance of,gene variants in schizophrenia genome,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,activation in brain in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
explaining,activation in,schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
antibody,mediated,knockdown of multiple schizophrenia gene products,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,immune activation,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,preponderance of,immune-related gene variants,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,immune activation in brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,preponderance of,gene variants,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,activation in brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
immune-related gene variants,is in,schizophrenia genome,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,immune activation in brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,immune activation in brain in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
antibody,mediated,knockdown of schizophrenia gene products,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,preponderance of,gene variants,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,are,immunogenic,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
immune activation,is in,schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,activation in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,activation in brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,explaining,immune activation,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,preponderance of,gene variants in schizophrenia genome,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,immune activation in brain in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
Many such proteins,preponderance of,immune-related gene variants,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,activation in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
explaining,activation in,brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
antibody,mediated,knockdown,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
immune activation,is in,brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
explaining,immune activation in,schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,preponderance of,immune-related gene variants in schizophrenia genome,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
explaining,immune activation in,brain,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,activation,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
such proteins,explaining,activation in brain in schizophrenia,"Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome."
pathogens,causing,acute infections,"Aerosol generating procedures (AGPs) may expose health care workers (HCWs) to pathogens causing acute respiratory infections (ARIs), but the risk of transmission of ARIs from AGPs is not fully known."
pathogens,causing,acute respiratory infections,"Aerosol generating procedures (AGPs) may expose health care workers (HCWs) to pathogens causing acute respiratory infections (ARIs), but the risk of transmission of ARIs from AGPs is not fully known."
pathogens,causing,respiratory infections,"Aerosol generating procedures (AGPs) may expose health care workers (HCWs) to pathogens causing acute respiratory infections (ARIs), but the risk of transmission of ARIs from AGPs is not fully known."
pathogens,causing,infections,"Aerosol generating procedures (AGPs) may expose health care workers (HCWs) to pathogens causing acute respiratory infections (ARIs), but the risk of transmission of ARIs from AGPs is not fully known."
neutropenia,were screened regarding,range of viruses for viruses detected in patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range for viruses detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses for viruses commonly detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of respiratory viruses for viruses commonly detected in severely immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,Patients with,hematological malignancies,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses for viruses commonly detected in patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses for viruses detected in immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses for viruses commonly detected in immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of viruses for viruses commonly detected in patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses for viruses commonly detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range for viruses detected in patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common respiratory viruses for viruses commonly detected in severely immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common viruses for viruses detected,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common respiratory viruses for viruses commonly detected in immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common viruses for viruses commonly detected,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses for viruses detected in patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range for viruses commonly detected in severely immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range in nasopharynx for viruses detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses for viruses,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses for viruses detected,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range in nasopharynx for viruses commonly detected in immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range in nasopharynx for viruses commonly detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses for viruses detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of respiratory viruses for viruses detected in severely immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common respiratory viruses for viruses detected in severely immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common respiratory viruses for viruses commonly detected in patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
viruses,detected in,immunosuppressed patients blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common respiratory viruses for viruses detected in severely immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range for viruses detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
viruses,detected in,patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range in nasopharynx for viruses commonly detected in severely immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range for viruses commonly detected in patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of viruses for viruses commonly detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range for viruses detected in severely immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of respiratory viruses for viruses detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of viruses for viruses commonly detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses for viruses detected,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of respiratory viruses for viruses detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range for viruses detected in severely immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of respiratory viruses for viruses commonly detected in immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
viruses,detected in,severely immunosuppressed patients blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of common viruses for viruses commonly detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range in nasopharynx for viruses commonly detected,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of viruses for viruses detected in immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range for viruses,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range of respiratory viruses for viruses,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of common respiratory viruses for viruses detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
viruses,commonly detected in,patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range in nasopharynx for viruses commonly detected in immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range in nasopharynx for viruses commonly detected in severely immunosuppressed patients in blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,range in nasopharynx for viruses commonly detected in immunosuppressed patients in peripheral blood,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range in nasopharynx for viruses detected in patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
neutropenia,were screened regarding,broad range of respiratory viruses for viruses detected in immunosuppressed patients,METHODOLOGY/PRINCIPAL FINDINGS: Patients with hematological malignancies and therapy induced neutropenia (nâ€Š=â€Š159) were screened regarding a broad range of common respiratory viruses in the nasopharynx and for viruses commonly detected in severely immunosuppressed patients in peripheral blood.
